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Study the efficacy, safety, acceptability and impact on quality of life (QoL) of the 
Reliance and FemAssist continence devices in the management of women with 
genuine stress incontinence (GSI). 
METHODS 
In a prospective trial, subjects with reasonable eyesight, mobility and manual dexterity were 
eligible. Exclusion criteria included recurrent urinary tract infection, diabetes, pregnancy or 
haernaturia. Assessments were made at baseline, one, three and six months. 
"Bothersome" foreign body sensation was noted and assessment of comfort, ease of 
placement and protection afforded with device utilisation were ranked. 
Outcome measures included the number of incontinence episodes QEPD), 
continence pads used (recorded on a urinary diary) and amount of leakage on a pad 
test (PWT). The Kings Health and Short Form 36 questionnaires were used to 
evaluate QoL. 
Safety was judged by urinalysis, Urine cultures, physical examination and reported 
adverse events. Womens experiences of device use were recorded. 
RESULTS 
53 women were selectively allocated to the FemAssist and 48 to the Reliance. Sub ects were 
well matched and the mean age was 50.2 years (range 30-77). 
Foreign body sensation was similar, but satisfaction (comfort, easy placement) was better with 
the FemAssist device, albeit required greater user skill. QoL scores significantly improved 
within both groups. Problems experienced were few With no serious adverse events. 
The Reliance achieved significantly greater reduction in PWT gains but other outcome 
measures were comparable. 
1) 
Reliance FemAssist 
Outcome measures Start 6 months Start 6 months 
1EPD 5.21 1.32 5.0 1 
Pads used 10.5 3.45 11.1 4.35 
PWT (g/hr) 32.6 1.3 28.7 3.6 
Dry (subjective) 19(39.6%) 20(37.7%) 
Improved 12(25%) 18(34%) 
UTI 10.4% 11.3% 
Lost to foflow-up Inhibition Urethritis Poor Effi'cacv 
FemAssist(n=17) 10 








Devices are beneficial and acceptable methods to contain urinary incontinence, confer 
. proved QoL and should be recommended to women with GSI. 
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The preface will act as a guide or template to the dissertation, describing briefly the 
composition of each chapter. In presenting this material I have drawn upon my own 
practical experience as well as the clinical experience and teaching of the subject of 
urogynaecology and urodynamics gained as a result of working with Linda Cardozo 
and other research fellows who have shaped and modified my approach to the subject. 
As an extension of the preface, THE COMPONENTS OF THE CONTINENCE 
SER VICE AT MNGS COLLEGE HOSPITAL AND THE SET77NG FOR THIS 
THESIS are described separately. The expectation is that the reader will understand 
why the research was performed and be confident that it took place in a unit dedicated 
to the care of incontinent women of all ages with exactly the criteria for a system able 
to fully manage the patient. This also helped to ensure that the thesis and my training 
were fully supervised by Prof Cardozo. It brings together a description of the present 
structure, organisational. fi-amework and method of functioning of the wide range of 
services available to the incontinent woman at the Urogynaecology Unit where this 
research was carried out. In undertaking such a description it is necessary to strike a 
balance between over-complexity and undue simplicity. So to preserve clarity only 
the broad aspects are presented and are in general terms correct. 
In chapter one entitled EPIDEMIOLOGYAND CLASSIFICA TION OF URINAR Y 
INCONTINENCE I deal with the concept of the cause of genuine stress 
incontinence. Outlined is the way in which the nature and frequency of urinary 
incontinence can vary within different groups of the population from one period of 
time to another. Examining the pattern of disease in populations in this way provides 
the starting point for studies which encourage service or treatment initiatives. 
To understand and appreciate the impact of continence devices on women with GSI, 
one must first describe its prevalence and the natural history of the condition. One 
must understand the pathophysiology of the condition and its consequences on the 
individual and society as a whole. 
Chapter two summan ses the modem TREATMENT OF FEM4LE GENUINE 
STRESS INCONTINENCE in a manner which emphasises the merit and validity of 
the study relevant to the way patients are managed. In order to observe the 
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consequences of the interventions used to contain urinary leakage in this study, it is 
important to examine other known methods to gauge their effects and uses. 
Chapter three describes the QUALITY OF LIFE AND IMPACT OF 
INCONTINENCE in women. Research has until recently concentrated on the 
prevalence, aetiology, diagnosis and management of urinary incontinence and 
relatively little us known about the effects of this chronic condition or indeed its 
management on quality of life and psychosocial functioning. Because urinary 
incontinence is a quality of life issue, the patient must be allowed to express her 
preference of options and the degree of intervention. 
Chapter four provides a RE VIEW OF THE LITERATURE ON CONTINENCE 
DEVICESANDAIDS. Clinical experience is too restricted a perspective to use to 
draw conclusions about how successful is individual treatment of urinary incontinence 
using continence aids. An accurate picture of the safety and efficacy of devices can 
be obtained from data collected and analysed in other studies. This may act as a 
helpful reference to test the clinical value of these aids to continence, and permit 
interpretation of the results of this trial in relation to the finidings of other authors. 
In chapter five I have introduced the UROD YNAMIC ASSESSMENT and main steps 
to be taken in diagnosing the health problems of the population of women studied 
with urinary symptoms. In an attempt to demystify it, I have put special emphasis on 
providing simple descriptions and definitions of the concepts involved and explained 
the urodynarnic; tests available. This also serves in part to outline the precise clinical 
and laboratory techniques used to obtain the data. 
The chapter on PATIENTS AND METHODS includes the study design, formulation 
of the aims of the study, stating the null hypothesis and defined targets, the study 
population and the selection of a suitable sampling frame. As the study units were 
patients at a hospital with a particular disease (genuine stress incontinence), how 
representative are these patients? Could the fact that these are patients attending a 
Urogynaecology unit somehow make them unrepresentative? Le. specialise in more 
severe cases. Does geographic location or condition have an effect? What was the 
target population compared with the study population? These issues will be 
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discussed. After the study units were selected, how the study was conducted is 
summansed. The inclusion and exclusion criteria for entry into the study are stated as 
well as the criteria for the disease or condition being measured. The intervention or 
continence devices are also described. 
Next, in chapter seven, it is essential to define the OUTCOME MEASUPES or 
objectives of the programme of continence device intervention against which 
outcomes are to be measured and to select an appropriate study design. Scientific 
evaluation of the outcome of therapeutic interventions in patients is not possible 
without appraisal before and after the intervention. Outcome is usually defined in 
terms of the achievement of or failure to achieve desired goals or objectives. This 
definition is common to both outcome and need and the same measures are often 
appropriate to each. In preparing the basis of this thesis I addressed the question of 
what to measure, from whose perspective and according to which criteria in addition 
to selecting the appropriate measures. 
Comments are made on how suitable is the chosen method for the purpose of the 
investigation, what is the power of the chosen measure to detect differences and how 
reproducible is the method in general terms. Outcome measurements should be based 
on repeated investigations performed under identical circumstances before and after 
the therapeutic intervention. The test/retest variation of the reporting centre are given 
in order to make evaluations of the results possible to interpret and evaluate by others. 
It is important to state the normal values in healthy women. One can then make 
inferences on how differences might be explained. A change can be defined as a 
value outside the test/re-test interval and an improvement as a change towards 
normality. 
There are several reasons why subjective indicators are of value in the assessment of 
the effects of these devices. It is perceived, and not necessarily actual situations 
which result in the adoption of health related behaviour, including the demand for 
continence aids. It is also important for clinicians to be aware of and to understand 
the beliefs and perceptions of the subjects whom they are treating. Only then can 
continence programs be made appropriate and relevant to perceived needs 
Chapter eight, the MEASURES OF THE CONSEQUENCES OF TREATMENT 
stresses that the appropriate methods of analysis are determined by the study design 
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so as to allow sound meaningftd interpretation of the results, and not just increase the 
quantity of data ftorn the combination of clinical observations and standard 
urodynamic measurements. Specific statistical methods are indicated and used to 
analyse the data to allow inferences to be made. Each method required a certain 
assumption of the data but are appropriate to the study design and scale of 
measurements. 
Chapter Nine provides a deliberation on the ASSESSMENT OF DEVICE SAFETY. 
The safety of each device was evaluated by urinalysis and urine culture, physical 
examination and any spontaneously reported adverse events. There is an explanation 
of what each means and detailed information in particular on the conditions of cystitis 
and urethritis, capillary fragility, petechial haemorrhages and bruising. 
Chapter ten depicts the OBJECTIVE RESULTS FOR THE RELMNCE AND 
FEAMSSIST DEVICES. In describing the results, I have tried to avoid merely 
cataloguing them, but have commented on their distinctiveness and highlighted the 
deficiencies. Throughout, the reader is made aware of the strengths and limitations of 
the data so as to avoid hasty or inaccurate interpretation of them and the practical 
difficulties involved in pursuing the goals of the study. 
Chapter eleven illustrates the RESULTS OF QUALITY OF LIFE ASSESSMENT. 
The value of appropriate designs and analysis of quality of life studies will be lost if 
one does not present the results clearly and concisely. Graphical presentations can be 
used to accomplish this objective and communicate the overall summaries of results. 
These can convey results in a manner than allows the reader to individually balance 
the importance of baseline versus post treatment differences among the two treatment 
groups. 
Chapter twelve records the SIDE EFFECTS EXPERIENCED BY THE RELMNCE 
AND FEMMSIST GROUPS as a consequence of device utilisation. 
Chapter thirteen displays the completeness of the data and ANALYSIS OF 
DROPOUTS AND NON-RESPONDERS. Some patients have missing data and if 
large then the credibility of the results should be questioned. In some studies any data 
in 
such as outliers are discarded. I did not discard any proportion of the data that does 
not support the research hypothesis maintaining scientific objectivity. 
Chapter fourteen presents the logic of the CONCLUSIONAND FUIVRE 
RESEARCH. Do they make sense? Can one reasonably use the results of this study 
to guide the treatment of other patients? 
II 
COMPONENTS OF THE CONTINENCE SERVICE 
AT KINGS COLLEGE HOSPITAL AND THE 
SETTING FOR THIS THESIS 
11) 
Education and training in Urogynaecology is still undergoing considerable evolution 
throughout the world. The first formalisation of Urogynaecology as a subspecialty 
occurred in Australia followed by the United Kingdom 1. The latter has two certified 
training programs which has produced one certified graduate to date. In the USA, 
Urogynaecology is now a formal subject required to be taught in post-graduate 
residency training programs. The department of urogynaecology and urodynamics at 
Kings College Hospital is a certified centre where the training of research fellows 
mirrors that of the Urogynaecology subspecialty trainee. 
KINGS COLLEGE HOSPFFAL 
The work contained in this thesis was undertaken at King's College Hospital, London, 
in the Department of Urogynaecology from August 1995 until February 1998. The 
setting at Kings College Hospital is a hospital based consultant-led continence service 
headed by Professor Linda Cardozo the designated co-ordinating consultant. The 
Urodynamic Unit at King's College Hospital is a tertiary referral centre established by 
Professor Cardozo in 1979 and has continued to expand since that time. Not only 
does the clinic benefit from direct consultant input, but it also employs four full time 
research registrars (of which I was one), a full time urodynamic nurse and contracts 
sessions from the District Continence Advisor. 
i'l 
W, At, u ý hr 
In 1991, the Department of Health 2 issued guidelines which suggested that the key 
components of an effective continence service should include the following: 
" Active, enthusiastic consultant with general manager involvement. 
" Continence advisors with management and teaching skills and a moderate 
caseload to maintain their clinical skills. 
"A computer to store patient information. 
" Active publicity work and sympathetic, knowledgeable telephone advice 
"A separate budget. 
Since the problem of incontinence involves many disciplines, Prof. Cardozo has 
arranged a formal structure to co-ordinate these and provides a readily accessible and 
well-recognised service. There is a defined method of entry for patients referred by 
general practitioners, nurses and hospital staff. There is ready access to appropriate 
diagnostic facilities and the full complement of modem urodynamic investigations, 
including ambulatory urodynamics, is available for patient assessment. 
There is access to medical and surgical consultants with a special interest 'in 
incontinence within the hospital and outside. There is also access to nurses and 
physiotherapists, with special training in treatment modalities for incontmence. 
Provision is made to ensure a direct role of a specialist continence advisor in the 
education of the public and associated carers in the maintenance of continence. With 
the hospital team, the continence advisor maintains a policy concerning the 
purchasing and supply of containment materials and equipment in the community and 
in the hospital proper. She also deploys other continence advisors and specially 
trained link nurses in the community. These structures and policies are subject to 
regular audit and quality assurance systems. This is achieved with the help of a 
designated manager and a multidisciplinary steering group with a financial budget to 
provide staff, their training and support services and containment materials and 
equipment. The service has an agreed and clearly written policy which is available to 
all relevant health professionals and purchasers within the hospital trust. 
Regular hospital based continence clinics are conducted involving the consultant, 
research fellows, specialist registrars, the nurse speciahst and continence advisor. A 
permanent office accepting telephone enquiries is available at all times during the 
day. Prof Cardozo has cultivated educational programme and audit procedures 
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around this continence service. With the particular advantages of access to diagnostic 
facilities, this programme has made available many opportunities to develop medical 
research. Within this agenda, simple cases are diagnosed and managed appropriately 
by the general practitioner with referral to a community continence advisor for 
supplies of continence products if required. More complex cases are referred to the 
hospital based continence clinic. 
In the latter months of 1992 the UCARE clinic (Urodynamic Clinic for the 
Assessment and Review of the Elderly) was established. This clinic, co-ordinated by 
the Urodynamic Nurse Specialist and the District Continence Advisor, was designed 
to cope with the increasing number of elderly women referred for urodynamic 
assessment, for whom it was felt that videourodynamics may have been unnecessary 
and additional unhurried time was needed for complete assessment. The clinic offers 
a full nursing assessment as well as uroflometry, cystometry and urethral pressure 
profilometry without radiological imaging. 
All referrals are made directly to and reviewed by the consultant and then allocated 
to one of three t3Ws of clinics; elderly or disabled patients with an uncomplicated 
history are seen in the UCARE clinic; routine urodynamic referrals are booked into 
one of the urodynamic clinics held four times a week and run by the research fellows. 
Complex tertiary referrals are seen by the consultant in the gynaccology clinic prior to 
videourodynamics performed in the consultant clinic. All complex cases and all 
UCARE patients are reviewed by Prof Cardozo and the team at a fortnightly video 
review meeting. 
As a tertiary referral centre many complex referrals are seen each year. The majority 
of patients however are primary or secondary referrals directly from general 
practitioners or from consultants at other regional hospitals as well as our own 
gynaecology clinic. 
A major criticism of many studies is that they are a reflection solely of the indigenous 
population in the locality of the study. As a tertiary referral centre situated in South 
London, the unit attracts referrals from a very large multi-racial, urban and suburban 
catchment area. Our referrals are therefore likely to mitigate against this form of 
I's 
selection bias, although such biases can never by discounted completely unless studies 
are conducted on a multi-centre national or international basis. 
A large proportion of women requires surgery in the form of urinary continence 
procedures and pelvic floor reconstruction. Operating lists are provided to 
accommodate this service and the research fellows are trained to carry out such 
operations until competent. 
The International Continence Society (ICS) was founded in 1970 to develop a 
multidisciplinary scientific approach to the management of continence. It is a 
multidisciplinary body of scientists and clinicians which first established a committee 
for the standardisation of terminology of lower urinary tract dysfunction in 1973. 
These standards have been revised and extended to keep pace with improvements in 
urodynamic techniques and have been adopted world wide to provide a common 
framework for clinical and research work in the field of urinary incontinence. Prof. 
Cardozo is closely involved with the activity and function of the society and abides by 
the standards set to ensure reliable high quality urodynamic practice. 
SUMNURY 
Why do we need this service? 
0 Incontinence of urine in women is very common 
0 An average health authority of 250,000 population can expect to have 10,000 
adults who are incontinent and many more who are unknown to the health 
services 
0 In England, the Department of Health has reviewed continence services and 
the National Health Service Management Executive have identified continence 
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services as a priority in its policies and planning guidelines for 1994-95 
Jolleys and Wilson have highlighted the lack of medical training in continence care at 
undergraduate and post-graduate levels in the U. K 5. It is obvious that political 
interest in the problem continues to grow, with a variety of clinical and service 




1 Ostergard D. Education and training in Urogynaecology. Int Urogynecol J 
1997; 8(l): 56. 
2 Department of Health. Community Service Division. An agenda for action on 
continence services. London: Department of Health 199 1. 
3 Department of Health, 199 1. An agenda for action on continence services. ML 
(91)1. Department of Health, London. 
4 NHS Management Executive, 1993. Priorities and Planning Guidance 1994-1995. 
EL(93)54. Department of Health, Leeds. 
: 'Jolleys J, Wilson J. Urinary incontinence: GPs lack of confidence. BMJ 
1993; 306: 1344. 
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CHAPTER ONE 
EPIDEMIOLOGY AND CLASSIFICATION 
OF URINARY INCONTINENCE 
IR 
INTRODUCTION 
Urinary incontinence is a common problem affecting two to three million women in 
the LJK. In many chronic diseases such as Urinary incontinence, complete recovery 
does not occur. The incidence of GSI is an estimate of the risk of developing the 
disease and hence is of value mainly to those concerned with searching for the cause 
or determinants of the disease. Knowledge of the prevalence of GSI is of particular 
value in planning health services, since it indicates the amount of incontinence 
requiring care. 
Epidemiological studies have attempted to measure the size of the incontinent 
population and to isolate risk factors common to incontinence sufferers. Studies are 
often limited by the reluctance of women to admit to incontinence and consequently 
the true extent of this distressing condition is probably underestimated. 
PREVALENCE STUDIES 
Epidemiological studies are fraught with methodological problems and biases which 
include the sample population chosen, the definition of incontinence adopted and the 
common problems of under reporting of embarrassing conditions. Prevalence surveys 
are usually conducted as personal interviews, postal surveys or by telephone and it is 
important to recogruse the limitations of each of these methods when interpreting 
data. Two previous studies on the prevalence of urinary incontinence have found that 
for every case of recognised incontinence (incontinence known to a member of the 
primary care team) there are about 20 unrecognised cases 12 
In a large general practice study, O'Brien et al (1991) showed a prevalence of 16.4% 
of women aged 35-64 reporting regular urinary incontinence and also confirmed the 
great reluctance of patients to bring their incontinence problems to the attention of 
members of the primary care team 3. However, among those who had discussed their 
problems, only 20% had been assessed within the past year and 30% had never had 
any form of assessment. The variation between reports on the prevalence of 
incontinence is probably due to the variety of definitions used with different time 
scales, such as ever incontinent, incontinent in the last two months, incontinence 
requiring the use of pads, a change of pants or underclothes. Reports also vary 
depending on the population surveyed, such as those at home, community dwelling, 
19 
institutionalised and the frail elderly as well as the method of information gathering. 
Brocklehurst (1993) in the analysis of a MORI poll found that in all, 14% of women 
were or had been incontinent 4.9.3% of women were incontinent in the previous year 
and 7.5% in the previous two months (Table 1.1). In this study, 60% of incontinent 
subjects were concerned or worried about their problem and 34% of women felt it 
affected their lifestyle considerably. Treatment was often prescribed without clinical 
examination or without a diagnosis being made. Fewer than 5% of those who 
consulted a doctor were referred to a nurse or continence advisor. 
Prevalence of incontinence in women 
Age N Ever Previous Previous 
Year Months 
30-49 921 100(10.9) 66(7.2) 50(5.4) 
50-59 363 56(15.4) 33(9.1) 23(6.3) 
>/= 60 840 141(16.8) 98(11.7) 86(10.2) 
TOTAL 2124 297(14.0) 197(9.3) 159(7.5) 
Table 1.1 Prevalence of incontinence in women of different age groups and at 
different periods of their lives. The ages are in years and the percentages in brackets. 
(Brocklehurst (1993)) 
Yarnell et al 1981 in a well-constfucted epidemiological study found that 3- 7% of 
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women in the general population complained of significant urinary incontinence 
The seventy of incontinence has been assessed in a number of ways but most often 
with reference to the frequency of leakage, varying from 'daily' to 'weekly' to 'once 
or twice a month'. Wyman et al (1990) assessed the subjective impact and frequency 
or urinary leakage using the 'Incontinence Impact Questionnaire' and a urinary diary 
6. They found only a modest correlation between the two. These findings suggest 
that severity cannot be measured in terms of the frequency of incontinence alone and 
other seventy criteria must be addressed. 
Incontinence is likely to be under reported, rather than over reported and therefore 
higher figures are likely to be more accurate. The phenomenon whereby only a 
proportion of patients make contact with health services and in particular hospital 
services is often referred to as the "tip of the iceberg". The processes which lead to 
this are plentiful: shame and embarrassment; an assumption that nothing can be done; 
lack of publicity for services to name but a few. 




Milne et al (1972) 
65+ year olds 34% 
Thomas et al (1980) 
25 - 64 year olds 18% 
65 + year olds 23% 
Yamell et al (1981) 
25 - 64 years olds 46% 
65 + year olds 49% 
Vetter et al (198 1) 
61 year olds 14% 
Diolno, et al (MESA) study (1986) 
65 + year olds 30% 
Table 1.2 The prevalence of 'any incontinence' amongst women residing 
independently in the community. 
THE PREVALENCE OF SEVERE URINARY INCONTMENCE 
Although prevalence studies have not attempted to validate the measures of severity, 
estimates of 'severe incontinence' are more consistent than those for 'any loss' (Table 
1.3). They range from 3% to 11% with the majority between 4% and 6% and are 
therefore considerably lower than those of any urinary leakage. Studies have 
estimated that almost 50% of nursing home residents are incontinent of unne 7 
Prevalence of severe urinary incontinence 
Study Prevalence 
Mine et al (1972) 5% 
Yarnell et al (1979) 11% 
Thomas et al (1980) 10% 
Vetter et al (1981) 5% 
Campbefl et al (1985) 3% 
Diokno et al (MESA) studv (1986) 4% 
Table 1.3 The prevalence of severe urinary incontinence. 
RISK FACTORS FOR URINARY INCONTINENCE 
The human female pelvis as a result of containing the abdominopelvic organs and 
resisting the forces of gravity and raised intra-abdominal pressure must confront the 
problems which quadruped mammals are not prone to. Parturition traumatises the 
1>1 
supportive muscles, figaments, connective tissue, fascia and nerves W1 I Ic ithin the pelvi 
cavity so intimately involved in the processes of Urinary and faecal continence and 
genital support. Added to this are the effects of ageing and oestrogen deficiency. 
Figure 1.1 The female pelvis. 
Race, smoking, constipation, obesity and gynaecological surgery have all been 
studied as potential aetiological factors. 
Age and Gender 
Urinary incontinence is commoner amongst women than men and its prevalence 
increases with age 89 (Table 1.4). Many elderly women actuafly consider their 
urinary symptoms to be a normal part of the ageing process rather than a 
in 'f 'on of disease 10. Malone Lee (1994) has shown that elderly women have a am estati 
reduced flow rate, an increased post void urinary residual, a higher end filling 
cystometric pressure (and maximum filling pressure), reduced bladder capacity and 
lower maximum voiding pressures ". 
Gender distribution of urinary incontinence 
Study Prevalence 
Female Male 
Varnell et al (1979) 
Over 65 years of age 17% 11% 
Thomas et al (1980) 
Over 65 years of age 31% 16% 
25 - 64 years old 27% 5% 
Vetter et al (1981) 
Over 65 years of age 18% 7% 
Michegan Generations 
follow up(1987) [In 
Herzog et al 1990] 
23 - 62 year olds 12% 2% 
Over 63 years of age 23% 11% 
Market Opinion Research 14% 7% 
International (1990) 
Table 1.4 The sex distribution of Unnary incontinence. 
Additional causes of incontinence in the elderly are illustrated in table 1.5. 
Additional causes of incontinence in the elderiv 
Urinary tract infection 
Faecal impaction 
Decreased mobility 
Acute illness / acute confusional state 
Drugs (e. g. diuretics, hypnotics) 




Endocrine abnormalities (e. g. Diabetes) 
Renal problems 
9 Dementia 
Table 1.5 Causes of incontinence in the elderly. 
Hormonal status 
In England and Wales there are approximately 10 million climacteric or 
postmenopausal women and therefore I In 5 of the population is potentially at nsk of 
the symptoms of urogemtal oestrogen deficiency 12 . At approximately 
40 years of age 
91 
the frequency of ovulation declines, initiating a period of waning ovarian function - 
the climacteric. This results sequentially in reduced ovulation, menstrual 
irregularities, the menopause and finally generallsed atrophy of all oestrogen - 
sensitive tissues. 
The female genital and urinary tracts develop in close proximity, both arising from 
the embryological urogenital sinus. Studies have shown that the adult female 
urogenital tissues are oestrogen sensitive and oestrogen and progesterone receptors 
have been identified in the human urethra, bladder, vagina, and pelvic floor, 
irrespective of hormonal 
13 14 
status At present the importance of oestrogen 
deficiency compared to that of the ageing process per se is unclear, although it is 
likely to be of significance in the maintenance, if not the genesis, or urinary problems 
in post menopausal women. In their large postal survey of almost 10,000 British 
women, Thomas et al (1980) showed that the prevalence of incontinence increased 
with age, but not specifically at the time of the menopause; whereas losif and 
Bekassey (1984) found that the prevalence of stress incontinence reached a peak at 
5 the age of 50 years and declined thereafter' . 
An analysis of both urinary symptoms and urodynamic findings amongst climacteric 
women was performed at the Dulwich Menopause Clinic 16 . 228 women referred 
for 
various climacteric complaints completed a detailed urinary symptom questionnaire 
and underwent urodynamic investigations comprising pad testing, uroflometry, 
videocystourethrography, cystometry and urethral pressure profilometry. Symptoms 
of stress incontinence occurred in over 50% of women and of urge incontinence in 
26%. Only 60% of women had normal urodynamic investigations. Despite the 
common finding of urinary symptoms and urodynamic abnormalities, no correlation 
was seen with the time or duration of the menopause. 
Race 
Racial differences in the prevalence of urinary incontinence are difficult to quantify as 
cultural factors alter the perception and presentation of urinary complaints. Although 
few epidemiological data are available, incontinence appears to be least common 
amongst Chinese, Eskimo and coloured women 17 . 
Bump (1992) compared clinical 
and urodynamic parameters of 54 black and 146 white women referred for evaluation 
of incontinence (154) and severe prolapse (46) 18 . He 
found the proportion of black 
and Caucasian patients with severe prolapse to be the same, but showed the causes of 
urinary incontinence to be significantly different between the two groups (Table 1.6). 
Urinary incontinence and racial ori i 
Race 
Variable Black White 
Symptoms of incontinence 
Stress incontinence 7% 31% 
Urge incontinence 56% 28% 
Mixed incontinence 37% 41% 
Cause of incontinence 
Genuine stress incontinence 27% 61% 
Detrusor instability 56 28% 
Mixed incontinence 17% 11% 
Table 1.6 The cause of incontinence and racial origin. (Bump 1992). 
Pregnancy and childbirth 
Pregnant women commonly complain of stTess incontinence and this has been 
attributed to the high level of progesterone during pregnancy. Van Geelen et al 
(1982) however performed urethral pressure profilometry on 43 pregnant women and 
found no change in the maximum urethral closure pressure despite high levels of 17 
hydroxyprogesterone 19. Also, displacement from the "nonnal" position may occur as 
a result of an increasingly gravid uterus. The pelvis and lower gemtourmary tract 
undergo profound changes that do not completely revert to the nulliparous state. This 
occurs for a variety of reasons including the hormonal effects, pressure from the 
gravid uterus and circumstances surrounding delivery. The effect of peptide 
hormones such as relaxin also plays a role in connective tissue metabolism during 
pregnancy 20 . 
This hormone attains highest plasma levels during pregnancy and has 
been shown to induce collagen remodelling and consequent softening of the tissues of 
the birth canal 21 22 . 
The prevalence of stress incontinence has been reported in a number of studies. 
Stanton (1980) reported a change from 0% prior to first pregnancy to a peak of 41% at 
23 38 weeks in multiparous women Cutner et al (1992) found a similar prevalence of 
stress incontinence, but it must be stressed that the patient groups were not 
"S 
homogeneous 24. losif (1981) in a retrospective postal survey of 1400 women found 
an overall incidence of 22% of stress incontinence 25 (Table 1.7). 
Incidence of stress incontinence 
relative to pregnancy (losif 981) 
Time of onset Percentage of symptoms Percentage of total 
Prior to pregnancy 8.5% 





Temporary in pregnancy 50% 11% 
Postnatal onset 19% 4% 
Table 1.7 Incidence of stress incontinence relative to pregnancy. 
Viktrup et al (1992) followed 305 women longitudinally 26 - They reported similar 
figures of 4% stress incontinence prior to delivery, increasing to 32% during 
pregnancy and 7% postnatally (Table 1.8). The authors correlated the development of 
postnatal urinary symptoms to birth weight, episiotomy and length of second stage of 
labour. They also found that caesarean section conferred some protection against 
developing incontinence. At three months postpartum all obstetric correlation's had 
disappeared in the women who remained symptomatic. At one year postpartum only 
3% of women admitted to urinary stress incontinence. 
Onset of stress incontinence (Viktrup 1992) 
Time of onset 
Prior to pregnancy 4% 
During pregnancy 32% 
Postnatally 7% 
Table 1.8 Onset of stress incontinence relative to pregnancy. 
All these studies suggest that symptoms of stress incontinence are common during 




Krue et al (1997) investigated birth weight in 194 women who delivered vaginally 
and found an increased incidence of both antenatal and postnatal symptoms for 
women having a baby of greater than four kilograms 27 (Table 1.9). 
Incidence of symptoms and 
birth weight over 4 kg (Krue 1997) 
Symptoms of stress Fetal weight Fetal weight 
Incontinence over 4 Kg Under 4 Kg 
Antenatal 10% 6.9% 
Postnatal 34% 30.6% 
Table 1.9 Incidence of symptoms of stress incontinence and birth weight over 4 kg 
The same group also reported an increased incidence of stress incontinence in women 
with a body mass index of over 30 Kg/m2 
Instrumental delivery is often cited as a factor in the development of urinary 
symptoms. In England the assisted delivery rate among primiparous women varies 
from 10-24% 28 . 
Given the relatively frequent use of these instruments there is a 
paucity of objective evidence to support the claim of their involvement in the 
aetiology of stress incontinence. Wilson et al (1996) in their epidemiological study of 
1800 women three months after delivery found no difference in the incidence of 
incontinence between women having a forceps delivery or a normal delivery (odds' 
ratio 0.8-1.6) 29. Jackson et al (1997) also showed little difference in incidence of 
incontinence regardless of the use of epidural anaesthesia or instrumental delivery 30 
The ethnic differences quoted in non-pregnant populations have also been described 
relating to pregnancy and childbirth. Burgio et al (1996) studied 523 women and 
found an incidence of stress incontinence of 62.5% in white women and 46.4% in 
blackS31. 
Caesarean section is often thought to protect against damage and pelvic floor 
dysfunction. In a recent survey 3 1% of female obstetricians described caesarean 
section as their personal preferred method of delivery, with 80% citing fear of pelvic 
floor damage as the reason 32. Wilson et al (1996) reported that caesarean section 
reduced the prevalence of urinary incontinence from 27% in women delivering 
vaginally to 5% after caesarean section 29 . 
There was little difference in this study 
between elective and emergency caesareans. The protective effect seemed to lessen 
97 
with subsequent operative deliveries and three caesarean sections conferred no 
advantage over vaginal births. 
Pelvic floor and nerve damage 
During parturition the pudendal nerve which supplies the pelvic floor is vulnerable to 
damage with disruption to the terminal branches supplying the pelvic floor, bladder 
and urethra. The pelvic floor itself may be marred by tearing during birth or by 
cutting at the time of an episiotomy. Also the use forceps increases the diameter of 
the head during delivery potentially increasing trauma to the birth canal. 
Sampselle (1990) showed in a small study of 20 women that pelvic floor 
contractility and strength correlate inversely with the development of symptoms after 
childbirth 33 . This suggests that pelvic 
floor exercises antenatally may protect against 
the development of stress incontinence. Genuine stress incontinence cannot however 
be explained wholly by the effects of vaginal delivery and urinary incontinence does 
not appear to be a invariable consequence of childbirth. 
Connective tissue factors 
Research has suggested that the collagen of women with prolapse and stress 
incontinence may be different from that of women who do not develop these 
conditions. Landon and Smith (1989) found that abdominal wall collagen was less 
stiff in women with stress incontinence than in continent controls and Sayer et al 
(1990) showed that the collagen of pubocervical fascia of stress mcontment women 
was weak due to an abnormal cross linking of collagen fibrilS34 35 . 
The composition 
of collagen in women with stress incontinence may therefore be abnormal and 
predispose them to urethral sphincter incompetence. 
Type I collagen forms thick, strong fibre units whereas, Type H collagen forms thin, 
weak and isolated fibres. Keane et al (1992) performed periurethral biopsies on 30 
nuiliparous women with genuine stress incontinence 36 . 
They found a decrease in 
Type I compared to Type H collagen, as well as a reduction in the total amount of 
collagen in GSI sufferers compared to continent controls. 
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Smoking, obesity and chronic constipation 
Any condition resulting in a chronically elevated intra-abdominal pressure is likely to 
increase the risk of developing or exacerbating stress incontinence. Obesity, chromic 
constipation and smoking have been suggested as important predisposing factors in 
the causation of genuine stress incontinence although insufficient data exists to refute 
or confirm these assumptionS3738 39. 
Hysterectomy and urinary incontinence 
Urinary incontinence may be a complication of hysterectomy. There are many 
potential mechanisms of incontmence following hysterectomy, namely derangement 
of the bladder supports, pelvic nerve damage and oestrogen deficiency resulting from 
4041 
concomitant oophorectomy 
Prolapse and Anterior repair 
Genital prolapse and urinary incontinence are common conditions and it is therefore 
not surprising to find both in some women. Rosenzwieg et a] (1992) have shown 
almost 60% of women with severe genital prolapse and no symptoms of incontinence 
to have underlying urinary incontinence revealed by urodynamic testing 42 . Thomas 
et al (1978) and Meyhoff et al (1985) reported stress incontinence 11119% and 25% of 
continent women following anterior colporrhaphy for prolapse and losif (1979) 
reported a decrease in urethral closure pressure following similar 
surgery 
43 44 45. 
CLASSIFICATION OF 
LOWER URINARY TRACT DYSFUNCTION 
The standardisation committee of the International Continence Society (ICS) have 
provided a common classification of lower urinary tract dysfunction (Tables 1.10 and 
1.11). The lower urinary tract comprises the bladder and urethra. Each has two 
functions, the bladder to store and void and the urethra to control and convey urine. 
?Q 
Together they form a single functional unit under complex neurological control and 
dysfunction of one or both can result in urinary incontinence. 
CLASSIFICATION OF 
















Normal adult >/= 400 mls 
Rise for filled volume </=500mls 
(normally </= 15cm H20 pressure) 
Normal 
Urethral sphincter Incompetence 
Table 1.10 Lower urinary tract dysfunction during the storage phase of the 
micturition cycle. 
CLASSIFICATION OF 




Underactive (Hypotonic bladder) 
Acontractile (Atonic bladder) 
Urethra Obstructive (mechanical; 
urethral stricture) 
Overactive; 
(detrusor sphincter dyssynergia) 
Table 1.11 Lower urinary tract dysfunction during the voiding phase of the 
micturition cycle. 
Stress incontinence is the commonest symptom with which women present to a 
gynaecologist and indicates the involuntary loss of urine during physical exertion. 
Urge incontinence is the involuntary loss of urine associated with a strong desire to 
V) 
void. Unconscious incontinence is urinary leakage in the absence of urgency and 
without conscious recognition of the urine loss. Enurests denotes any involuntary loss 
of Unne, although it is usually used to describe incontinence during sleep (nocturnal 
enuresis). Post micturition dribble and continuous incontinence are other 
symptomatic forms of urinary leakage often associated with prolapse, a urethral 
diverticulum or fistula. Major causes of urinary incontinence are listed in table 1.12. 
Mýjor causes of urinary incontinence 
Genuine stress incontinence (GSI) 
" Detrusor instability (DI) (Detrusor hyperreflexia) 
" Overflow incontinence 
" Fistulae (vesicovaginal, uterovaginal, urethrovaginal) 
" Congenital (e. g. epispadias / ectopic ureter) 
" Urethral diverticulae 
" Temporary (e. g. urinary tract infection, faecal impaction, drugs) 
" Functional (e. g. immobility) 
Table 1.12 The causes of urinary incontinence 
GENUINE STRESS INCONTMNCE 
The terin "stress incontinence" was coined by Sir Eardley Holland in 1928 and refers 
to the loss of Urine during physical effort. Genuine stress incontinence, detru-sor 
instability and overflow incontinence are the most common causes of urinary 
incontinence in women. Genuine stress incontinence is the commonest cause of 
urinary incontinence in women and can be due to weakness in any component of the 
urethral sphincter mechanism (Table 1.13 . 
Genuine stress incontinence accounts 
for 50% of cases and detrusor instability 40%. Overflow incontinence accounts for 
most of the remaining 10%47 
Mechanisms for urethral competence 
Supporting structures Pubourethral ligaments 
Intrinsic sphincter mechanism 
Pubovesical ligaments 
Rhabdosphincter 
Collagen and fascia 
Intact nervous system 
Urethral vascularity 
(smooth muscle) 
Extrinsic sphincter mechanism Pelvic floor musculature 
Table 1.13 The mechanisms involved in urethral competence. 
11 
The contents of the female abdominal and pelvic cavities depend on the pelvic floor 
for support. The urethra, vagina and rectum pass through this structure, so its role is 
not solely supportive, but it must augment urinary and faecal continence as well as 
accommodating parturition. The pelvic floor supports are not rigid and unyielding but 
consist of smooth and striated muscle, collagen, fibrous and connective tissue capable 
of movement or dynamic changes under conditions of stress. Urinary continence is 
thought to be achieved by an intact urethral sphincter mechanism as well as the 
adjacent structures of the pelvic floor 48 49 50 (Figure 1.2). 
Stma IncDofinence 
Abdommal Pressure 105 cm H20 
Abdaminal PressLve S cm H20 
Figure 1.2 Mechanisms of unnary continence. 
The work of Enhorning provides strong evidence as to the mechanism of bladder 
neck and urethral closure during physical effort in continent women5l. With the 
urethra correctly positioned in the pressure zone of the abdominal cavity, raised intra 
abdominal pressure is transmitted equally to the bladder and urethra, closing off the 
bladder neck and preventing leakage of unne. In addition, structures outside the 
lower urinary tract aid continence and are referred to as the extrinsic continence 
52 53 54 55 
mechanism . This mechanism assists both passive and active bladder neck 
closure in women, by Virtue of the structural supports of the urethra and the stability 
11) 
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hiatus, which is bordered by the medial edge of the levator ani muscle, consists of the 
pubococcygeus and ileococcygeus which are attached to and have a major role in 
upholding the pelvic viscera and lower urogenital tract 58 . Damage to the levator ani 
contributes to urogenital prolapse. In addition, activity in the striated muscles of the 
levator ani is thought to constrict the urogenital hiatus and assist in active closure of 
the structures which pass through it. Thus, both periurethral support structures and 
the levator ani muscle function to sustain the pelvic viscera as well as contTibuting to 
resting urethral pressure and urethral closure during raised intra-abdominal 
59 
pressure 
Weakness or damage to the pubourethral ligaments and the levator am muscles 
results in descent of the proximal urethra such that it is no longer an intra-abdominal 
organ under the control of intra-abdominal pressure variations. 
Various factors are thought to predispose to the development of GSI and these are 
shown in table 1.14. 
Raised intra-abdominal pressure Pregnancy 
Chronic bronchitis 
Abdominal / pelvic mass 
Ascites 
Damage to the pelvic floor 
Scarred "drainpipe" urethra 
Childbirth 
Menopause 
Radical pelvic surgery 





Table 1.14 Predisposing factors in the pathophysiology of GSI. 
DETRUSOR INSTABILITY 
The unstable detrusor is one that is shown objectively to contract, spontaneously or on 
provocation, during the filling phase of cystometry whilst the patient is attempting to 
inhibit micturition. These contractions may result in the leakage of urine. The 
incidence increases with age and DI is the commonest cause of urinary incontinence 
'Al 
in the elderly 11. Detrusor contractions may be either phasic, or systolic where they 
mimic the normal voiding reflex or the bladder wall may demonstrate low 
compliance. Women usually present With multiple symptoms; most commonly 
urgency, urge incontinence, frequency and nocturia. A list of the common causes of 
frequency and urgency of micturition is shown in table 1.15. 
The pathophysiology of detrusor instability is poorly understood and an underlying 
cause for the condition is rarely found. In the majority of cases therefore, the term 
'idiopathic detrusor instability' is used. Detrusor instability can arise de novo 
following surgery for genuine stress incontinence. 
Causes of frequency and urgency of micturition in women 
Type Example 
Gynaccological/Urological Detrusor instability 
Urinary tract infection 
Inflammation (e. g. interstitial cystitis) 
Atrophy (menopause) 
Fibrosis (radiation) 
Urethral pathology (e. g. urethral syndrome) 
Intravesical lesion (e. g. calculus) 
External pressure (e. g. pelvic mass/fibroids) 
Pregnancy 
Medical/Psychological Drugs (e. g. diuretics) 
Diabetes 
Neurological disease (e. g. multiple sclerosis) 
Excessive fluid intake 
Habit 
Table 1.15 The causes of frequency and urgency of micturition 
Any neurological condition which interrupts the cortical inhibition of reflex detrusor 
contractions will result in unstable detrusor contractions. This is known as detrusor 
hyperreflexia and causes include multiple sclerosis and spinal cord lesions. 
LOW COMIPLUNCE 
In this condition there is an excessive rise in detrusor pressure associated with bladder 
filling. There are a variety of causes which include recurrent urinary tract infection, 
radiotherapy, radical pelvic surgery and pelvic masses. These patients are often 
symptomatically the same as those with detrusor instability (table 1.16). 
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Table 1.16 The types of detrusor instability 
OVERFLOW INCONTINENCE 
Overflow incontinence is a condition in which the bladder becomes a large flaccid 
bag with little or no detrusor activity. Occasionally where there is chronic outflow 
obstruction the bladder becomes small and trabeculated due to fibrosis but again there 
is little or no detrusor activity. The woman fails to void and the bladder merely leaks 
each time it becomes full. In addition, due to the very small functional bladder 
capacity, she may develop frequency of micturition and recurrent lower and indeed 
upper unnary tract infections. 
Fistulae secondary to obstetric tra-uma are a common cause of incontinence in 
developing countries. In the developed world, fistulae are usually secondary to 
gynaecological surgery although they are fortunately rare. 
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CHAPTER TWO 
THE TREATMENT OF 
FEMIELE GENUINE STRESS INCONTINENCE 
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THE TREATMENT OF 
FEMALE GENUtNE STRESS tNCONTINENCE 
All currently available treatment modalities in addition to continence devices were 
available to patients treated in the unit except for major reconstructive urological 
procedures and implantation of artificial urinary sphincters. As it is important to 
understand the methods of treatment in order to follow the outcome of the women, 
this chapter of my thesis reviews both the conservative and surgical treatment of 
female genuine stress incontinence. 
CONSERVATIVE MANAGEMENT OF GSI 
The conservative management of incontinence generally refers to a broad range of 
non-surgical therapies which are easy, inexpensive, and readily available. They have 
few complications and do not compromise future surgery. Conservative management 
is the first line of treatment of female urinary incontinence but the overall approach to 
the individual depends upon the outcome of thorough evaluation. An assessment 
should be made of the woman's mental state and her ability for self-care. Home 
circumstances should be assessed for factors which may contribute to urinary 
incontinence such as, inappropriate furniture heights (bed, chair, toilet), excessive 
distance to toilet, poor lighting as well as cool temperatures. If mobility is restricted, 
moving to a bedroom closer to the toilet or providing a bedside commode or rails at 
the toilet may correct functional incontinence. Apart from specific treatment 
modalities there are many simple measures that can improve or resolve incontinence 
(Table 2.1). 
There are many causes of urinary incontinence in the elderly and many individuals 
may have more than one reason for their incontinence. Atrophy of the pelvic floor 
muscles can lead to poor sphincter tone and compound stress incontinence. Many 
diseases (stroke, diabetes and urinary tract infections) which become more common 
with advancing years may also cause continence problems. Other acute problems 
may result in a temporary loss of continence as a result of general debility or illness. 
Treatment depends on the needs and expectations of the woman and she must be 
counselled with regard to the efficacy of the treatment and possible side effects. The 
general principles of management are listed in table 2.2. 
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Simple conservative measures in 
the management of urinary incontinence 
Exclude urinary tract infection 
Fluid restriction (<1=1.5 litres) / timing of intake 
Timed / double voiding 
Provision of a commode 
Barrier cream 
Treat chronic conditions (e. g. cough / constipation) 
Monitor medication (e. g. diuretics) 
Wei2ht reduction (uncertain value) 
Table 2.1 Conservative treatment options in the management of urinary 
incontinence. 
Principles of Management of Incontinence 
Establish pathophysiological basis of the disorder 
Try conservative measures first 
Involve the patient in choice of treatment options 
Patient with mixed diagnosis should have the predominant problem 
treated first 
Provide teaching, counselling and support 
Planned regular review of treatment progress 
Use of both subjective and objective outcome criteria 
Multidisciplinary planning co-ordination and communication 
Regular audit of outcomes and feedback to practitioners 
Table 2.2 General principles In the management of incontinence. 
Who can benefit from physiotherapy? 
It Is Widely accepted that surgery is the definitive treatment of severe or persistent 
GSI, but may not be appropriate (table 2.3). Recent studies found that 90% of women 
with stress incontinence initially decide on a non-surgical treatment and 60% would 
be willing to try a new non-surgical treatment if offered 1. Where women have mixed 
symptoms surgery should only be undertaken with caution and therefore conservative 
management is pivotal to initial treatment. Age is not a banner to learning PFEs, but 
close monitoring is important to ensure correct instructions are canned out and to 
ensure motivation. 
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Factors precluding surgery as first line treatment 
Pregnancy or planning Pregnancy 
Post partum breast feeding 
Family incomplete 
Medically unfit 
Unwilling to undergo surgery 
Occasional incontinence 
Incontinence not a problem despite severity of urodynamic diagnosis 
Major voiding difficulty 
Table 2.3 The main factors precluding surgery as first line treatment. 
The rationale is that conservative therapy is relatively inexpensive and readily 
available, has few complications and does not compromise future surgery (Table 2.4). 
IndiVidualised exercise programmes optiMise the cure rates achievable. The 
instructor must however be familiar with the chosen technique and flexible in their 
approach to teaching as no one single technique will suit all. Continence Advisors are 
invaluable in the overall management 2. 
Conservative management of GSI 
Pelvic floor re-education Pelvic floor exercises 
Vaginal cones / perineometer 
Medication 
Electrical treatment 




Drugs acting on the urethra 
Hormone replacement therapy 
Faradism * 
Interferential. 
Maximal electrical stimulation 
Indwelling catheters (suprapubic and urethral) 
Clean intermittent self cathetensation (CISC) 
Pads and pants, commodes 
Tampon / sponge / pessary 
Adhesive urethral devices 
Urethral plug devices 
0 Commode / prompted or timed voiding 
0 Incontinence aids (pads / pants / catheters) 
40 Adequate laundry facilities 
0 Faecal disimpaction 
Table 2.4 Methods of conservative management used for the treatment of urinary 
incontinence. * Not routinely used in our department. 
41 
Regular review is also required to maintain motivation and encourage the 
incorporation of these exercises into the daily routine of the woman to ensure the best 
long-term outcome. 
PHYSIOTHERAPY 
The urethra is surrounded by striated muscle fibres fon-ning the external sphincter 
mechanism (Figure 2.1). This sphincter mechanism interdigitates with the 
musculature of the pelvic floor 3. It is this relationship between the smooth and 
striated voluntary muscle in the region of the bladder neck and urethra which forms 
the rationale for pelvic floor exercises in the treatment of GSL The aim is to improve 
the activity of the support musculature of the pelvic floor and thereby aid closure of 
the sphincter mechanism by a secondary means and thus reduce or prevent urinary 
leakage. 
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Female urethra, midsagittal section. 
Figure 2.1 The female urethra. 
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The pelvic floor needs to be in a constant state of muscle activity and be able to 
respond immediately to any increase in intra-abdominal pressure. Pelvic floor 
METHODS OF CONSERVATIVE MANAGEMENT 
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exercise programmes must cover both of these aspects and should include simple 
repetitive and stress specific exercises. 
PELVIC FLOOR EXERCISES 
Pelvic floor exercises were first described by Kegel in 1948 as a method of re- 
educating the pelvic floor and are still the mainstay of physiotherapy treatment of 
genuine stress incontinence 4. Identification and awareness of the pelvic floor 
musculature and objective assessment of pelvic floor function is important prior to 
commencing the exercise programme. This can be done by digital examination and 
contraction of the pelvic floor muscles to squeeze the intravaginal fingers so as to 
grade the pelvic contraction. An alternative assessment can be obtained using devices 
such as the perineometer which allow either an analogue or digital read out of the 
pressure obtained similar to that described by Kegel (1948) (Figure 2.2). The 
perineometer is a vaginal resistance chamber attached to a meter that registers an 
increase in pressure when the appropriate muscles contract. Not only is this a helpful 
method of identifying the pelvic floor musculature but is also a useful objective 
assessment of progress following PFEs. The usefulness of these is limited as they 
measure pressure and therefore are not selective for pelvic floor contraction. 
Figure 2.2 Permeometer with feedback training through windows software and 
display. 
Pelvic floor contractions can be of two types, fast (lasting I sec) and slow (lasting 3- 
4 sec or more), to exercise both the fast and slow twitch muscle fibres. The length of 
maximurn contraction is also recorded in seconds, as is the number of repetitions 
per-formed. A score of 3/4/5 represents a moderate contraction held for four seconds, 
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which is repeated five times. The incorporation of repetition with endurance exercise 
is aimed at strengthening both the fast twitch fibres, thought to be important in 
generating contractions of high pressure and of short duration to counteract transient 
raised intra-abdominal pressures (for example sneezing), with slow twitch fibres 
which are important in maintaining resting tone. 
No study has been performed to quantify the most appropriate number of 
contractions required daily. Nfillard (1987) recommends 10 daily sessions and up to 
400 contractions a day, slightly more than that recommended by Kegel (1948) (300 
contractions / day) 5. Women often find this number of contractions excessive, 
resulting in poor treatment compliance for less motivated subjects. Bo et al (1988) 
found that one third of women joining their PFE program did not know how to 
contract their pelvic floor and 70% of women performing PFEs at home were doing 
them incorrectly 6. Nfillard (1987) obtained similar results and suggested that 30% of 
women were unable to contract their pelvic floor to command and that this may 
contribute to the failure Of pFE7S 7. These patients require remedial tuition to learn 
the correct exercise. 
Results and meta-analysis of PFE's 
Although there is much indirect evidence to support the use of these non-surgical 
treatments for stress incontinence, there is little direct evidence for beneficial effects 
based on randomised controlled trials. Tapp et al (1989) in a randomised comparison 
of pelvic floor physiotherapy with the Burch colposuspension in the treatment of GSI 
found that after six months of treatment 43% of patients treated with PFEs were cured 
or improved, compared with 96% of the operative group8. Cure was defined as an 
absence of subjective symptoms of incontinence and normal urodynamic 
investigations. Improvement was either a subjective and/or objective reduction of the 
degree of incontinence. Interestingly 53% of the PFE group requested surgery at the 
end of the study. 
Kegel's initial work involved 500 women exercising with a perineometer for 20 
minutes 3 times a day and 5 contractions ('drawing up and in') every half hour over a 
six to eight week period. Women were seen weekly to ensure correct muscle 
contraction and to maintain motivation. In this study 85% of the women were 
subjectively cured. This was, however, an uncontrolled study With no attempt to 
4A 
determine the type or degree of incontinence prior to treatment and the results have 
never been repeated_ 
Fedorkow (1993) reviewed the existing literature on the non-surgical management of 
stress incontinence using a strategy which yielded 86 articles 9. No one method for 
performing PFEs appeared to be clearly superior. The only adjunct to traditional 
PFEs which appears to confer benefit over the exercises above is intensive PFEs. 
These involve regular follow-up, monitoring and encouragement in the continued 
performance of traditional PIFEs 
COMPLEWENTARY THERAPIES 
Some women performing pelvic floor exercises show improvement in leakage 
episodes soon after starting such a program or long before any muscle hypertrophy 
can have taken place. Indeed, Miller et al (1996) found that a precisely timed 
volitional levator ani muscle contraction, learned in one week, was a simple and 
efficient technique to reduce urine leakage by over 60% during a cough 10. 
POSTURAL CHANGES 
In a study by Norton and Baker (1994) most women with GSI could reduce or 
eliminate urine loss using postural changes with coughing ". A combination of 
crossing the legs and bending forward was effective, but bending forward alone was 
not sufficient while crossing one's legs was the most effective position and produced 
continence in nearly 73% of subjects. The mean reduction in fluid loss was 14.7g 
(95% Cl = 21.2g to 8.2g) using the best posture compared with the standing position. 
However, postural changes are not useful in reducing urine loss associated with 
walking, running, jumping or other activities involving movement of the lower limbs. 
The mechanism of action is unknown but it is postulated that crossing the legs may 




Women often have difficulty isolating the pelvic muscle groups and to overcome this, 
adjunctive "biofeedback" therapies have been developed to assist the correct 
performance of these exercises 12 . 
These include the use of a perineometer, vaginal 
cones and electrical stimulation. 
The perineometer can be used to aid pelvic floor exercises by enabling the woman to 
gauge the strength of the contraction which she generates (Figure 2.2). The use of a 
penneometeT is easy to teach and requires less follow-up supervision. They are 
generally acceptable to all women and are useful in improving compliance to 
traditional pelvic floor exercises which still form an essential part of treatment. 
VAGMAL CONES 
Plevnik (1985) showed that women could learn to contract the muscles of the pelvic 
floor by retaining cones of increasing weight in the vagina ". The feeling of losing 
the cone helps to identify and assess the muscles of the pelvic floor. Pelvic floor 
contraction is essential to keep the weights in the vagina as contracting the abdominal 
or gluteal muscles Will not aid retention of the cones. A set of vaginal cones consists 
of weights ranging firom 20 to I OOg with a nylon thread to facilitate removal (Figure 
2.3). A cone is inserted into the vagina, base uppermost, and the heaviest weight 
retained without voluntary holding is called the passive weight, reflecting resting 
pelvic floor tone. The heaviest weight retained with voluntary pelvic floor 
contraction is the active weight. 
Figure 2.3 Vapnal cones. 
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Starting with the passive weight the patient is asked to insert and retain the cone in the 
vagina for 15 minutes twice a day. Once successful on two consecutive occasions she 
progresses to the next weight. By gradually increasing the cone weight, the strength 
of the pelvic floor contractions will increase and the woman can monitor her progress. 
In the short term, upwards of 70% of patients are cured or improved and 90% find it 




FARADISM AND INTERFERENTIAL THERAPY 
Electrical stimulation can take the form of Faradism. or Interferential therapy. 
Faradism involves the passage of a low frequency current of bearable but sufficient 
strength to stimulate the levator ani muscles of the pelvic floor. Two electrodes are 
used, one placed over the sacrum and a second placed on the permieum or in the 
vagina. 
Alternatively interferential produces a low frequency stimulating current by the 
passage of two cross firing medium frequency currents applied from different 
directions. The point of maximal stimulation is the peak intersection of these currents 
and this produces a contraction of the muscle. Four electrodes are usually used, two 
attached to the abdomen and two to the adductor muscles of the thigh. This technique 
is thought to allow a greater degree of stimulation of the designated muscle group. 
The aim of treatment is to re-educate awareness of muscle contractility and increase 
muscle tone. 
Sand et al (1995) conducted the first prospective randomised, double blind, placebo 
controlled trial of transvaginal electrical stimulation with no adjunct strength training 
to treat GSI 16 . There was also a 
32% cure/improvement rate on pad testing in the 
control group, demonstrating a significant benefit from the placebo devices. They 
compared the use of an active pelvic floor stimulator with a sham device over 15 
weeks. Significant improvement in pelvic floor muscle strength and GSI were found 
in the women using active devices but not in controls. Pad testing showed that stress 
incontinence was improved by at least 50% in 62% of patients using an active device 
compared with only 19% of women using a sham device (p = 0.01). Voiding diaries 
also showed at least 50% improvement in 48% of active-device patients compared 
J 4Q 
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with 13% of women using a sham device (p = 0.02). Probably one of the most 
limiting factors in the use of electrical stimulation is the high incidence of side effects. 
No irreversible adverse effects were noted in either group but 50% experienced side 
effects With the active stimulator including vaginal irritation, pain, vaginal infections 
and UTIs. 
MAXEMLAL AND LONG TERM STIMULATION 
The underlying principle is the stimulation of a sustained contraction of the urethral 
and periurethral striated muscles by vaginal or rectal electrodes to increase urethral 
pressure. Stimulators consist of a battery operated portable pulse generator connected 
to a vaginal or anal plug electrode (Figure 2.4). 
Ono"" 
Figure 2.4 Pelvic floor electrical stimulators with vaginal and anal probes. 
In conditions with incompetent urethral closure mechanism, long term stimulation on 
a daily basis with a programmable stimulator appears to give the best efficacy. 
Despite its use for over two decades maximal electrical stimulation has still not 
achieved widespread approval. Improvement rates with electrical stimulation vary 
widely from study to study and with the same device. Improvement rates varying 
17 from 35% to 70% and cure rates ranging from 0% to 50% have been reported 
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Practical points in the conservative management of GSI 
Pelvic floor exercises are useful in the treatment of many forms of 
urinary incontinence 
Motivation is the most important factor 
Patients require detailed assessment to optimise results 
Tailored exercise programmes give the best outcome 
Treatment takes 3-6 months to demonstrate improvement 
0 Exercises need to be continued long terin to maintain any benefit 
Table 2.5 Practical points in the conservative management of GSI. 
In a proportion of women, incontinence is intractable and the aim of management is to 
mifflmise the severity of the problem and render her socially continent. This may be 
achieved with the use of absorbent pads, pants and indwelling catheters. Toileting 
aids which may enable continence, such as hand-held urinals, commodes and toilet 
adaptations are used. Table 2.5 illustrates some practical points III the conservative 
management of GSL 
SURGICAL MANAGEMENTOF GSI 
Continence surgery is warranted when conservative measures fail or when definitive 
treatment is indicated. Surgery carries a risk of morbidity and mortality which should 
not be overlooked. It is also used to correct a urethral diverticulum, stricture, fistula 
or congenital abnormality and severe refractory urethral incompetence. 
Black and Downs (1996) have made some disturbing observations in their relatively 
recent systematic review of eleven randomised controlled trials, 20 non-randomised 
trials/prospective cohort studies and 45 retrospective cohort studies 18 . 
The objective 
of this review was to determine the methodological quality of studies evaluating the 
effectiveness of surgery for GSI and the frequency of complications associated with 
each procedure. They found that the methodological quality of the prospective 
studies reporting effectiveness of surgery was poor so it would be difficult and 
speculative to draw conclusions about efficacy and value of the different procedures. 
They found that there was inadequate case definitions, variations in how surgical 
procedures are undertaken, low external validity, ill defined outcomes with no 
evidence of the reliability and validity of measurements, lack of patient-perceived 
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outcomes regarding quality of life, insufficient statistical power and inadequate 
handling of confounding variables. Valid and reliable data on the frequency of 
complications following surgery were lacking, so the safety of the procedures was 
unclear. 
There is no prevailing agreement as to the surgical procedure of choice for women 
with GSI. Surgical procedures to remedy stress incontinence generally aim to elevate 
and/or support the urethro-vesical. junction, but there is disagreement about the precise 
mechanism by which continence is achieved (table 2.6) 19. The clinical guidelines 
panel of the American Urological Association recently analysed 457 articles on 
outcome data for potential benefits and risks of surgical approaches to treating GSI in 
women 20. The found that the currently available surgical literature regarding GSI 
demonstrated that after 48 months, retropubic suspensions and sub-uretbral slings 
offer greater chance of success than do transvaginal suspensions or anterior repairs. 
Surgical approach for the 
Treatment of genuine stress incontinence 
OPERATION WDICATION 
I. Anterior colpoffhaphy (combined with Significant uterovaginal prolapse, but 
Kelly or Pacey buttressing sutures) seldom the procedure of choice for 
Primary GSI. 
2. Marshall-Marchetti-Krantz procedure Primary or secondary GSI 
3. Colposuspension 
4. Long needle bladder neck 
suspensions, 
(Pereyra or Stamey) 
5. Sling procedures* 
6. Periurethral injectables 
Primary or secondary GSI 
GSI in the sUrgically difficult pelvis 
Severe recurrent GSI 
Surgically difficult pelvis 
7. Complex surgical procedures" Intractable recurrent urethral sphincter 
(e. g. artificial sphincter, neourethra) incom2etence - Table 2.6 Surgical approach for the treatment of genuine stress incontinence. ** Not 
available in our unit, * Not routinely performed 
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The success and adverse events associated with these procedures have been reviewed 
by Jarvis (1994) (Table 2.7)21. He showed that despite operator preferences, the 
current literature showed that no single procedure should be advocated for all women 
with genuine stress incontinence. Evidence would suggest that suprapubic procedures 
such as the Colposuspension have excellent subjective and objective cure rates, 
although are more often associated with side effects and surgical complications. 
Success rates of continence surgery 
Operation First procedure Recurrent incontinence 
(% continent) (% continent) 
Bladder Buttress 67.8 N/A 
Marshall-Marchetti-Krantz 89.5 N/A 
Colposuspension 89.8 82.5 
Endoscopic bladder neck 86.7 86.4 
Suspension 
Sling procedures 93.9 86.1 
Injectables 45.5 57.8 
Table 2.7 Success rates of continence surgery. [Jarvis (1994)] 
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ANTERIOR COLPORRHAPHY 
In comparison with abdominal surgery, the vaginal approach is simpler, resulting in 
less operative morbidity fewer complications and requiring a shorter in-patient 
hospital stay. Anterior colporrhaphy has been used to treat primary GSI in the 
presence of a cystourethrocele but whilst this is the best operation for the treatment of 
anterior vaginal wall prolapse, it is not the best treatment of GSI 21 . 
The technique 
involves an anterior longitudinal vaginal wall incision, mobilisation of the bladder 
neck and the insertion of Kelly or Pacey sutures to elevate the bladder neck, prior to 
approximation of the pubovesical fascia and closure of the vaginal Wall 22 23 (Fig 2.5). 
Figure 2.5 Stages in an Anterior Repair. 
COLPOSUSPENSION 
The colposuspension was described by Burch in 1961 and has since been modified by 
a number of different authors 24 . 
Indeed the Burch colposuspension is one of the most 
effective surgical procedures for the cure of GSI in women. No other operation has 
been demonstrated to work more successfully either in randonllsed or non-randomised 
comparisons 25 26 27 28 . 
Although it is normally performed through a low transverse 
suprapubic incision, recent attempts have been made to carry out laparoscopic 
colposuspension. The success rates are very good, but randomised trials with open 
surgery are awaited 29. 
Retropubic dissection is required to mobilise the bladder neck medially off the 
underlying fascia, prior to the insertion of two to four long term absorbable or non- 





Figure 2.6 Suture placement at colposuspension. 
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The complications of this procedure include operative blood loss, urinary tract 
damage and infection and the later problems of voiding difficulties, detrusor 
instability and enterocele or rectocele formation. 
It is important to be aware of the success rates of surgery locally. In a subjective and 
objective analysis of the results of 100 colposuspensions performed at King's College 
Hospital (1996-1997), a subjective cure rate of over 90% and objective urodynamic 
cure rate of over 80% was found 9 months after surgery (Cardozo unpublished data), 
(Table 2.8). Cardozo et al (1999) also reported the outcome of colposuspension in 52 
women who had previously undergone bladder neck surgery at KCH (Table 2.8) 30. 
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Analysis of 100 primary colposuspensions performed at King's College Hospital 
and 52 performed as a repeat operation 
A. Cure rate 
Assessment All Cases First Repeat 
Operation Operation 
Objective (Cystometry and 82% 91% 78% 
Videocystourethrography) 
Subjective (Symptom 81% 93% 80% 
Analysis) 
B. Improvement rate 
Assessment All Cases First 
Operation 
Objective (Cystometry and 91% 93% 
Videocystourethrography 
Sub ective (Symptom 90% 96% j 
Analysis) 
Table 2.8 Analysis of 100 colposuspensions performed at King's College Hospital as 
a primary procedure and 52 women having repeat surgery. ( (1991-1992) (Cardozo, 
unpublished data)) * Cardozo et al 1999. 
NMRSHALL-MARCHETTI-KRANTZ 
The MMK procedure (Marshall, Marchetti & Krantz, 1949) is the predecessor of the 
colposuspension. It involves the insertion of sutures between the paravaginal fascia 
on either side of the bladder neck and the penosteum of the pubis (Figure 2-7) 
Figure 2.7 Suture placement during a Marshall, Marchetti & Krantz procedure. 
Although this is a very successful operation for the treatment of GSI, it does not treat 
anterior vaginal wall prolapse and osteitis pubis may be a post-operative problem 
occurring in about 5% of cases 
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ENDOSCOPICALLY GUIDED BLADDER NECK SUSPENSION 
Many different endoscopically guided procedures have been described and utilise two 
nylon sutures passed blindly from the paravagmal fascia to the rectus sheath or vice 
versa. 
/ 
Figure 2.8 Suture placement during an endoscopically guided procedure. 
They are easier to perform than procedures in the surgically difficult pelvis where 
recurrent surgery has made the usual anatomical landmarks less discernible. The cure 
rates are less than that following colposuspension or MMK. 
SLMGS 
These procedures are advocated for the treatment of recurrent GSI especially where 
there is limited mobility of the anterior vaginal wall and bladder neck and a deficient 
urethral sphincter 
Ak 
Figure 2.9 Sling. 
The sling can be fashioned from organic material, strips of the patients own rectus 
sheath or fascia lata or inorganic material such as Mersilene or Goretex. Cure rates 
appear to be high, however, complications including voiding difficulties are common 
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following these operations sometimes requiring clean intermittent self-catheterisation 
indefinitely 
PERIURETHRAL INJECTIONS 
Periurethral injections of bulking material have been used extensively in treating 
women with GS, 32. Injections of bulk-enhancing agents in the periurethral tissues 
with its simplicity, low morbidity and repeatability have been suggested as an 
alternative to classical surgical approaches particularly for patients who are poor 
candidates for open surgery 33 . The 
bulking of the proximal urethra is thought to 
improve the urethral seal by reapposition of the urethral mucosa. Published reports 
have shown a 60-90% early cure and improvement rateS34 . These 
figures seem to 
decrease with time and repeated injections may be necessary to produce a long-term. 
satisfactory result. 
COMPLEX PROCEDURES 
(RESTORATION OF OUTLET RESISTANCE) 
When repeated attempts have failed to restore outlet resistance in severe GSI insertion 
of an artificial sphincter or the construction of a neo-urethra is indicated. These 
complex surgical procedures have an accordingly high morbidity and are usually only 
performed in specialist centres. 
PHARMACOLOGICAL TREATMENT 
Phannacotherapy using drugs, which increase outlet resistance, has been advocated in 
the treatment of stress incontinence. The nerves of the bladder and urethra arise from 
both the somatic and autonomic nervous systems. Somatic Innervation is mediated 
through the pudendal nerve. Autonomic nerves supplied via the pelvic plexus provide 
both sympathetic and para-sympathetic innervation. Alpha-adrenergic receptors are 
most prominent at the urethrovesical junction and along the length of the urethra. 
Stimulation results in smooth muscle contraction and an increase in the maximum 
urethral closure pressure. It is this relationship, along With finding of oestrogen 
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receptors III the bladder, urethra and surrounding tissues, which are the foundations 
for the various pharmacotherapies. 
PHENYLPROPANOLAMINE 
Phenylpropanolamine hydrochloride (PPA), a pure alpha-adrenergic stimulator has 
been used in the treatment of stress incontinence. Descriptive studies have reported 
beneficial effects on stress incontinence and in comparison studies consistently 
positive treatment effects have been noted. Overall however it has been shown that 
not only are the results modest in the treatment of stress incontinence but may have 
considerable side effects. 35 
OESTROGEN THERAPY FOR STRESS INCONTINENCE 
For continence to exist a positive urethral closure pressure is produced by the four 
functional layers of the urethra; namely the epithelium, connective tissue, vascular 
tissue and muscle. All these layers are affected by oestrogen status 3637 . These 
accounts as well as the epidemological data indicating that urinary incontinence is 
particularly prevalent among older post menopausal women have led to the 
hypothesis that the lack of oestrogen is a factor in the development of urethral 
sphincter incompetence and bladder dysfunction. An extension of this is that 
oestrogen replacement may be of value in the treatment of genuine stress 
38 
incontinence . 
Oestrogens may aid continence by increasing urethral resistance, 
raising the sensory threshold of the bladder, increasing alpha receptor sensitivity in 
the urethral smooth muscle, or possibly by a combination of all three. In addition 
oestrogen therapy has been shown to increase the number of intermediate and 
superficial cells in the vagina of postmenopausal women and similar changes have 
3940 been demonstrated in the urethra and bladder Urodynamic testing has also 
shown that variations in oestrogenic states influence urethral closure pressure urethral 




In a randomised, placebo-controlled, double blind trial, Fantl et al (1996) assessed 
the efficacy of cyclical conjugated oestrogens (0.625mg) and medroxyprogesterone 
(10mg) cyclically for 3 months in treating urinary incontinence 42 . 
Eighty-three 
159 
hypoestrogenic women with evidence of genuine stress incontinence and/or detrusor 
instability were included. They concluded that therapy did not affect either clinical or 
quality of life variables of incontinent, hypoestrogenic women. 
However, Sartori et al (1995) managed thirty postmenopausal women with genuine 
stress incontinence but without detrusor instability 43. They used conjugated 
estrogens and progesterone for 3 months but without a control group. Forty-six 
percent of women were judged to be cured and 43% markedly improved. Maximum 
urethral closure pressure, maximum cystometric capacity and mean flow were 
significantly increased. Residual urine and diurnal and nocturnal voluntary 
micturition. were markedly decreased (p< 0.05). 
Fantl et al (1994) applied a meta-analysis to available data to evaluate the efficacy of 
oestrogen therapy in the management of postmenopausal women with urinary 
incontinence 44. They found an overall significant effect of oestrogen therapy on 
subjective improvement for all subjects (p <0 .0 1) and for subjects with genuine stress 
incontinence alone (p < 0.05). The results showed no significant effect on quantity of 
urine loss but a significant effect (p < 0.05) on maximum urethral closure pressure. It 
would appear from this analysis that oestrogen subjectively improves urinary 
incontinence in postmenopausal women. However, the studies included 
nonhomogeneous groups, and the diagnostic criteria, therapeutic interventions, and 
outcome assessments vaned considerably. 
Sultana and Walters (1994) reviewed the efficacy of oestrogen therapy for urinary 
incontinence by examining published trials and to review the epidemiological and 
physiologic evidence for its action 45 . Eight controlled and 
14 uncontrolled 
prospective trials were identified. All types of oestrogen treatment and outcome 
measurements were included. They concluded that the published trials did not 
support oestrogen replacement as efficacious therapy for stress urinary incontinence. 
It may however, be useful for incontinence associated with urgency and frequency. 
CONCLUSION 
The comer stone of effective management is making an accurate diagnosis of the type 
and cause of incontinence. The overall effect is seldom the result of a single 
underlying factor, so a thorough evaluation is vital. Management depends on the 
health and expectations of the sufferer, her misery and disruption to her quality of life 
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as well as the clinical findings. Urinary symptoms are remarkably unreliable and 
there is often a discrepancy between urinary complaints and the results of diagnostic 
tests. Hence, urodynamic investigations may be necessary. Other pelvic pathology 
may be present and must be actively sought and treated as incomplete therapy or 
therapy for these pelvic disorders at a future date may be detrimental to previously 
successful management of incontinence. 
Pelvic floor exercises are a non-invasive and safe method of treating stress 
incontinence. The treatment takes 3-6 months to be effective and must be maintained 
long term. Patients who tend to have a more successful outcome following PFEs are 
younger, better motivated, have a shorter duration and lesser degree of GSI and have 
not undergone previous pelvic surgery. It is important to recognise that improvement 
in symptoms rather than an absence of incontinence episodes is the more common 
outcome reported in non-surgical studies and this ought to be anticipated. 
Physiotherapeutic adjuncts require additional equipment and costs and do not appear 
to be clearly better than conventional PFE's. Support is essential for women to cope 
with their problems and periodic review to assess a change in the clinical picture or 
the possibility of a new therapeutic option is essential. Community services are now 
more readily available than before and a great deal of help can be given which enables 
an older person to remain at home. It is hoped that this is one area in which devices 
may be of benefit to this age group. 
The need for secondary specialist referral is quite clear in most cases. Women 
should be referred if initial conservative therapy fails after a reasonable trial of at least 
6 months. Referral may also be indicated in women with concurrent gynaecological 
problems such as uterovaginal prolapse or menstrual dysfunction which require 
treatment or in cases of recurrent incontinence following surgery. Urodynamic testing 
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CHAPTER THREE 
QUALITY OF LIFE AND 
IMPACT OF URINARY INCONTINENCE 
AA 
EFFECT ON HEALTH 
Loss of urinary control Is a distressing and disabling condition causing significant 
morbidity within society. It affects the social, psychological, occupational, domestic, 
physical and sexual lives of 15-30% of women of all ages 1. Sufferers give up many 
aspects of their usual lifestyle with obvious detriment to their social interactions, 
interpersonal and sexual relationships, careers and psychological wellbeing. 
Activities such as household chores, physical recreation and hobbies are often 
particularly affected and a new way of life organised around the location of toilets and 
the avoidance of potentially embarrassing situations develop. 
Incontinence also has a social stigma in that women may severely restrict their 
activities due to fear of urine loss and concerns about odour in public 2. Many factors 
affect the perception of incontinence as a significant health problem including, 
culture, diagnosis, race, social class, marital status, sexual problems, duration of 
symptoms and the severity of the urinary leakage. 
Norton et al (1988) M their study of women referred for urodynarnic assessment 
found sigmficant delay from the time the urinary symptoms first become troublesome 
until a general practitioner's advice was sought 3. Two fifths of women consulted a 
doctor within one year of symptoms becoming troublesome. A third delayed for I-5 
years and a quarter waited more than five years. The most frequently reported 
restrictions on their daily life were avoidance of fluids and the need to wear pads. 
They were less able to carry or lift as part of their daily activities, avoided public 
transport or going far from home. More than half of the women felt their urinary 
problems affected their work. They very often felt odd and different and less 
attractive because of their symptoms and would avoid other people. The study also 
highlighted the fact that up to 50% of adult women with urinary incontinence avoid 
sexual activity through fear of leakage. 
An equally distressing finding is that many women who do tell their doctor about 
their urinary symptoms are told either to live with them, or briefly instructed to do 
pelvic floor exercises without training or explanation. Often patients do not benefit 
from this advice reinforcing the belief that little can be done to help their incontinence 
and spreading this pessimistic outlook to their friends and relatives. 
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IMPACT ON MENTAL HEALTH 
Serious psychiatric morbidity has been reported in 25% of women attending a 
urodynamic assessment clinic 4. The psychological effects of urinary incontinence 
can be more devastating than the social and health consequences. Many women, 
particularly older patients suffer intense embarrassment, loss of self-esteem, 
depression, anxiety and feelings of helplessness, all of which contribute to reluctance 
5 to stray far firom toilet facilities and to withdraw from social contacts . Psychosocial 
problems and urinary incontinence thus appear to be related although it Is unclear 
whether psychological distress is a result or a cause of lower urinary tract dysfunction. 
Research would suggest that, for the majority of women, the former is true as both the 
objective and subjective severity of urinary incontinence correlate significantly with 
the degree of psychological disturbance 6. 
SEXUAL PROBLEMS AND URINARY INCONTWENCE 
Sexual dysfunction is a common cause of morbidity amongst incontinent women and 
as such demands particular mention. There are many reasons why urinary 
incontinence and sexual dysfunction are associated apart from the close proximity of 
the urinary and genital tracts. Many incontinent women are embarrassed or ashamed 
of their condition and studies have shown that incontinence can result in deterioration 
in women's interpersonal relationshi PS 7. Lack of libido and dinunished self esteem 
due to a fear of leakage are major factors, however urinary leakage during penetration 
or at orgasm, as well as dyspareunia secondary to urine dermatitis or incontinence 
surgery, play a major roll. 
Over fifty per cent of sexually active incontinent women suffer sexual dysfunction as 
a result of their urinary symptoms and one in four are incontinent during sexual 
intercourse. Long-standin urinary symptoms and sexual difficulty are however, a 9" 
source of appreciable morbidity and can, once established become incorporated into 
an individual's lifestyle and personality. This may have major implications for the 
management of incontinent women, as the successful treatment of lower urinary tract 
symptoms may not necessarily improve their sexual dysfunction. 
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ECONOMIC ISSUES AND URINARY INCONTINENCE 
Studies of the economic impact of urinary incontinence are scarce, primarily because 
of the varying results of prevalence studies, the absence of reliable risk factor analysis 
and cost data and wide diversification of treatment strategies. Most of the available 
data has been collected in the United States of America and has focused on the cost of 
caring for incontinent people in nursing homes. Health care costs of urinary 
incontinence in the USA and Sweden account for about 2% of the national health care 
budgets and Hu et al (1994) estimated cost of managing incontinence in the USA 
grew from $8.1 billion to $10.3 billion 9 10. These studies highlighted the direct and 
indirect costs of unnazy incontinence. Direct costs include those required to diagnose, 
treat, care for and rehabilitate incontinent patients. Indirect costs include lost 
productivity of patients and unpaid carers and other expenses due to ill health. Based 
on multiple assumptions regarding incontinence prevalence rates and cost 
information, the entire economic cost in 1984 of urinary incontinence was $8.1 
billion; $6.6 billion direct costs and $1.5 billion indirect costs. Costs incurred by 
nursing homes, which were all direct costs, totalled $1.8 billion which represented 
about 10% of nursing home expenditure. 
The exact financial cost of incontinence in the UK is unknown The health care 
costs when transposed to the UK population are thought to be similar and equates to 
f 1.4 billion per annum for our population of 56 million. It has been estimated in 1991 
that the NHS spends E56 million per year on continence products, of which f36 
million is spent on absorbents, mostly disposables and f20 million on devices 12 
The direct cost of pads and appliances used in UK hospitals and long-term care 
facilities in 1986 was over f50 million, with a further f 18 million in prescription 
items in England and Wales 13 . 
These costs are simply for the containment of urinary 
incontinence. 
Financial constraints within an already over-utilised and under-funded health service 
have introduced the need for effective cost utility analysis, resource allocation and 
"needs assessment". The economic burden of continence care is considerable but 
difficult to accurately quantify. Whether the investigation and treatment of urinary 
incontinence actually decreases the economic burden of Urinary incontinence is 
unproven but likely to be the case. Ouslander and Kane (1983) showed that active 
evaluation and treatment of nursing home residents resulted in considerable cost 
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savings 14 . Irrespective of direct financial incentives, the effective treatment of 
urinary incontinence considerably improves the quality of life of sufferers; the cost of 
which is difficult to quantify. 
AGE AND URINARY INCONTINENCE 
Although urinary incontinence is not specifically a condition of the elderly, several 
small scale studies have reported the commonly held belief that incontinence is a 
normal part of ageing- A study by Gjorp (1987) found that 72% of a sample of 79 
elderly women with genitourinary symptoms felt them to be normal for elderly 
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people 
Norton et al (1988) have shown that elderly women tend to present later for the 
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assessment and treatment of urinary incontinence . This may be due to a greater 
tolerance of urinary symptoms or the reluctance of doctors to refer elderly women for 
urodynamic assessment. Mitteness (1987) and Simons (1985) have shown that a 
substantial number of incontinent women are told that there is little that can be done 
17 18 to help their incontinence and that it is a normal part of ageing . Jolleys (1992) in 
a national study found that many doctors felt their knowledge and training M the 
management of incontinence to be inadequate and many felt unable to satisfactorily 
manage and advise incontinence sufferers 19. These findings may explain this 
erroneous advice. 
Although older women present later for the assessment and treatment of urinary 
problems, there is insufficient evidence to support the assumption that their urinary 
symptoms are less troublesome. It is possible that in the study by Norton et al (1988) 
the earlier presentation of younger women reflects a greater knowledge about 
incontinence and its treatment as neither the symptom seventy nor diagnosis affected 
presentation to the same degree 3. It is also possible that urinary incontinence may 
affect the young and old differently. Longevity of suffering however undoubtedly 
results in a modification of lifestyle and adaptive change and it is likely that this too 
plays a major role in determining the qual-ity of life impairment of sufferers. It is 
conceivable that young patients are more often able to modify their lifestyle and cope 
with physical disability than their older counterparts. 
Little is therefore known about the effect of age on the subjective seventy of urinary 
incontinence. Although it is likely that the young and old respond differently to 
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incontinence and that young patients are now better educated and less likely to 
tolerate this unacceptable departure from health than their older counterparts, these 
issues have never been adequately resolved. 
HISTORICAL PERSPECTIVES 
'QUALITY OF LtFE, WHAT IS TO BE MEASURED? 
There is no consensus definition of quality of life or indeed subjective health status. 
Subjective health status or health related quality of life has come to mean a 
combination of patient assessed measures of health including physical function, social 
function, emotional or mental state, burden of symptoms and sense of wellbeing. 
Health related quality of life (HRQL) is a multidimensional construct that refers to an 
individual's perception of their state of health or disease and its subsequent treatment. 
Primary domains of HRQL include physical, psychological and social functioning, 
overall life satisfaction/wellbeing and perceptions of health status. Secondary 
domains include somatic sensations (symptoms), sleep disturbance, intimacy and 
sexual functioning and personal productivity (e. g. household, occupational, volunteer 
or community activities). The term is influenced by a broad spectrum of human 
experiences including diseases, accidents, treatments, interpersonal relationships and 
social support. Until relatively recently however, the severity of physical conditions 
and the results of treatment were measured in terms of death, disability or cure. It is 
however recognised that a patient's quality of life and psychosocial. adjustment to 
illness are equally important as the status of their physical disease and the success of 
treatment can no longer be measured in terms of clinical parameters alone (table 3.1). 
Dimensions of interest in 
Quality of life assessment 
Physical function: e. g. mobility, self care, exercise 
Emotional finiction: e. g. depression, anxiety, worry 
Social function: e. g. intimacy, social support, social contact, leisure 
activities 
Role perforniance : e. g. work, housework, shopping 
Pain 
Sleep / fatigue 
Disease snecific svmDtoms 
Table 3.1 The major dimensions of interest in QoL assessment 
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APPLICATIONS OF QUALITY OF LIFE MEASURES 
QoL questionnaires have many different applications (Table 3.2). QoL data have 
been shown to be better than conventional measures for the prediction of long term 
outcome in certain medical conditions. QoL measures for example have been shown 
to more accurately predict morbidity and mortality for patients with rheumatoid 
arthritis than conventional clinical parameterS2021. 
Applications of quality of life measures 
Screemng and monitoring for psychosocial problems in inchvidual 
patient care 
Population surveys of perceived health problems 
Medical audit 
Outcome measures in health services or evaluation research 
Clinical trials 
Cost utility analysis 
0 Anadjunct to the clinical interview. 
Table 3.2 The applications of quality of life measures. 
SUNUM"y 
Over the last few decades, interest in the incorporation of patient assessed health 
status measures into the evaluation of medical care has increased. Several studies 
have shown that clinicians' and patients' judgements of quality of life differ 
substantially. This has increased recognition of the patient's view as central to the 
assessment of disease severity and evaluation of medical care. Functional status and 
well being are both highly valued by patients and are therefore essential outcome 
measures. This view has brought with it a multitude of approaches for the 
measurement of subjective well being. In an attempt to understand the plight of the 
incontinent population and the efficacy of our therapeutic interventions, quality of life 
assessment is however intuitively appealing. Not only would it allow us to quantify 
the distress caused by this condition but also enable us to understand how lives are 
affected, adaptive changes are made and what are the benefits of therapeutic 
intervention. As the primary goal in health care is to maximise function in everyday 
life and to achieve the highest possible level of well being for patients, some method 
by which to assess this goal is required. As outcome measures these would be of 
7'1 
great benefit when comparing treatments such as aids to continence with little 
apparent difference in clinical outcome but, where by methodology or limitation of 
side effects, they confer benefit over standard and accepted techniques. Generic and 
disease specific quality of life questionnaires and their use will be elaborated in the 
chapter on outcome measures. 
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REVIEW OF THE LITERATURE 
ON CONTINENCE DEVICES AND AIDS 
Impressions about individual conditions such as urinary incontinence - how common 
they are, what course it follows, how successful treatment is - are largely formed on 
the basis of clinical experience. Such a perspective is inevitably too restricted to be 
used to draw general conclusions. Before undertaking to provide a new service such 
as the use of continence devices or making adjustments to existing services concerned 
with continence aids, those involved with the management of female urinary 
incontinence must have an accurate picture of the safety and efficacy of such devices. 
There is no single source which provides all the information needed on continence 
devices. We can piece together information from different sources, the different types 
of devices with a common purpose and to which differing levels of importance are 
attached so as to gain a composite picture. I have looked at information and data 
collected and analysed in other studies describing the results of the Reliance and 
FemAssist and other continence devices as a valuable source to measure the clinical 
value of these aids to continence. This will also permit interpretation of the results of 
this trial in relation to the findings of other authors experimenting with the same or 
similar aids to continence. 
PRODUCTS FOR INCONTINENCE 
In the directing of continence and toileting aids provided by the Association for 
Continence Advice over 3,000 products are marketed by over 100 companies'. 
Cottenden (199 1) in a review of aids and appliances found that there is very little 
research on which to base decisions on the choice of products and of the few trials 
which have been published, a high proportion are methodologically unsound 2. 
MSTORICAL PERSPECTIVE 
For centuries women have relied upon mechanical devices to control urinary leakage. 
Court ladies at Versailles had strategically placed Limoges porcelain "gravy boats" 
hidden under their elaborate gowns 3. Edwards (1975) reported that ancient Egyptian 
papyrus writings made reference to the use of external Urine continence devices for 
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women 4. Edwards also noted that Hypocrites suggested inserting a finger Into the 
vagina to support a defective bladder neck mechanism and thus prevent incontinence. 
Female devices were often occlusive and designed as a gold phallus-type structure 
which was placed intra-vaginally and potentially relieved stress incontinence. 
Continuous wear devices were probably not considered until rubber was 
manufactured. Early continuous-wear devices were in the shape of a wide-neck 
rubber funnel that completely enclosed the vulva and was firmly attached to the body 
with a support belt. Some had flannel walls and a steel spring wire which prevented 
the device from collapsing from the pressure of the thighs '. Modifications were 
made to the funnel so as to prevent crushing when the wearer was seated and to 
prevent excessive pressure on the perineum. 
Since the discovery of rubber, many materials have been invented that tend to be 
both non-irritating and rugged. Medical grade latex and silicone have FDA approval 
for human use. They are soft and durable. These products are cost effective and have 
been used for condoms and indwelling catheters. Beyond biocompatability concerns, 
material selection is generally a manufacturing issue. 
APPLICATION 
Continence aids tend to be applied either over the labia or placed between the labia 
minora. Either form may be designed with or without a vaginal locator to help 
position and secure the device. 
Terman (1964) and Fielding and Wells (1975) described devices that cover the labia 
and have a vaginal locator 67 . Terman 
invented a single-piece structure device that 
has a front section covering the labia and lower abdomen, a urine-receiving section 
and flexible drainage. It curves posteriorly to insert into the vagina. Fielding and 
Wells, who are nurses, tested a cup-shaped device that covers the labia, had a vaginal 




Figure 4.1 Fielding and Wells device (1975) 
These products would be relatively easy to apply since only the vagina must be 
located, not the urethra. Twelve elderly patients wore the device for 2 to 10 days and 
ill-defined success in urine collection was reported to range from 0 to 92 per cent of 
applications. During testing, Fielding and Wells (1975) noted that the device caused 
pressure markings and erosion of the soft tissue of the vulva. The nursing staff 
expressed reservations about the appearance of the device and the placement of the 
vaginal locator. The authors concluded that the device was unsuitable for elderly 
patients. 
The Hollister Female Urinary Pouch (1986) is a one-piece system that encompasses 
the vulva but lacks a vaginal locator " (Figure 4.2). The mons pubis area is shaved, 
cleaned and dried. The genital area where the pouch will be applied is then wiped 
with a skin gel wipe. The vulval opening is measured and the synthetic skin barrier 
cut to fit the woman. 
The barrier has adhesive properties and adheres to the labla majora and perinewn. An 
adhesive tape helps to further secure it. The drainage pouch may be attached to 
drainage tubing. 
Other devices are positioned between the labia minora to surround the urethra. 
Breece's (1965) patent includes a circular ring which is placed between the labia 
minora to encompass the urethra 9. To help contain urine leakage, the ring is encased 
in a triangular support piece placed over the entire lower pubic area. 
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Figure 4.2 The Hollister Female Urinary Pouch (1986) 
FEMEX, (1982) was manufactured and marketed for a short time 10. FEMEXý a 
small flexible umbrella-shaped device, was positioned midway between the clitoris 
and vaginal opening to surround the urethra and was held in place by a liquid 
adhesive for up to 24 hours. Women were to wear undergarments, cutting a small 
hole in the crotch and threading the catheter drainage tubing through it. 
MISSTIQUE (Michaud 1981) is ovoid and also fits between the labia 
minora It is held in place by a silicone sealant and suction (Fig. 4.3). Suction is 
created by a vented one-way valve that allows urine to drain and prevents the return 
flow of urine from the collection unit. Women may purchase panties and panty liners 
with holes to accommodate the drainage tube. 
Figure 4.3 MISSTIQUE (Michaud 1981) 
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A modification of the placement of a device between the labia minora was made 
from Blackmon's patent (1984) 12 . The Blackmon device is placed between the labia 
majora; the labia m-inora are positioned inside the drainage opening (Figure 4.4)). 
Figure 4.4 Blackmon's patent (1984) 
Some devices placed between the labia also include a vaginal insert. This is true of 
the earliest U. S. patent awarded for a continence aid. The Williams (1949) patent 
consisted of a cylindrical hollow tube that was positioned into the vagina and a 
13 - faceplate that rested against the labia (Figure 4.5) . Urine was to 
flow back to the 
tube and drain to a collection bag. The faceplate was held in place by a suspensor belt 
to the waist, much like Breece's. 
Figure 4.5 The Williams device (1949) 
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Michaud (198 1), working for National Aeronautics and Space Administration, 
received a patent for a device that fit between the labia and had a vaginal insert to 
help position it and prevent Unne flow into the vagina (Figure 4.6). The device 
included a body of %Nricking matenal to absorb unne before leakage and thus move 
unne away from the skin. This patent was received when women were actively 
involved in the space program. 
Figure 4.6 Michaud device (1981) 
Products placed between the labia require that a woman has some degree of lower 
limb flexibility since the urethra must be located for proper placement. A woman's 
dexterity, vision and comfort in touching the genitalia will affect its usability. Its use 
also depends on health care personnel to teach the woman the necessary skills to place 
the device correctly. 
Johnson et al (1989) evaluated an extemal unne collection device, analogous in 
function to the condom catheter for men 14 . The 
device utilises an adhesive similar to 
that used on ostomy appliances and is positioned onto the patient so that the urethral 
meatus, vaginal introitus and labia are contained within the opening. The device is 
designed to funnel Urine through a connecting tube into a bedside collector. The 
median device wear time was 48 hours in the 7 patients (63 applications of the device 
for 125 patient days). Through 24 hours of continuous use, only 8 of 63 devices 
(13%) leaked urine and only 2 of those were in sufficient quantity to require 
replacement. At 48 hours, only 9 of 63 devices (14%) required replacement due to 
unacceptable urine leakage. 
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A continence device should be suitable for both day and night use as well as for 
bedfast, sedentary and active women. Some devices have included suction 
equipment, which may limit use with very active women. Urovac (Keane, 1971) for 
example, consisted of a suction head that was placed over the labia majora, a 
corrugated suction tube that ran from the suction head to the urine container and a 
clear plastic breather tube that provided a constant flow of air into the suction head so 
that the vacuum applied to the tissue remained very low 15 . The airflow also 
dried the 
tissue after urination. Urovac, was held in place by accurately fitted, light elastic 
shoulder straps. It was designed to be worn by the woman in bed to remove postural 
diuresis, thus promoting rest. The device, however, is not commercially available. 
Crowley et al (1971) introduced a device called the vestibulo-vaginal insert. It used 
suction to produce a seal between the periurethral tissues and the suction disc of the 
collection device (Figure 4.7) 16. The insert was made of inert plastic. To prevent 
irritation and oedema of the urethra as a result of suction, a fine protective netting 
covered the suction disc. The vaginal piece of the device had a canal to drain 
secretions. Principles of physics governed the suction in the device's inverted water 
bottles. 
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Figure 4.7 The vestibulo-vaginal insert (Crowley et al 1971) 
The device was tested on 54 women, aged 15 to 70, who had normal bladder function 
and had delivered at least one child. The women wore white briefs that were 
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inspected for leakage of urine. Three individuals had leakage of 2-3ml of urine; the 
other women were completely dry after urinating. The number of voidings vaned 
from I to over 10 per individual; the average urine excreted was 250 ml. The authors 
reported that there was no periurethral oedema or infection. They stated that the 
device was comfortable to wear, unobtrusive and free from side effects; in addition, 
some women were able to sit, stand and walk with it in place. 
Patents for devices generally state that it can be wom by active or bedfast women 
unless the product is designed as a female urinal. Female urinals are held in place and 
lack a support belt or adhesive. For example, Hall (1976) patented a disposable 
female urinal that enabled a woman to void in a lying or sitting position 17 . 
The 
device resembled an open duck's bill. It was placed between the labia with one sup- 
like projection positioned in the vagina; the other, around the urethra. The drainage 
receptacle was attached. 
Li (1977) invented Sanifem, a trough-shaped device to facilitate urination when a 
woman is "exposed to weather, insects or unsure footing" as an "answer to wilderness 
restroom problems" 18 . 
There are also female urinals that resemble male urinals, for 
example, Viscots "Millie" the Urinal. 
Edwards and Malvern (1973) developed and evaluated a device that controlled 
urinary incontinence by applying pressure on the urethra. '9 They reported a poorly 
defined success rate of 69 per cent. 
Linden (197 1) developed a funnel-shaped device held in situ by a pessary 20 . The 
report of this device is limited to statements that the device worked well with the 
patient in the standing, sitting or lying positions and did not impede walking. There 
was no detailed information about device effectiveness or adverse reactions. 
To our knowledge none of the devices described in the literature currently are 
available commercially. Results from this preliminary evaluation suggest that 
external urinary incontinence devices held in situ by adhesive similar to that used on 
ostomy appliances may provide a useful alternative to other methods of long-term 
management of urinary incontinence in non ambulatory women. Additional studies 
R3 
for longer, more clinically relevant periods appear to be warranted. Once long-term 
efficacy is established the impact of external device use can be investigated. 
PADS 
For some women the provision of incontinence aids will be necessary. Absorbent 
incontinence products are not prescribable and are therefore obtained through the 
community nursing services. The cheapest pads are usually the least effective and 
often prove to be a more costly long-term option. There are many different types of 
product available and a careful assessment of both the severity of the incontinence 
and the needs of the patient are required prior to selecting the most appropriate pads. 
Pads are usually in close fitting pants but in cases of slight incontinence, the patient's 
own underwear is adequate and often more comfortable. 
Patients living in their own or residential homes who require absorbent products may 
be supplied by their Health Authority (HA). The HA has discretionary powers to 
provide "in the light of local needs and circumstances". Each may determine its own 
budget and criteria for supply. In practice there are great variations between areas. 
HAs must supply to people in residential homes on the same basis as they supply to 
people in their own homes. Social services are responsible for purchasing pads for 
people they have placed in nursing homeS21 . The Department of Health has 
suggested that a good service may actually decrease costs and recommends that there 
should be no changes in supply without an assured alternative being in place, so as not 
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to leave vulnerable individuals without supply 
CATHETERS, COLLECTING DEVICES AND BED ALARMS 
Some women are managed in the community with either an indwelling urethral or 
suprapubic catheter or by means of clean intermittent self-catheterization (CISQ. 
The most common indications for catheterization are acute and chronic retention, 
postoperative bladder drainage, the neuropathic bladder and intractable urinary 
incontinence (Figure 4.8). 
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Figure 4.8 Urine bags 
An indwelling urethral or suprapubic catheter is the most commonly used method. 
Long-term urethral catheterization has the drawback of discomfort, urethral traurna 
and a high incidence of symptomatic urinary tract infection by contamination from 
perineal flora. Suprapubic catheterization is often more comfortable, particularly in 
patients who are sexually active and the lower density of bacteria on the anterior 
abdominal wall results in fewer significant urinary tract infections 23 . In the short 
term catheterised patient clamping of the suprapubic catheter allows voiding per 
urethram, an advantage not shared by the urethral catheter. Women must be 
motivated and often have to catheterise themselves despite major neurological 
deficits, lack of perineal sensation, intention tremor and even blindness. Only through 
correct patient selection and detailed explanation of the technique is it likely to be 
effective. Most women can be taught as outpatients by a doctor or at home by a 
continence advisor or suitably trained nurse. They should be given clearly illustrated 
instructions on both catheter insertion and care. Sterility is not essential but women 
should be instructed to wash their hands and then wash or wipe clean the area around 
their urethral onfice prior to catheter insertion. The catheter should be washed in tap 
water and then either boiled for thirty seconds or left immersed in 0.0 16% sodium 
hypochlonte solution. 
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Plastic "lo fric" catheters are more rigid and easy to pass and last for about a month 
if kept in hypochlonte solution. Stainless steel catheters will last for years and are 
easily sterilised in a domestic oven. Severe adverse effects are uncommon although 
bleeding, false passage formation, urethral stricture and bladder calculi can occur. 
Overall, the technique is surprisingly acceptable and relatively free from side effects 
(Figure 4.9). 
Figure 4.9 Conveen EasiCath, a disposable catheter with a specially treated surface 
for better comfort in CISC. 
Whichever method is adopted, close supervision by a suitable trained district nurse or 
specialist continence advisor is required to avoid complications. 
For incontinent women, the design and attachment of external devices capable of 
collecting urine has been a continuing problem, although the incidence of bacteriuria 
appears to be even lower than that found with urethral catheters. 
ANALPLUGS 
Disorders involving the multiple systems in the pelvic floor are common. Women 
who suffer urinary dysfunction may also suffer faecal incontinence, as there is likely a 
common pathophysiology such as neuromuscular abnormalities and connective tissue 
damage. Products are also available for this condition and an anal plug has been 
described. This is illustrated below (Figure 4.10). 
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Figure 4.10 Anal plugs. 
CONTRACEPTIVE DIAPHRAM 
For many centuries numerous kinds of mechanical devices have been used for the 
control of incontinence in women. Among these non-surgical modalities, vaginal 
pessaries. and contraceptive diaphragms have been used commonly not only to relieve 
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vaginal wall prolapse and uterine descent but also symptoms of stress incontinence 
Contraceptive diaphragms can support the urethrovesical junction. Despite frequent 
relief of urinary incontinence observed with the use of the vaginal pessary, the manner 
in which a pessary restores continence is poorly understood. With a diaphragm in 
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place, studies have shown a significant reduction in the mean peak urine flow rate 
These studies have also demonstrated that the degree of outflow obstruction however 
is of a relatively small magnitude. Urethral profilometry with the diaphragm in place 
caused a marked increase in maximum urethral closure pressure. 
Suarez et al (199 1) have used standard contraceptive diaphragms successfully in the 
management of women with stress incontinence 26 . 
Realini and Walters (1990) 
performed a similar trial and found that diaphragms could produce a 40% response 
rate based on improvement in the outcome measures of pad weight test (PWT) gains, 
decreased number of weekly leakage episodes on urinary diary and subjective 
improvement Of Symptoms 27 - The studies by Realini and Walters (1990) and Suarez 
et al (1991) did not test for the treatment of exercise induced incontinence and most 
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studies have not examined the activity levels of women when reporting treatment 
success. Success rates may be lower if women participated in more provocative 
activities. In a prospective randomised study, Nygaard (1995) assessed the efficacy of 
two mechanical devices, the Hodge pessary and a tampon in the management of 
exercise-induced incontinence 28 . 
Eighteen women participated in 3 separate 
standardised 40-minute aerobics sessions. One group used Hodge pessaries, the 
second group used Tampax super tampons and the third group used no device. 
Assessments were made of urinary leakage based on pad weight gain at the end of the 
exercise session. All women voided and then drank 240 ml of water one hour before 
exercising. Four women remained continent during the control session (no device) 
despite reporting stress incontinence and a positive cough stress test at initial 
evaluation. Table 4.1 summarises the results for the PWT gains for the 14 women 
with incontinence during exercise. 
Efficacy of mechanical devices 
(Hodge pessary & Super tampon) 
Groups Pad weight gain(grams) Pad weight 
Before use gain(grams) 
After use 
Mean(range) Mean(range) 
Control 45.3 (4.1-140) ? 
Hodge Pessary 36.4 (0.2-256) ? 
Tamt)on 31.0 (0.7-137) ? 
Table 4.1 Pad weight gains without devices and with each of the two devices (n = 14) 
during standardised exercises. [Nygaard (1995)] 
Table 4.2 shows the success of each device in dealing with varying degrees of 
incontinence and with incontinence in general. 
Efficacy of each method 






All women 36% 58% 
Table 4.2 Success of each device in dealing with varying degrees of incontinence and 
with incontinence in general (n = 14). [Nygaard (1995)]. 
The devices were most effective in women with mild degrees of incontinence. 
Interestingly, the severity of exercise incontinence did not correlate well with the 
severity as judged by the cough stress test performed with a comfortably full bladder. 
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Overall comfort was reasonable with each device, but those who found the tampon 
uncomfortable (6) were different from women who thought the pessary was 
uncomfortable (4). The study did not address whether women can easily void with 
either device. A pad weight gain of <4. Og was considered to indicate clinical 
continence. This seems quite generous. Women can initiate treatment on their own if 
using a tampon which is an advantage over a pessary. However, the Hodge pessary is 
reusable and this is a significant cost saving. The precise aetiology of incontinence 
during exercise is unknown, and failure of the devices may be due to detrusor 
instability. However these devices are still useful without formal urodynamics 
SMITH-HODGE PESSARY 
The Smith Hodge pessary when used during urodynamic testing has also been shown 
to be simple, inexpensive and reliable for the evaluation Of urinary incontinence 
(Figure 4.11). It aids in the pre-operative selection of incontinent women suitable for 
continence surgery by simulating the anatomic results of surgery for GSI and may 
help to predict the successful outcome of surgical therapy 29 . 
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Figure 4.11 Hodge pessary 
Bhatia et al (1983) investigated the urodynamic effects of a Hodge vaginal pessary 
in women with GS, 30 . Following placement of the vaginal pessary, 
detailed 
urodynamic studies were performed on 12 women with GSL They demonstrated 
consistent and significant (p<0.005) increases in urethral functional length and 
urethral closure pressure under varying stressful conditions, when compared with pre- 
pessary studies. Clinically, 10 of the 12 women became continent with the device in 
place. There was no evidence of outlet obstruction based on uroflometry and pressure 
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flow studies. Post-pessary urodynamic alterations and Q-tip test changes provided an 
objective explanation that the vaginal pessary restored continence by stabilising the 
urethra and urethrovesical junction. This allowed proper pressure transmission and 
actively increased urethral resistance to escape of urine under resting and provocative 
conditions. 
INCONTINENCE RING 
Leong and Brubaker (1996) assessed the use of a modified intravaginal ring pessary 
to control leakage in women with stress incontinence 3 1. Thirty-six women were 
recruited but II found the device unsatisfactory. Of the remainder, patient symptoms 
were controlled satisfactorily in 69.4% of cases. No objective data on outcome 
measures of the efficacy of the ring were reported. 
A NEW INTRAURFTHRAL SPHINCTER PROSTHESIS 
WITH A SELF CONTAINED URINARY PUMP 
Devices have also been used successfully in women with chronic retention of urine as 
an alternative to intennittent self or long-term catheterization 32 . An 
intraurethral 
sphincter prosthesis with a self contained urinary pump for the management of the 
atonic bladder and intractable incontinence in women was developed and tested by 
Nativ et al (1997) 33 (Figure 4.12). The prosthesis is comprised of a short, self- 
retaining silicone catheter in which there is a valve and pump. Available in a range of 
lengths and diameters according to urethral size, its insertion is similar to that of a 
urethral catheter. The prosthesis is secured by a novel fixation method that has soft 
expandable silicone fins at the bladder neck and a flexible flange at the external 
meatus. A small hand-held control device activates it. To urinate, the activator is 
placed on the lower abdominal area and the "on" button is pressed, providing energy 
to the pump by a magnetic coupling method. Once activated, the valve opens and the 
pump rotates at a high speed, drawing urine from the bladder and pushing it forward, 
allowing the patient to "void" with a urine flow of 10 to 12ml/sec. When the bladder 
is completely evacuated the pumping ceases and the valve closes, restoring 
continence. 
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Figure 4.12 Intraurethral sphincter prosthesis with a self contained urinary pump. 
The device was evaluated clinically in 17 women. Fifteen of the patients had a range 
of use of 2 weeks to 16 months during which they were dry and had complete bladder 
emptying. Two patients did not tolerate the device because of uninhibited detrusor 
contractions and,, in both cases, it was removed without complication after 5 days. 
ADHESIVE PATCH 
North (1998) evaluated a disposable adhesive patch in the management of women 
with stress incontinence 34 (Figure 4.13). The device is formulated from polyurethane 
foam, backed with an adhesive made from poly-2-hydroxyethyl methacrylate and 
polyethylene. It is triangular in shape, with a protruding "fin" to facilitate placement 
and removal from between the inner labia. The device is designed to seal the urethral 
opening and prevent leakage utilising the adhesive. 
91 
Figure 4.13 Adhesive continence patch. 
Thirty-seven women used the device for 12 weeks. The study group included women 
with the primary symptom of mild to moderate stress incontinence. Overall leakage 
was reduced by 60% from 1.1 [± 0.3 SEMI grams/hour without the patch to 0.44 [± 
0.11 SEMI g/hour while using the device (p<0.05). With the patch in place urinary 
diaries showed that the number of incontinence episodes per week decreased by 67%, 
from 13.3 [±1.9 (SEM)] to 4.3 [± 0.9 (SEM)] leakage episodes per week (p<0.05). 
Out of 201 unnalysis, only one was positive for leukocytes. Haemolysed blood was 
found in 30 specimens. No UTIs were recorded. The vestibular tissues showed an 
increase in the proportion of superficial cells during patch use. Vaginal microflora 
demonstrated no overall change. 
Based on an incontinence impact questionnaire, device use was associated with a 
significant overall reduction in the impact of incontinence on quality of life (p<0.05), 
and many activities of daily living were made easier. The majority of women 
described the patch as easy to use and comfortable. 
It is interesting to note that the urinary diaries showed significant improvement in 
the number of leakage episodes in the post-test control period when the patch was no 
longer used. The authors proposed that it acted as a form of biofeedback training 
increasing sensory awareness of the urethral musculature. 
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CAPSURE SHIELD 
Another device called the CapSure (Re/Stor) continence shield has been tested by 
Bellin et al (1998) for the treatment of stress incontinence 35. The CapSure device is a 
small extra-urethral suction device made from biocompatible silicone (Figure 4.14). 
When positioned over the urethral meatus and squeezed it adheres to the mucosa. A 
thin coating of petroleum ointment is applied to the rim of the device to improve 
adhesion. 
A 
Relta. w the suction cap 
and allow the device to 
adhere within the vagina 
so that it completely covers 
the urinary opening. 
Figure 4.14 The CapSure (Re/Stor) continence shield and steps for application. 
The device, like the FemAssist, is re-usable - subjects are instructed to wash the 
device with soap and water, rinse and dry thoroughly before each application. It was 
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advised that a new device be used every 2 weeks. Women with GSI were recruited to 
the 6-month study from 7 clinical centres in the USA. Efficacy outcome measures 
included a short PVV7, a provocative stress test, incontinence diary, quality of life 
questionnaires and a satisfaction survey, performed prior to enrolment, while using 
the CapSure shield and after discontinuation of the device. One hundred women were 
enrolled but 84 completed the study. There were no real differences between those 
who completed the study and the "withdrawal group" based on the demographics, 
severity of incontinence and pad weight data. At enrolment the mean incontinence 
episodes on the diary for women completing the study was 3.36 per day (range 0.9- 
8.6). The mean age of subjects was 53.2 years (± 12.4years). The effectiveness of the 
device as determined by the PWT gains, the incontinence episodes on urinary diary 
and the examiners subjective graded assessment of urinary leakage on a provocative 
stress test (PST) at baseline and with use of the device is illustrated in Table 4.3. 
The PST was graded as follows: 
0 No leakage 
(Nfild) small amount of dribbling from the meatus 
2 (Moderate) a spurt of urine 
3 (Severe) a stream of Unne from the meatus 
By 12 weeks, 82% of the subjects were dry (</= 0.2g) on pad weight testing (n = 84) 
and 48% dry (0 episodes/day) on urinary diary With device usage. If analysed on an 
intention to treat (ITT) basis, these correspond to 69% and 40% respectively. 
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The Quality of Life (QoL) questionnaire used was the Wagner I-QoL 
Comparison between the scores before and after device use for 12 weeks showed an 
improvement in QoL while using the device. Exactly which QoL domains were 
improved was unclear. Patient satisfaction surveys also showed an improvement. 
During device use, 4 of 270 urine cultures were positive, yielding a low prevalence of 
1.5%. Three per cent of women enrolled in the study and 3.5% of patients completing 
the study had positive urine cultures. None of the subjects withdrew because of a 
positive culture. Otherwise adverse events were few and required no therapeutic 
intervention. It is important to note that the PWT was not one recommended by the 
ICS. Thus it is difficult to interpret these PWT gains. The device was thought to 
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have a therapeutic effect as well since PWTs and incontinence episodes per day 
remained lower than baseline 6 weeks after discontinuing the trial. 
Efficacy of CapSure shield 
Outcome Baseline Week I Week 4 Week 12 *Ave 
Measure N=100 n--97 n=88 n=84 
PVff gain(g) 
Mean 6.67 0.24 0.11 0.19 0.18 
Range (0.55-25.9) (0-6.7) (0-2.8) (0-2.5) (0-2.5) 
Incontinence 
episodes 
Mean number/day 3.4 1.1 0.4 0.3 0.6 
Range (0.9-8.6) (0-8.2) (0-4) (0 - 2.7) (0 - 3) 
Table 4.3 Improvement in urine loss at baseline and during CapSure device use 
throughout the trial (Bellin et al (1998)). *Ave = Average based on all data available 
for weeks 1,4 and 12. 
CONTINENCE CONTROL PAD 
The continence control pad (CCP) is a small non-invasive adhesive pad (Advanced 
Surgical Instruments, San Clemente, Ca, USA) which is fitted by the patient over the 
external urethral meatus between micturitions. It is a hydrogel-coated contoured foam 
occlusive pad and the adhesive hydrogel sticks to wet skin with no loss of strength for 
up to 5 hours. The pad has a tapered end that is oriented towards the front of the 
patient and a blunt end that is oriented towards the vagina. 
Eckford et al (1996) assessed the use of this pad in women with symptoms of stress 
incontinence 37 
. 
Nineteen women [median age 47 years (range 36-72), median parity 
2 (range 0- 6)] completed the study. Assessment was made the week before and 
again after using the CCPs for 2 weeks by a review of symptoms, urinary diary kept 
for seven days and a pad weight test. In the week before the trial, a median of 4 
sanitary pads were used per day (range 2- 9). There was a significant decrease in the 
number of incontinence episodes per week (p = 0.002) with 3 women completely dry 
and 14 having fewer episodes of leakage and 2 having the same or an increased 
number of incontinence episodes. They defined success as a cessation or reduction in 
the number of incontinence episodes. Use of the CCP was associated with a cure or 
improvement in 17 women. There was also a significant decrease in the pad test 
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leakage (p = 0.002) with device use. The values for the median and range of pad 
weight gains were not stated so it is difficult to interpret whether these data are also 
clinically significant. Also the subjects were older and obese so the device may have 
been more difficult to put in place. No patient complained of urethral discomfort or 
experienced dysuria or haernaturia. Table 4.4 shows complications encountered in the 
study. 
Complications of the continence control pad 
Introital discomfort on placement I 
Introital discomfort on removing 2 
Poor adherence to skin 4 
Urinary infection I 
Urinary urgency/frequency 2 
Table 4.4 Complications encountered in 19 women using the continence control pad. 
[Eckford et al (1996)] 
CONVEEN CONTINENCE GUARD 
Thyssen and Lose (1996) developed a disposable vaginal device (Conveen 
Continence Guard) and tested its efficacy in a short-term study in women with the 
symptom of stress incontinence 38 (Figure 4.15). The guard is a vaginal device made 
of soft, smooth and highly hydrophilic polyurethane foam. It is arch-shaped and 
available in 3 sizes. The product is intended to support the bladder neck partly 
because it is elastic and partly because of the pressure maintained by the two wings. 
A special applicator ensures correct placement in the vagina and a string attached to 
the device facilitates removal after use. To prevent the absorption of moisture fTom 
the vaginal mucosa, the device is first saturated with water before use. It then 
becomes soft and enlarges by 30%. A daily change to a fresh device is recommended 
to minimise the risk of infection. The approved maximum duration of wear is 16 
hours per 24-hour period. It may be worn during menstruation but should be changed 
every 4-6 hours 39. 
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Of the three sizes, the women were instructed to use the largest size that gave 
minimum discomfort. The device was used in the waking hours only. Table 4.5 
shows the results of uroflometry and residual urine with and without the device in 
place. 
Urodynamic variables 
with & without use of the CCG device 
Variables Without device With device Level of 
significance 
Peak Flow (mls/s) 30.6 (14.7 - 60.6) 29.2 (11.6 - 63) NS 
Voided Vol (ml) 359 (132 - 983) 263 (147 - 713) NS 
Residual urine(ml) 20(0-60) 10(0-100) NS 
Table 4.5 Peak flow rate, voided volume and post void residual without and with the 
vaginal CCG device in place (n = 22). Values are median (range). (Thyssen and 
Lose (1996)). NS - Not significant. 
Of the 22 women who completed the study, 9 were subjectively cured and 10 
improved while 3 experienced unchanged incontinence. All were said to have 
decreased leakage on the basis of the 24-hour pad tests with the device in place 
(p < 0.005). The average number of pads used was reduced from 3.2 to 1.4 per day (p 
< 0.00 1). Eight women had < 8g/24hr leakage. The median and range of values of 
the PWT gains with and without the device were not reported in the study. 
It is interesting to note that the studies reviewed in this thesis suggest those PWT 
gains of greater than 7-8 g/ 24 hrs are abnormal and associated with incontinence. 
Thus,, the data suggest an objective cure in 8(36.4%) women. If analysed on an 
intention to treat basis this would be 30.7%. 
Subjective complaints were few and no vaginal or urinary infections were found. 
Nineteen of the 22 women wished to continue device use. 
Thyssen et al (199 8) have assessed the Conveen continence Guard in women with 
the symptoms of stress incontinence in a more recent Stud y 40. Of 55 women 
recruited, 41 (74.5%) completed the study. Before and after 3 months use of the 
device, the women were assessed by a 48 hour home pad test, a2 day urinary diary, 
urine culture and a generic QoL questionnaire (SF 36) and an incontinence specific 
instrument (Incontinence Impact Questionnaire HQ). Fourteen women withdrew 
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because of discomfort when using the device. Subjective cure was achieved in 
11(27%) women and improvement in 27(66%), while 3(7%) reported unchanged 
incontinence. The 48 hour pad test leakage decreased significantly and in 72.5% of 
the women the leakage decreased by more than 50%. The exact figures for the 
median and range of PWT gains with the device in situ were not given so it is difficult 
to interpret whether these changes were also clinically significant. If analysed on an 
ITT basis 20% were subjectively cured and 49% improved. The number of pads used 
and the number of leakage episodes on the urinary diary also reduced significantly. 
The quality of life measured by the IIQ was significantly improved in all the 4 
subscales and in the total score. The SF-36 general health questionnaire showed no 
significant changes. Thirty-two (78%) women completing the study Wished to 
continue device use. Twenty-four women became more physically active during the 
study period. 14 women who completed the study experienced discomfort. 
Hahn and Milsom (1996) also evaluated the clifflcal efficacy of the Conveen 
Continence Guard in women with stress incontinence in a multicentre trial4l (Tables 
4.6 & 4.7). They included 90 women with the symptom of stress incontinence, aged 
20-65 years, using absorbent pads on a daily basis. Women with a history of urge 
incontinence, vaginal irritation or discomfort were excluded. They did not comment 
on whether stress incontinence was the sole symptom or if women with frequency or 
urgency were excluded from the trial. 
Objective tests of urinary leakage were based on a 24hour home provocative perineal 
pad-weighing test (with physiological bladder filling) before commencing treatment 
and again during the last week of the trial. The women drank sufficient water to feel 
the desire to void, so the volume of fluid in the bladder in each case was unknown. 
Only women with urinary leakage Ig or greater were included in the test. The 
patients subjective assessment of control of leakage was evaluated using a 
questionnaire 42 . No validated 
disease specific instrument was used. 
After receiving instructions on how to use the device, women were given a test pack 
of 3 available sizes and recommended to use the size which gave the best 
improvement and comfort. The device was kept in the vagina all day but removed 
overnight for a period of 4 weeks. 90 women (mean age 47.5 years, range 31-65) 
completed the study. 85 women successfully performed and completed the 24-hour 
pad-weighing test. Objective results were quoted based on the number completing the 
trial and not on any intention to treat basis. 
QR 
Conveen Continence Guard 
Before treatment During Treatment Significance 
level 
Mean(SEM) Range Mean(SEM) Range 
Leakage(g) 41.6(7.6) 2-530 13.9(3.2) 0-187 P<0.001 
Pads/dav 2.5(0.2) 1-12 1.6(0.2) 1-7 D<0.001 
Table 4.6 Results of the 24 hour pad test performed before treatment and at the end 
of the treatment with the CCG device (n = 85). {Hahn and Milsom (1996)) 
Conveen Continence Guard 
Degree of protection % change 
Completely Dry 46% 
Smaller leakage 29% 
Same leakage 17% 
Greater leakaae 8% 
Table4.7 Degree of protection conferred as assessed by changes during pad test with 
the CCG device in situ (n = 85). (Hahn and Nfilsom (1996)) 
Seventy four per cent of women had a subjective improvement in the degree of 
leakage or episodes of leakage; 76% also noted a positive effect on the frequency of 
episodes of leakage. Thirty three per cent of the women were not aware of the device 
during wear and 34% felt it only slightly; 8% thought the device unpleasant. The 
device was considered to be satisfactory in 72% of the patients. The subjective 
evaluation of the device is shown in table 4.8. 
Conveen Continence Guard 
Subjective measures Mean (SD) 
Inserting device 4.0(1.8) 
Local discomfort 3.9(l. 0) 
Voiding problems 4.6(l. 9) 
Defecation problems 3.7(2.4) 
Function of the appliance 4.1(2.8) 
Removing the device 4.2(l. 3) 
Overall assessment 3.90.1) 
Table 4.8 Subjective assessment of the CCG device according to a bothersome scale 
of I to 5; (1 = major problems, 5= no problems), performed by 90 women. (Hahn 
and Nfilsom (1996)). SD = Standard deviation. 
Many of the women (62%) reported some local discomfort during the test, including 
soreness, irritation, itching and vaginal discharge. However, 72% of these wished to 
continue device use. Sixty per cent of all women expressed a wish to continue with 
the same form of treatment after completion of the study, while 19% did not want to 
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continue and 21% had no opinion. Age did not influence the efficacy or comfort of 
the device. The authors agreed that a 24-hour pad test was not the best way to assess 
leakage and that a short reproducible provocative pad test with a standardised bladder 
volume would be more suitable. 
The CCG has also been evaluated in the treatment of urge incontinence in women 43 
Of 24 women with urge incontinence and detrusor instability, two were subjectively 
continent and 15 reported improvement while 7 were unchanged when using the 
device. Overall, there was a significant reduction (p = 0.005) in the 24 hour pad test 
and the number of pads used was also significantly decreased (p = 0.04). The number 
of voids and the maximum voided volumes recorded in the urinary diary were 
unchanged however. It is not reported in the study if the women also had a degree of 
sphincter incompetence as well as DI. 
The effect of the device in improving sphincter incompetence may explain the 
reduction in episodes of incontinence with urgency. It is known that women with DI 
are more likely to have urge incontinence in addition to symptoms of urgency if they 
have a weak sphincter mechanism. 
The changes to the bacterial flora in the vagina of 14 women after re-using the 
Conveen Continence Guard have been recently investigated 44 . 
The results of 98 
guard cycles showed 50% more qualitative bacterial growth in the cervix, but no 
major quantitative increase of bacteria. Only one patient developed vaginal 
colonisation by Staph Aureus. No symptoms of toxic shock syndrome were 
experienced. Overall, re-use of the device caused changes in the vaginal flora but did 
not increase the infection rate. However, if reused the device was thought to be less 
effective in controlling stress incontinence. 
INTROL BLADDER NECK SUPPORT PROSTHESIS 
Introl bladder neck support prosthesis (BNSP) is a flexible device made from medical 
grade silicone material marketed by Johnson and Johnson Medical PTY Ltd (Figure 
4.17 & 4.18). When placed in the vagina, the ridges elevate the urethrovesical 
junction returning it to a more normal position. This is thought to improve 
urodynamic parameters in a manner similar to a retropubic urethropexy procedure. 
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The gutter formed by the ridges ensures the urethra is not compressed by the 
prosthesis. Unlike vaginal pessaries, the device is loosely fitting and is intended to 
function under dynamic conditions. 
Figure 4.17 Introl Bladder Neck Support Prosthesis. 
The use of the Introl Bladder Neck Support Prosthesis was first reported in 1988, for 
the treatment of GSI and since that time several authors have studied its short-terin 
efficacy 45 . The 
BNSP received FDA approval for marketing in May 1995 based on 
the clinical data obtained in the study by Davila and Osterman (1994) 45 . 
Success 
rates of 83% - 91 % have been reported for usage periods up to 4 weeks in these 
studies. 
Contraindications to the use of this device include: 
Vaginal infections or lacerations 
Pregnancy 
Recent vaginal surgery 
Premalignant changes present in the lower genital tract or frank malignancy. 
INTROL" BNSP A 
L 
Figure 4.18 Introl Bladder Neck Support Prosthesis in place in the vagina. 
Foote et al (1996) carried out a longer-term study of 12 months to assess the use of 
the BNSP in women with GSI 46. Evaluation was begun after the women had been 
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wearing the device successfully for 4 weeks. They were assessed at 3 monthly 
intervals and at each visit the urine was cultured, clinical examination performed as 
well as aI -hour pad weight test. Quality of life questionnaires were completed at the 
beginning and at the end of the trial, but these were not validated urinary symptom 
specific questionnaires. Of the 26 women who were wearing the device at week 4,15 
(58%) continued to wear the device for I year. Success was defined as either 
completely dry or >50% reduction in urinary leakage (on both pad test and frequency 
volume chart). Subjectively, 87.5% of women gave the device a >85% rating for 
comfort and success. The objective success rate at 12 months was 87.5%. Table4.9 
illustrates the change in PWT, leakage episodes on the diary and adverse QoL scores 
rated out of 10. 
Introl bladder neck su pport prosthesis 
Baseline 12 months Significance level 
Mean PWT gains(g) 57 9 p<0.05 
Leak episodes per day 4.0 0.4 p<0.003 
Adverse OoL/ 10 8.1 1.5 ])<0.001 
Table 4.9 Results at Baseline and 12 months of BNSP usage showing change in 
PWT, leakage episodes on the urinary diary and adverse quality of life scores rated 
out of 10. (n = 15). {Foote et al (1996)). 
The UTI rate was 15.4% (4 women). Increased vaginal discharge was reported in 
54% (14) of women. Superficial vaginal abrasions and polyps were also reported, 
related to the pressure areas of the ring in the posterior fomix. What is interesting is 
that 50% of the withdrawals were due to a residual effect, with continuing reduction 
in urinary leakage after the device was removed. This was not seen in the previous 
short-term studies and the authors proposed that it could be due to connective tissue 
remoulding over time around the paraurethral prongs, creating additional bladder neck 
support. 
The BNSP was also assessed by Kondo et al (1997) with respect to safety and 




measures included an assessment of symptoms, a urinary diary for one week, 60 
minute PWT and uroflometry at baseline and at the end of the study (12 weeks). 
Ninety-three women were recruited but 67 completed the trial. Table 4.10 shows the 
reasons for dropout. 
107 
Introl bladder neck sup ort prosthesis 
Reasons for dropout No. of subjects 
Poor manual dexterity I 
Strong apprehension 3 
Vaginal bleeding 2 
Vaginitis 2 
irritative urinary symptoms 2 
Unnary frequency I 
Lost to follow-up 3 
Tight introitus 2 
Total 26(28%) 
Table 4.10 Reasons for dropout (n = 26) in women using the Introl device. {Kondo 
et al (1997)) 
There was no evidence of urinary obstruction on uroflometry with the device in place. 
Urine loss decreased from a mean PWT gain of 20.6g to 4.8g (p<0.001). Twenty-two 
(29%) women reported complete continence and 39(5 1 %) had decreased severity of 
incontinence by more than 50%. Nfinor adverse events occurred in 26% of the 
patients. Cystitis occurred in 2 of the patients. There was also a statistically 
significant improvement in the subjective impression of the frequency of incontinence 
episodes, bothersome scores related to incontinence, urgency and the amount of urine 
lost with incontinence. 
On a practical note the prosthesis is available in 25 different ring sizes and 3 
different prong heights. Hence it is difficult and complicated to get the fit right to 
achieve optimal results. This is thought to be made more so in the presence of 
uterovaginal. prolapse. 
Women who were not satisfied had the following considerations 
Younger (reproductive age) 
Planning further childbearing 
Leaked with specific activities 
Urogenital atrophy 
Scarred vaginal canal from previous surgery 
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URETHRAL PLUG 
In 1990, Nielsen et al introduced the urethral plug (Pharmaplast, Copenhagen, 
Denmark) as a new form of treatment for women with GS, 48. 
They developed the urethral plug which was to ultimately become the forerunner to 
the Reliance device. Twenty-two women completed that study of a device with two 
spheres, one sat in the urethra and the other distally at the bladder neck. The spheres 
were already inflated and were 7mm in diameter. The subjective and objective 
improvement rates were in the region of 73% in women with GSI. There were 
problems however with device insertion and study design. In this study, there was a 
high rate of patient compliance and a large subjective and objective success rate. 
However, the treatment was not without problems. The plug was very soft and 
insertion was often difficult. Also, the plug was individually fashioned according to 
the urethral closure pressure profile results. This process was cumbersome and 
expensive. To avoid these problems, the urethral plug 11 was developed. The plug is 
composed of non-toxic thermoplastic elastomer material and comprises an oval 
meatal plate, a soft stalk and I or 2 spheres 7mm in diameter along the stalk. Inside 
the stalk there is a semi-rigid removable guidepin. On the 2-sphere plug the distal and 
proximal spheres are located 1.8 and 3 cm respectively from the meatal plate. On the 
I-sphere plug the sphere is located 2.0 cm from the meatal plate. These distances 
were based on the median distances from the external urethral orifice to the maximal 
urethral closure pressure profile results reported in the first study. 
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Nielsen et al (1993) assessed the efficacy of this improved design of urethral plug in 
women with GS, 49 . The study consisted of 
3 trial periods. Patients were allocated 
randomly to either the 2-sphere or the 1 -sphere plug during period 1 (2 weeks). In 
period 2 (2 weeks) they used the other device. They then chose what they considered 
to be the better plug and continued to use it for a further 2 months (period 3). 
Assessment at each stage was by means of symptom analysis, urine culture, 
uroflometry and the pad-weighing test at 50% bladder capacity with the plug in the 
urethra. Forty women were assessed, 20 to each of the two devices in period 1, but 
only 18 (45%) completed the trial. Fourteen of the 18 preferred the 2-sphere plug. 
Subjectively and objectively 17(43%) were continent or only rarely incontinent with 
the preferred plug. Overall, there was no difficulty with insertion. The plugs were 
equally effective in women with mild or severe GSI. Six women developed UTIs and 
2 of these had the plug migrate into the bladder. Loss of plugs falling out of the 
urethra during use was a problem. This occurred in cases where the distances from 
the meatal plate to the distal sphere was less than the measured distance from the 
external urethral orifice to the maximal urethral pressure on the UPP. If the distal 
sphere was above the sphincter at the bladder neck than this was not a problem 
generally. 
FEMASSIST 
FemAssist Urinary Incontinence Device is a cap-shaped device, composed of silicone 
rubber (Figure 4.20). It is designed to be placed directly over the urethra where it will 
be held in place by its own mild vacuum action. When using the FemAssist Urinary 
Incontinence Device, a small amount of lubricating gel is placed on the surface which 
comes in contact with the body. This helps maintain the vacuum seal and protects 
against accidental urine loss. The device stays in place for as long as is comfortable. 
When the woman wishes to void, she removes the device by pulling the base away 
from the urethra. The device should then be cleaned with soap and warm water and 
replaced in the urethra. The device should be disposed of at the first signs of wear or 







FemAssist Personal - Ufinory Control Deke 
Figure 4.20 Placement of the FemAssist device 
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Mechanism of Action 
It is uncertain how the FemAssist device works in practice to prevent urinary leakage 
under conditions of raised intra abdominal pressure. When positioned over the 
urethral meatus and squeezed, the device creates a vacuum which causes a negative 
pressure that may permit coaptation of the sidewalls of the urethra and presumably 
increases urethral resistance. During a cough, intra abdominal and intravesical 
pressures may rise to as high as 150cm H20. To prevent urinary leakage in women 
with GSI the device would have to generate as much an increase in urethral resistance 
to counteract these rises in intra abdominal pressure. 
LITERATURE REVIEW (FENUSSIST) 
Versi et al (1997) evaluated the safety and efficacy of the FemAssist device in women 
with the symptom of stress incontinence 50 . No urodynamic diagnosis was made Prior 
to entry to the study. Assessment consisted of a symptom questionnaire, 
gynaecological examination, visual analogue score (VAS) to document the severity of 
symptoms, quality of life questionnaire (Incontinence Impact Questionnaire (11Q) and 
Distress Inventory (DI), urine culture, I hour pad test and a 48 hour home pad test. 
These baseline assessments took place before and after 4 weeks of device usage. A 
urinary diary was completed in week 4, recording the number of days dry while using 
the device, any irritation and the level of comfort, convenience and satisfaction. 
Ninety-one women completed the study, with a mean age of 54 years (range 29 -8 1). 
The efficacy data is shown in the tables below (Table 4.11 & 4.12) 
Efficacy of FemAssist device 
Symptom % Days dry %Decrease in PVVT(g) 
(Diary: Week 4) 
Stress (n = 38) 73% (p = 0.005) 74% (p< 0.02) 
Urge (n = 9) 90% (NS) 99% (NS) 
Mixed (n = 44) 62% (p = 0.001) 62% (p = 0.005) 
Total (n = 91) 69% fi) < 0.001) 68% (D = 0.001) 
Table 4.11 The percentage (and significance level) of dry days recorded in the 
urinary diary and the change in the PWT (and significance level) while wearing the 
FemAssist device analysed according to groups where the predominant symptom was 
stress, urge or mixed incontinence. (Versi et al (1997)1. NS = not significant. 
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Efficacy of FemAssist device 
Symptoms % improvement in % Decrease in Distress 
HQ Scores Inventory scores 
Stress (n = 38) 55% (p < 0.0001) 40% (p < 0.001) 
Urge (n = 9) 67% (NS) 32% (NS) 
Mixed (n = 44) 52% (p < 0.0001) 27% (p <0.001) 
Total (n = 91) 54% (P < 0.0001) 32% (D < 0.0011 
Table 4.12 Quality of life improvement (HQ and DI instruments) with significance 
levels while wearing the FemAssist device analysed according to groups where the 
predominant symptom was stress, urge or mixed incontinence. {Versi et al (1997)) 
NS = not significant. 
Irrespective of the type of symptom of incontinence, the device was effective in 
reducing incontinence and improving the quality of life scores. VAS scores improved 
(p < 0.00 1) for incontinence (stress: 6.0 to 3.3; urge: 4.0 to 2.7) and urgency (3.9 to 
3). There was no increase in asymptornatic bacteriUna or cystitis. 
Rabin (1997) also assessed the safety and efficacy of the FemAssist device in 
women with GSI or mixed incontinence 51 . Thirty-eight women were recruited to the 
trial which lasted one month. Subjective assessment included quality of life 
questionnaires, daily voiding and activity diaries while objective assessment included 
urine microscopy and culture and clinical examination. All subjects completed the 
trial and over 50% reported an improvement in their quality of life including comfort, 
convenience and overall satisfaction. In total for all the women, the device was worn 
on a total of 886 days; 82% of these were dry days. Similar results were obtained for 
women regardless of the urodynamic diagnosis. One in five reported vulval irritation 
or urethral discomfort at some point, but this did not correlate with percentage of dry 
days. The rate of bacteritina and cystitis was not reported but it was stated that there 
was no significant increase in these adverse events over and above the patients 
baseline experiences. 
Prashar et al (1997) also evaluated the changes in quality of life in women using the 
FemAssist device 52 
. 
The device was offered to women complaining of stress, urge or 
mixed incontinence, but a urodynamic diagnosis was not made as part of the inclusion 
criteria. Subjects underwent a pad test, dipstick urinalysis and a cost of continence 
questionnaire. Quality of life was assessed using the IIQ and DI instruments. Patients 
were randomised to control (device plus a leaflet on good bladder habit) and treatment 
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groups (device plus pelvic floor exercises and/or bladder drill). Women were 
assessed weekly for 6 weeks. Of the 65 women recruited, 19 (29.2%) did not 
complete the protocol as shown in table 4.13.26 completed the trial and 20 were 
ongoing. 
FemAssist 
Reasons for dropout No. of subjects 
Inability to apply device 6 
Extreme anxiety 5 
Can not touch genitalia 5 
Disliked the device I 
Requested other therapy I 
Lack of time I 
Table 4.13 Reasons for dropout (n = 19) in women using the FemAssist device. 
{Prashar et al (1997)) 
The average age was 64.1 years (range 25 - 87). Of the 26 women who completed 
the trial, 7 were objectively dry and a further 7 had minimal loss (PWT < 2g). Both 
groups had similar improvements in PWT and QoL scores as illustrated in table 4.14. 
Weekly personal cost of incontinence fell from a mean of Aus$3.90 to Aus$1.35. All 
26 women found the device comfortable, easy to use and would continue to use it. 
FemAssist 
Efficacy of device 
Outcome measures Baseline 6 weeks Significance 
(mean value) level 
PWT(g) 55.7 g 17.8 g P<0.01 
QoL score 52.6 37.5 p<0.001 
Table 4.14 The changes in mean PWT gains and mean Q of L scores from baseline 
after 6 weeks of FemAssist device use (n = 26). {Prashar et al (1997)1 
Tincello et al (1997) have evaluated the efficacy and acceptability of the FemAssist 
urinary control device in women with GSI and a pad test result which was 
representative of their daily IOSS53 .A repeat 1 -hour perineal pad test was performed 
with the device positioned on the patient by a member of the nursing staff After the 
pad test, all women were given a questionnaire containing three I OOMM visual 
analogue scales (VAS) to measure discomfort, acceptability and embarrassment 
associated with wearing the device (Table 4.15). 
U)Q 
Fem ssist 
Efficacy of device 
PWT (g) Without Device With FemAssist Significance level 
Median (range) 21 (1 - 94) _ 
4.9 (0 - 65) __ 
P< 0.01 
Table 4.15 Pad weight tests results with and without the FemAssist device in place (n 
= 27). [Tincello et al (1997)). 
Seven women (26%) were made "wetter" with the device in place with a median 
increase in pad weight gain of 7g (0.6 - 24.4g). Twenty women (74%) were made 
"drier" with the device with a median reduction in pad weight gains of Bg (0.6 - 
43.1g). Table 4.16 shows the VASs for each subjective measure of the device. 
FemAssist 
Subjective outcome measures 




Table 4.16 Visual analogue scores for each subjective measure associated with 
FemAssist device use. Jincello et al (1997)) 
The scores for discomfort were significantly greater in the patients who were wetter 
with the device than in the drier group (p < 0.05). There was a negative correlation 
between the acceptability score and the discomfort score (R = 0.53, p<0.01). 
Acceptability was also correlated negatively with embarrassment (R = 0.39, p<0.05) 
and with patient age (R = -0.30, not significant); embarrassment was correlated 
positively With discomfort (R = 0.47, p<0.05). Fifteen women (56%) said they 
would consider using the device as a permanent continence aid, six (22%) would not 
and six were undecided. 
There are some interesting issues posed by Tincello's study of the FemAssist device. 
They found that the amount of benefit was not predictable. Benefit did not relate to 
the severity of the initial problem or severity of GSI. There was a variable degree of 
improvement in those who were made drier. The reason for the wide range of benefit 
observed with the device (based on the PWTs) is unclear. Several women were 
actually made worse when using the device which was not anticipated. It is possible 
that urethral irritation or discomfort may trigger abnormal detrusor activity. It was 
noted that increased discomfort VASs were recorded among women who were wetter 
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with the device in place compared with those who benefited. The devices were put in 
place over the urethra by the investigators for trial tests. It may be that, in practice, 
patients would be much better at placement. The investigators used the Sutherst 
method of PWT, which has problems of reproducibility 54 . Acceptability was also 
variable and discomfort was a major factor determining acceptability. 
RELLAACE 
The Reliance device is composed of non-toxic, thermoplastic material and comprises 
an oval meatal. plate, a soft stalk and one sphere located at the distal end of the stalk 
(Figure 4.2 1). It is intended to act as a temporary barrier inside the urethra, to keep 
urine from leaking out of the bladder until the woman is ready to go to the lavatory. 
The device is gently inserted into the urethra. Then a small balloon at the tip of the 
device is inflated, using a syringe-like applicator, to block the bladder neck opening 
and prevent the flow of urine. The applicator is then removed, and the device remains 
comfortably in place as the bladder fills normally. When the woman desires to go to 
the lavatory, a simple tug on the device's string will deflate the balloon, allowing her 
to easily remove it. After urinating, she simply inserts a new Reliance. 
Figure 4.21 Reliance device 
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LITERATURE REVIEW (RELIANCE) 
Staskin et al (1996) have published the largest study to date on any continence device 
and evaluated the safety and efficacy of the Reliance urethral insert in the 
management of women with stress or mixed incontinence55. They included women 
aged 18 - 75 years with pure or mixed incontinence (cystometric motor urgency < 20 
cm H20) 56 who experienced three or more incontinence episodes per week. All 
patient evaluations (at entry and at 4 months) included clinical examination, urine 
microscopy and culture, cystoscopy and cystometry. If women were thought to have 
intrinsic sphincter deficiency, urethral function was assessed by Valsalva leakpoint 
pressures, urethral pressure profiles or standing video fluoroscopy. Other outcome 
measures included a standardised PWT, 7 day urinary diary (monthly) and subjective 
assessment of urinary leakage (I to 5 scale), ease and comfort of use. 
The SF-36 general health quality of life questionnaire was also completed at the start 
and end of the study. A total of 215 women were enrolled in the study but 80 (37%) 
withdrew before 4 months. The reasons for withdrawal are illustrated in table 4.17. 
Reliance device 
Reason for withdrawal 
Dropout No of Patients (%) 
Discomfort 25(11.6) 
Inability to use device 18(8.4) 
Urgency 6(2.8) 
Recurrent cystitis 6. (2.8) 
Lost to follow-up 5(2.3) 
Leakage with device 5(2.3) 
Haematuria or urethral irritation 4(1.9) 
Non-compliance with protocol 3(1.4) 
Otherreasons 8(3.7) 
Table 4.17 Reasons for withdrawal before completion of 4 month study (n = 215). 
f Staskin et al (1996)) 
No statistical differences were observed between patients who completed the study 
and those who did not when demographic characteristics, urologic history or 
presenting symptoms were examined (p > 0.05). Pad test weight data were available 
on 114 of the 13 5 patients and the clinical efficacy of the device as assessed by PWT 
gains at baseline and at 4 months are illustrated in table 4.18. 
III 
Efficacy of the Reliance device 
Baseline Period 
Urine loss* Urine loss* Change in Significance level 
without device with device Urine loss* 
42.7(4.5) 2.2(0.6) 40.5(4.3) P<0.0001 
4 month Period 
Urine loss Urine loss Change in Significance level 
without device* with device* Urine loss* 
43.3(4.9) 3.2(0.7) 40.1(4.7) P< 0.0001 
Table 4.18 Analysis of improvement in urine loss based on PWT gains at baseline 
and at the end of the study. * Mean PWT gain in grams (standard error of mean). 
(Staskin et al (1996)) 
Device use resulted in a statistically significant improvement in urine loss irrespective 
of the type of GSI (anatomic or intrinsic sphincter deficiency) or the presence of 
previous continence surgery. The authors state the data reveal that 80% of the women 
were completely dry and 95% achieved >80% improvement in urine loss. There was 
also an improvement in incontinence symptoms in 89% based on daily urinary diaries. 
What is unclear is whether or not these data were analysed on an intention to treat 
basis (n = 215) or were they analysed based on the core group with available PWT 
data (n = 114) who attained 4 months of device use. Based on an ITT, the data would 
correspond to 50.2% (108) clinical effectiveness and 47% (101) improvement on 
urinary diary. Therefore their conclusions that the device, in this study, compared 
favourably With other currently available non-surgical therapies is probably 
inaccurate. 
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Adverse events during the study were transient and required only minor medical 
intervention. The rate of UTI is shown in the table 4.19. 
Safety of the Reliance device 
Urinary tract infections 
Positive culture 52(39%) 
(not treated) (>/= 10 
4 
CfU/ml) 
Positive culture (treated) 42(31%) 
Asymptornatic 15(11%) 
Svmptomatic 27(20%) 
Table 4.19 Urinary tract infections observed during the 4 month study (n = 135) 
(Staskin et al (1996)) 
All but a few cystoscopic examinations indicated normal urethra and bladder mucosa. 
Urodynamics showed no compromise in bladder function at the end of the trial. What 
was observed which gave rise to some concern was a trend towards an increased urine 
loss without device use from baseline to 4 months. This trend was statistically 
significant in the case of women with intrinsic sphincter deficiency with prior surgery 
{n = 11, mean PWT gain 68.6g at baseline, 92.3g at 4 months, P<0.01). The authors 
felt that uninhibited bladder contractions (not noted on cystometry) may have 
contributed to the degree of urine loss observed in this group. They did not comment 
on the possibility that the insert itself may cause deterioration in the already 
compromised sphincter mechanism due to repeated device insertions. By the end of 
the study, patients' perception of acceptability, degree of incontinence, symptom 
improvement, ease of learning, comfort and time to habituation also showed 
improvements. 
There are problems in conducting a multicentre trial however. This was a 
multicentre (7) study, and exactly what measures were taken to ensure that all women 
were studied in a consistent manner (i. e.: urodynamic standards of practice and 
equipment as well as computer software and calibration) was not made clear. 
The Reliance device was also evaluated in a French multicentre trial 57. One 
hundred women with GSI or mixed incontinence were recruited to use the device over 
3 months. Women underwent clinical assessment, urodynamics, PWTs and 
completion of a one-week diary. The mean age was 56.4 years and 32% had previous 
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continence surgery. Sixty one per cent had pure GSI- The dropout rate was 36%, due 
to discomfort, difficulty with insertion or persistent leakage while using the device. 
Of the 64 women completing the 3-month study, the PWT showed an improvement 
from a baseline mean of 36g without the device to 10g with the device in situ. In 71% 
of cases, the PWT was negligible with the device in situ. Total clinical experience 
represented 293 patient months and the use of 26,300 devices. Fourteen UTIs, 14 
haematuria and 2 intra-vesical device migrations were reported. More than half those 
completing the study wished to continue device use. 
Miller and Barendam. (1996) have published their 12-month experience of the 
effectiveness and safety of the Reliance Urinary Control Insert 58. Sixty-three women 
with pure GSI or mild mixed incontinence who experienced three or more 
incontinence episodes per week were recruited. Women with urge incontinence and 
involuntary detrusor contractions >20cm H20 were excluded. The mean age of the 
subjects was 55 years [± 1.5 (SEM)l with a mean duration of incontinence of 12.5 
years [± 1.3 (SEM)] and a parity of 2.4 [± 0.17 (SEM)]. Twenty-eight (44%) were on 
hormone replacement therapy and one third had undergone previous continence 
surgery. Urodynarnics showed that 62 (98%) had pure GSI and one had mixed 
incontinence. Monthly evaluations included a vaginal examination and urine 
microscopy and culture. Cystoscopy and cystometry were repeated at 4 and 12 
months. Effectiveness was analysed by aI -hour pad weight test and a urinary diary. 
The PWT was conducted at 4 and 12 months and the diaries were kept for 7 days at 
baseline and monthly intervals. Objective assessments of safety were made through 
routine urinalysis, urine cultures and cystoscopy to assess mucosal changes of the 
urethra and bladder., as well as any adverse events reported. Subjects used an average 
of 3 inserts daily, each worn for 2-3 hours. 
Fifty-six women completed the 12-month PWT analysis (table 4.20). At the study 
outset, 46 women (82%) were completely dry and 9 (16%) were significantly 
improved. At 12 months 44 (79%) remained completely dry and 9 significantly 
improved. Three women exhibited <50% improvement in PWT at 12 months but had 
significant improvement in incontinence episodes on their urinary diaries. 
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Efficacy of the Reliance device based on reduction in mean PWT gains 
Baseline Period 
Urine loss Urine loss Change in Significance 
Without device* with device* Urine loss* Level 
46.4(7.2) 2.4(0.9) 44.0(6.8) p< 0.0001 
12 month follow-up 
Urine loss Urine loss Change in Significance 
Without device* with device* Urine loss* Level 
41.5(6.2) 5.3(2.3) 36.2(5.7) P< 0.001 
Table 4.20 Reduction in urine loss with and without the Reliance device from the 
baseline period to 12 months (n = 56) based on PWT analysis. {Nfiller and Barendam 
1996). * Expressed as mean PWT gains in grams (SEM). 
Women who had previous failed continence surgery had a significantly higher mean 
PWT gain at baseline, but the device produced a similar reduction in leakage. Table 
4.21 illustrates the degree of protection achieved with device use comparing baseline 
diary data with that of device use at I month and 12 months. 
Subjective degree of protection afforded by the Reliance device 











Completely Completely Completely dry 
dry dry / sig. sig. Improved 
Improved 
34 87 96 0.001 
27 84 88 0.003 
14 69 84 0.001 
10 88 90 0.001 
20 100 92 0.005 
0 100 89 0.005 
Couahine 3 73 84 0.002 
Table 4.21 Percentage of women reporting dryness or significant improvement 
during Reliance use. Completely dry = rating of </= 1.09 on a scale of 1-5 (1 = no 
leakage, 5= large leakage). Significant improvement = >50% reduction in rating 
urine loss during insert use compared with before use. {Nfiller and Barendam 1996). 
Patients rated the ease of insertion and comfort of use on a scale of I-5 {(easy - 
difficult) and (comfortable - very uncomfortable)). The results are shown in table 
4.22. 
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Subjective outcome measures of the Reliance device 
Measure I month 12 months Significance level 
Ease of insertion 1.74 1.20 P< 0.0001 
Comfort of use 2.49 
, 
1.52 p< 0.0001 
Table 4.22 Ease of insertion and comfort of use at one and twelve months use of the 
Reliance device. The numbers refer to the mean score f scale of I-5 (1= easy, 
5= difficult) and (1= comfortable - 5= very uncomfortable)} at the period of 
assessment. tNfiller and Barendam 1996) 
After one week of use, 22 (35%) women experienced a foreign body sensation and 
this declined to 4 (7%) women at one year. The adverse events experienced during 
the trial and the cystoscopic findings are shown in table 4.23. 
Adverse events experienced with the Reliance device 






Mild mucosal inflammation 
Nfild mucosal erythema of bladder neck 
Trigone erythema 






Table 4.23 Adverse events noted over 12 months of Reliance device use. (Miller and 
Barendam 1996). 
There was no significant change in urine loss without the device ftom baseline and at 
12 months (46.4 ± 7.2 g at baseline; 41.5 ± 7.1 g at 12 months, mean and standard 
deviation). The success rates of 80% (completely dry on PVV'T) to 95% (completely 
dry or significant improvement on diaries) obtained in this study compare favourably 
with those observed with surgical interventions 59 . 
The PWT data also correlated well 
with the urinary diaries kept by the subjects. There were good results achieved with 
most provocative activities. Efficacy was maintained consistently at I- 12 months 
and previous surgery did not interfere with the results. There was also no 
deterioration in the PWT results without the device at the end of trial as a result of 
using the device: - inferring no deterioration in the continence mechanism. 
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The rate of 30% symptomatic cystitis in 12 months was well within the range 
observed for the incontinent female population, where recent studies have estimated 
rates of 28% - 35% for the ageing woman 
60. 
CONCLUSION 
Product development and testing is an arduous area of research; yet for patient safety 
it is one in which nurses and clinicians should become more actively involved. The 
development of continence aids may provide women with a treatment and cost 
alternative from protective clothing, pads and diapers as well as enhance their quality 
of life. In addition, nursing time needed for incontinence care may also decrease. 
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Patients usually consult their doctor seeking alleviation of symptoms and treatment of 
problems. Women are unlikely to introduce the subject of urinary incontinence unless 
the symptoms are incapacitating. Failure to discuss these issues prevents women 
from taking advantage of possible treatment options that have become available 
Before any treatment is instituted however, one must determine the nature of the 
complaint. Diagnosis and clinical evaluation of the problem is the initial and Vital 
element in the management of women with urinary symptoms. The cause and the 
outcome of the illness are often influenced by the physician's ability to reach an early 
and correct diagnosis. 
The patient's medical history is the most important part of the clinical database 2 
In general medical terms a patient's history probably serves as a basis for 70 - 80% of 
correct diagnoses 3. Patients are given sufficient time to discuss their problems and 
complaints, but we provide direction to the consultation using the KHQ. With direct 
questioning, additional information is obtained for further clarification of the urinary 
symptoms. It is important to reallse that these symptoms are not experienced 
similarly or expressed with the same intensity by all women. Patients vary widely in 
their responses to the same disease process, based on their age, cultural background 
and constitutional and genetic make-up. Patients may present with common, 
complex, mixed or atypical urinary symptoms. Symptoms may also be forgotten, 
suppressed, or exaggerated by patients. 
Clues may be so definite that their presence confirms the diagnosis or so sensitive that 
their absence effectively eliminates certain diagnoses 4. However, most women with 
urinary incontinence present with mixed symptoms. Even though GSI is the most 
common condition, an audit of the symptomatology in women attending a 
urodynarnic clinic revealed that only 2.4% of them complained of stress incontinence 
alone 5. 
Symptoms are unreliable 
D- 
Research has shown that urinary symptoms inaccurately reflect the cause of lower 
urinary tract dysfunction. Bates et al (1970) coined the phrase "the bladder often 
proves to be an unreliable witness" and with good reason. In a study of 75 women 
1 ? IS 
with recurrent incontinence, despite surgery for the symptom of stress incontinence, 
on formal urodynamic testing, 45 had DI without GSI, 30% had continuing GSI and 
25% had no demonstrable urinary leakage 67 . 
Jarvis et al (1980) compared the results of clinical and urodynamic diagnosis for 100 
women referred for investigation of lower urinary tract disorders 8. The referring 
gynaecologist made a diagnosis of stress incontinence in 41 women and detrusor 
instability in 59 on the basis of their urinary symptoms alone. There was agreement 
in 28 cases (6 8%) of genuine stress incontinence and only 30 cases (5 1 %) of detrusor 
instability. The study found that although nearly all the women with genuine stress 
incontinence complained of symptoms of stress incontinence, 46% of them also 
complained of urgency. Of the 35 women with detrusor instability, 26% complained 
of symptoms of stress incontinence. 
Byrne et al (1987) found that even if the patients only symptom is stress 
incontinence, DI might still be present in 20% 9. No major urinary incontinence was 
present though 45 (3 1.1 %) women actually reported themselves incontinent at 
interview. It may be that factors other than the amount of urine lost determine 
whether an individual considers herself incontinent of urine or not. 
Lagro Janssen et al (199 1) showed that symptoms of stress incontinence in the 
absence of symptoms of urge incontinence had a sensitivity of 78%, specificity of 
84% and a positive predictive value of 87% GSI 10. Versi et al (199 1) determined the 
accuracy of an analysis of symptoms alone for the diagnosis of GSI. Using the 
urodynamic diagnosis as the "gold standard", symptoms analysis achieved a correct 
classification of 81% with a false positive rate of 16% ". 
The clinical diagnostic accuracy of urinary symptoms in women when assessed by 
urodynamiC studies is illustrated in table 5.1. 
Accuracy of urinary symptoms 
Study 
12 
Clinical Diagnostic Accuracy 
Jarvis et al (1980) 76% 
Glemmng (1984) 13 56% 
Sand et al 88 14 58% 
Versi et al (1991) 15 81% 
Lajzro-Janssen (199 1) 87% 
Table 5.1 Clinical diagnostic accuracy of urinary symptoms in women when 
assessed by urodynamic studies. 
1? A 
When the available published information at the time was combined by means of a 
meta-analysis, Jarvis (1984) found that the overall diagnostic accuracy of urinary 
symptoms in women with GSI was only 69.2%, while the overall diagnostic accuracy 
16 
in DI is only 70.4% 
These observations are extremely important in a study designed to assess the effects 
of continence devices and quality of life impairment of women with GSI. Without a 
sound diagnosis it is impossible to compare the results of women with the same 
pathology and hopeless to perform any form of detailed assessment following 
intervention with continence devices. Despite these findings however the majority of 
similar studies to date have omitted to perform urodynamic investigations. 
PHYSICAL EXAMINATION 
Physical examination reveals information that is comparatively more objective, 
measurable and reproducible. It is performed complete and systematically but with 
particular reference to the lower urogenital tract. A good medical knowledge of 
urogenital tract dysfunction including pathophysiology and clinical manifestations of 
these conditions is also important. 
GOOD URODYNAMIC PRACTICE 
Urodynamic techniques vary from simple pad tests, frequency volume charts, 
eyeball" urodynamics and ultrasound, to sophisticated synchronous multichannel 
computerised video/ pressure/ flow studies, ambulatory urodynamics and 
electromyography. Multichannel video urodynamics offers the most comprehensive 
artefact free way to arrive at the correct diagnosis, but is expensive and requires 
considerable manpower, expertise and time. The introduction of ambulatory 
urodynamics may provide an even more accurate method of evaluation but this is still 
unclear 17 . Regardless of the 
diagnostic strategies employed, appropriate diagnostic 
studies are selected and pursued until the nature, severity and cause of the disease is 
established. The aim of urodynamics is to reproduce the patient's symptoms under 
the condition of precise measurement in order to identify the underlying causes of the 
symptom and to quantify the related pathophysiological parameters. 
1')7 
it is a skilled procedure in terms of the appropriate selection of patients, setting up the 
equipment for each investigation and in the interpretation of the resultant 
pressure/flow recordings. A recent report on the causes, management and provision 
of services for incontinence recognised that urodynamics requires appropriately 
trained staff to perform and interpret the results 18 . Hosker et al (1997), to audit the 
provision of urodynamic services in the UK, sent out a questionnaire to 163 centres 
carrying out these tests 19. They found no standardised training has been established 
to carry out urodynamics and no studies have investigated who carried out 
urodynamic investigations in the UK or the training that these personnel have 
received. Only half the respondents considered their training to be adequate even 
though they were responsible for investigating over 29,000 patients per year. 
URODYNANHC INVESTIGATIONS 
Variation between measurement obtained by urodynamics is an important 
consideration as it may be a source of systematic bias. Discrepancy can be reduced 
by strict quality control such as good urodynamic practice and calibration of the 
instruments. Standardising the procedures in the study can also reduce variations. 
The ICS established a committee for the standardisation of urodynamic practice and 
terminology of lower urinary tract function in 1973. The standards are recommended 
to facilitate comparison of results by different investigators, especially when 
urodynamic methods are used 20 . Accurate 
interpretation depends on good 
equipment, correct placement of pressure lines and transducers, a standardised 
technique of performing each study and the presence of an experienced investigator 
with attention to good urodynamic practice. We work closely and abide by the codes 
of practice recommended by the International Continence Society. 
LABORATORY DIAGNOSIS 
The need for each test should be evaluated in terms of its sensitivity, specificity, 
predictive value, cost, safety and patient comfort. We need to determine which test 
should be performed, how does it clarify the patient's problem and what underlying 
pathophysiologic mechanisms of the disease will be explained by the test. 
Urodynamics are not without their problems. Benness and Manning (1997) have 
I? R 
shown that the majority of women experience discomfort during testing and in many, 
this continued following completion of the test and may even affect the performance 
of normal activities. Anxiety prior to testing and embarrassment during the studies 
were common. Pre-test information was appreciated by patients and despite these 
findings the vast majority of women felt that the investigations were acceptable and 
21 worth while 
Indications for urodynamies 
0 Women who complain of urgency prior to surgery for supposed GSI 
a Women thought to have an unstable bladder but fail to respond to treatment 
0 incontinent despite surgery for GSI 
0 Voiding difficulties 
0 Neurological abnormalities 
I will describe, and included technical details, those urodynamic techniques that were 
employed to reach the correct diagnosis for women included in this study. The 
routine method of urodynamic assessment performed on patients attending our clinic 
will be described but more objective data will be provided in the chapter on outcome 
measures. 
FREQUENCY VOLUME CHART 
The frequency / volume chart is a specific urodynamic investigation recording fluid 
intake and urine output per 24 hour period, and ensures that clinical questions about 




patients are often the most co-operative and accurate in their completion of the chart 
22 
. 
One practical consideration is that the chart involves the patient in the diagnosis of 
her condition and helps her to become an active partner in the treatment process. 
PAD WEIGHT TEST 
Verifying and quantifying incontinence by weighing perineal pads was initially 
proposed by Sutherst et al in 198 1. This test was modified and accepted by the 





pad test is a simple method of assessing Urinary leakage 
1? Q 
UROFLONIETRY 
Uroflometry is the measurement of the flow rate which represents the value in 
millilitres of urine expelled from the urethra in unit time. It characterises abdominal 
activity, detrusor contractions and urethra] relaxation. Measurement of Urine flow 
provides an objective assessment of voiding ability. Uroflometry is rapid, non- 
invasive, physiological and requires little specialist equipment apart from a commode 
and a flow meter. It allows the measurement of voided volume, maximum flow rate, 
acceleration of flow rate, average flow rate, flow time and time to maximum void. 
The three main parameters of interest are flow rates, flow patterns and volume 
recordings. It is important to get a "representative" flow pattern with the subject 
relaxed and comfortably full. Difficulties arise if the woman is anxious or the bladder 
is too full and over-stretched and the detrusor temporarily decompensates. Flow is 
also age and volume dependent 26. In women, a normal flow rate in a full bladder, 
which empties completely, excludes obstruction 27 
Many high flow rates of up to 40ml/s do not always 'indicate good detrusor function. 
It may be seen in women with long standing detrusor instability and neurogenic 
bladder dysfunction. 
Nomograms have been established to provide a normal reference range for the 
maximum and average urine flow rates over a wide range of voided volumes for both 
men and women 5- The characteristic of the trace or the patterns seen may be 
indicative of certain conditions. Normal female voiding produces a bell-shaped curve 
on uroflometry. Voiding dysfunction may give rise to an intennittent or multiple 
peaked flow. A low flow rate may be due either to bladder outlet obstruction, 
detrusor sphincter dyssynergia (DSD), or impaired detrusor contractility. 
Simultaneous cystometric recording of detrusor pressure during voiding can be 
performed in such cases to exclude detrusor dysfunction and urethral pressure 
profilometry and sphincter EMG to evaluate outflow obstruction. Obstruction may 
take the form of high pressure/low flow voiding or normal pressure/low flow voiding. 
In a review of obstructed voiding in women the incidence of obstruction was 
approximately 2.7% (excluding DSD and overt neuropathy) 28. In general tenns, 
there are no symptoms or group of symptoms in women except retention which are 
diagnostic of outlet obstruction. Detrusor instability may give rise to a high peak flow 
attained rapidly within the first few seconds, a short voiding cycle and the flow 
IV) 
retums to zero with a rapid fall. A long voidmg cycle with a low peak and average 
flow is characteristic of outflow obstruction. Detrusor failure may give rise to a 
similar tracing so a diagnosis on the basis of flow rate alone is not possible. 
CYSTONMTRY 
Cystometry is a method by which the pressure volume relationship of the bladder is 
measured. It is used to assess detrusor contractility, sensation, capacity and 
compliance. The International Continence Society has established detrusor 
classifications of normal, hyperreflexic or hyporeflexic based on the results of 
cystometry 23 . Normally cystometry is performed with the patient supine, but the 
patient may be seated or standing. A change in posture during cystometry is 
provocative and is used to test for detrusor instability. 
Filling Medium 
Generally cystometry is performed using a liquid radiological contrast medium called 
urografin, kept at room temperature. Filling is conducted with the subject supine and 
once the bladder is full the patient is brought to the erect position by tilting the X-ray 
table. 
Filfing Rate 
Although there are many techniques for performing cystometry the most commonly 
used method is retrograde filling of the bladder with fluid at a constant rate, 
measuring the intravesical pressure and generating a pressure / volume curve of the 
results. A filling rate of 100 ml/min (fast fill cystometry) is 60 times the normal 
physiologic rate. Often a slower filling rate of 30 ml/min is appropriate for patients 
with suspected detrusor hyperreflexia. Medium fill cystometry is employed in our 
unit With a fill rate of 50ml per minute. 
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Measurement of intravesical pressure 
Intravesical pressures can be measured directly with microtip transducers, or via a 
manometer system connected to an external transducer placed at the level of the 
superior edge of the symphysis pubis. Simultaneous measurement of abdominal 
pressure by means of a rectal or vaginal transducer allows calculation of the detrusor 
pressure by electronic subtraction of the intra-abdominal from the intravesical 
pressure recording. The calculation of deftusor pressures in this manner results in far 
more reproducible investigations less susceptible to artefact errors. 
Filling Study 
The vulval and urethral meatus are cleansed with Savlon and the urethra is lubricated 
with gel. The pressure line is introduced piggy-backed to the filling catheter with its 
tip in the side hole of the filling catheter. Once the fdling catheter is in the bladder, 
the pressure line is disconnected by pulling back sharply with the filling line held still. 
The filling line is ftirther advanced so as to coil within the bladder. Both tubes are 
held in place with adhesive tape onto the inner thigh. The filling catheter is first 
allowed to drain into a bowl to ensure the bladder is empty prior to the start of the test 
and to measure the residual volume. 
Rectal Catheter 
Rectal pressure is thought to accurately reflect intra abdominal pressure. We use 
ready prepared fine 5F flWd filled tubes with side holes to measure pressure. Faecal 
occlusion is prevented with a rubber covering with a split to allow transmission of 
pressures. The top is also lubricated and the catheter introduced completely into the 
rectum well beyond the anal sphincter. If it is too low it will record sphincter 
contractions and interfere with the subtracted detrusor pressure. 
If the patient can not tolerate a rectal catheter, the intra abdominal pressure is 
approximated using a transducer placed in the vagina. Rectal pressure and vaginal 
pressure are not the same but are reasonable approximations of each other during 




once filling and pressure recordings have begun the woman is asked to cough. This 
acts as a potential provocative stimulus and is performed at the start and at every 
I 00ml of fluid instilled in the bladder. The patient is asked to report the first 
sensation to void, any urgency or leakage and bladder fullness. All events are 
recorded on the trace. Video radiographic screening is not normally recorded during 
the filling phase. However, in the event of detrusor over-activity, the subject is 
screened at that time to observe the bladder morphology, urge incontinence and the 
presence and grade of any vesicoureteric reflux. At the end of this phase the filling 
line is removed. Bladder compliance is a measure of the degree of stiff-hess of the 
detrusor muscle wall and indicates the change in volume for a unit change in pressure. 
At a filling rate of up to 100 ml/min the vesicoelastic and geometric properties of the 
bladder prevent a rise in vesical pressure of more than 15 cm H20. This is considered 
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Figure 3.2. Normal Videocystometrogram. 
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Voiding Phase 
When cystometric capacity has been reached, filling is stopped and the filling catheter 
removed. It is usual to ask the patient to stand and cough several times to check once 
again for leakage due to provoked detrusor instability and genuine stress incontinence. 
The patient is asked to void into the flow meter with the pressure lines in situ. The 
transducers are adjusted so that they are at the level of the symphysis. The subject Is 
left in privacy and a pressure flow plot is obtained on the trace. 
The course of InIcturition depends on both bladder contraction strength and urethral 
resistance 30 . The maximum detrusor pressure during voiding is a result of 
contraction of the bladder against the resistance of the urethra. Normally voiding 
occurs by coordinated contraction of the detrusor and relaxation of the urethral 
sphincter; the urethral sphincter relaxing before the onset of detrusor activity. Factors 
which may affect detrusor contraction strength include the age of the subject, voided 
volume, the presence of detrusor instability and previous pelvic surgery 31 . Any 
residual volume is assessed by comparing the filled and voided volume. 
Once the procedure is completed, the cystometry trace is marked with the patient 
details and a set proforma completed. 
VIDEOCYSTOURETHROGRAPHY (VCU) 
The purpose of the combined video study is to image the lower urinary tract whilst 
simultaneously monitoring intravesical pressure. The advantages of VCU include 
easier visualisation of urinary leakage, the assessment of the position and mobility of 
the bladder neck (especially after previous surgery), the estimation of residual urine 
and the opportunity to diagnose morphological abnormalities such as bladder or 
16 
urethral diverticulae,. urethral stenosis or vesico-ureteric reflux . However, 
it is 
more expensive to provide and involves the use of ionising radiation with potential 
risks to the patient. The test is considered the most accurate or "Gold Standard" 
diagnostic method available for the detection of neurological lower urinary tTact 
32 33 dysfunction 
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URETHRAL PRESSURE PROFILE 
We are aware that little effort is required to overcome the urethral resistance of 
women with severe GSI compared to women with less severe incontinence. Hilton 
and Stanton (1983) suggested it is reasonable to assume that the magnitude of the 
compromise in urethral resistance is correlated with the severity of the individual 
patient's incontinence 34 . The urethral pressure profile (UPP) is a plot of pressure 
against distance obtained by withdrawing a pressure recording transducer from the 
bladder through the urethra at a constant speed. The UPP is obtained at rest and 
during a series of coughs. These transducers measure a stress component at right 
angles to their surface rather than hydrostatic pressure and therefore measurements 
will be affected by their orientation within the urethra. The urethral pressure recorded 
is maximum with the transducer facing anteriorly and minimum with it facing 
posteriorly. As a compromise the transducer may be used in either the 3 or 9 o'clock 
position which provides an average measurement. 
The static or resting urethral profile is the intraluminal pressure along the length of the 
urethra with the bladder at rest. The UPP trace shows a low-pressure value in the 
bladder, which gradually rises from the bladder neck, through the proximal urethra, is 
maximum in the mid-urethra, from where it gradually falls to zero at the external 
meatus. 
Stress UPP 
The urethral pressure profile is performed with a subjectively full bladder with the 
patient in the supine position. The transurethral catheter is withdrawn through the 
urethra at a rate of 0.5 min/second using a mechanical pulley system. The patient 
coughs repeatedly during the test. Pressure transnuission ratios are calculated for each 
cough spike during the stress UPP using the formula: 
Pressure transmission ratio Change in urethral pressure x 100 
Change in vesical pressure 
11's 
The pressure transmission ratios are calculated for every cough and averaged for each 
one-third of the functional urethral length (proximal, middle and distal). If a positive 
area remains under the pressure profile curve with any cough the test is considered 
negative. If pressure equalisation occurs with each cough throughout the length of the 
urethra, then the test is considered positive 35 . The presence or absence of Urine loss 
dunng the test is also noted. 
COMMONLY USED URODYNAMIC TECHNIQUES 
The following is a list of commonly used urodynamic techniques and urodynamic 
variables which can be detected and interpreted during the various investigations. 
Filling CMG 
Residual urine 









Descent and rotation of bladder neck - degree, severity 
Incompetence related to detrusor or abdominal pressure rise 
Ballooning of urethra 
Urethral diverticulum 
Fir tree bladder 
Conical bladder 





rt, related to bladder over-activity 
Abnormality of the bony pelvis 
Voiding CMG 
Bladder 
can initiate a detrusor contraction 
sustained contraction 
pressures attained 
r* isometric contraction on "stop-test" 
* straln to void 
r* good correlation between uroflometry and flow during voiding CMG 
Outflow tract 
Obstruction 
Detrusor Sphincter Dyssynergia 
Normal Study 
Bladder capacity: 400 - 500ml 
0 sensation: 150ml 
st urge to void: 350ml 
Detrusor rise on filling: < 15cm H20 for a volume of 500ml 
Free Flow Rate: > 15ml/sec for a volume of 150ml 
Voided Volume: > 150ml 
Detection of the presence of GSI 
Bladder base descent 
Degree of bladder neck descent 
E* Stable CMG 
Seventy of sphincter incompetence 
Anatomical assessment of dynamic changes associated with GSI 




Early I' sensation 
r* Reduced bladder capacity: (<350ml) 
* Stable bladder 
Hypo contractile bladder 
minimal "flat" detrusor activity 
large capacity bladder 
little sensation of bladder filling 
strain to empty with poor or intermittent flow pattern 
significant residual 
Poor Detrusor Compliance 
Slow rise in intravesical pressure on filling CMG, associated with urgency 
The pressure rise subsides when filling is stopped 
EQUIPMENT USED 
The same equapment was used for all of the investigations carried out in this thesis 




Uroflometry was performed using an RS component load cell and strain gauge 
amplifier to weigh the voided fluid. The equipment was checked prior to each 
investigation session for calibration with zero mls and 500 mls of water. The volume 
signal was differentiated electronically to give the flow rate signal. 
Volume Range; -- 1800 mls 
Accuracy; +/- I ml 
Flow rate range; 0- 100 ml/s 
Accuracy; +/- 2% 
1 '1 R 
Subtracted eystometry 
Subtracted cystometry was performed with water filled pressure Imes connected to 
Spectramed P23XL pressure transducers situated at the level of the superior border of 
the symphysis pubis (Range -5 cm H20 to+ 100 cin H20; Accuracy +/- 3%). The 
equipment was calibrated prior to each investigation session; zero was set at the level 
of the symphysis pubis and the gain was set to a 50cm column of water. Recordings 
were made on a Neomedex Aquadata computerised recorder where the inftised 
volume, rectal pressure, intravesical pressure, detrusor pressure and flow rate could be 
simultaneously shown. A paper speed of 5 cm/min was used for filling cystometry 
and 15 cm/min for uroflometry and voiding cystometry. 
Urethral Pressure Profilometry 
Urethral pressure profilometry was performed using a7 French silicone coated 
Gaeltec 16CT/S-2 dual sensor catheter with two microtip pressure transducers set 6cm 
apart. The catheter was calibrated prior to each investigation session (zero to 100 cm 
water). The withdrawal device was a Wiest CP 4302N puller. 
CONCLUSION 
The following is the protocol for assessment of lower urinary tract dysfunction used 
in Prof. Cardozo's unit and applied in this study. 
(1) On arrival a detailed urinary and medical history is taken, including a 
symptom questionnaire and visual analogue chart completed by the patient. 
(ii) A thorough pelvic examination. 
(Ili) Uroflometry is peirfonned 
(iv) Subtracted cystometry and videocystourethrography is performed. 
Voiding is then commenced over a flow meter and additional imaging 
is performed. The patient is asked to interrupt their urinary stream and 
further imaging is performed. 
The pressure catheters are removed, the patient is asked to empty their 
bladder and radiological assessment of any urinary residual is made. 
1,19 
Often this assessment is adequate for the evaluation of the incontinent patient. 
Complex cases however require ffirther investigation. 
(V) Urethral pressure profilometry is performed on patients with evidence of 
voiding difficulties, previous failed incontinence surgery, evidence suggestive 
of a urethral diverticulum or urethral stricture and patients With a diagnosis of 
both detrusor instability and urethral sphincter incompetence. 
(vi) Patients with normal findings but symptoms of incontinence are offered a pad- 
weighing test. 
(vii) Ambulatory urodynamics is available for the assessment of patients with a 
history of incontinence but both a negative pad test and normal 
videourodynamics. 
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CHAPTER SIX 
PATIENTS AND METHODS 
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INTRODUCTION 
A given therapeutic approach must stand up to the rigors of comparison studies before 
it can be deemed effective. Often therapies are widely adopted into clinical practice 
before such evaluation has occurred. Descriptive cases although a popular method for 
clinical investigation, do not account for any placebo effect or change in any 
individual's condition over time. The only valid method for determining clinical 
effect comes from comparison studies. Study designs which allow such comparisons 
include cohort studies and case-control studies. 
In the description of the design of the study I wish to formulate the aims of the 
investigation, state the methodology used, how the sample population was recruited, 
and determine the criteria for the disease being measured. The nature of interventions 
to be tested, conditions of administration and assessment and interpretation of 
outcome will be summarised. The inclusion and exclusion criteria used will be 
defined and the statistical methods utilised will also be outlined. 
A discussion of the choice of outcome measures selected and techniques of 
measurement as well as the methods of analysis of treatment effect will be given in 
subsequent chapters. In the design of the study we also defined the criteria for a 
complete or maximum response, improvement and deterioration. 
THE PURPOSE OF THE STUDY 
In defining the objectives of continence devices one is really characterising the 
reasons for this specific study and what we as investigators want to show. This thesis 
attempts to present the best available evidence to support the use of continence 
devices for the symptom of stress incontinence in women. In simplest terrns, the 
objectives of continence devices are the improvement or cure of the symptom of 
stress incontinence. But there are other secondary objectives at different levels, 
involving the individual, her family, community and society as a whole, which are not 
explicitly defined. 
The primary objective is to study the clinical efficacy, acceptability and safety of the 
Reliance Urinary Control Insert and the FemAssist Incontinence Device in the 
management of women with objectively demonstrated urinary incontinence. 
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The secondary objective is to study the effect of the introduction and use of novel 




Women with a history of urinary incontinence, referred for assessment to King's 
College Hospital (KCH) Urogynaecology Department were considered for entry to 
the study. In taking a sample from this population, we examine this subgroup in 
detail so inferences can be drawn about the whole population. There are a number of 
different ways of obtaining a random sample but all have the following in common - 
the results can be generalised to the total population from which the random sample 
was derived and probabilities calculated for possible effects and differences between 
the unknown true value and the value obtained from the sample. 
The sampling frame was all women referred with the symptom of stress 
incontinence. As a sampling frame representative of the general population I 
recognise that this has earnest limitations. In conditions such as stress incontinence a 
proportion of women afflicted will not make the decision to seek health care even 
though they may recognise themselves as incontinent. A further proportion will visit 
their GP only whilst others will come to the attention of hospital services as 
outpatients or inpatients. The processes which lead to this are complex and depend on 
many factors such as: the woman's perception of her ill health, her own attitudes and 
those of her family, friends and society in general to illness and the availability of 
continence services. Thus, a certain unknown proportion of women are already 
excluded i. e. women who are not in contact with the Health Services and have 
incontinence but do not seek treatment. 
DEFINITION OF INCONTINENCE 
Urinary incontinence is defined as the "involuntary loss of urine which is a social or 
hygienic problem and objectively demonstrable"'. It is a symptom and not a disease. 
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Genuine stress incontinence is defined as an involuntary loss of urine when the 
intravesical pressure exceeds the maximal urethral pressure in the absence of a 
detrusor contraction. Strict criteria must be fulfilled in order that a woman is counted 
as having GSL In previous studies on the efficacy of devices it was not always 
apparent what the criteria were. It is essential to adhere to a working definition or the 
results collected will have no meaning outside the context of this clinical trial. The 
definition of intrinsic sphincter deficiency (ISD) remains unclear and its significance 
in the management of incontinence remains elusive and a definition based on 
reproducible quantitative urodynamic parameters and physical examination is 
lacking 2. Hence, no distinction or stratification was made of women having ISD as 
the cause of GSL 
There is no agreed standard criterion for making the diagnosis of GSI, so there is still 
confusion about which technique can best provide an accurate diagnosis in the patient 
suspected of having GS, 3. The techniques range in complexity from a cough stress 
test or observation of urine leakage from the external urethral meatus during a cough, 
cough UPP, a one, two or 48 hour pad test to video-cystourethrography involving 
multichannel urodynamic pressure studies with simultaneous fluoroscope examination 
of the lower urinary tract. The data from the study by Swift and Ostergard (1995) 
showed that no single test is 100% sensitive or specific for deleting GSI. Observed 
loss with a cough during multichannel urodynamics was the best individual predictor 
of GSI. In women with pure GSI, a positive cough stress test with a negative 
preceding cystometrogram was close to being 100% sensitive and specific. This is the 
most reliable predictor of GSI and if it is negative, then the diagnosis of GSI should 
be questioned. 
Rigorously defined clinical criteria are highly reliable in predicting the presence of 
GSI at the time of urodynamic testing. Nidela and Wall (1998) found that if a woman 
has the following: 
" predominant complaint of stress incontinence 
" positive cough stress test result 
" post-void residual urine volume of less than 50ml 
"a functional bladder capacity of at least 400ml as determined by a completed 24 
hour frequency/volume chart, 
4 
- then GSI could be predicted in 72 (97%) of 74 patients 
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These criteria together with observed loss on coughing during multichannel 
videocystourethrography and a negative cystometrogram were used in this study to 
detect GSI. For the assessment of the devices, a mean of two or more incontinence 
episodes per day was chosen as the event rate signifying the presence of moderate or 
worse stress incontinence. Based on pad weight test gains, a urine loss of 2g/h or 
more was classified as incontinent (according to the ICS) 1. A mean PWT gain of less 
than or equal to Ig was considered to signify continence. 
INCLUSION CRITERIA 
Women with a history of urinary incontinence. 
Women capable of understanding and having signed the informed consent 
after full discussion of the research nature of the therapy and the potential 
for adverse events. 
" Women with urodynamically proven GSL 
" Mobile women able to attend an outpatient clinic. 
EXCLUSION CRITERIA 
Women with any disease which in the opinion of the investigator makes her 
unsuitable for inclusion. 
Women with conditions contra-indicating daily introduction of a catheter- 
like device into the urethra. 
" Women who are pregnant or considering pregnancy. 
" Women with recurrent urinary tract infections (RUTI's) defined as 
treatment for UTI on 3 or more occasions in the last year. 
" Women with symptomatic acute urinary tract infections (UTI) during the 
run-in period. 
" Women with uninvestigated haematuria or haematuria secondary to 
malignant disease. 
" Any drug therapy for urinary urge incontinence, with the exception of any 
oestrogen therapy. 
" Women who have received any electrostimulation therapy or bladder 
training within the last 14 days or who expected to start such therapy during 
the study period. 
" Women aged greater than 80 years or less than 18 years. 
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DEVICE ALLOCATION 
Once women satisfied the inclusion criteria they were selectively allocated to one or 
other of the devices by alternating the type of device for the next subject. The study 
was non-blinded and the women acted as their own controls. I did not stratify the data 
according to age groups or degree of incontinence although this may have helped to 
ensure adequate representation of these different sections of the population. This was 
restricted due to the time constraints and resource limitations on the trial. On four 
occasions patients were incorrectly allocated the FemAssist device, hence the 
discrepancy in the numbers recruited to each group. 
PATIENT CHARACTERISTICS 
Demographic information, particularly related to the patients' age, race and family 
history, knowledge of the prevalence and the geographic distribution of the disease 
process are all commonly employed to exclude or confirm certain diagnostic 
possibilities. Because of the potential for co-morbidity in women over the age of 65, 
all women being considered for entry to the study were assessed for co-existing 
medical conditions and factors such as faecal impaction, confusional states, functional 
disabilities, hypertension and particular reference to the use of medications which 
may contribute to incontinence or might affect the outcome of the study. The 
following baseline characteristics were recorded for all women: 




" Urodynamic investigation 
" Disease history, primarily considering the lower urinary tract 
" Continence surgery 
" Type of urinary symptoms 
" Previous treatment for incontinence and the results regarding efficacy and 
adverse events 
" Present status of the woman 
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0 Concurrent diseases and symptoms 
All concomitant medication taken by the patient were recorded together with 
administration form, dose, frequency, start date and, when applicable, stop date at 
each visit. 
THE WTERVIENTION 
FEMASSIST URINARY INCONTINENCE DEVICE 
FemAssist Urinary Incontinence Device is a cap-shaped device, composed of silicone 
rubber. Patients were taught to place it directly over the urethra where it will be held 
in place by its own mild vacuum action (Figure 6.1). A small amount of lubricating 
gel was placed on the surface which comes in contact with the body. This helps 
maintain the vacuum seal and protects against accidental urine loss. When the woman 
wishes to void, she removes the device by pulling the base away from the urethra. 
The device should then be cleaned with soap and warm water and replaced over the 
urethra. The device should be disposed of at the first signs of wear or after 7 days. 
The device was sold by the manufacturer in boxes of four at a cost of E30. 







UrinaFy ((mbol Dowke 
Figure 6.1 Placement of the FemAssist continence device. 
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The intervention related complications, morbidity, risks and hazards associated with 
the devices have been described in detail in the chapter on continence aids. 
Women were trained in the safe use and method of use of each of the devices by the 
specialist nurse practitioner and myself. 
RELIANCE URINARY CONTROL INSERT 
This device is composed of non-toxic, thermoplastic material and comprises an oval 
meatal plate, a soft stalk and one sphere located at the distal end of the stalk. There 
are five siZes available and each subject was measured for the best fit (Figure 6.2). 
Figure 6.2 Five sizes of the Reliance device. 
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Patients were instructed in the method of how to gently insert the device into the 
urethra. Then a small balloon at the tip of the device is inflated, using a syringe-like 
applicator, to block the bladder neck opening and prevent the flow of urine (Figure 
6.3). The applicator is then removed, and the device remains comfortably in place as 
the bladder fills normally. When the woman desires to go to the lavatory, a simple 
tug on the device's string will deflate the balloon, allowing her to easily remove it. 
After urinating, she simply inserts a new Reliance. 
Women were given advice to use the device as they felt necessary and to adjust the 
timing and number used to accommodate their particular lifestyle and life events. 
The device was sold by the manufacturer in boxes of 50 at a cost of 00. 
No prophylactic antimicrobial therapy was used at any time during the study. 
TREATMENT SCHEDULE 
Visits were required at base line, after one, three and six months follow-up or 
whenever the woman was withdrawn. Any adverse events present at the end of the 
treatment were followed for at least 2 weeks. 
The investigations that were performed during the study are in the table 6.1. 
Schedule of events 
Recordings/Measurements Baseline 1Month 3Months 6Months 
Written infonned consent x 
Inclusion & exclusion criteria met 
Demographic data X 
Disease history X X X X 
Previous drugs for urge incontmence X 
Concurrent disease or symptoms X X X X 
Concomitant medications X X X X 
Blood pressure & physical examination X X X X 
Assessment of urinary diary X X X X 
Quality of life profile X X 
Patient self-assessment X X X X 
Weighted pad test X X X X 
Mid stream specimen of urine xxxx 
Table 6.1 Schedule of investigations that were performed during the study. 
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Differences in outcome can be expected depending on the time chosen for assessment 
in relation to the intervention. Short and long term results might be different. The 
outcome was evaluated after 6 months duration of therapy. We do not know what 
would be ideal. Whatever one chooses, if the subject was not in a stable phase at the 
time of assessment, further improvement or deterioration could be expected but not 
predicted. 
The following is a copy of the informed consent and infonnation leaflet given to each 
patient at entry to the trial. 
INFORMED CONSENT 
M Doctor Boos has explained to me the advantages and disadvantaged, the 
risks and the discomforts of the study. I have read the information, and I 
have had the opportunity to ask questions. I have had enough time to think 
it over. I understand the nature and the purpose of the study. 
01 understand that participating in this study is voluntary and that I can 
decide to withdraw without any reason given. This will not influence my 
further treatment and the relation with my doctor. 
MI know that for this study relevant medical data about me will be used for 
scientific study and for a possible publication. Herewith I agree, as long as 
my privacy is safeguarded. 
MI agree voluntarily to participate in this study. 









You are invited to participate in a clinical study involving the Reliance Urinary 
Control Insert and FemAssist Urinary Incontinence Device which are intended to act 
as a temporary barrier to keep urine from leaking out of the bladder until you are 
ready to go to the lavatory. 
A Reliance device is gently inserted into the urethra (outlet to the bladder). Then a 
small balloon at the tip of the device is inflated, using a syringe-like applicator, to 
block the bladder opening and prevent the flow of urine. The applicator is then 
removed, and the device remains comfortably in place as the bladder fills normally. 
When you desire to go to the lavatory, a simple tug on the device's string will deflate 
the balloon, allowing you to easily remove it. After urinating, you simply insert a 
new Reliance. 
For Reliance to work most effectively, your urethra will be measured by your doctor 
to ensure that the proper size is given to you. You will then be provided with 
Reliance devices tailored to your personal needs. You will also receive an applicator 
for properly inserting and inflating the Reliance devices. 
The FemAssist is a cap-shaped device, composed of silicone rubber. It is designed to 
be placed directly over the urethra where it will be held in place by its own mild 
vacuum action. 
A small amount of sealing lubricating gel is placed on the surface which comes in 
contact with the body. This helps maintain the vacuum seal and protects against 
accidental urine loss. The device stays in place for as long as is comfortable. When 
you wish to pass urine, you remove the device by pulling the base away from the 
urethra. The device should then be cleaned with soap and warm water and replaced. 
The device should be disposed of at the first signs of wear or after 7 days. 
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You may feel a bit nervous the first few times you practice using your device. This is 
perfectly normal. Just as inserting a tampon takes most women a few tries before it 
becomes a natural activity, all you need is some experience using a continence device 
before it becomes a simple and easy part of your daily routine. A series of activities 
has been carefully designed to familiarise you with how to use your device, starting 
outside your body so that you become completely comfortable with handling the 
device and its applicator before you begin using them in 'real life'. This will help you 
gain experience and build your confidence. Step-by-step instructions will be given to 
you by your Doctor and specialist Nurse. 
WHAT WILL HAPPEN DURING THE STUDY? 
You will be selectively allocated to use one of the two devices at the start of the study. 
We need to follow your progress over 6 months. This means that we will ask you to 
come to the centre at 1,3 and 6 months during the study. Before the treatment is 
started you will be asked a few questions about your disease and general condition. 
At each visit we will measure your blood pressure and perform a physical 
examination. A mid-stream sample of urine will be taken and a pad weight test 
performed at each visit. The pad weight test will be made clear to you and explained 
in detail by the doctor before each visit. You will also be required to complete a 
urinary diary and a brief Quality of Life questionnaire. 
WHAT RISKS ARE INVOLVED? 
In previous studies both devices were well tolerated and no serious side effects were 
seen. The incidence of adverse events is well within the range expected with other 
commonly accepted self-catheterization techniques. Moreover, these events tend to 
decrease in frequency overtime. Study results indicate that there is a learning curve 
with use of the insert. Women become more comfortable with the devices as they 
gain experience with continued use. 
154 
WHAT ARE THE BENEFITS? 
The results of clinical studies of these devices in women demonstrated that use is an 
effective means of managing urinary stress incontinence. Objective and subjective 
data indicate that women also experienced a significant improvement in their quality 
of life. 
Overall, there is high user satisfaction with both devices as an early non-surgical, 
non-implantable option in the control of urine leakage in stress incontinence. 
However, if you experience any adverse effects or other discomfort during the study it 
is important that you inform your doctor as soon as possible. 
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CONFIDENTIALITY 
Your family doctor will, if applicable, be informed of your study participation. The 
results of your treatment will be recorded on special forms. Your data will be stored 
confidentially and analysed after the study. The results of the study may be inspected 
by the Department of Health and authorised persons but confidentiality will always be 
maintained. The study is approved by the Medical Ethics Committee of your hospital. 
Your participation in this study is entirely voluntary. If you feel that you do not 
want to take part, just say so. Should you decide to participate, you would be free to 
withdraw from the study at any time. You should however first inform the doctor or 
specialist nurse involved with the study and return all devices. Such withdrawal will 
not in any way affect the standard of your future medical care and whether or not you 
participate, your doctors will give you the same standard of treatment. 
If you have any problems at all during the study, please contact: Professor Linda 
Cardozo, Department of Urogynaecology, Telephone: 0171737 4000. 
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in making a choice of outcome measures it is essential to have an understanding of 
the principles of measurement with regard to GSI. Measurement consists of the 
application of a set of rules for assigning values to events so as to represent quantities 
or categories of attributes. The rules must be clear-cut, unambiguous and 
standardised, so that the same results will be obtained by different researchers using 
the same instruments. Each instrument should also measure what it is intended to 
measure. In selecting the appropriate outcome measures for this thesis, we were 
mindful of the need for measures with established reliability and validity, the 
problems of responsiveness as well as practical considerations and feasibility. 
The use of health-related measures allows discrimination between individuals so that 
we can describe differences in health experience 1. We require a measure which is 
capable of detecting GSI so that we can identify and target this group for the 
interventions. The outcome measures are used for the purpose of evaluation, focusing 
attention on changes between points A and B, which are attributable to the 
intervention of continence devices, utilising not only quantitative and qualitative 
changes but also those of health and quality of life. Within these broad categories we 
are interested in detecting differences in groups and not individuals and measuring the 
magnitude of these differences or outcomes. The level of precision required of the 
outcome measure will be determined by the expected magnitude of differences. To 
assess the efficacy of two continence devices may require a much more precise 
measure as the expected changes may be relatively small. 
The outcome measures and methods of measurement are described in the thesis 
stating their objectives and intended purpose. The background and development are 
described, the method of scoring and scaling is summarised and available evidence on 
reliability and validity reviewed. Reproducibility data is provided or its absence 




PRINCILPLES AND CHOICE OF MEASURE 
The selection of an outcome variable depends on the nature of the interventions being 
studied. The end points were picked so that they best reflect the essence of the study. 
Outcome is to define and estimate the degree of reestablishment of function, 
complications, quality of life and morbidity related to device utilisation. No single 
measure can My express the outcome of an intervention. The study includes not 
only the outcome as judged by the patient, but also as it is estimated by the clinician 
and possibly society. Because these are difficult to render precise one must 
acknowledge that there is a hazard that the measures selected will reflect primarily the 
objectives of the clinician. There is a large difference between the outcome for the 
patient and the outcome assessed by the patient. A woman with GSI may be made 
"dry" with a continence device and be satisfied with the result but she still considers 
herself incontinent. 
The reliability of the methods and measurements used to assess the outcome of a 
study are vital to the scientific evaluation of that study so as to allow useful precise 
interpretation of the outcome 2. The reliability of a test depends on the accuracy and 
reproducibility of the method of measurement. The diagnostic accuracy is determined 
by verifying test results against a reference standard that defines true disease status. 
A combination of outcome measures will enhance the overall significance and value 
of the study. The measure chosen should reflect the degree of change or improvement 
with a high degree of correlation. These will all clarify the strength of the various 
measures. The following definitions and terms were applied'. 
Accuracy: conforming to a standard or a true value (accuracy is distinguished from 
precision in this way: a measurement or statement can reflect or represent a true value 
without detail). 
Precision: the quality of being sharply defined or stated through exact detail. 
Reliability: the degree of stability exhibited when a measurement is repeated under 
identical conditions. 
YgiLty: an expression of the degree to which a measurement measures what it 
purports to measure. 
lAn 
RESPONSIVENESS 
it should also be recognised that the usual methods of establishing reliability and 
validity do not necessarily indicate how responsive an outcome measure is to change. 
Responsiveness to clinically significant changes in individuals over time is a major 
consideration in this study where the aim is to evaluate the impact of continence 
devices. Many measures used in the assessment of women with GSI are not suitable 
for intervention studies because of lack of standardisation, poor or unproven 
reliability and validity and failure to identify small but clinically significant changes 
attributable to the intervention. In this thesis, I have given a description of such 
measures and a critique of their application. I have also described some outcome 
measures used in trials of similar devices which at first were considered inherently 
useftd but were excluded from use in the trial. 
Scientific criteria are vital but practical considerations are likewise important. The 
choice of the best measure for a particular property will often be a compromise 
between scientific rigor and practical constraints. The administration of the measure 
is one example. It may be self administered by the patient or administered by the 
researcher. When administered by the researcher, there are certain advantages and 
disadvantages. There are constraints of time and resources, and the sample population 
may be restricted to a small geographic area. In general the response rate is higher 
than self-administered measures. 
OUTCOME MEASURES IN 
LOWER URINARY TRACT DYSFUNCTION 
We have the methods to measure QoL, direct observations made by the physician 
(PWT, MSU, urinary diary) and patient (subjective measures of comfort, me of 
insertion, urinary leakage with device in situ). The woman may be satisfied with the 
device because the symptom of stress incontinence is reduced or "cured7, but the 
clinician may be dissatisfied because the degree of PWT improvement was less than 
expected. Society at large may be content as the patient can go to work and the 
patient's relatives may be pleased because she can participate in common activities 
once more. The outcome of the trial Will be described with measures from the 
following domains: 
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1. PATEENT'S OBSERVATIONS 
2. CLINICIAN'S OBSERVATIONS 
3. QUALITY OF LIFE AND IMPACT OF SYMPTOMS 
All methods, definitions and units conform to the standards recommended by the 
International Continence Society, except where specifically noted 4. 
DOMAIN OF PATIENT'S OBSERVATIONS 
MEASUREMENT OF PATIENT OBSERVATIONS AND SYMPTOMS 
Patient self-assessment is fundamental but as an outcome measure, patient derived 
symptoms response is insufficient on its own 'in diagnosing the aetiology of bladder 
dysfunction or response to intervention. We acknowledge that the accuracy of self- 
reported data is questionable and interpretation of clinical versus statistical 
significance is difficult. It is a common clinical experience that a stoical individual 
may cope well with symptoms of incontinence which in a more fastidious patient 
would prove intolerable. To help improve the quality of the data, the presence and 
degree of severity of urinary symptoms was assessed using the Kings Health urinary 
symptom questionnaire and will be described later. 
FOREIGN BODY SENSATION 
Women were asked to note whether or not they experienced any bothersome foreign 
body sensation with device use. Subjects were instructed to consider any unpleasant 
or uncomfortable sensation within the vagina as "irritating". They were also asked to 
note if it persisted for the duration of device use or if it wore off over the time of that 
single device use. They also noted any persistence of foreign body sensation after the 
device was removed. 
EASE AND COMFORT OF DEVICE USE 
Patient ratings on ease of placement and comfort of use, assessment of urine loss with 
specific activities and the overall protection afforded by device use were recorded at 
each follow-up visit. 
I Al 
Self-assessment of ease of placement of each device was graded via a five point scale. 
This also allowed comparison of patient experiences during use of devices. 
E I= Very easy to place device 
E 2= Easy 
0 3= Manageable 
0 4= Difficult 
N5= Very difficult 
Self-assessment of the comfort of use of each device was graded via a five point scale. 
0 I= Very comfortable 
0 2= Comfortable 
0 3= Mild discomfort 
N 4= Uncomfortable 
0 5 = Very uncomfortable 
URINE LOSS WITH SPECIFIC ACTIVITIES 
Self-assessment of urine loss before and after device insertion via a five point rating 
scale was used. This allowed comparison of patient experiences during various 
activities prior to and during use of the devices. 
N 1= No urine loss 
0 2= Slight urine loss 
0 3= Mild urine loss 
E 4= Moderate urine loss 






Low impact exercise 
Higli impact exercise 
Cough/sneeze/laugh 
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ASSESSMENT OF OVERALL DEGREE OF DRYNESS 
Women rated the overall degree of protection afforded (dryness) using a five point 
rating scale. 
N 1= No urme loss 
E 2= Slight 
E 3= Mild urine loss 
0 4= Moderate urine loss 
N 5= Severe urine loss 
DOMAIN OF CLINICUN'S OBSERVATIONS 
QUANTIFICATION OF URM LOSS 
To assess and compare the results of treatiment of incontinence in different centres, the 
ICS Standardisation Committee has issued guidelines on tests to measure or quantify 
urine IOSS4 . The number of incontinence episodes experienced per week, the number 
of continence pads used per week, both recorded on a urinary diary and the amount of 
fluid lost on a quantitative pad weight test are three standardised and validated 
measures of incontinence severity in women (Table 7.1)56. 
Standardised measures of incontinence severity 
1. The number of incontinence episodes experienced per week recorded 
prospectively on a 5-day urinary diary. 
2. The number of continence pads used per week recorded prospectively on a5 
day urinary diary 
3. The amount of fluid lost on a quantitative pad test. 
Table 7.1 Standardised and validated measures of incontinence severity in women. 
I AA 
URINARY DIARY 
Symptoms such as the frequency of incontinence episodes are susceptible to error of 
recollection. It is thus of great importance to gain an objective assessment not only as 
an aid in deciding on the presence and severity of a problem but also on the results of 
its management. This would also be important in evaluating interventional therapies 
such as continence devices and for comparing results not only within the trial but also 
with other clinical trials of similar devices. The frequency/volume chart is one such 
objective measure and records the systematic registration in point of time of voiding 
and voided volume performed by the patient for a specified period of time. The chart 
can be supplemented with the registration of incontinence episodes. Measurements 
obtained from the frequency/volume chart include total voided volurne per 24 hours, 
frequency of micturition, mean voided volumes, range of voided volumes and 
incontinence episodes. It is a simple and non-mvasive method of documenting urine 
loss and has the potential to be reliable and sensitive to therapeutic interventions 7. A 
3 day diary indicating frequency of micturition, voided volumes and incontinence 
episodes is very helpful and even a 48 hour frequency volume chart has been shown 
to be a valuable and credible instrument for assessing micturition patterns in women 5 
8 
. Urinary 
diaries have been shown to be a particularly reliable method for assessing 
the frequency of incontinence episodes and have been used successfully in studies of 
women with GSI 5- Since the chart represents an objective account of the patient's 
history it carries by definition a high degree of internal validity. It is a recording of a 
real life event whereas a urodynamic investigation is an attempt to recreate a situation 
in a laboratory setting 9. 
Wyman et al (1988) investigated the use of a one-week urinary diary in the 
evaluation of 50 community-dwelling incontinent women 5. Diurnal micturition 
frequency, nocturnal frequency and number of incontinent episodes were highly 
reproducible and did not differ by urodynamic diagnosis. Test-retest correlation was 
highest with diurnal frequency and incontinence episodes. The value of routine 
registration of flUld intake would appear to be limited mostly to those with irritative 
urinary symptoms and in studying the results of treatment in patients with these 
symptoms of frequency, urgency and urge incontinence 9- Registration of fluid intake 
on the follow-up diaries was not recorded in the study. The mere task of recording 
may of course increase the awareness of the bladder which could lead to modified 
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voiding behaviour. This approach relies on the ability and willingness of the subjects 
to comply with the study. 
NORNLAL VALUES 
There are good data available on what should be considered a normal 
frequency/volume chart. Kassis and Schick (1998) established baseline data on 
normal asymptomatic women. They found that the functional bladder capacity was 
larger at night and voided volume tended to double the daytime volume. Nocturia 
was rarely seen and frequency was about 6 times per day. The mean total voided 
volume was 1473ml (± 386ml) and the ratio between night-time and daytime diuresis 
was 0.81 (± 0.3) 10. The parameters of the urinary diary are summarised in table 7.2. 
Parameters of the urinary diary 
Parameters Daytime period 
Mean voided volume (ml) 237 (± 67) 
Frequency 5.63 (± 1.26) 
Diuresis (ml/min) 1.11 (± 0.35) 
Time to next voiding (min) 222 (± 60) 
Total voided volume (ml) 1005 (± 497) 
Output per 24 hr (ml) 1473 (± 510) 
Night-time period 
379 (± 132) 
0.08 (± 0.16) 
0.84 (± 0.27) 
454 (±50) 
409 (±130) 
Diuresis ratio (night/day) 0.81 (± 0.30) 
Table 7.2 The parameters of the urinary diary. Mean (± Standard Deviation) 
Normal values with reference to the frequency volume diary for a healthy female 
population as well as values for women with GSI and with urge incontinence have 
been documented by Larson and Victor (1988) 11. Table 7.3 shows the median, 2.5 
and 97.5 percentile of the measures of the frequency/volume chart. 
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Frequency / voluMe chart 
Normal Urge Stress 
Incont. Incont. 
Total voided vol (ml/24hrs) 1350 1490 1550 
2.5 and 97.5 percentile 630-2580 630-2390 750-2800 
Frequency of micturition/24hrs 5.5 9.5 6.5 
2.5 and 97.5 percentile 3.5-9 5.5-14.0 4-10.5 
Mean voided vol (ml) 240 170 220 
2.5 and 97.5 percentile 120-430 70-270 110-430 
Voided vol (ml) 350 250 400 
2.5 and 97.5 percentile 140-950 70-650 180-790 
Largest single voided vol (ml) 450 330 500 
2.5 and 97.5 percentile 200-1000 150-700 200-850 
Table 7.3 The median, 2.5 and 97.5 percentile of the measures of the 
frequency/volume chart. {Larson and Victor (1988)). 
It was a requirement of this trial that women completed a 5-day urinary diary for the 
week preceding their urodynamic investigations recording fluid intake, urine output, 
incontinence episodes and the number of pads used. At follow-up visits, similar 
diaries were kept but without measurement of voided volumes. 
PAD VVEIGIUING TESTS 
The health care attendants subjective assessment of "wetness" has been shown to be 
an extremely crude indicator of the degree of incontinence when compared to weight 
gains in pads in the same individual 12 . 
Difficulties with determining "wetness" can 
be overcome by weighing pads before and after specified time intervals. The pad- 
weighing test is one of the earliest, best known and most extensively used measure of 
the presence and severity of urinary incontinence in women and is reliable and 
reproducible 13 14 15 . The indications 
for a pad test are to quantifý urine loss either 
before or after an intervention or treatment or to confirm incontinence in a woman 
who is not incontinent during a more formal urodynainic investigation. Objective 
assessment of the seventy of stress incontinence by weighing perineal pads influences 
16 
the t)W of treatment and can be used to monitor the response to treatment . 
The 
PWT is designed for completion by an observer. It is easily performed and readily 
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applicable in a clinical situation. For these reasons it is well suited for use in routine I- it 
clinical and research practice. 
Pad tests fall into two broad categories, those that are carried out in hospital, 
laboratory or office and those that are conducted by the patient in the home or work 
17 
environment 
The 24-hour home pad test has the advantages of being performed in familiar 
surroundings and can include known provocative situations which may be impossible 
to duplicate in a laboratory. However, studies suggest that the reproducibility of the 
test seems insufficiently satisfactory to allow its use in comparative scientific studies 
18 
To standardise the pad test, the ICS introduced the one-hour pad-weighing test 
which measures the urine loss as weight gain of perineal pads under standard 
conditions 4. The reproducibility is improved by having a standardised volume in the 
bladder but this does require catheterisation of the patient and adds to the invasive 
nature of the test 19. Clear and unambiguous instructions also ensures high levels of 
reliability. 
The amount of urine lost during the investigation is determined by weighing a 
collecting device such as a nappy or absorbent perineal pad. Immediately before the 
test begins the collecting device is weighed to the nearest 0.5 gram. The pad is wom 
inside the subjects underpants. Care is taken to use the correct size of pad in relation 
to the expected quantity of leakage based on the patient's guidance and the 
urodynarruc test results. At the end of the one-hour test the collecting device is 
removed and reweighed. In interpreting the results weight increases of less than I 
gram can be due to perspiration, discharge and weighing error. If the collecting 
device becomes saturated during the test it is removed, weighed, and replaced by a 
fresh one. 
The following is the typical test schedule for the ICS pad test as practised at KCH 
and used in the trial. 
PAD VVEIGHT TEST SCHEDULE 
Patient voids to completion. 
2. The patient is catheterised using an aseptic technique and the residual volume 
recorded. 
IAR 
3. The bladder is filled via the indwelling catheter with 250ml of normal saline using 
gravity fill. The catheter is then removed. 
4. The pre-weighed pad is put on and the I hr test begins. 
5. The subject does not drink during the test. 
6. Over a 30-minute period, the subject walks, including stair-climbing equivalent to 
one flight up and down. 
7. During the remaining period, the subject performs the following activities 
* standing up from sitting, 10 times 
* coughing vigorously, 10 times 
r* starjumps for I minute 
r* bending to pick up a small object from floor, 5 times 
* washing hands in running water for I minute. 
8. At the end of the 1 -hour test the pad is removed and weighed. 
9. If the test is regarded as representative, the subject voids and the voided volume 
recorded. 
Certain modifications to the PWT schedule are sometimes necessary. If the pad 
becomes saturated during the test, it is removed and weighed and replaced by another 
fresh pre-weighed one. The activity programme is modified according to the 
individual's physical ability. Any variations are noted so that the same level of 
activity is performed in subsequent visits for that individual subject. 
Versi and Cardozo (1986) investigated the sensitivity of perineal pad testing and the 
videographic diagnosis of GSI in postmenopausal women 20. They found that despite 
individual variations, the severity of GSI detected videographically was corroborated 
by the findings on pad testing. If the videographic diagnosis of GSI was accepted as 
the "Gold Standard" then the pad weighing test had a 14% false-negative rate,, 
implying that videographic testing was more sensitive and probably more specific 
than pad tests in the diagnosis of GSI. However, the technique they used involved 
physiological filling of the bladder by drinking 500m] of water over 20 minutes prior 
to the I -hour test. The test was not performed with a standard volume of urine in the 
bladder for all subjects. The 99% upper confidence limit for pad weight gains in 90 
normal women was 1.4g. There was no statistical difference between the mean pad 
weight increase in young or postmenopausal women (0.33g Vs 0.40g respectively). 
The overall mean pad weight gain was 0.3g. 
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NORMAL PNW 
Sutherst et al (1981) assessed 50 healthy women with normal unnary control and 
performed a 1-hour pad weight test so as to provide data to compare in women with 
16 GSI . The mean PWT increase per hour was 0.26g (SD 0.36, range 0-2.1). The 
greatest weight increase in any 10 minute period averaged 0.15g (SD 0.17, range 0- 
0.8). It was thought that these small weight gains were due to perspiration or vaginal 
discharge. In 95% of women (mean + 2SD) the total weight gain was less than Ig 
over the whole hour and not more than 0.5g in any one pad. 
Lose et al (1989) found that the 95% upper confidence limit was 8g over 24 hours, 
so it is reasonable to assume that the home pad test will result in a background loss of 
21 less than Ig every 3 hour of pad use 
Wall et a] (1990) performed the ICS standardised PWT In 23 asymptomatic 
continentwomen. The maximum PVVT gain was 0.7 g (mean 0.1g) 
In a later study by Versi et al (1996) it was demonstrated that the mean PWT 
increase over 48 hours in continent women was 7.13g (SD 4.32) giving a 95% upper 
confidence level of less than 15 g 22. 
The findings of various authors on the pad weight test gains in normal women is 
depicted in table 7.4. 
Pad weight test gains in normal women 
Study PVff gain (mean) 
Sutherst (1981) 0.26g (max 2.1 g) per hour 
Versi (1986) 0.3g per hour 
Lose (1989) 8g per 24 hours 
Wall (1990) 0.1 g (max 0.7g) per hour 
Versi (1996) 7.13e, t)er 24 hours (SD 4.32) 
Table 7.4 Illustration of the findings of various authors on the pad weight test gains 
in normal women. 
MEASURES TO ASSESS URETHRAL FUNCTION 
The correlation of urodynamic measures of urethral resistance with clinical measures 
of incontinence seventy in women with pure genuine stress incontinence is not 
straightforward. 
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URETHRAL PRESSURE PROFHE 
The urethral pressure and the urethral closure pressure are idealised concepts which 
represent the ability of the sphincter mechanism to prevent leakage. Urethral pressure 
measurement is a procedure used for assessment of the urethral sphincter function 
during storage. In current urodynarnic practice the urethral pressure is measured by a 
number of different techniques which do not yield consistent values. Not only do the 
values differ with the method of measurement but also there is often lack of 
consistency for any single method 4. 
Urethral pressure transmission ratios of less than or equal to 90% is considered a 
positive result 23. If it occurs in any one third of the urethra it has limited 
discriminatory ability with a 54% sensitivity and 79% specificity. If it occurs 
throughout the length of the urethra this is more specific (93%) but has such a poor 
sensitivity (22%) that it is of little clinical use in detecting GSI. 
The techniques available are subject to pitfalls in interpretation and test-retest 
variation. The UPP parameters do not 1) discriminate stress incontinence from other 
disorders, 2) provide a measure of the severity of the condition and 3) return to 
normal after successful incontinence surgery. It is however helpful in demonstrating 
a low pressure urethra which may have therapeutic implications 24 25. 
PRESSURE TRANSMISSION RATIOS 
The correlation between the degree of urethro-vesical junction mobility and the 
urethral pressure transmission ratio (PTR) is not a reliable predictor of increased 
bladder neck mobility 26 . It is widely accepted that pressure transmission ratios are 
subject to marked variation and the overlap in values between normal and women 
with GSI is so great that the PTR cannot be regarded as a valid method of predicting 
whether the urethral closure mechanism is competent or not to start with 2728 . Hence 
it can not be reliably used to detect any change in the continence mechanism or 
urethral function as a result of using one or other of the devices for the period of the 
study. 
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VALSALVA LEAK POINT PRESSURE 
The Valsalva leak point pressure (VLPP) is a recently introduced urodynamic study 
that was described by McGuire et al (1993) as the measure of the total abdominal 
pressure to initiate urinary leakage demonstrated on VCU with the subject 'in the 
upright position with aI OF catheter in situ and 150ml in the bladder 29. It has rapidly 
gained favour in the investigation of adult female urinary incontinence. It is currently 
being endorsed as a severity measure for dysfunction of the continence mechanism 
and for evaluating women with GSI and to diagnose the condition termed intrinsic 
sphincter deficiency QSD). The values attained in urodynamic testing are being 
advocated for use in clinical trials despite a relative lack of outcome data. 
Multiple parameters have been shown to affect the VLPP: catheter calibre, catheter 
location (vaginal versus intra vesical), bladder volume, the use of coughing versus 
Valsalva as the provocative manoeuvre, patient position and the use of absolute or a 
change in measured pressure 30 . But most importantly, there is no agreement on how 
to perform the test. Until a standardised validated technique is defined and accepted, 
investigators will not be able to compare data in clinical trials or make 
recommendations regarding patient management 3 1. 
In summary, UPP, PTR and Valsalva LPP measurements are unnecessary to make 
the diagnosis of GSI or quantify urine loss according to the criteria of the ICS. 
Dynamic UPP variables have no correlation with the severity of urethral sphincter 
dysfunction. In addition it is not known whether UPP or Valsalva LPP are valid 
measures of urethral sphincter dysfunction in women with anterior vaginal wall 
prolapse of varying degrees since pelvic organ prolapse can affect both active and 
passive measures of urethral resistance. Hence we felt that the stress UPP and the 
VLPP could not be used as baseline and outcome measures to assess urethral 
sphincter function prior to and following the interventions used in the study. For 
these reasons the pad weight test gains Without the device in situ at the completion of 
the study were compared to the baseline test results and used as a measure of change 
in urethral function as a consequence of device use over time. 
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DOMAIN OF QUALITY OF LIFE WASUREMENTS 
AND IMPACT OF SYMPTOMS 
WEALTH STATUS PROFMES 
Regardless of how it is derived, an index of health should have certain desirable 
properties: 
Reliability validity and sensitivity to change 
Consists of clearly defined component parts 
Each question makes an independent contribution to the event 
measured 
0 Scoring and interpretation is simple and meaningful 
Two measurement approaches are commonly used to assess health-related quality of 
life (HRQL): generic and condition-specific. Generic HRQL instruments are 
designed to be used across multiple disease states or conditions and gender norms. 
These may include instruments that measure only a single area of HRQL or those that 
measure multiple areas. Generic measures are designed for general applicability 
rather than specifically for a single condition. Instruments able to measure single or 
multiple HRQL areas are available, however, few of these have been tested for 
reliability and sensitivity in incontinent female populations. Results firom generic 
measures can of course be compared with data from other populations and illness 
groups. For example, normative data can be used to compare health status data from 
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a particular patient group with that of the general population 
Where generic measures are insufficiently responsive to clinically significant 
change, a disease specific measure is necessary which is designed to measure the 
impact of a particular condition. or are used to detect the effect of intervention. These 
instruments tend to be more responsive than generic instruments in detecting 
treatment effects. Generally, the symptom scales include measurement of the 
presence of a symptom as well as the "bothersome" or "troublesome" nature of it. It 
is however still important that disease specific measures are used alongside the 
generic measures to elucidate certain aspects of III health that are unique to particular 
illnesses. Questionnaires are often developed and used in studies without prior 
piloting and validation or previously validated instruments are used inappropriately 
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without due consideration for the sensitivity required of the instrument or its 
33 
applicability to the study population 
THE UK SHORT FORM 36 
HEALTH SURVEY QUESTIONNAME (SF-36) 
The SF-36 is a health status questionnaire developed as a result of two large scale 
American studies. The first, the Rand Health Insurance Experiment (RHIE), was a 
research project to determine the best possible methods for measuring a broad array of 
functioning and health status concepts and to compare the outcomes of different 
methods of delivering care 34 . The Medical Outcomes Study (MOS) developed and 
refined these measures further and was a large scale test of the feasibility of self- 
administered questionnaires and generic scales to assess the outcome of medical 
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care 
Description of the SF-36 
The SF-36 is a short questionnaire with 36 items which measure eight variables 
(Table 7.5). There is a further unscaled single item on changes in respondent's health 
over the past year. This item was not analysed for the purpose of this thesis as follow- 
up was performed six months following treatment and rewording the questionnaire 
was not appropriate. 
Dimensions of the Short Form 36 
0 Physical function (10) 
0 Social function (2) 
0 Role limitation due to physical problems (4) 
0 Role limitation due to emotional problems (4) 
0 General mental health (5) 
0 Energy / vitality (4) 
0 Bodily pain (2) 
0 General health perceptions (5) 
Table 7.5 Dimensions of the Short Form 36 (Numbers in brackets refer to the 
number of questions in each dimension). 
Scores on each of the dimensions are obtained by summing item responses and with 
the use of a scoring algorithm, transforming these raw scores into a scale from 0 
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(worst possible health state) to 100 (best possible health state). By this method each 
of the individual domains which contain a different number of items are scored out of 
the same total and can therefore be compared with one another. The developers 
suggest that the SF-36 should take respondents approximately 5 to 10 minutes to 
complete. Evidence from studies in the United Kingdom suggest that respondents 
find it easy to complete and response rates in postal surveys using the questionnaire 
are high 36. 
VALUDATION, RFLIABHFfY TESTING 
AND NORMATIVE VALUES 
Two recent British studies have confirmed the reliability and validity of the SF-36 and 
provided normative data. The first, 'The Oxford health life survey', was a postal 
survey in which the SF-36 and questions on lifestyle, demographics and medical 
health were sent to 13,042 randomly selected subjects aged 18 to 64 years residing in 
Bershire, Buckinghamshire, Northamtonshire and Oxfordshire. The response rate to 
questioning was 72%. The internal consistency of the variables in the SF-36 was 
assessed with the Chronback's alpha statistic and results are shown in table 7.6. 
Internal consistency testing of the SF-36 
Dimension Chronback's 
AlPha 
Physical function 0.90 
Social function 0.76 
Role limitation due to physical problems 0.88 
Role limitation due to emotional problems 0.80 
General mental health 0.83 
Energy / vitality 0.85 
Bodily pain 0.82 
General health perceptions 0.80 
Table 7.6 The internal consistency testing of the SF-36. (Jenkinson et al 1993) 
Garrett et a] (1993) used the SF-36 to evaluate four different medical conditions. 
1,787 patients aged 16 to 86 were selected from four large group general practices in 
the Grampian area. All of the patients had either low back pain, menorrhagia, 
suspected peptic ulcer or varicose veins. A random sample of 900 members of the 
general population, selected from the electoral register for Aberdeen served as a 
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comparison group. The response rate to questioning was 75.5% from the patient 
group and non-responders were significantly younger than responders. 60.2% of the 
control group completed the questionnaire. Chronback's alpha coefficients for all 
eight scales of the questionnaire exceeded 0.8 satisfying the cniteria for internal 
consistency testing. Validity testing confirmed that modifying the questionnaire to 
make it suitable for the British public had not altered its validity. The designers of the 
questionnaire suggest that where normative data sets exist these can be used for 
comparison purposes with other populations and samples and this was performed in 
this thesis. 
ADVANTAGES AND LIMITATIONS OF THE UK SF-36 
The SF-36 is short, acceptable to patients and covers a wide range of areas that may 
be adversely affected by health. The questionnaire has the potential advantage that it 
may be more sensitive to lower levels of dysfunction and disability. Scoring is by a 
discrete adjectival as opposed to a dichotomous scale which may explain its greater 
sensitivity. Population norms are available for use in the UK and are published in the 
SF-36 users manual. 
DISEASE SPECIFIC QUALITY OF LIFE ASSESSMENT 
KINGS HEALTH QUESTIONNAME 
The Kings Health Questionnaire (KHQ) was developed and validated as a condition- 
specific instrument to measure and objectively evaluate the quality of life and impact 
of symptoms of women with urinary incontinence 37 . It has also 
been used as a 
predictor of the course of incontinence, needs of care and ftinctional outcome of 
women with GSI. The intention of the authors was to acquire a measure which could 
be used in both research and clinical practice to judge the efficacy of different 
interventions III the management of urinary incontinence. The questionnaire is 
intended for use alongside a generic questionnaire such as the SF36. By using both 
questionnaires simultaneously the QoL of women with urinary problems can be 
compared to that of women with other conditions whilst retaining the additional 
sensitivity of the specific measure for intervention studies. 
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The KHQ is designed to be self-administered by the patient and should be completed 
in approximately 10 minutes by most women. It is also designed for postal survey. 
There are 21 questions presented in eight different domains, with a separate scale for 
measurement of the severity of urinary symptoms. A four-point scoring system is 
used for each of the items, and includes an inapplicable option to enable all 
respondents to answer each item of the questionnaire. This system allows each of the 
domains to be scored out of the same total and therefore each contributes similarly to 
the overall questionnaire score. Scores in each domain range between zero and 100, a 
higher score indicating a greater impairment of quality of life. The KHQ is designed 
for the assessment of urinary incontinent women and therefore the domains of 
incontinence impact, urinary symptoms and incontinence seventy measures are not 
found in the SF36. In addition, sleep disturbance and sexual impairment are both 
major determinants of the QoL impairment of urinary incontinent women and both are 
included in the KHQ Unfortunately no questions relating to these aspects of the QoL 
of respondents are included in the SF36 which is a major criticism of the value of the 
SF36 used to assess urinary incontinent women. Despite these differences there are 
domains common to both questionnaires and these are shown below (Table 7.7). 
Domains common to both questionnaires 




Incontinence severity measures 














Energy / vitality 40 0 
Table 7.7 Domains common to the SF-36 & KHQ. 
RF, LLA, BH, ITY AND VA-LI]DrfY 
Internal consistency was measured using Chronbach's alpha statistic 38 - An alpha 
value of 0.7 or more is thought to be acceptable. internal consistency exceeded this 
requirement in all domains (Table 7.8). The reliability of the questionnaire was 
excellent in terms of its internal consistency and its test-retest reliability. 
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Domain of Internal Test Retest scores Rho 
KHQ consistency 
Limitations Mean (SD) 
Role 0.785 Test 1 35.89(29.41) 0.94 
Test 2 37.84(27.33) 
Physical 0.725 Test 1 42.79(28.92) 0.96 
Test 2 44.29(28.20) 
Social 0.785 Test 1 20.32(22.65) 0.80 
Test 2 22.87(21.57) 
Personal 0.892 Test 1 10.51(14.72) 0.87 
Test 2 12.61(15.27) 
Emotional 0.876 Test 1 37.34(28.30) 0.92 
problems Test 2 39.16(26.64) 
Sleep/energy 0.784 Test 1 46.40(26.05) 0.88 
upset Test 2 48.10(25.30) 
Severity 0.778 Test 1 44.44(28.77) 0.94 
measures Test 2 47.00(25.62) 
Table 7.8 Internal consistency (Chronbach's alpha statistic) and test-retest reliability 
scores for the KHQ (Spearman's rho non-parametric correlation coefficients). 
CRITERION VALIDITY TESTING 
The criterion validity of the KHQ was confirmed against the UK SF-36. Spearman's 
correlation coefficients were used to compare the results of the KHQ and the SF-36 in 
the common domains (table 7 . 
9)37 
. 
There was a significant correlation between the 
common domain scores for both questionnaires. 
Correlation coefficients between domain scores on the SF-36 and KHQ 
Domain Spearman's correlation IR (Significance)) 
General health -0.648 (p<0.001) 
Incontinence Impact 
Urinary symptoms 
Incontinence severity measures 










-0.342 (p < 0.01) 
-0.461 (p < 0.005) 
-0.512 (p < 0.001) 
-0.465 (p < 0.001) 
NA 
. 
Energy / vitality -0.617 (p < 0.001) 
Table 7.9 Domains covered by the Kings Health Questionnaire and the UK Short 
Fonn 36 health survey questionnaire applicable to urinary incontinent women. 
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(Correlation coefficients (Spearman's) between domain scores on the two 
questionnaires). (Kelleher et al 1996) 
CONCLUSION 
Health is more than the absence of disease and its negative consequences and much 
emphasis has been placed on the quality of life of the individual and positive health. 
The concept of positive health has important implications for attempts at 
measurement. Outcome measures must incorporate ways of assessing the subjective 
experiences of the individual while using a particular device. We can measure patient 
satisfaction with the intervention in terms of the individual's own particular frame of 
reference or against universal criteria. The measures developed for the KHQ have 
been thoroughly tested for reliability and validity. Initial validation studies of the 
KHQ have shown that it possesses the basic psychometric properties required of a 
condition specific questionnaire for the assessment of women with urinary 
incontinence. Women who completed the King's Health Questionnaire also 
completed the UK Short Form 36 health survey questionnaire. This questionnaire 
was chosen as it is the most recently developed of the accepted generic quality of life 
measures. In addition the questionnaire is presented in the same manner as the KHQ. 
The major difference between the two questionnaires is that high scores on the KHQ 
represent a poorer QoL whereas higher scores on the SF36 indicate a better QoL. 
The aim of the follow up phase of the thesis was to present the same questionnaires 
completed at enrolment into the study at a suitable interval following treatment with 
the continence devices. In order to allow follow up of a large group of women, an 
interval of six months following the commencement of therapy was chosen as a 
reasonable time over which to detect some change in QoL. 
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CHAPTER EIGHT 
NWASURES OF THE CONSEQUENCES OF TREATMENT 
I Rl 
Evaluation of the treatment of stress incontinence with devices necessitates an 
assessment of effect. The outcomes against which success or failure are measured 
have traditionally been defined in terms of the presence or absence of disease. The 
medical model views disease within the following framework: 
Aetiology - Pathology - Manifestations. 
The test of continence devices is to eliminate the manifestations of urethral sphincter 
incompetence, namely the symptom of stress incontinence, through preventative 
means. While one is setting about obtaining a cure, it should be possible to alleviate 
the impact of the disease. It is not a treatment for the underlying conditions in which 
case our intervention would be measured in terms of a simple dichotomy, the presence 
or absence of ailment. But outcome needs to be defined as more than the lack of the 
manifestations of disease and must include other measures of the health of the 
individual patient. It is useful to think in terms of the consequences of GSL Any two 
women suffering from stress incontinence will have widely differing needs because of 
the particular manifestations of the disease and its severity at a point in time. 
Over the years, a variety of terms have been developed to provide a framework for 
describing the consequences of disease. The World Health Organisation (WHO) 
International Classification of Impairments, Disabilities and Handicaps is useful as it 
provides a clear distinction between the consequences of disease at three different 
levels; the continence mechanism, the individuals performance and the response of 
society (Table 8.1). Firstly, something abnormal occurs within the individual giving 
rise to urinary dysfunction (pathology) which then becomes evident. The pathological 
state becomes exteriorised and the woman is aware she is unhealthy because of the 
symptoms of incontinence. This heralds the recognition of impairment. Next, 
alterations in performance or behaviour of the individual result and represent the 
consequences of impairment and are termed disability. Finally, impairment or 
disability may place the woman at a disadvantage compared to others in society. This 
experience of disadvantage represents handicap 
VMO concept of consequence of disease or disorder 
Disease or impairment Disability Handicap 
Disorder 
Intrinsic Experience Experience Experience 
Situation extenonsed objectified socialised 
Table 8.1 The WHO International Classification of Impairments, Disabilities and 
Handicaps. 
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This concept provides a useful and comprehensive framework not only for classifying 
the consequences of GSI for the individual, but also for evaluating the effects of our 
intervention, namely continence devices. 
FACTORS TO CONSILDER FOR OUTCOME STUDIES IN PATIENTS WITH 
LOWER URINARY TRACT DYSFUNCTION. 
GRADING OUTCOME 
Bo et al compare the effect of pelvic floor exercises, electrical stimulation, vaginal 
2 cones, and no treatment for genuine stress incontinence . The main outcome 
measures included the following: Maximum closure pressure, Pelvic floor muscle 
strength, Episodes of leakage in 3 days, Stress pad test (g), 24 h pad test (g), Leakage 
index and Social activity index. After 6 months there was no difference in the 
outcome measures of the women in the untreated group. This is a very good study 
demonstrating the natural history of genuine stress incontinence in women over a six 
month period. 
Elimination of the symptom of stress incontinence is the goal of treatment and this 
comprises the expected outcome. A responder may be characterised by a response in 
the direction towards the normal and of a size exceeding the value of the test-retest 
variations. The definition of cure and normalisation is difficult in this study because 
the intervention is directed against symptoms and not against the underlying defect in 
the continence mechanism, so we can never expect to heal. The woman who uses a 
continence device might experience normalisation but the structural and functional 
defects remains: the PWT are the same or worse after 6 months. It may be better to 
evaluate continence devices in terms of the degree of improvement of symptoms 
(Table 8.2). 
Evaluation of the outcome of 
The use of continence devices 
Cure 
Normalisation. 
Degrees of improvement 
Restoonders or non-resi)onders 
Table 8.2 Factors to consider in the evaluation of the outcome. 
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it is impossible to accurately measure or even be aware of all potentially confounding 
variables when examining the relationship between the use of continence devices and 
the outcomes of that intervention. In order to measure and compare the benefits and 
risks of various continence devices one may utilise a number of approaches. The 
efficacy of the devices can be assessed against the standards set by other conservative 
and surgical methods of management already available. The following are measures 
of efficacy and treatment effect which were applied to the results of the study (table 
8.3). 
Measures of efficacy and treatment effect 
1. Relative risk reduction 
2. Absolute risk reduction 
3. Number needed to be treated 
Table 8.3 The measures of efficacy and treatment effect used in the trial. 
RMIJECALATIVE RISK REDUCTION 
Relative risk reduction is the reduction of adverse events achieved by a treatment, 
expressed as a proportion of the control rate. It is the difference in event rates 
between the control and treatment groups, divided by the event rate in the control 
group. One disadvantage of this measure of efficacy is that it does not reflect the 
magnitude of the risk without therapy. It Will therefore overestimate or underestimate 
the absolute impact of therapy when adverse events in untreated patients are very rare 
or very uncommon respectively. Incontinence before use of a device was very 
common, so its clinical usefulness as a measure of efficacy suffers somewhat. 
ABSOLUTE RISK REDUCTION 
The absolute risk reduction or attributable risk reduction is the difference in event 
rates between the control (pre-treatment) and treatment groups. The advantage over 
the relative risk reduction is that it is an expression of the consequences of giving no 
treatment and therefore provides an additional measure of clinical effect. 
NUMBER NEEDED TO BE TREATED 
I RA 
The "number needed to be treated" is the number of patients who must be treated in 
order to prevent one adverse event. Mathematically, this is equivalent to the 
reciprocal of the absolute risk reduction. It expresses efficacy in a manner that 
incorporates both the baseline risk without therapy and the risk reduction with 
therapy. It illustrates how much effort must be expended to prevent one event. 
The relative risk reduction, the absolute risk reduction and numbers needed to be 
treated were calculated for each of the outcome measures Two or more incontinence 
episodes per day (IEPD), three or more continence pads used per 5 days and two or 
more grams lost on a one hour PWT were chosen as rates of adverse events signifying 
significant urinary incontinence. 
NUSSING DATA 
The problem of missing data in clinical research trials is by no means a trivial one. 
Missing data are often described as either "dropout" or "intermittent". Dropout 
occurs when a subject, once missing an assessment, is never observed again. 
Internuttent missing data occurs when a subject misses an assessment but is later 
observed. While we are limited to the observed data, there is information to be gained 
from it which may give an insight to the mechanism giving rise to drop outs. For 
example, subjects who have worse QoL may be more likely to miss assessments but 
this is debatable 3. The possible mechanisms for "dropouts" tested is given in table 
8.4. 
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Use of HRT 
Foreign body sensation 
Ease and comfort of use of the device 
Urine loss with specific activities 
Overall degree of control of "wetness" 
Quality of life disruption assessed by questionnaires 
Mean number of IEPD 
Mean number of incontinence pads used per 5 days 
Seventy of GSI 
Moderate 
Severe 
Mean PWT gain - baseline 
Measures of urinary leakage assessed at one month 
SF36 
KHQ 
Table 8.4 Data which may offer an insight to the mechanism giving rise to drop outs. 
STATISTICAL METHODS 
Data were stored on computer and a statistician was consulted for advice and 
recommendations in the application of tests and statistical analysis. Analysis was 
assisted using SPSS for Windows statistical package. Data are presented as the mean 
(sd) and median values unless otherwise specified. To determine the correlation 
between variables, the non-parametric Spearman's rank correlation statistic was used. 
The level of sigmficance employed in this thesis was the 5% level (p<0.05). Discrete 
variables were expressed as counts or percentages; continuous data as means with 
standard deviations, with calculation of 95% confidence intervals to measure the 




A power calculation was performed and set a saimple size of 50 in each group of the 
trial would be sufficient to show a difference between groups of 10% in each outcome 
measure at 6 months With power 90% and p<0.05. 
Comparison of paired means. 
In a case-control study such as this where the patient acts as her own control, 
comparisons are made of paired or individually matched samples. Every individual in 
one group (baseline) has a unique match in the other (device user) group. There is 
self-pairing - where the same individual belongs to both comparison groups. The 
approach to hypothesis testing in this paired situation is to take advantage of this 
situation. If, under the null hypothesis, the means of the two populations (before and 
after intervention) are the same, then the mean of the differences calculated on a 
sample of pairs of individuals should be close to zero. For such comparisons, the 
parametric paired t test was used for testing the two samples and the sample meanS4 . 
The appropriate test statistic for the paired situation is given by 
t [d - 0] / sd -. 
4n on n- I degrees of freedom. 
d The observed mean of the differences 
sd = The standard deviation of the differences 
n= The number of pairs In the study 
The 95% confidence interval for the mean difference between the two populations are 
calculated from 
d±t, x [sd /4 nj 
sd 4n= The standard effor of the mean difference 
L= is the two-sided 5% critical value for the t distribution. 
Certain assumptions were made: - a) that the distribution of the variable is not 
markedly skewed in either of the two populations; b) the population variances were 
unequal; and c) the sample size in both groups combined was greater than 60 with 
numbers in each group roughly the same. 
When performing statistical analysis of results obtained from two independent 
samples such as the urine loss on PWTs between groups, the ICS Standardisation 
Committee has suggested that non-parametric statistics should be employed, since the 
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values are not normally distributed. The Wilcoxon signed rank sum test was used to 
assess the differences between the results obtained in each group of device users. 
COMPARABLE GROUPS 
The main features of this intervention design are the aim of producing two groups of 
women with GSI comparable in respect of features known to affect outcome, except 
for the different interventions (Reliance or FemAssist) which it is planned they will 
receive. Women in each group were matched for characteristics like age, menopausal 
status and HRT, as well as the quality of life scores with the purpose of eliminating 
such characteristics from the analysis of efficacy of each intervention. The two 
groups were evaluated to check that there was a good "case-mix" so analysis was 
made of the comparability of the groups with respect to the baseline severity of 
incontinence as assessed by the PWT gains and the number of incontinence episodes 
per day and the number of pads used per five days recorded in the urinary diary. 
Statistical analysis was performed using the Wilcoxon signed rank sun test. 
ASSESSMIEN'f OF SUBJECTIVE DEGREE OF DRYNESS 
The response to treatment while performing specific activities and the overall degree 
of protection afforded by each device as rated by the patients were categorised as 
"Completely Dry", "Significant improvement", "No better" or "Worse". The 
responses were defined as follows: 
A) "Completely Dry" with device use was computed as I (scale I to 5) 
B) "Significant improvement" was defined as >50% reduction in rating of urine 
loss during insert use (scale I to 5) compared with before insert use. 
C) 'Wo better" was defined as no statistically significant change in the rating. 
D) "Worse" was defined as a statistically significant change in the rating III a less 
favourable direction. 
ANALYSIS OF THE URINARY DIARY VARIABLES 
Analysis was also performed for the baseline and one, three and six months post 
treatment Urinary diary variables. 
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INCONTINENCE EPISODES PER DAY 
Assessment was made of whether or not there was any difference in the degree of 
protection afforded by each device as judged by the number of incontinence episodes 
per day (IEPD) on the urinary diary at baseline without a device and after one, three 
and six months while using the particular device. 
individual patient responses on the urinary diary were categorised as follows: 
1. "Dry"= no lEPD 
2. "Significantly improved" = 75% reduction in IIEPD 
3. "Moderately improved" = 50% to 74% reduction in IETD 
4. "Slightly improved" = 25% to 49% reduction in IEPD 
5. "No change" =± 25% change from baseline 
6. "Worse" = greater than 25% increase in IEPD]. 
INCONTINENCE PADS USED OV1FR 5 DAVS 
Similar comparisons were made of the mean number of incontinence pads used over 5 
days while using a device at the one, three and six months visit assessments with that 
obtained at study inclusion. This helped to assess if there was any difference in the 
degree of protection afforded by each device. Individual patient responses on the 
urinary diary were categonsed as follows: 
I. "Completely dry" = No pads used over 5 days of recordings 
2. "Significantly improved" = 50% reduction in pad usage 
3. "No change" =± 25% increase change from baseline 
4. "Worse" = greater than 25% increase from baseline pad usage 
PAD WEIGHT TESTS 
Comparisons were made, for each device group, of the PWT gains at baseline and at 
one, three and six months of device use. Using these methods we could then 
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determine If there were any statistically and clinically significant differences in the 
mean PWT gains at each visit as a consequence of device use. Individual patient 
responses were categorised as follows: 
1. "Completely dry" -Ig of Urine or less on PWT gains (the error limit of the 
measuring scale is ± 0.2g) 
2. "Significantly improved" - less than 2g in urine loss but not completely dry 
3. "Moderately improved" -between 2. lg and 3g in urine loss 
4. "Slightly improved" - between 3.1 g and 4.9g in urine loss 
5. 'No change" - 5g or more in urine loss 
6. "Worse" - greater than 25% increase from baseline PWT gains. 
URETHRAL FUNCTION 
Assessment of urethral function as a result of device use was based on PWT gains at 
the start and end of the trial. The PWT data were compared using the parametric t- 
test evaluating the difference in PWT gains at baseline and at the 6-month visit when 
the test was performed without a device in place. This analysis was performed for 
each group. 
ANALYSIS OF QUALITY OF LIFE 
Analysis was performed for the baseline and six months post treatment quality of life 
variables for each group of device users. The two groups, Reliance users and 
Fem-Assist users were also compared using the non-parametric Wilcoxon signed rank 
test. In adopting generic and condition-specific instruments, it is recommended to 
compare results obtained m the study population with published norms. I wished to 
assess whether there was any disruption to the general health of women with GSI in 
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this study and how this might compare to the poorer quality of life experienced by 
women with other medical complaints. 
Two published data sets have been incorporated into this study to allow these 
comparisons, a) The Oxford healthy life survey 5 and b) the study by Garratt et al 
(1993)6 . The data from these two studies were used to compare the SF36 results of 
women in this study with those of the general population and those of women with 
other medical complaints. Analysis and interpretation based on minimum difference 
which is important to patient was also considered. 
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ASSESSMENT OF DEVICE SAFETY 
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The safety of each device was evaluated by unnalysis and urine culture, physical 
examination and any spontaneously reported adverse events. 
ADVERSE EVENTS 
An adverse event was any undesirable clinical event occurring to a subject during the 
clinical trial, whether or not it was considered related to the devices under 
investigation. If no adverse event occurred during the period concerned, this was also 
noted. The following definitions of "seventy" were used: 
A Serious adverse event includes any event which is life-threatening or has resulted in 
" Death 
" Hospitalisation; initial or prolonged 
" Disability 
" Required intervention to prevent permanent impairment/damage. 
Data recorded for all types of adverse events included: 
" type of adverse event 
" duration 
" severity 




Mld adverse event - awareness of symptoms/signs, but easily tolerated (acceptable). 
Moderate adverse event - enough discomfort to interfere with usual activity 
(disturbing). 
Severe adverse event - incapacity to work or to do usual activity (unacceptable). 
IQ's 
WITHDRAWAL FROM TREATMENT 
A patient was withdrawn from the study treatment if, in the opinion of the 
investigator, it was medicaRy necessary, or if it was the wish of the patient. 
The following situations were accepted as criteria for withdrawal: 
N Insufficient efficacy requiring withdrawal from treatment. 
N Adverse event where the clinical opinion was to withdraw the treatment, 
including concurrent diseases. 
Major protocol violation occurring during the course of the study. 
Ineligibility; women who after start of study treatment were found to have 
violated a major inclusion/exclusion criterion. 
0 Consent withdrawn. 
Lost to follow-up; patient does not show up to a scheduled visit and all 
contact is broken thereafter. 
CVSTfIrIS 
Cystitis is a term used to describe inflammation of the urinary bladder. The 
inflammatory response arises in a variety of clinical situations and may have an 
infectious or non-infectious aetiology. Infections cystitis may be classified as acute, 
chronic or recurrent infection. It broadly describes the inflammatory response to 
microbiological invasion of the bladder, encompassing not only the clinical symptoms 
of urinary frequency, urgency and dysuria. Infection is characterised by large 
numbers of organisms and leucocytes in the urine with varying signifficance and 
severity. The natural history of the disease depends on the type of urinary pathogen, 
its virulence and resistance to antimicrobial agents, as well as certain host factors and 
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special circumstance. Diagnosis is based on the clinical manifestations, microscopic 
examinations, non-culture techniques as well as the results of urine culture. it may 
require the use of certain criteria to make an accurate diagnosis. The principles of 
management are to verify the diagnosis and select the appropriate antimicrobial agent 
most likely to be effective. 
Prevalence 
Bacterial cystitis is the most common bacterial infection occurring in women. It has 
been estimated that women have at least a 50% chance of developing at least one 
urinary infection during their lifetime '. Studies have also shown that the prevalence 
of bacteriuria in schoolgirls is one to two percent, about ten times higher than boys 23. 
URETHRMS 
This is defined as inflammation of the urethra. Women may complain of retropubic 
pressure, dyspareunia, diurnal urinary frequency, dysuria, and urethral irritation 4 
The micro-orgamsms isolated from cases of urethritis show the same virulence factors 
as those seen in uropathogens causing acute cystitis. It should be noted 
that inflammation is often not limited to the urethra but may also involve the bladder 
wall 5. 
Instrumentation of the urinary tract 
Inflammatory reactions of the urethral wall are also known to occur by repeated 
introductions of a catheter or catheter like devices in the urethra. This may result in 
nunor degrees of inflammation to frank urethritis and post inflammatory urethral 
stricture formation 6. There is approximately a5 percent incidence of urinary tract 
infection and cystitis following cathetensation of a normal bladder, despite a sterile 
technique. This is modified by the duration of catheterisation as well as the general 
well being of the patient 7. Indeed, with long-term follow-up, urethritis has been 




The urinary stream may become contaminated by small numbers of bacteria hence the 
term "bacteriuria" which means bacteria in the urine, regardless of source. 
Bactenuria may or may not be associated with symptoms and the presence of pyuria. 
From a clean freshly voided specimen of urine,, one may expect less than 10,000 
colony-forming units (cfu) per ml. Kass (1956) proposed a useful cut off point of 
100,000 cfu/mI to define significant bactenuria so as to differentiate it from 
contamination 9. 
There is much debate regarding the significance of bacterial colonisation of urine 
versus infection. A concentration of 10 2 cfu/ml can cause an acute urinary tract 
infection in the healthy woman ". 
Urine coHection 
There is no standard method of collection, transport or processing of urine specimens 
or reporting of results. Contamination of the specimen may occur if the urine flushes 
onto the vulva and vagina. This may be minimised by instructing the woman to 
separate the labia, and wash and dry the penurethral region. She should void with the 
labia spread and collect a mid-stream specimen. This method can provide reliable 
specimens and was utilised in this study. 
Urinalysis 
Urinalysis may provide additional supportive evidence of cystitis to allow a pre- 
emptive diagnosis of infection. Some of the elements of information provided by 
urinalysis are more valuable than others. For instance, cloudy urine indicates white 
cells or crystals and can be due to the presence of bacteria but this is unreliable. 
Proteinuria 
Dipstick tests for protemuria have a poor predictive value in detecting renal disease 
due to their low specificity. Up to 6% of school children have proteinuna and the 
IQR 
rates rise with age ". The presence of proteinuria is more a reflection of renal disease 
and is not normally judged a sign of bladder infections. 
Pyuria 
Pyuria implies the presence of polymorphonuclear leucocytes in the urine. When 
viewed under the microscope more than two white cells per high-powered field 
represents abnormal pyuna. It may be helpful in the interpretation of the clinical 
2 
significance of urine culture results 1. Detection of pyuria is a helpful pointer to the 
presence of infection with 96.6% of symptomatic bacteriuric patients having ten or 
more white cells per mm 3 compared to 1.6% in abactenuric asymptomatic subjects 13 
An MSU with greater than 10 pus cells per hpf has an 87% chance of being infected 
14 
compared with 10% in specimens with less than two pus cells per plif . In the 
absence of pyuria, one should question the diagnosis of infective cystitis. 
Haematuria 
The presence of red blood cells commonly occurs when there is an infection in the 
mucosa of the bladder wall. It tends to occur in association with bacteriuria and 
pyuna. Of normal Unne samples, 90% have less than one red blood cell per high 
power field. More than 3 red blood cells per high power field usually signify an 
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abnormality of the urinary tract 
Urine Culture 
A mid stream specimen of urme (MSU) for culture was taken at each visit. Women 
with symptomatic urinary tract infection (UTI) were treated before inclusion in the 
study. Any UTI that developed during the study was treated and device use 




The ability of capillary walls to withstand distending pressure may be reduced in a 
vAde variety of general diseases; including infection and trauma. Some women have 
an increased susceptibility and bruise more readily than others. An increased bruising 
tendency is not uncommon in the elderly 16 . 
BRUISE 
Bruises are due to blood leaking from vessels into the dermis. They result when 
blood vessels are sufficiently damaged for red blood cells to escape *into the 
surrounding connective tissue. The breakdown of haemoglobin provides the colour 
17 
changes associated with the lesion 
Bruises are classified according to their shape and size. Petechiae are small bruises 
or pinpoint haemorrhages that occur in the subcutaneous or submucosal tissues. The 
petechiae are tiny because the endothelial lesion is contained by the supporting 
perivascular tissue. The mechanisms involved are due to trauma of sufficient power 
to damage normal vessels, as a result of minor trauma to fragile vessels in the elderly, 
or because the supporting tissue has become defective. 
Ecchymosis are large, more diff-use haemorrhagic areas. These clot haemoffhages 
do not blanch with pressure. 
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CHAPTER TEN 
OBJECTWE RESULTS FOR 
THE RELIANCE AND FEMASSIST DEVICES 
1) () 1) 
OBJECTIVE RESULTS FOR 
THE RELIANCE AND FEMASSIST DEVICES 
The results will be presented under the following headings; 
Presentation of results 
Baseline Data Comparable 
Domains of patient observations with device use 
Foreign body sensation 
Ease of placement and comfort of device use 
Control of incontinence 
Urine loss with specific activities 
Overall degree of dryness 
Domains of clinicians observations 
Quantification of urine loss 
Incontinence episodes per day 
Continence pads used over 5 days 
Pad weight test gains 
Change in urethral function as a consequence of device use 
Further comparison of Reliance & FemAssist groups 
Quality of life and impact of symptoms 
Adverse events 
Table 10.1 Presentation of results 
BASELM DATA COMPARABLE 
The two groups were evaluated before the interventions to check that they were 
comparable in respect of features known to affect outcome: age, parity, menopausal 
status and the use of oestrogen replacement therapy and the severity of incontinence 
[number of incontinence episodes per day, the number of continence pads used per 5 
days recorded in the urinary diary and PWT gains]. As these are independent 
samples, the statistical analysis was performed using the non-parametric Wilcoxon 
rank test as described previously. 
MI 
AGE 
I assessed whether there was any difference in the ages of women in each group. 
Calculations were made using the Wilcoxon rank sum test for independent samples. 
There was no difference in the median ages of the subjects in each group. Also, the 
age distributions were roughly the same in each group (tablelO. 2 & 10.3). 
Groups Total Min Max Median 
Reliance 48 32 65 50.6 






Table 10.2 The age of patients at study inclusion for each group /and for the 
aggregated data. (Min=nnnimum, Max=maximum. ) 
Age (years) istribution at study inclusion 
Age 21-30 31-40 41-50 51-60 61-70 71-80 Total 
Groups 
Reliance 1 8 21 15 3 0 48 
(2%) (16.7%) (43.7%) (31.3%) (6.3%) 
FemAssist 1 10 21 16 4 1 53 
(1.9%) (18.9%) (39. (30.2%) 1.9%) 
Table 10.3 The patient age distribution at study InClusion for each group. 
NMNOPAUSAL STATUS AND 
USE OF OESTROGENS 
The menopause status of the women in each group and the use of hormone 
replacement therapy (HRT) are presented in table 10.4. The data for the groups 
combined is also presented. The study patients were well matched for menopausal 
ý1- - status and the use of oestrogens. 
? 04 
Menopausal status and use of 
oestr gen replacement therapy 
Groups Menopausal Treated with 
oestrogens 
Reliance 27(56.3%) 19(39.6%) 
FemAssist 21(39.6%) 14(26.4%) 
Total 48(47.5%) 33(32.7%) 
Table 10.4 The menopausal status and use of oestrogen replacement therapy at study 
inclusion for each group and for the groups when aggregated. The Wilcoxon rank 
sum test statistic was employed. 
All subjects in both groups were parous. 
BASELINE SEVERITY OF INCONTINENCE 
The baseline severity of incontinence was assessed by analysis of the number of 
incontinence episodes per day and the number of continence pads used per five days 
recorded in the urinary diary and the PWT gains prior to the use of devices. 
URINARY DIARY 
1 INCONTINENCE EPISODES 
I assessed whether or not there was any difference in the severity of incontinence 
between the two groups on entry to the study based on the number of incontinence 
episodes per day recorded in the urinary diary. 
Null Hypothesis 
The median numbers of incontinence episodes per day at baseline in both groups 
before use of a device are equal. 
, )()IS 
Number of incontinence episodes experienced at study inclusion 
for each group (Reliance and FemAssist) 







Table 10.5 The number of incontinence episodes experienced at study Inclusion for 
each group (Reliance and FemAssist) is illustrated. [MfN = minimum, MAX 
maximum] 
There was no statistical difference in the number of incontinence episodes 
experienced between the groups based on the data in the urinary diary (Table 10.5). 
2 CONTWENCE PADS USED 
I assessed whether or not there was any difference in the severity of incontinence 
between the two groups on entry to the study based on the number of continence pads 
used per five days recorded in the urinary diary. 
Null Hypothesis 
The median number of continence pads at baseline in both groups before use of a 
device is equal. 
Number of continence pads used at study inclusion 
for each group (Reliance and FemAssist) 
MIN MAX MEDUN Paired 
differences P- 
value 
Reliance 8 12 10.6 
n--48 0.22 
FemAssist 8 15 11.1 
n=53 
Table 10.6 The number of continence pads used per five days at study inclusion for 
each group (Reliance and FemAssist) is illustrated. [MIN = minimum, MAX 
maximum] 
There was no statistical difference in the number of continence pads used by women 
in the two groups based on the data in the urinary diary (Table 10.6) 
IM 
3 PAD WEIGHT TEST GAINS 
Pad weight test data at study inclusion for each group prior to use of a device is 
presented in tablelO. 7. Assessment was made of whether or not there was any 
difference in the severity of incontinence between the two groups, FemAssist and 
Reliance, on entry to the trial based on their PWT gains. The null Hypothesis is that 
the median PWT gains at baseline in both groups before use of a device are equal. 
Baseline pad weight test data for each group 
(Reliance and FemAssist) prior to device use 
MIN MAX MIEDLAN Paired 
differences P- 
value 
Reliance 0.8 99 31.2 
n=48 0.43 
FemAssist 1.1 128 28.3 
n--53 
Table 10.7 The baseline pad weight test data for each group (Reliance and 
FemAssist) prior to device use is illustrated. [MIN = minimum PWT gain, MAX 
maximum PWT gain] 
PRODUCT USE 
FEMASSIST DEVICE 
We were unable to ascertain accurately how many applications patients performed in 
one day as they were not compliant in recording these events. The impression was 
that they applied the device frequently for shorter periods than the Reliance. Each 
subject used approximately one device over the course of seven days. However the 
vast majority felt that the Fem. Assist was in good condition, worked well and could be 
used for much longer periods. During the 6 months period approximately 948 
FemAssist devices were used. 
RELUNCE DEVICE 
In the first month 42 women used 2,772 devices at a mean rate of 2.2 per day. In the 
next two months 29 women used 4,350 devices at a mean rate of 2.5 per day. In the 
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next three months 31 women used 2,772 devices at a mean rate of 2.1 per day (total 
12,981). 
DOMAI[NS OF PATIENT OBSERVATIONS 
WITH DEVICE USE 
FOREIGN BODY SENSATION 
There was a reduction in foreign body sensation while wearing the device over time in 
both groups. After I month, 9 (20.5%) women experienced a bothersome foreign 
body sensation with the Reliance and 11 (23.4%) with the FemAssist device, which 
reduced slightly in both groups at 3 months. At the end of the study 5 (16.1%) 
women noted this foreign body sensation with the Reliance and 5 (13.9%) with the 
FemAssist devices respectively. The results are illustrated in table 10.8. If women 
noted this sensation initially, then it resolved over time. If they did not note it at the 
beginning of the study, it did not arise over time with sustained use of the devices 
(Figure 10.1). Once a device was removed, there was no residual foreign body 
sensation if this was felt with device use. 
Foreign body sensation while wearing 
The devices over time 
1 MONTH 3 MONTHS 6 MONTHS 
Reliance 9(20.5%) 7(21.2%) 5(16.1%) 
FemAssist 11(23.4%) 7(17.1%) 5(13.9%) 
No. M each group 
at each visit 
Reliance 42 29 31 
FemAssist 47 41 36 
Table 10.8 The incidence of bothersome foreign body sensation experienced while 
wearing a device as recorded at each visit. The numbers in the groups at each 
assessment visit are also recorded. 
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Figure 10.1 Percentage of women experiencing a foreign body sensation over the 
duration of the study. Analysis based on the number using device at any given point 
in time. 
EASE AND COMFORT OF DEVICE USE 
Patient ratings on ease of device placement and comfort of use recorded at each 
follow-up visit are shown in tables I-7. Over time, it would appear that there is a 
trend for the devices to become more comfortable to wear and easier to place (Table 
10.9 & 10.10). 
Patient rating of "ease" of placement of each device 
Over the period of the trial 
1 Month 3 Months 6 Months 
Score Reliance FemAssist Reliance FemAssist Reliance FemAssist 
1 4 8 6 14 5 17 
2 23 24 14 23 15 16 
3 12 10 8 2 10 2 
4 4 3 1 2 1 1 
5 1 2 0 0 0 0 
41 61 19 12 17 17 
ble 10.9 Patient ratings on ease of device placement recoraect at eacti toiiow-up 
it for each group. (Score 1= Very easy, Score 5= Extremely difficult) 
1)()Q 
I Month 3 Months 6 Months 
Patient rating of "comfort" of device use 
Over the period of the trial 
1 Month 3 Months 6 Months 
Score Reliance FemAssist Reliance FemAssist Reliance FemAssist 
1 2 8 5 12 5 12 
2 12 18 12 22 11 20 
3 23 13 11 6 13 3 
4 5 6 0 1 2 01 
5 2 2 1 0 0 0 
4 6 19 12 17 17 
Table 10.10 Patient ratings on comfort of device use recorded at each follow-up visit 
for specific groups. (Score 1= Very comfortable, Score 5= Extremely uncomfortable) 
Figures 10.2-10.5 illustrate graphically the ease of placement and comfort of use of 












Ease of placement of the Reliance device 
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Figure 10.2 Patient rating on ease of placement of the Reliance device over time. 













Figure 10.3 Patient rating on comfort of the Reliance device over time. Comfort 
level was rated on a scale of I to 5 (1 = Very comfortable; 5= extremely 
uncomfortable). 
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Figure 10.4 Patient rating on ease of placement of the FemAssist device over time. 
Ease of placement rated on a scale of I to 5 (1 = Very easy; 5= Extremely difficult). 
711 
month 3- months 
Comfort of use of the Reliance device 
Comfort of use of the FemAssist device 
100% 
























Figure 10.5 Patient rating on comfort of the FemAssist device over time. Comfort 
level was rated on a scale of I to 5 (1 = Very comfortable; 5= extremely 
uncomfortable). 
Most women demonstrated a reasonably high mean response to comfort of use. There 
was a slightly better response at month 6 compared to months I and 3, primarily 
attributed to initial inadequate device placement. As the women become more 
proficient at correct placement, discomfort decreased. The level of comfort and ease 
of placement was better in the FemAssist group at the first month. This difference 
was maintained, but not as evident, over the duration of the trial. With longer follow- 
up Reliance users felt less discomfort and found placement easier. 
CONTROL OF INCONTINENCE WITH DEVICE USE 
ASSESSMLENT OF SUBJECTIVE DEGREE OF DRYNESS 
BASELINE SEVERITY OF WETNESS SCORES 
The degree of "wetness" or the seventy of incontinence as assessed by the women in 
each group on entry to the trial is given in tables 10.11 and 10.12. Each activity was 
scored as described in the chapter on methods of analysis. 
? 1? 
Baseline severity of "wetness" for each activity 
Of women in indivi ual groups 
Score Rel I Fem Rel I Fem Rel I Fem Rel Fem 
Sitting/lying Standin g Walldng LiftAbending 
1 17 19 11 18 5 8 2 0 
2 11 16 14 16 13 14 2 2 
31 17 18 15 19 14 14 16 15 
4 4 3 0 8 0 14 17 19 22 
55 01 0 0 
1 
0 2 0 f-9 14 
Table 10.11 The scoring of the degree of "wetness" or the severity of incontinence as 
assessed by the women in each group on entry to the trial for the activities of 
sitting/lying, standing, walking, lifting and bending. [(I = no urine loss, 5= severe 
loss) Rel = Reliance group, Fern = FemAssist group] 
Baseline severity of "wetness" for each activity 
of women in individual gro ps 







1 2 0 0 0 11 0 
2 1 2 0 2 1 1 
3 6 11 0 11 2 12 
4 22 2 5 22 4 22 
5 17 16 40 18 40 1 
Table 10.12 The scoring of the degree of "wetness" or the severity of incontinence as 
assessed by the women in each group on entry to the trial for the activities of low 
impact exercise, high impact exercise and coughing/sneezing/laughing. [(I = no urine 
loss, 5= severe loss) Rel = Reliance group, Fem = FemAssist group] 
PATIENT RATED DRYNIFSS 
WITH SPECWIC ACTIWIIES 
The response to treatment as rated by the patients wMe performing specific groups of 
activities was categorised as "Completely Dry", "Significant improvemenf', "No 
better" or "Worse". The responses were defined in the chapter describing the 
methods of analysis, but are repeated for convemence; f "Completely Dry" with 
device use was computed as I (scale I to 5), "Significant improvement" was defined 
as >50% reduction in rating of unne loss during insert use (scale I to 5) compared 
with before insert use, "No better" was defined as no statistically significant change in 
the rating, "Worse" was defined as a statistically significant change in the rating in a 
less favourable direction). The scores in response to treatment with each device as 
rated by the patients while perfonning specific exercises is given in tables 4-6. The 
data illustrate the degree of protection afforded for the activities tested with the 
Reliance and FemAssist devices comparing baseline seventy of "wetness" With that 
of device use at each subsequent visit (Tables 10.13 - 10.19). The percentages were 
analysed on an intention to treat basis. As shown, there was a significant increase in 
the percentage of patients reporting complete dryness or significant improvement with 
device use. The increase in dryness was evident for less strenuous manoeuvres such 
as sitting and standing but particularly SO for the more provocative manoeuvres such 
as coughing, lifting, low and high impact exercise. A trend to increased patient 
participation in more provocative manoeuvres over time was also noted for both 
groups. No subject was made worse with device use in either group. 
Patient rated dryness for the activities tested at 
each visit as a change from baseline severity of 
wetness with each device 
Sitting/ 1 3 6 
Lying month month month 
Reliance (no. 42 29 31 
_at 
each visit) 
Dry 42 29 31 
87.5% 60.4% 64.6% 
Significantly 0 0 0 
improved 
No better 0 0 0 
47 41 36 
FemAssist(no. 
at each visit) 
Dry 47 41 36 




I--- I -I I Table 10.13 The degree of protection afforded for sitting/lying with the Reliance and 
FemAssist devices comparing baseline severity of "wetness" with that of device use at 
each subsequent visit. 
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Patient rated dryness for the activities tested at 
each visit as a change from baseline severity of 
wetness with each device 
Standing 1 3 6 
month month month 
Reliance (no. 42 29 31 
at each visit) 
Dry 42 29 31 
87.5% 60.4% 64.6% 
Significantly 0 0 0 
improved 
No better 0 0 0 
47 41 36 
FemAssist(no. 
at each visit) 
Dry 44 38 34 
83% 71.7% 64.2% 
Significantly 3 3 2 
improved 5.7% 5.7% 3.8% 
1 No better 1 01 0 
10 
Table 10.14 The degree of protection afforded for standing with the Reliance and 
FemAssist devices comparing baseline severity of "wetness" with that of device use at 
each subsequent visit. 
Patient rated dryness for the activities tested at 
each visit as a change from baseline severity of 
wetness with each device 
Walking 1 3 6 
month month month 
Reliance (no 42 29 31 
at each visit) 
Dry 40 27 29 
87.5% 56.3% 60.4% 
Significantly 2 2 2 
improved 4.2% 4.2% 4.2% 
FemAssist(no. 47 41 36 
at each visit) 
Dry 30 31 33 
56.6% 58.5% 62.3% 
Significantly 6 6 5 
unproved 11.3% 11.3% 9.4% 
No better 11 4 5 
20.8% 7.5% 9.4% 
Table 10.15 The degree of protection afforded for walking with the Reliance and 
FemAssist devices comparing baseline seventy of "wetness" with that of device use at 
each subsequent visit. 
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Patient rated dryness for the activities tested at 
each visit as a change from baseline severity of 
wetness with each device 
Lifting/ 1 3 6 
Bending month month month 
Reliance (no. 42 29 31 
at each visit) 
Dry 40 27 31 
83.3% 56.3% 64.6% 
Significantly 2 2 1 
improved 4.2% 4.2% 2.1% 
No better 0 0 0 
47 41 36 
FemAssist(no. 
at each visit) 
Dry 27 31 33 
50.9% 58.5% 62.3% 
Significantly 8 6 3 
improved 15.1% 11.3% 5.7% 
No better 0 3 0 
1 5.7% 
Table 10.16 The degree of protection afforded for lifting/bending with the Reliance 
and FemAssist devices comparing baseline severity of "wetness" with subsequent 
visits. 
Patient rated dryness for the activities tested at 
each visit as a change from baseline severity of 
wetness with each device 
Law impact 1 3 6 
exercise month month month 
Reliance (no. 42 29 31 
at each visit) 
Dry 38 27 29 
79.2% 56.3% 60.4% 
Significantly 3 2 2 
improved 6.3% 4.2% 4.2% 
FemAssist(no. 47 41 36 
at each visit) 
Dry 22 26 28 
41.5% 49.1% 52.8% 
Significantly 14 10 2 
26.4% 18.9% 3.8% 
No better 11 5 6 
?0 . 
4% 11-3% 
Table 10.17 The degree of protection afforded for low impact exercise with the 
Reliance and FemAssist devices comparing baseline severity of "wetness" with that 
of device use at each subsequent visit. 
I]A 
Patient rated dryness for the activities tested at 
each visit as a change from baseline severity of 
wetness with each device 
High impact 1 3 6 
exercise month month month 
Reliance (no. 42 29 31 
at each visit) 
Dry 24 12 17 
50% 25% 35.4% 
Significantly 14 14 13 
improvo 29.2% 29.2% 27% 
No better 0 0 0 
47 41 36 
FemAssist(no. 
at each visit) 
Dry 0 5 5 
9.4% 9.4% 
Significantly 10 4 1 
unproved 18.9% 7.5% 1.9% 
No better 37 32 30 
169.8% 60.4% 56.6% 
Table 10.18 The degree of protection afforded for high impact exercise with the 
Reliance and FemAssist devices comparing baseline severity of "wetness" with that 
of device use at each subsequent visit. 
Patient rated dryness for the activities tested at 
each visit as a change from baseline severity of 
wetness with each device 
Cough/sneeze/ 1 3 6 
laugh month month month 
Reliance (no. 42 29 31 
at each visit) 
Dry 31 21 19 
64.6% 43.8% 39.6% 
Significantly 11 8 12 
improved 22.9% 16.7% 25% 
FemAssist(no. 47 41 36 
at each visit) 
Dry 17 19 20 
32.1% 35.8% 37.7% 
Significantly 28 20 18 
improved 52.8% 37.7% 34% 
No better 2 2 3 
3.8% 1 3.8% 5.7% 
Table 10.19 The degree of protection afforded for coughing/sneezing/laughing 
? 17 
with the Reliance and FemAssist devices comparing baseline seventy of "wetness" 
with that of device use at each subsequent visit. 
The bar charts below (Figures 10.6 & 10.7) illustrates the number of women who 
were dry or significantly improved with use of the Reliance and FemAssist devices 
while performing each activity at each period of assessment. 









Sit Stand Walk Lift Low High Cough 
Figure 10.6 The number of women who were dry or sigmficantly improved with use 
of the Reliance device while perfonning each activity at each penod of assessment. 
[ITT = Intention to treat basis] 
Dry or significantly improved 
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Sit Stand Walk Lift Low High Cough 
Figure 10.7 The number of women who were dry or significantly improved with use 
of the FemAssist device while performing each activity at each period of assessment. 
[ITT == Intention to treat basis] 
? IR 
Reliance device use with each activity 
OVERALL DEGREE OF PROTECTION 
The overall degree of protection afforded by each device as rated by the patients was 
similarly categorised as "Completely Dry", "Significant improvernent", "No better" 
or "Worse" and defined in the chapter on methods of assessment. This was carried 
out at the 1,3 and 6 months visits and is illustrated in table 10.20 and figures 10.8 - 
10.12. Numbers above the bars in the figures represent the percentage of the total 
number of women in each group. 
No subject was made worse by the use of either device. 
Patient rated overall degree of protection afforded 
b the devices assessed at each visit 
1 3 6 
month month month 
Reliance (no. 42 29 31 
at each visit) 
Dry 29 20 19 
60.4% 41.7% 39.6% 
Significantly 10 9 12 
improved 20.8% 18.8% 25% 
No better 3 0 0 
6.3% 
47 41 36 
FemAssist 
(no. at each 
visit) 
Dry 15 18 20 
28.3% 34% 37.7% 
Significantly 25 21 13 
improved 47.2% 39.6% 25.4% 
No better 7 2 3 
13.2% 3.8% 5.7% 
Table 10.20 Patient rated overall degree of protection afforded by each device. 
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Figure 10.8 The subjective treatment outcome of women with GSI managed with the 
Reliance (n = 48) and FeniAssist (n=53) devices. The overall degree of protection 
afforded by each device as assessed at one-month follow-up is illustrated. 












Figure 10.9 The subjective treatment outcome of women with GSI managed with the 
Reliance (n=48) and FernAssist (n=53) devices. The overall degree of protection 
afforded by each device as assessed at three months follow-up is illustrated. 
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Dry Sig. Improved No better 
Dry Sig. Improved No befter 







Dry Sig. Improved No befter 
1: 1 Reliance 
M FemAssist 
Subjective assessment of overall control of leakage 
Figurc 10.10 The subjective treatment outcome of women with GSI managed with 
the Reliance (n=48) and FemAssist (n--53) devices. The overall degree of protection 







Overall protection afforded by the Reliance 




Dry Sig. Improved No better 
N3 Months 
06 Months 
Subjective assessment of overall control of leakage 
Figure 10.11 The subjective treatment outcome of women with GSI managed with 
the Reliance (n=48) device. The overall degree of protection afforded by the device 
as assessed over tiMe, is illustrated. 
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Overall protection afforded by the FemAssist 
device over time 
50 47. -2 
40 34 
37.7 09.6 
28. % IWO p%3 0- 
a. 10- 
Dry Sig. Improved No befter 
131 Month 
03 Months 
El 6 Months 
Subjective assessment of overall control of leakage 
Figure 10.12 The subjective treatment outcome of women with GSI managed with 
the FemAssist (n--53) device. The overall degree of protection afforded by the device 
as assessed over time is illustrated. 
Of all the women treated with a Reliance device (n=48), 31(64.6%) women felt that 
they were cured or significantly improved at the end of the trial and felt that the 
device was effective. 
Of all the women treated with a FemAssist device (n--53), 33(62-3%) felt that they 
were cured or significantly improved at the end of the trial and felt that the device was 
effective. 
DOMAIN OF CLINICIANS OBSERVATIONS 
QUANTIFICATION OF URINE LOSS 
RELIANCE GROUP 
INCONTINENCE EPISODES PER DAY 
Analysis of Unnary leakage by IIEPD was determined from the mean number of lEPD 
at each visit as recorded in the diaries (Table 10.2 1). 
Comparison of IEPD for the Reliance group 
at baseline and after each follow-up visit 
No assessed Mean Range SD 
IEPD 
Baseline 48 5.11 4-7 0.74 
1 Month 42 1.58 1-2 0.5 
3 Months 29 1.31 1-2 0.47 
6 Months 31 1.33 1-2 0.48 
Table 10.21 Comparison of the mean number of EEPD while using the Reliance 
device at the one, three and six months visit assessments with that obtained at study 
inclusion. 
I assessed whether or not there was any difference in the degree of protection afforded 
by the Reliance device as assessed by the number of incontinence episodes per day 
(IEPD) on the unnary diary at baseline without a device and after one, three and six 
months while using the device. 
BASELINE VS I MONTH IEPD 
Null Hypothesis 
The means of the two populations, incontinence episodes per day at baseline and at 
one month, are equal. The table shows the mean IEPD recorded at baseline and after 
one month's device use. 
Comparison of IEPD for the Reliance group 
at baseline and after I month (n=42) 
Vadable No of pairs Mean Range SD SE of mean 
Baseline 4.9 4-6 0.75 0.125 
IEPD 42 
1 Month 1.58 1-2 0.50 0.083 
IEPD 
Paired differences 
Mean Standard Standard 2-tail Sig. 95% 
deviation error of mean confidence 
interval 
_3.53 
0.736 0.123 0.000 3.279,3.777 
Table 10.22 The IIEPD data at baseline and after one month use of the Reliance 
device as well as the mean paired differences. 
1 
The null hypothesis states that the population mean difference should be zero. There 
was a statistically significant difference between the means of the two populations, 
therefore one can re . ect the null hypothesis (Table 10.22). ,j 
BASELINE VS 3 MONTHS IEPD 
The null hypothesis was that the mean number of incontinence episodes per day at 
three months while using the device was equal in both groups. 
Comparison of IEPD for the Reliance group 
at baseline and after 3 months (n=29) 
VaHable No of pairs Mean Range SD SE of mean 
Baseline 4.8 4-6 0.66 0.131 
IEPD 29 
3 Months 1.31 1-2 0.47 0.078 
EEPD 
Paired differences 
Mean Standard Standard 2-tail Sig 95% 
deviation error of mean confidence 
interval 
3.81 0.71 0.118 0.000 3.57,4.08 
Table 10.23 The IEPD data at baseline and after three months use of the device as 
well as the mean paired differences. 
There was a statistically significant difference between the means of the two 
populations, therefore one can reject the null hypothesis (Table 10.23). 
BASELM VS 6 MONTHS EEPD 
I also assessed if there was any difference in the degree of protection afforded by the 
Reliance device based on the number of incontinence episodes in the urinary diary at 
the end of the trial. The null hypothesis was that the mean number of incontinence 
episodes per day at six months while using the device was equal in both groups. 
'7? 4 
Comparison of EEPD for the Retiance group 
at baseline and after 6 months (n=31) 
Variable No of pairs Mean Range SD SE of mean 
Baseline 4.91 4-6 0.67 0.133 
IIEPD 31 
6 Months 1.33 1-2 0.48 0.080 
IIEPD 
Paired differences 
Mean Standard Standard 2-tail Sig 95% 
deviation error of mean confidence 
interval 
3.78 0.89 0.15 0.000 3.474,4.082 
Table 10.24 The IEPD data at baseline and after six months use of the device as well 
as the mean paired differences. 
There was a statistically signIficant difference between the means of the two 
populations, therefore one can reject the null hypothesis (Table 10.24). 
CONTROL OF INCONTINENCE 
(CHANGES IN INCONTINENCE EPISODES PER DAY) 
Seventeen of the patients did not have six-month urinary diary data to assess the 
number of lEPD at the end of the study. Thus, the analysis includes 31 patients. The 
effectiveness (control of incontinence) as determined by the number of lEPD revealed 
a significant reduction in urine loss during device use at each period of assessment. 
MIVIUDUAL PATIENT RESPONSES 
(CHANGES IN INCONTINENCE EPISODES PER DAY) 
The individual patient responses based on the changes in incontinence episodes per 
day after 1,3, and 6 months of Reliance Urinary Control Insert use are illustrated in 
table 10.25 and figures. The table also illustrates the per cent of individual responses 
categonsed by degree of improvement at each visit based on the IEPD recorded in the 
dianes. 
No subject was made worse with device use in either group. 
The individual patient responses after 1,3, and 6 months 
of Reliance Insert use 








I month 0 15 21 6 0 
3 months 0 19 10 0 0 
6 months 0 20 11 0 0 
Table 10.25 The number (percentage) of individual patient responses categonsed as 
changes in incontinence episodes per day on the urinary diary. [Dry = no JEPD; 
significantly improved = 75% reduction in IEPD; moderately improved = 50% to 
74% reduction in IEPD; slightly improved = 25% to 49% reduction in IEPD; no 
change =: ± 25% change from baseline; worse = greater than 25% increase in fEPD]. 
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Figure 10.13 Individual patient responses categonsed as changes in incontinence 
episodes per clay on the unnary diary. 
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EFFICACY CONSISTENCY 
(CHANGES IN INCONTINENCE EPISODES PER DAY) 
As women progressed through each visit to completion, the consistency in 
improvement in the IEPD with device use was also determined (Table 10.26). 
Efficacy consistency in terms of improvement in IEPD as 
women progressed through each visit to completion 
Sig. improved at 1 Status at 3 Months Status at 6 Months 
month 
(n=15) Dry (n=O) Dry (n=O) 
Sig. Improved (n-- 10)20.8% Sig. Improved (n--l 1)22.9% 
Mod. Improved (n=D) Mod. Improved (n=2)4.2% 
Sl improved(n=0) Sl improved(n=O) 
Md. improved at lmonth 
(n--2 1) 
Status at 3 Months 
Dry (n=O) 
Sig. Improved (n--9)18.6 % 
Mod. Improved (n-77)14.6% 
Status at 6 Months 
Dry (n=O) 
Sig. Improved (n--9)18.6% 
Mod. Improved (n=7)14.6% 
SI. Improved (n=O) SI. Improved (n=, O) 
Sl improved at Imonth 
(n--6) 
Status at 3 Months 
Dry (n=O) 
Sig. Improved (n=O) 
Mod. Improved (n=3) 6.3% 
Status at 6 Months 
Dry (n--O) 
Sig. Improved (n=O) 
Mod. Improved (n--2)4.2% 
SI. Improved (n==O) SI. Impro ed (n=O) 
Table 10.26 Efficacy consistency of the Reliance device in terms of maintenance of 
improvement in lEPD as women progressed through each visit to study completion. 
The data suggest that the Reliance device significantly reduced urine loss as 
determined by the number of incontinence episodes per day for all women and these 
reductions were maintained through 6 months of device use. 
DOMAIN OF CLINICIANS OBSERVATIONS 
QUANTIFICATION OF URINE LOSS 
-x! j 
lill't"I'LIANCE GROUP 
NUMBER OF CONTINENCE PADS USED OVER 5 DAYS 
Similar comparisons of the mean number of continence pads used over 5 days while 
using a Reliance device at the one, three and six months visit assessments with that 
obtained at study inclusion is illustrated in table 10.27. 
Comparison of the number of pads used over 5 days for the 
Reliance group 
at baseline and after each follow-up visit 
HSU No assessed Mean no. Range SD 
ofpads 
used 
Baseline 48 10.6 8-12 1.23 
I Month 42 5.00 4-6 0.67 
3 Months 29 3.62 3-5 0.72 
6 Months 31 3.43 3-5 0.65 
Table 10.27 Comparison of the mean number of continence pads used over 5 days 
recorded in the urinary diary while using a device at the one, three and sIX months 
visit assessments with that obtained at study inclusion. 
BASELINE VS I MONTH PAD USE 
Null Hypothesis 
The means of the two populations, number of continence pads used over 5 days, at 
baseline and after application of the Reliance device at I month are the same (n = 42 
pairs of observations). The table (10.28) shows the pad use data at baseline and after 
one-month use of the device. 
?? R 
Comparison of pad use data for the Reliance group 
at baseline and after I month (n=42) 
Variable No of pairs Mean Range SD SE of mean 
Baseline 10.5 8-12 1.3 0.203 
pad use 42 
1 Month 5.00 4-6 0.67 0.11 
pad use-- 
Paired differences 
Mean Standard Standard 2-tail Sig 95% 
deviation error of mean confidence 
interval 
5.62 1.16 0.191 0.000 5.234-6.01 
Table 10.28 The continence pad use data at baseline and after one month use of the 
Reliance device as well as the mean paired differences. 
The null hypothesis states that the population mean difference should be zero. There 
was a statistically significant difference in the means of the two populations, therefore 
one can reject the null hypotheses. 
BASELM VS 3 MONTHS PAD USE 
Null Hypothesis 
The means of the two populations, continence pad use at baseline and after 
application of the Reliance device at 3 months are the same (n =29 pairs of 
observations). The table shows the pad use data at baseline and after three months use 
of the device. 
Comparison of pad use data for the Reliance group 
at baseline and after 3 months (n=29) 
Vadable No of pairs Mean Range SD SE of mean 
Baseline 10.3 8-12 1.33 0.223 
pad use 29 
3 Months 3.62 3-5 0.72 0.118 
_pad use 
Paired differences 
Mean Standard Standard 2-tail Sig 95% 
deviation error of mean confidence 
interval 
7.00 1.53 0.251 0.000 6.491,7.509 
Table 10.29 The continence pad use data at baseline and after three months use of 
the device as well as the mean paired differences. 
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There was a statistically significant difference in the means of the two populations, 
therefore one can reject the null hypotheses (Table 10.29). 
BASELINE VS 6 MONTHS PAD USE 
Null Hypothesis 
The means of the two populations, pad use at baseline and after application of the 
Reliance device at six months are the same (n = 31 pairs of observations). The table 
(10.30) shows the pad use data at baseline and after six months utilisation of the 
device. 
Comparison of pad use data for the Reliance group 
at baseline and after 6 months (n=31) 
Variable No of pairs Mean Range SD SE of mean 
Baseline 10.8-12 1.41 0.263 
pad use 31 
6 Months 3.43 3-5 0.647 0.106 
pad use 
Paired differences 
Mean Standard Standard 2-tail Sig 95% 
deviation error of mean confidence 
interval 
7.19 1.51 0.248 0.000 6.687,7.692 
Table 10.30 The pad usage data at baseline and after six months use of the device as 
well as the mean paired differences. 
There was a statistically significant difference in the means of the two populations, 
therefore one can reject the null hypotheses. 
CONTROL OF INCONTINENCE 
(CHANGES IN CONTINENCE PAD UTHISATION) 
Seventeen of the patients did not have six-month continence pad usage data available 
at the end of the study. Thus, the analysis includes 31 patients. The effectiveness 
(control of incontinence) as determined by incontinence pad usage revealed a 
significant reduction in urine loss during device use at each period of assessment. 
?,; 
INDIVEDUAL PATIENT RESPONSES 
(CHANGES IN CONTINENCE PAD UTILISATION) 
The individual patient responses based on the changes in continence pad utilisation 
after 1,3, and 6 months of Reliance Urinary Control Insert use are illustrated in table 
10.31 and figure 10.14. 
The individual patient responses after 1,3, and 6 months of 
Reliance insert use 





I month 0 32(66.7%) 10(20.8%) 0 
3 months 29(60.4%) 1 0 0 
6 months 
1 
0 31(64.6%) 1 0 0 
Table 10.31 The number (percentage) of individual patient responses categonsed by 
degree of improvement. ["Completely dry" = No pads used over 5 days of 
recordings; "significantly improved" 50% reduction in pad usage; "no change" 
25% change from baseline; "worse" greater than 25% increase from baseline pad 
usage] 
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Figure 10.14 Individual patient responses categorised by degree of improvement 
over time in women using the Reliance device. 
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EFFICACY CONSISTENCY 
(CHANGES IN CONTINENCE PAD UTILISATION) 
Efficacy consistency as assessed by the maintenance mi reduction in continence pad 
utilisation was also determined for the Reliance device as women progressed through 
each visit to completion (Table 10.32). 
Efficacy consistency (pad use) for the Reliance device as 
women progressed through each visit to completion 
Sig. improved at 1 month Status at 3 Months Status at 6 Months 
(n--32) Dry (n=O) Dry (n--O) 
Sig. Improved (n--27)56.3% Sig. Improved (n=29)60.4% 
No change (n=O) No change (n=O) 
2 diaries missing 
No change at I month Status at 3 Months Status at 6 Months 
(n=10) Dry (n=O) Dry (n=O) 
Sig. Improved (n--2)4.2% Sig. Improved (n7-2)4.2% 
No chanize (n=O) No chame (n=O) 
Table 10.32 Efficacy consistency as determined by the maintenance of reduction in 
pad usage for the Reliance group as women progressed through each visit to study 
completion. 
The data suggest that the Reliance device significantly reduced unne loss as 
determined by incontinence pad use and these reductions were maintained through 6 
months of device use. 
DOMAIN OF CLINICIANS OBSERVATIONS 
QUANTIFICATION OF URINE LOSS 
RELIANCE GROUP 
PAD VVEIGIEff TEST DATA 
The mean PWT gains while using a Reliance device at the one, three and six months 
visit assessments with that obtained at study inclusion is illustrated in table 10.33. 
Comparison of PWT data for the Reliance group 
at baseline and after each follow-up visit 
r1sit No assessed Mean Range SD 
PWT(g) 
Basefine 48 31.2 1-99 32.1 
1 Month 40 0.76 0-3.5 0.71 
3 Months 29 0.93 0-4.6 0.93 
6 Months 31 1.30 0.1-2.0 3.43 
Table 10.33 Comparison of the mean PWT gains while using a device at the one, 
three and six months visit assessments with that obtained at study inclusion Note that 
of the 42 patients reviewed at one month, there was missing PWT data on two of the 
individuals who actually attended the visit. 
Comparisons were made, for the Reliance group, of the PWT gains at baseline and at 
one, three and 6 months of device use. 
BASELM VS I MONTH PNVT RESULTS 
Null Hypothesis 
The means of the two populations, PWT gains at baseline and after use of the 
Reliance device at one month are the same (n = 40 pairs of observations). Table 
10.34 shows the PWT data at baseline and after one-month use of the device. 
Comparison of PWT data for the Reliance group 
at baseline and after I month_(n=42) _ Variable No of pairs Mean SD SE of mean 
Baseline 32.64 33.81 5.35 
PWT(g) 40 
1 Month 0.76 0.705 0.11 
PWT(g) 
Paired differences 
Mean Standard Standard 2-tail Sig 95% 
deviation error of mean confidence 
interval 
31.88 33.78 5.34 0.000 21.07,42.68 
Table 10.34 The PWT data at baseline and after one month use of the device as well 
as the mean paired differences. 
III 
The null hypothesis states that the population mean difference should be zero. There 
was a statistically significant difference in the means of the two populations, therefore 
one can reject the null hypotheses. 
BASELM VS 3 MONTHS PVVT RESULTS 
Null Hypothesis 
The means of the two populations, PWT gains at baseline and after use of the 
Reliance device at three months are the same (n = 29 pairs of observations). Table 
10.35 shows the PWT data at baseline and after three months use of the device. 
Comparison of PWT data for the Reliance group 
At baseline and after 3 months (n=29) 
Vaiiable No of pairs Mean SD SE of mean 
Baseline 35.26 38.05 7.07 
PWT(g) 29 
3 Months 0.93 0.93 0.17 
PWT(9). 
Paired differences 
Mean Standard Standard 2-tail Sig 95% 
deviation error of mean confidence 
interval 
34.33 37.79 7.02 0.000 19.95,48.71 
Table 10.35 The PWT data at baseline and after three months use of the device as 
well as the mean paired differences. 
There was a statistically sigaificant difference in the means of the two populations, 
therefore one can re ect the null hypotheses. i 
BASELINE VS 6 MONTHS PWT RESULTS 
Null Hypothesis 
The means of the two populations, PWT gains at baseline and after use of the 
Reliance device at six months are the same (n=31 pairs of observations). Table 10.36 
shows the PWT data at baseline and after six months use of the device. 
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Comparison of PNW data for the Reliance group 
At baseline and after 6 months (n=31) 
Variable No of pairs Mean SD SE of mean 
Baseline 33.77 36.94 6.63 
PWT(g) 31 
6 Months 1.30 3.43 0.62 
PWT(9) 
Paired differences 
Mean Standard Standard 2-tail Sig 95% 
deviation error of mean confidence 
interval 
32.47 36.91 6.63 0.000 18.932 6.01 
Table 10.36 The PWT data at baseline and after six months use of the device as well 
as the mean paired differences. 
There was a statistically significant difference in the means of the two populations, 
therefore one can re*ect the null hypotheses. j 
CONTROL OF INCONTMNCE 
(CELA, NGE IN PAD WEIGHT TEST GAINS) 
Seventeen of the patients did not have 6-month PWT data available at the end of the 
study. Thus, the PWT analysis includes 31 patients. The effectiveness (control of 
incontinence) as determined by pad weight testing revealed a significant reduction in 
urine loss during device use at each period of assessment. 
INDWIDUAL PATIENT RESPONSES 
(CHANGE IN PAD NVEIGHT TEST GAINS) 
The categories of individual patient responses for the PWT gains were described in 
Ene chapter on methods of analysis but are repeated for convemence and are as 
follows: "completely dry" =Ig of urine or less on PWT gains; "significantly 
improved" = less than 2g in urine loss but not completely dry; "moderately Improved" 
= between 2.1 g and 3g in urine loss; "slightly improved" = between 3.1 g and 4.9g in 
urine loss; "no change" = 5g or more in urine loss and "worse" = greater than 25% 
increase from baseline PWT gains. 
?I 
The individual patient responses after 1,3, and 6 months of Reliance Urinary Control 
Insert use are illustrated in table 10.37 and figure 10.15. 
The individual patie t responses after 1,3, and 6 months of Reliance Insert use 

















I month 31(64.6%) 6(12.5%) 3(6.3%) 1(2%) 0 0 
3 months 22(45.8%) 14(8.3%) 12(4.2%) 1(2%) 0 0 
6 months 25(52.1) 13(6.3%) 12(4.2%) 10 0 10 
Table 10.37 The number (percentage) of individual patient responses categonsed by 
degree of improvement. 
No subject was made worse as a consequence of device use in either group. 
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Figure 10.15 Individual patient responses categorised by degree of improvement 
based on pad weight tests. 
TI A 
EFFICACY CONSISTENCY 
(CHANGE IN PAD NVEIGHT TEST GAINS) 
Efficacy consistency was also determined for the PWT data as women progressed 
through each visit to completion (Table 10.38). 
Efficacy consistency for the PVff data as 
women progressed through each visit to_ completion 
Dry at I month Status at 3 Months Status at 6 Months 
(n=31)64.6% Dry (n--20) 41.7% Dry (n--20) 41.7% 
Sig. Improved (n--1) 2% Sig. Improved (n--1) 2% 
Mod. Improved (n=1) 2% Mod. Improved (n--2) 4.2% 
SI. improved (n--1) 2% SI. Improved (n--O) 
Sig. improved at I month Status at 3 Months Status at 6 Months 
(n=6)12.5% Dry (n--2) 4.2% Dry (n=5)10.4% 
Sig. Improved (n--2) 4.2% 
Mod. Improved (ný 1) 2% 
S1. improved (n--O) 
Sig. Improved (n--I) 2% 
Mod- Improved (n=O) 
S1. Improved (n--O) 
No change (n=O) Worse (n=-O) 
Md. improved at 1 month Status at 3 Months Status at 6 Months 
(n--3)6.3% Dry (n7--O) Dry (n=O) 
Sig. Improved (n=1) 2% Sig. Improved (n--I) 2% 
Mod. Improved (n=O) Mod. Improved (n--O) 
S1. improved (n=O) SI. Improved (n-0) 
A improved at 1 month Status at 3 Months Status at 6 Months 
(n--1)2% Dry (n=O) Dry (n=O) 
Sig. Improved (n=O) Sig. Improved (n==O) 
Mod. Improved (n=O) Mod. Improved (n=O) 
SI. imDroved (n=1) 2% SI. Improved (n--I) 2% 
Table 10.38 Representation of efficacy consistency for the PWT data as women 
progressed through each visit to study completion. 
The data suggest that the Reliance device significantly reduced urine loss as 
determined by pad weighing tests and these reductions were maintained through 6 
months of device use. 
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DOMAIN OF CLINICIANS OBSERVATIONS 
QUANTIFICATION OF URINE LOSS 
FEMASSIST GROUP 
INCONTINENCE EPISODES PER DAY 
Analysis of unnary leakage by the number of incontinence episodes per day was 
determined from the mean number of IIEPD at each visit as recorded in the diaries 
(Table 10.39). 
Comparison of IUEPD for the FemAssist group 
at baseline and after each follow-up visit 
HSU No assessed Mean Range SD 
IFPD 
Baseline 53 5.04 4-8 0.9 
1 Month 47 1.63 1-2 0.49 
3 Months 41 2.05 1-3 0.63 
6 Months 36 1.00 0-2 0.59 
Table 10.39 Comparison of the mean number of lEPD while using the FemAssist 
device at the one, three and six months visit assessments with that obtained at study 
inclusion. 
I assessed whether or not there was any difference in the degree of protection afforded 
by the FemAssist device as assessed by the number of EEPD on the urinary diary at 
baseline without a device and after one, three and six months while using the device. 
BASELM VS 1 MONTH EEPD 
Null Hypothesis 
The means of the two Populations, incontinence episodes per day at baseline and at I 
month, are equal. Table 10.40 shows the mean IEPD recorded at baseline and after 
one months device use. 
? IR 
Comparison of EEPD for the FemAssist group 
At baseline and after I month (n=47) 
Variable No of pairs Mean Range SD SE of mean 
Baseline 5.04 4-7 0.9 0.14 
EEPD 47 
1 Month 1.63 1-2 0.49 0.07 
EEPD 
Paired differences 
Mean Standard Standard 2-tail. Sig 95% 
deviation error of mean confidence 
interval 
3.4 0.96 0.14 0.000 3.13,3.69 
Table 10.40 The IEPD data at baseline and after one month use of the device as well 
as the mean paired differences. 
The null hypothesis states that the population mean difference should be zero. There 
was a statistically significant difference between the means of the two populations, 
therefore one can re . ect the null hypothesis. Ij 
BASELM VS 3 MONTHS IEPD 
The null hypothesis was that the mean number of InContinence episodes per day at 
three months while using the device was equal in both groups. 
Comparison of ILEPD for the FemAssist group 
at baseline and after 3 months (n=41) 
Vadable No of pairs Mean Range SD SE of mean 
Baseline 4.97 4-7 0.82 0.13 
IIEPD 41 
3 Months 2.05 1-3 0.63 0.1 
LEPD 
Paired differences 
Mean Standard Standard 2-tail Sig 95% 
deviation error of mean confidence 
interval 
2.93 0.87 0.14 0.000 2.65,3.20 
Table 10.41 The lEPD data at baseline and after three months use of the device as 
well as and the mean paired differences. 
There was a statistically significant difference between the means of the two 
populations, therefore one can reject the null hypothesis (Table 10.4 1). 
TIQ 
BASELM VS 6 MONTHS IEPD 
I also assessed if there was any difference in the degree of protection afforded by the 
FemAssist device based on the number of incontinence episodes in the urinary diary 
at the end of the trial. The null hypothesis was that the mean number of incontinence 
episodes per day at six months while using the device was equal in both groups. 
Comparison of IEPD for the FemAssist group 
at baseline and after 6 months (n=36) 
Vaiiable No of pairs Mean Range SD SE of mean 
Baseline 4.94 4-7 0.83 0.14 
IEPD 36 
6 Months 1.00 0-2 0.59 0.098 
EEPD 
Paired differences 
Mean Standard Standard 2-tail Sig 95% 
deviation error of mean confidence 
interval 
3.94 1.01 0.17 0.000 3.6,4.3 
Table 10.42 The IEPD data at baseline and after six months use of the device as well 
as the mean paired differences. 
There is a statistically significant (lifference between the means of the two 
populations, therefore one can reject the null hypothesis (Table 10.42). 
INDI)VIDUAIL PATIENT RESPONSES 
(CHANGES IN INCONTINENCE EPISODES PER DAY) 
The individual patient responses after 1,3, and 6 months of FemAssist use are 
illustrated in table 10.43. The table also illustrates the per cent of individual 
responses categorised by degree of improvement at each visit based on the IEPD 
recorded in the diaries. 
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The individual patient responses after 1,3, and 6 months 
of FemAssist use (n=53) 









1 month 0 9(17%) 20(37.7%) 
1 
7(13.2%) 11(20.8%) 0 
3 months 0 2(3.8%) 19(3 5.8% 13 24.5%) 7(13.2%) 0 
6 months 6 18(34%) 11(20.8%) , 1(1.9%) 0 0 
Table 10.43 The number (percentage) of individual patient responses categonsed by 
degree of improvement. 
Individual patient responses on the five-day urinary diary revealed a large number of 
women categonsed as dry Or significantly improved based on the number of 
























Figure 10.16 Individual patient responses on the five-day urinary diary in women 
using the Reliance device. 
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EFFICACY CONSISTENCY 
(CFLA, NGES IN INCONTINENCE EPISODES PER DAY) 
As women progressed through each visit to completion, the consistency in 
improvement in the lEPD with device use was also determined (Table 10.44). 
Efficacy consistency in terms of improvement in IEPD as 
women progressed through each visit to completion 
Sig. improved at 1 month Status at 3 Months Status at 6 Months 
(n--9)17% Dry (n==O) Dry (n=1)1.9% 
Sig. Improved (n--1)1.9% Sig. Improved (n--8)15. I% 
Mod. Improved (n=8)15. I% Mod. Improved (n=O) 
SI. improved Cn=-O) SI. Improved (n=O) 
Md. improved at 1 month Status at 3 Months Status at 6 Months 
(n---20)37.8% Dry (n=O) Dry (n---3)5.7% 
Sig. Improved (n= 1) 1.9% Sig. Improved (n--9)17% 
Md. Improved (n7--11)20.8% Mod. Improved (n=6)11.3% 
SI. unproved (n7--2)3.8% SI. Improved (n=O) 
No ch; knge(n---2)3.8% No change(n--O) 
S1. improved at I month Status at 3 Months Status at 6 Months 
(n--7)13.2% Dry (n=O) Dry (n--2)3.8% 
Sig. Improved (n=O) Sig. Improved (n= 1) 1 
. 
9% 
Mod. Improved (n=O) Mod. Improved (n=-4)7.5% 
S1. improved (n--5)9.4% SI. Improved (n=O) 
No change(n---2)3.8% No change(n=O) 
No change at I month Status at 3 Months Status at 6 Months 
(n=1 1)20.6% Dry (n=O) Dry (n=O) 
Sig. Improved (n=O) Sig. Improved (n7--O) 
Mod. Improved (n=O) Mod. Improved (n=1)1.9% 
S1. improved (n=-6)11.3% S1. Improved (n-- 1) 1.9% 
No chan2e(n---3)5.7% No change(n=O) 
Table 10.44 Efficacy consistency of the Fem-Assist device in terms of maintenance of 
improvement in IEPD as women progressed through each visit to study completion. 
*= Two diaries were not available for evaluation at 3 months. 
Twenty women were moderately improved at I month. When followed up at 3 
months, two were lost to follow-up and two women reviewed did not complete 
diaries. Eleven women were unchanged at one month. When followed up at 3 
? 4? 
inonths, 2 were lost and when reviewed at 6 months, a ftirther 7 were lost to follow- 
UP- 
The data suggest that the Fem-Assist device significantly reduced urine loss as 
determined by the number of incontinence episodes per day for all women and these 
reductions were maintained through 6 months of device use. 
DOMAIN OF CLINICIANS OBSERVATIONS 
QUANTIFICATION OF URINE LOSS 
FENUSSIST GROUP 
NUMBER OF CONTMENCE PADS USED OVER 5 DAYS 
The mean number of continence pads used over five days while using a FemAssist 
device at the one, three and six months visit assessments with that obtained at study 
inclusion is illustrated in table 10.45. 
Comparison of the number of pads used over 5 days for the 
FemAssist group 
at baseline and after each foHow-up visit 
risit No assessed Mean no. Range SD 
of pads 
used 
Baseline 53 11.2 8-15 1.68 
I Month 47 5.75 5-9 0.91 
3 Months 41 4.61 4-5 0.49 
6 Months 36 4.33 4-5 0.48 
Table 10.45 Comparison of the mean number of continence pads used over five days 
recorded in the urinary diary while using a FemAssist device at the one, three and six 
months Visit assessments with that obtained at study inclusion. 
Similar comparisons were made, for the FemAssist group, of the differences in the 
mean number of continence pads used over five days at baseline and at one, three and 
six months of device use. 
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BASELME VS 1 MONTH PAD USE 
Null Hypothesis 
The means of the two populations, number of pads used over 5 days, at baseline and 
after application of the FernAssist device at one month are the same (n = 47 pairs of 
observations). Table 10.46 shows the pad use data at baseline and after one-month 
use of the device. 
Comparison of pad use data for the FemAssist group 
at baseline and after I month (n=47) 
Variable No of pairs Mean Range SD SE of mean 
Baseline 11.2 8-15 1.68 0.25 
pad use 47 
1 Month 5.78 5-9 0.9 0.13 
pad use__ 
Paired differences 
Mean Standard Standard 2-tail Sig 95% 
deviation error of mean confidence 
interval 
5.4 1.84 0.3 0.000 4.67,5.96 
Table 10.46 The pad use data at baseline and after one-month use of the FemAssist 
device as well as the mean paired differences. 
The null hypothesis states that the population mean difference should be zero. There 
was a statistically significant difference in the means of the two populations, therefore 
one can reject the null hypotheses. 
BASELINE, VS 3 MONTHS PAD USE 
Null Hypothesis 
The means of the two populations, pad use at baseline and after use of the FemAssist 
device at three months are the same (n=-41 pairs of observations). Table 10.47 shows 
the pad use data at baseline and after three months use of the device. 
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Comparison of pad use data for the FemAssist group 
at baseline and after 3 months (n=41) 
Variable No of pairs Mean Range SD SE of mean 
Baseline 11.2 8-15 1.76 0.28 
pad use 41 
3 Months 4.6 4-5 0.5 0.08 
pad use 
Paired differences 
Mean Standard Standard 2-tail Sig 95% 
deviation error of mean confidence 
interval 
6.6 1.86 0.3 0.000 6.02,7.22 
Table 10.47 The pad use data at baseline and after three months use of the FemAssist 
device as well as the mean paired differences. 
There was a statistically significant difference in the means of the two populations, 
therefore one can reject the null hypotheses. 
BASELINE VS 6 MONTH PAD USE 
Null Hypothesis 
The means of the two populations, pad use at baseline and after application of the 
FemAssist device at six months are the same (n7--36 pairs of observations). Table 
10.48 shows the pad use data at baseline and after six-month use of the device. 
Comparison of pad use data for the FemAssist group 
at baseline and after 6 months (n=36) 
Variable No of pairs Mean Range SD SE of mean 
Baseline 11.4 8-15 1.7 0.3 
pad use 36 
6 Months 4.35 4-5 0.48 0.08 
_pad use 
Paired differences 
Mean Standard Standard 2-tail Sig 95% 
deviation error of mean confidence 
interval 
7.05 1.76 0.3 0.000 6.427.67 
Table 10.48 The pad usage data at baseline and after six months use of the 
FemAssist device as well as the mean paired differences. 
There was a statistically significant difference in the means of the two populations, 
therefore one can reject the null hypotheses. 
? 4's 
CONTROL OF INCONTINENCE 
(CHANGES IN CONTINENCE PAD UTILISATION) 
Seventeen of the patients did not have 6 month pad usage data available at the end of 
the study. Thus, the analysis includes 36 patients. The effectiveness (control of 
incontinence) as determined by incontinence pad usage revealed a significant 
reduction in urine loss during device use at each period of assessment. 
PliDPADUAIL PATEENT RESPONSES 
(CHANGES IN CONTINENCE PAD UTILISATION) 
The indiVidual patient responses based on the changes in continence pad utilisation 
after L. 3, and 6 months of FemAssist use are illustrated in table 10.49 and figure 
10.17. 
The individual patient responses after 1,3, and 
6 months of FemAssist device use 




1 month 0 13(24.5%) 34(64.2%) 
3 months 0 39(73.6%) 2(3.8%) 
6 months 0 34(64.2%) 2(3.8%) 
Table 10.49 The number (percentage) of indiVidual patient responses categorised by 
degree of improvement. 
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Figure 10.17 Individual patient responses categorised by degree of improvement in 
the number of continence pads used in the FemAssist group. 
EFFICACY CONSISTENCY 
(CULANGES IN CONTINENCE PAD UTILISATION) 
Efficacy consistency was also determined for the Fem-Assist device as women 
progressed through each visit to completion (Table 10.50). 
Efficacy consistency (pad use) for the FemAssist device as 
women progressed through each visit to completion 
Sig. improved at 1 month Status at 3 Months* Status at 6 Months 
(n= 13) Dry (n=O) Dry (n=O) 
Sig. Improved (n= 11)20.8% Sig. Improved (n--9)17% 
No change (n=O) No change (n=2)3.8% 
2 drop out at 3 months 
No change at I month Status at 3 Months Status at 6 Months 
(n=34) Dry (n=O) Dry (n=O) 
Sig. Improved (n=28)52.8% Sig. Improved (n--25)47.2% 
No chanLye (n=2)3.8% No change (n=O) 
** == 4 drop out at 3 months and a fin-ther 5 at 6 months 
Table 10.50 Efficacy consistency as determined by the maintenance of reduction in 
pad usage for the FemAssist group as women progressed through each visit to study 
completion. 
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The data suggest that the FemAssist device significantly reduced urine loss as 
determined by incontinence pad use and these reductions were maintained through 6 
months of device use. 
DOMAIN OF CLINICIANS OBSERVATIONS 
QUANTIFICATION OF URINE LOSS 
FENIASSIST GROUP 
PAD NWIGHT TEST DATA 
The mean PWT gains while using a Fem-Assist device at the one, three and s11X months 
visit assessments with that obtained at study inclusion is illustrated in table 10.51 
Comparison of PWT data for the FemAssist group 
At baseline and after each follow-up visit 
risit No assessed Mean Range SD 
PWT(g) 
Baseline 53 28.7 1.1-128 23.7 
I Month 47 3.27 0.5-6 1.06 
3 Months 41 3.44 2-6 0.94 
6 Months 36 3.61 2-5 0.65 
Table 10.51 Comparison of the mean PWT gains while using a FemAssist device at 
the one, three and six months visit assessments with that obtained at study inclusion. 
To determine if there were any differences in the mean PWT gains at each visit as a 
consequence of device use, comparisons were made, for the FemAssist group, of the 
PWT gains at baseline and at one, three and siX months of device use. 
BASELM VS 1 MONTH PNff RESULTS 
Null Hypothesis 
The means of the two populations, PWT gains at baseline and after application of the 
FemAssist device at one month are the same (n = 47 pairs of observations). Table 
10-52 shows the PWT data at baseline and after one-month use of the device. 
IAR 
Comparison of PWT data for the FemAssist group 
at baseline and after 1 month (n=47) 
Vatiable No of pairs Mean SD SE of mean 
Baseline 28.7 23.7 3.45 
PWT(g) 47 
1 Month 3.28 1.09 0.16 
PWT(g) 
Paired differences 
Mean Standard Standard 2-tail Sig 95% 
deviation error of mean confidence 
interval 
25.4 24 3.5 0.000 18.37,32.5 
Table 10.52 The PWT data at baseline and after one month use of the Fem. Assist 
device as well as the mean paired differences. 
The null hypothesis states that the population mean difference should be zero. There 
was a statistically significant difference in the means of the two populations, therefore 
one can reject the null hypotheses. 
BASELM VS 3 MONTH PVVT RESULTS 
Null Hypothesis 
The means of the two populations, PWT gams at baseline and after application of the 
FemAssist device at three months are the same (n = 41 pairs of observations). Table 
10.53 shows the PWT data at baseline and after three months use of the device. 
Comparison of PWT data for the FemAssist group 
at baseline and after 3 months (n=41) 
Vatiable No of pairs Mean SD SE of mean 
Baseline 28.6 25.3 3.9 
PWT(g) 41 
3 Months 3.43 0.94 0.14 
PWT(g) 
Paired differences 
Mean Standard Standard 2-tail Sig 95% 
deviation error of mean confidence 
interval 
. 
25.25 25.54 4.0 0.000 17.11133.3 
Table 10.53 The PWT data at baseline and after three months use of the FemAssist 
device as well as the mean paired differences. 
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There was a statistically significant difference in the means of the two populations, 
therefore one can reect the null hypotheses. 13 
BASELU'4E VS 6 MONTH PVVT RESULTS 
Null Hypothesis 
The means of the two populations, PWT gains at baseline and after application of the 
FemAssist device at six months are the same (n == 36 pairs of observations). Table 
10.54 shows the PWT data at baseline and after six months use of the device. 
Comparison of PAW data for the FemAssist group 
at baseline and after 6 months (n=36) 
Variable No of pairs Mean SD SE of mean 
Baseline 29.66 26.17 4.3 
PWT(9) 36 
6 Months 3.63 0.7 0.12 
PWT(g) 
Paired differences 
Mean Standard Standard 2-tail Sig 95% 
deviation error of mean confidence 
interval 
26.04 26.3 4.3 0.000 17.14,33.9 
Table 10.54 The PWT data at baseline and after six months use of the device as well 
as the mean paired differences. 
There was a statistically significant difference in the means of the two populations, 
therefore one can re ect the null hypotheses. i 
CONTROL OF INCONTMNCE 
(CELANGE IN PAD VVEIGHT TEST GAINS) 
Seventeen of the patients did not have six-month PWT data available at the end of the 
study. Thus, the PWT analysis includes 36 patients. The effectiveness (control of 
incontinence) as determined by pad weight testing revealed a significant reduction in 
urine loss during device use at each period of assessment. 
1150 
INDIVIDUAL PATIENT RESPONSES 
(CHANGE IN PAD VVEIGHT TEST GAINS) 
The individual patient responses based on the changes in pad weight test gains after 
1,3, and 6 months of FemAssist device use are illustrated in table 10.55 and figure 
10.18. 


















I month l(l. 9%) 2(3.8%) 20(37.7%) 16(30.2%) 8(15.1%) 0 
3 months 0 9(17%) 6(11.3%) 25(47.2%) l(l. 9%) 0 
6 months 0 l(I. 9%) 9(17%) 24(45.3%) 2(3.8%) 0 
Table 10.55 The number (percentage) of individual patient responses categorised by 
degree of improvement. 
1) 1%, 1 
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Figure 10.18 Individual patient responses categonsed by degree of improvement 
based on the pad test in the FemAssist group. 
EFFICACY CONSISTENCY 
(CHANGE IN PAD VVEIGHT TEST GAINS) 
Efficacy consistency was also determined for the PWT data as women progressed 
through each visit to completion (Table 10.56). 
Efficacy consistency for the PWT data as 
women progressed through each visit to completion 
Dry at I month Status at 3 Months Status at 6 Months 
_(n=l) 
Dropped out Dropped out 
Sig. improved at I month Status at 3 Months Status at 6 Months 
(n=2) Dry (n=O) Dry (n=1)1.9% 
Sig. Improved (n--2)3.8% Sig. Improved (n=1)1.9% 
Mod. Improved (n=O) Mod. Improved (n=O) 
SI. improved (n=O) SI. Improved (n=O) 
Md. improved at I month Status at 3 Months Status at 6 Months 
(n--20) Dry (n=O) Dry (n=O) 
Sig. Improved (n---7)13.2% Sig. Improved (n=O) 
Mod. Improved (w=6)11.3% Mod. Improved (n=6)11.3% 
S1. improved_(n--7)13.2% S1. Improved (n--7)13.2% 
SI. improved at 1 month 
(n7-16) 
Status at 3 Months 
Dry (n--) 
Sig. Improved (n=O) 
Mod. Improved (n-==O) 
St. improved (n7-16)30.2% 
Status at 6 Months 
Dry (n=O) 
Sig. Improved (n=O) 
Mod. Improved (n=3)5.7% 
S1. improved (n--13)24.5% 
No change No change 
No change at 1 month Status at 3 Months Status at 6 Months 
(n=-8) Dry (n=O) Dry (n=O) 
Sig. ]Improved (n=O) Sig. Improved (n--O) 
Mod. Improved (n=-O) Mod. Improved (n=O) 
SI. improved (n---2)3.8% S1. improved (n=4)7.5% 
No chanee(n-M. 9% No chanae(n--2)3.8% 
Table 10.56 Representation of efficacy consistency for the PWT data as women 
progressed through each visit to study completion. 
Twenty women were moderately improved at I month but following their 3-month 
visit, 7 dropped out. Eight women experienced no change at I month- When 
reviewed at 3 months, 2 had been lost to follow-up and 3 had missing diaries. 
However the latter were followed up at 6 months and had complete diaries then. 
The data suggest that the FernAssist device also significantly reduced urine loss as 
determined by pad weighing tests for all women and these reductions were maintained 
through 6 months of device use. 
CHANGES IN URETHRAL FUNCTION AS 
A CONSEQUENCE OF DEVICE USE 
RELIANCE GROUP 
Possible changes in urethral finiction as a result of Reliance device use were evaluated 
by comparing PWT gains at the start and end of the trial assessed without a device in- 
situ. (Missing data= 17 (35.4%) patients. I 
T51 
Null Hypothesis: The mean difference of the two populations, PWT gains before and 
after a period of 6 months device use is the same. The table illustrates the PWT gains 
at baseline and after six months use of the Reliance device as well as and the mean 
paired differences (table 10.57) 
Comparison of PWT data for the Reliance group (without a device) 
at baseline and after 6 month (n=31)__ 
Variable No of pairs Mean SD SE of mean 
Baseline 33.8 36.9 6.635 
PWT(9) 31 
6 Months 27.3 22.7 4.07 
IrWT 
Paired differences 
Mean Standard Standard 2-tail Sig 95% 
deviation error of mean confidence 
interval 
6.44 34.67 6.23 0.31 -6.28,19.15 
Table 10.57 The PWT gains at baseline and after s11-X months use of the Reliance 
device as well as the mean paired differences to determine possible changes in 
urethral function. 
The urme loss without the Reliance insert decreased from a mean of 33.8 grams at 
baseline; to 27.3 grams at 6 months, although this result was not statistically 
significant (p>0.05). The means of the two populations were the same so one can 
accept the null hypotheses. 
FENUSSIST GROUP 
Possible changes in urethral function as a result of FemAssist device use were 
similarly evaluated by comparing PWT gains at the start and end of the trial assessed 
without a device in-situ. (NlissIng data= 17 (32.1%) patients. ) 
Null Hypothesis 
The mean difference of the two populations, PWT gains before and after a period of 
Six months device use is the same. The table illustrates the PWT gains at baseline and 
after six months use of the FemAssist device as well as and the mean paired 
differences (table 10.58) 
? '54 
Comparison of PWT data for the FemAssist group (without a device) 
at baseline and after 6 month (n=36) 
Variable No of pairs Mean SD SE of mean 
Baseline 29.7 29.27 5.26 
PWT(g) 36 
6 Months 27.3 22.66 4.07 
PWT (a) 
Paired differences 
Mean Standard Standard 2-tail Sig 95% 
deviation error of mean confidence 
interval 
2.37 36.28 6.51 0.72 -10.93; 1 
15.68 
Table 10.58 The PWT gains at baseline and after six months use of the FernAssist 
device as well as the mean paired differences to determine possible changes in 
urethral function. 
The urine loss without the insert decreased from a mean of 29.7 grams at baseline; to 
27.3 grams at 6 months, although this result was not statistically significant (p>0.05). 
The means of the two populations were the same so one can accept the null 
hypotheses. 
Women with moderate GSI responded much the same to device use overall compared 
to women with greater severity of urinary leakage. 
FURTHER COMPARISON OF DEVICE GROUPS 
RELIANCE Vs FEMASSIST 
Inter group analysis was performed, comparing the number of incontinence episodes 
per day, the number of continence pads used over five days and the PWT gains 
obtained with each device, at each period of assessment. The two groups, Reliance 
users and FemAssist users were evaluated using the non-parametric Wilcoxon rank 
sum test for two independent populations. The Null hypothesis was that the medians 
of the two independent populations, Reliance group and FemAssist group, were equal 
for each of the continuous variables and sample sizes studied. 
IIS'S 
PAD TEST WEIGHT DATA 
FENUSSIST VS RELIANCE 
Assessment was made of whether or not there was any difference in the degree of 
protection afforded by each device in the two groups as evaluated on the PWT gains 
at 1,3 and 6 months (Tables 10.59 - 10.61). 
Pad weight test data for Reliance and FemAssist users 
At I month 
NIIIN MAX NIEDUN Paired 
differences 
p-value 
Reliance 0 3.5 0.76 
n--42 0.000 
FemAssist 0.5 6 3.28 
n=47 
Table 10.59 The Pad weight test gains of the women in each group at I month 
follow-up assessment. 
Pad weight test data for Reliance and FemAssist users 
at 3 months 
MIN NLAX NMDLAN Paired 
differences 
p-value 




Table 10.60 The Pad weight test gains of the women in each group at 3 months 
follow-up assessment. 
Pad weight test data for Retiance and FemAssist users 
at 6 months 
NIIIN NLAX MIEDIAN Paired 
differences 
p-value 




Table 10.61 The Pad weight test gains of the women in each group at 6 months 
follow-up assessment. 
INDIVIDUAL PATIENT RFSPONSES 
(CHANGES IN PAD NVEIGHT TEST GAINS) 
The following data illustrates the proportion of women with GSI who were made dry 
or improved with use of a device based on the individual patient responses obtained 
r__ - itum the PWT gains after 1,3, and 6 months of FemAssist and Reliance device use. 
Proportion "completely dry" with a device, 




Figure 10.19 The proportion of women dry With device use at one month (PWT) 
9'57 
Proportion "dry" with a device, 
Reliance or FemAssist at 3&6 
months 
0% 13 FemAssist 
N Reliance 
Figure 10.20 The proportion of women dry with device use at 3 and 6 months (PWT) 
Proportion "significantly improved" 
with a device, Reliance or FemAssist 
0 FemAssist 
N Reliance 




at I month 
Proportion go significantly improved" 
with a device, Reliance or FemAssist 
11 FernAssist 
N Reliance 
Figure 10.22 The proportion of women significantly improved with device use at 3 
months (PWT). 
Proportion "significantly improved" with 
a device, Reliance or FemAssist 








Figure 10.23 The proportion of women significantly improved with device use at 6 
months (PWT) 
? ISQ 
at 3 months 
Proportion "moderately improved" vAth a device, 





Figure 10.24 The proportion of women moderately improved with device use at I 
month (PWT). 
Proportion 21moderately improved" vAth a device, 
Reliance or FemAssist at 3 months 
YO iM F) 
0 FernAssist 0 Reliance 
7 
Figure 10.25 The proportion of women moderately improved with device use at 3 
months (PWT). 
IAO 
Proportion "moderately improved" with a 
device, Reliance or FemAssist at 6 months 
13 FernAssist 
0 Reliance 
Figure 10.26 The proportion of women moderately improved with device use at 6 
months (PWT). 
Proportion "slightly improved" vAth a device, 






Figure 10.27 The proportion of women slightly improved with device use at I month 
(PWT). 
IAI 
Proportion "'slightly improved" vAth a device, 






Figure 10.28 The proportion of women slightly improved with device use at 3 
months (PWT). 
Proportion "slightly improved" with a device, 






Figure 10.29 The proportion of women slightly improved with device use at 6 
months (PWT) 
? A? 
Vill I 1IRR 
tin 
Proportion experiencing "no change" 
with a device, Reliance or FemAssist 
at 1,3 &6 months 0% 
11 FemAssist 
0 Reliance 
Figure 10.30 The proportion of women experiencing no change with device use at 1, 
3 or 6 months (PWT). 
It can be easily grasped that proportionally more women with GSI experienced a 
higher degree of control of urinary leakage using a Reliance device. 
INCONTINENCE EPISODES PER DAY 
FEMASSIST VS RELUNCE 
Assessment was made of whether or not there was any difference in the degree of 
protection afforded by each device in the two groups as evaluated on the number of 
IEPD at one, three and six months (Tables 10.62 - 10.64). 
fEPD for Reliance and FemAssist users 
at 1 month 











IEPD for Reliance and FemAssist users 
at 3 months 







Table 10.63 The number of IEPD of the women m each group at 3 months follow-up 
assessment. 
JEEPD for Reliance and FemAssist users 
at 6 months 







Table 10.64 The number of EEPD of the women in each group at 6 months follow-up 
assessment. 
There was no significant difference between the groups at I month but significant 
differences were observed subsequently, With women using the Reliance having less 
incontinence episodes at 3 months and FemAssist better at 6 months. 
EN-DIVIDUAL PATIENT RESPONSES 
(CHANGES IN INCONTINENCE EPISODES PER DAY) 
The following data illustrates the proportion of women with GSI who were made dry 
or unproved with use of a device based on the individual patient responses obtained 
from the urinary diary (IEPD) after 1,3, and 6 months of FemAssist and Reliance 
device use. 
964 
Proportion "'significantly improved" 
with a device, Reliance or FemAssist 
at I month 
11 FernAssist 
N Reliance 
Figure 10.31 Proportion of women significantly improved with device use at I 
month (IEPD) 
Proportion "significantly improved" 




Figure 10.32 Proportion of women significantly improved with device use at 3 
months (IIEPD) 
3 months 10% 
Proportion "'significantly improved" with a 
device, Reliance or FemAssist at 6 months 
53% 
47% 13 FernAssist 
0 Reliance 
Figure 10.33 Proportion of women sigrifficantly improved with device use at 6 
months (EEPD) 
Proportion "moderately improved" with a 
device, Reliance or FemAssist at I month 
51% 49% 13 FernAssist 
m Reliance 
re 10.34 Proportion of women moderately improved with device use at I month 
(IEPD) 
166 
Proportion "moderately improved" Wth a device, 
Reliance or FemAssist at 3 months 
13 FernAssist 
0 Reliance 
Figure 10.35 Proportion of women moderately improved with device use at 3 months 
(IEPD) 
Proportion "moderately improved" vAth a device, 
Reliance or FemAssist at 6 months 
50% 50% 11 FernAssist 
0 Reliance 
Figure 10.36 Proportion of women moderately improved with device use at 6 months 
? 67 
Proportion "slightly improved" vAth a device, 




Figure 10.37 Proportion of women slightly improved with device use at I month 
(fEPD) 
Proportion "slightly improved" with a device, 










Proportion "slightly improved" vAth a device, 





Figure 10.39 Proportion of women slightly improved with device use at 6 months 
(IEPD) 
CONTINENCE PADS USED OVER FIVE DAYS 
FEMASSIST VS RELIANCE 
Assessment was made of whether or not there was any difference in the degree of 
protection afforded by each device in the two groups as evaluated on the number of 
continence pads used at 1,3 and 6 months. 
Comparison of pad use data for the Reliance and FemAssist groups 
at I month 











Comparison of pad use data for the Reliance and FemAssist groups 
at 3 months 







Table 10-66 The number of continence pads used by the women in each group at 3 
months. 
Comparison of pad use data for the Reliance and FemAssist groups 
at 6 months 







Table 10.67 The number of continence pads used by the women in each group at 6 
months. 
There were no significant differences in the reduction in pad usage between the 
groups. 
')70 
INDPADUAL PATIENT RESPONSES 
(CHANGES IN CONTINENCE PAD USE) 
The following data illustrates the proportion of women with GSI who were made dry 
or improved with use of a device based on the individual patient responses obtained 
from the urinary diary (continence pads used over 5 days) after 1,3, and 6 months of 
FemAssist and Reliance device use. 
Proportion "significantly improved" vAth a device, 





Figure 10.40 Proportion of women significantly improved with a device at I month 
(pads used). 
? 71 
Proportion "significantly improved" vAth a device, 




Figure 10.41 Proportion of women significantly improved with a device at 3 months 
(pads used). 
Proportion "significantly improved" vAth a device, 
Reliance or FemAssist at 6months 
48% 13 FernAssist 
52% 0 Reliance 
Figure 10.42 Proportion of women significantly improved with a device at 6 months 
(pads used). 
77'1 
Proportion experiencing I'no change" vAth a 
device, Reliance or FemAssist at 1 month 
11 0 FernAssist 
0 Reliance 
Figure 10.43 Proportion of women experiencing no change with a device at I month 
(pads used). 
Proportion experiencing "no change" with a 





Figure 10.44 Proportion of women experiencing no change with a device at 3 and 6 
months (pads used). 
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RELATIVE RISK REDUCTION 
ABSOLUTE RISK REDUCTION 
NUMBERS NEEDED TO BE TREATED. 
The relative risk reduction, the absolute risk reduction and numbers needed to be 
treated were calculated for both objective and subjective outcome measures. 
Relative risk reduction is the reduction of adverse events achieved by a treatment, 
expressed as a proportion of the control rate. it is the difference in event rates 
between the control and treatment groups, divided by the event rate in the control 
group. The absolute risk reduction or attributable risk reduction is the difference in 
event rates between the control (pre-treatment) and treatment groups. The "number 
needed to be treated" is the number of patients who must be treated in order to prevent 
one adverse event. 
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INCONTINENCE EPISODES PER DAY ON URINARY DIARY 
CONTINENCE PADS USED OVER 5 DAYS 
RELIANCE GROUP 
Calculations were made for the mean number of incontinence episodes and pads used 
per 5 days recorded in the urinary diary of the Reliance group before and at 
completion of the trial and are illustrated in table 10.68 
Reliance group rates of adverse events: 
IEPD and pads used per 5 days 
Rates of adverse events 
Before Treat with Relative 
Treatment Reliance Risk 
Device reduction 
2 or more 1 0.12 88% 
incontinence 
episodes/day 
3 or more 1 0.31 69% 
pads used per 
Absolute Number 
risk needed to 




Table 10.68 Incontinence episodes per day OEPD) and pads used per five days 
illustrated as rates of adverse events before treatment (control) and after device use 
(treatment). Included are the relative risk reduction, the absolute risk reduction and 
numbers needed to be treated. 
FEMASSIST GROUP 
A table of similar adverse events is shown for the FemAssist group before and after 
device use, with the calculation of the relative risk reduction, the absolute risk 
reduction and numbers needed to be treated as described previously (Table 10.69). 
')TS 
FemAssist group rates of adverse events: 
IEPD and pads used per 5 days 
Rates of adverse events 
Before Treat with Relative Absolute 
Treatment FemAssist Risk risk 
Device reduction 









3 or more 1 0.36 64% 0.64 1.6 
pads used per 
5 days 
Table 10.69. Incontinence episodes and pads used per five days illustrated as rates of 
adverse events before treatment (control) and after device use (treatment). Included 
are the relative risk reduction, the absolute risk reduction and numbers needed to be 
treated. 
PAD NWIGHT TEST 
RELLANCE GROUP 
The table illustrates the mean pad weight test gains for the Reliance group before and 
after 6 months of device use, with the calculation of the relative risk reduction, the 
absolute risk reduction and numbers needed to be treated (Table 10.70). 
Reliance group rates of adverse events 
(mean PVff gains) 
Rates of adverse events 
Mean PNVT Treat with Before Relative Absolute Number 
Gains Reliance Treatment Risk risk needed to 
Device reduction reduction be treated 
31! or less 0.625 0.146 76.6% 0.479 2.1 
Table 10.70 The mean PWT gain for the Reliance group before and after treatment 
for women with three grams or less loss on testing as an adverse event. Included are 




Table 10.71 similarly illustrates the mean pad weight test gains data obtained for the 
FemAssist group. 
FemAssist group rates of adverse events 
(Mean PWT Gains) 
Rates of adverse events 
Mean PWT Treat with Before Relative 
Gains FemAssist Treatment Risk 
Device reduction 
Absolute Number 
risk needed to 
reduction be treated 
3g or less 0.302 0.038 87.4% 0.264 3.8 
Table 10.71 The mean PWT gain for the FemAssist group before and after treatment 
for women with two grains or more and one gram or less loss on testing as an adverse 
event. Included are the relative risk reduction, the absolute risk reduction and 
numbers needed to be treated. 
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CHAPTER ELEVEN 
QUALM OF LIFE AND E%IPACT OF SYMIPTOMS 
AT BASELINE AND AS A CONSEQUENCE OF DEVICE USE 
? 7R 
The results will be presented under the following headings for each device group and 
each QoL questionnaire: 
1. Baseline quality of life scores 
2. Quality of life scores after treatment 
3. Comparison of pre and post treatment scores 
4. Aggregated baseline data (FemAssist and Reliance patients pre-treatment) 
compared with population norms (UK SF-36) 
5. Comparison of post treatment scores with population norms (UK SF-36) 
The following inter-group (FemAssist Vs Reliance) comparisons will be presented: 
* Groups comparable at baseline 
0 Comparison of post treatment QOL scores 
There were 48 copies of the Kings Health and SF-36 questionnaires returned by 
patients randomised to the Reliance group and 53 by the women randomised to the 
FemAssist group. All were completed correctly and all questions answered. Each 
sub scale of the Kings Health Questionnaire has a maximum score of 100 and 
minimum of 0, a maximum score indicating the worst possible impainnent in that 
domain and a minimum score no impairment at all. 
Each sub scale of the LJK SF-36 questionnaire similarly has a maximum score of 100 
and minimum of 0, but a maximum score indicates no impairment at all in that 
domain and a minimum score the worst possible impairment. 
The number of women completing 6 months follow-up is shown in Table 11.1. In 
Total 69 (68.9%) women completed follow-up QoL questioning. All the 
questionnaires were completed correctly. The percentage follow-up for each device is 
9.79 
shown in Figure 11.1. A greater percentage of women completing the questionnaires 
and the study had used the FemAssist device. 
Stage Reliance FemAssist Total 
Enrolment 48 53 101 
Completed 31(64.6%) 
follow-up (%) 





Tablell. 1 The number of women completing the SF-36 and KHQ quality of life 
questionnaires at enrolment into the study and at 6-month follow-up. 









Lii I" I 
Figure 11.1 Women completing QoL questionnaires at follow-up, for each group. 
Reliance (n--3 1); FemAssist (n=36). Percentage values above bars. 
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1A BASELINE QUALITY OF LIFE SCORES 
RELL4, NCE GROUP 
KINGS HEALTH QUESTIONNAHZE 
The baseline Kings Health Questionnaire quality of life scores for women randomised 
to use the Reliance device (n=-48) are illustrated in table 11.2 and figure 11.2. 
MEAN SCORES ON THE DOMAINS OF 
THE KINGS HEALTH QUESTIONNAHLE 
PRE TREATMENT 
Domains GHP InImp EL RL S/E PersL Physl, SL SM 
Mean 28.9 75.9 40.8 51 26.7 28.8 58.5 34.4 53.5 
SD 20.89 23.94 27.57 25.66 23.90 23.20 20.88 26.06 19.15 
Min 0 22.2 11 0 0 0 16.6 0 26.6 
Max 75 100 100 100 
1 
83.3 100 100 100 80 
Table 11.2 Summary of the mean baseline KHQ scores for women with GSI 
randolMsed to use the Reliance device. SD = standard deviation, Min = minimum 
value recorded, Max = maximum recorded. {GBP = General health perception, InImp 
= Incontinence impact, EL = Emotional limitation, RL = Role limitation, S/E = Sleep/ 
energy disturbance, PersL = Personal limitation, PhysL= Physical limitation, SL = 







GHP InImp EL RL SIE PersL PhysL SL Sm 
Domains of the KHQ 
Figure 11.2 Mean baseline scores on each domain of the KHQ for women with GSI 
randomised to use the Reliance device. 
The majority of women completing the KHQ considered their general health to be 
good. Incontinence impact scores were higher than those of all other domains. Sleep 
and energy were least affected and personal and social limitation was slightly affected 
while emotional limitation was moderately higher in comparison. Physical and role 
limitations were moderately influenced. 
? R? 
Mean scores on each domain of the KHQ pre treatment 
75.9 
(Reliance) 
1B BASELME QUAMY OF LIFE SCORES 
RELLANCE GROUP 
UK SHORT FORM-36 
" &JL_LM 
luuco SURVEY QUESTIONNAME 
The baseline SF-36 questionnaire quality of life scores for women randomised to use 
the Reliance device (n=48) are illustrated in table 11.3 and figure 11.3. 
MEAN SCORES ON THE DOMAINS OF 
THE UK SHORT FORM-36 
PRE TREATMENT 
Domains PF SF PRL ERL Mll E/F PAIN GHP 
Mean 68.3 68.6 36.5 62.5 60.7 53.4 61.6 60.3 
SD 5.10 5.66 8.03 5.04 3.66 5.52 5.13 3.13 
Min 59 58 20 50 54 40 50 54 










Table 11.3 Summary of the mean baseline scores for women with GSI randomised to 
use the Reliance device. SD = standard deviation, Min = minimum value recorded, 
Max = maximum recorded. [PF = physical function, SF = social function, PRL = 
physical role limitation, ERL = emotional role limitation, MH = mental health, OF = 







PF SF PRL ERL MH E/F Pain GPH 
Domains of the SF-36 
Figure 11.3 Mean baseline scores on each domain of the SF-36 questionnaire for 
women with GSI randomised to use the Reliance device. 
The results suggest that the domain of physical role limitation was particularly 
influenced, and all other domains indicated moderate disruption to the quality of life 
of incontinent women. 
? 94 
Mean scores on each domain of the SF-36 questionnaire pre 
treatment (Reliance) 
1C BASELINE QUALITY OF LIFE SCORES 
FEMASSIST GROUP 
KINGS HEALTH QUESTIONNAHUE 
The baseline Kings Health Questionnaire quality of life scores for women randomised. 
to use the FemAssist device (n---53) are illustrated in table 11.4 and figure 11.4. 
MEAN SCORES ON THE DOMAINS OF 
THE KINGS HEALTH QUESTIONNAIRE 
PRE TREATMENT 
Domains GHP InImp EL RL S/E PersL Physl, SL SM 
Mean 32.7 77.1 39.8 43.2 27.1 24.6 55 31 50.5 
SD 25.7 25 30.43 26.21 24.7 29.76 23.04 26.76 19.8 
min 0 0 0 0 0 0 0 0 6.6 
Max 80 100 100 100 83.3 100 100 100 80 
Table 11.4 Summary of the mean basehne scores for women with GSI randomised to 
use the FernAssist device. SD = standard deviation, Min = minimum value recorded, 
Max = maximum recorded. JGBP = General health perception, InImp = Incontinence 
impact, EL = Emotional limitation, RL = Role limitation, S/E = Sleep/ energy 
disturbance, PersL = Personal limitation, PhysL= Physical limitation, SL = Social 








GHP InImp EL RL S/E PersL PhysL SL Sm 
Domains of the KHO 
Figure 11.4 Mean baseline scores on each domain of the KHQ for women with GSI 
randomised to use the FemAssist device. 
Women randomised to the FemAssist device showed a similar disruption to their QoL 
as those randomised to the Reliance. The domains of incontinence impact, physical 
limitation and severity measures were most Influenced by Incontinence. The majority 
of women with GSI however considered their general health to be good. 
? R6 
Mean scores on each domain of the KHQ pre treatment 
(FemAssist) 
ID BASELINE QUALITY OF LIFE SCORES 
FENUSSIST GROUP 
UK SHORT FORM-36 
HEALTH SURVEY QUESTIONNAME 
The baseline SF-36 questionnaire quality of life scores for women randomised to use 
the FeniAssist device (n-753) are illustrated in table 11.5 and figure 11.5. 
MEAN SCORES ON THE DOMAINS OF 
THE UK SHORT FORM-36 
PRE TREATMENT 
Domains PF SF PRL ERL Mll E/F PAIN GRP 
Mean 64.4 63.5 38.0 59 58.4 56.3 60.2 60 
SD 12 13.12 12.75 10.37 8.39 8.16 8.28 6.85 
Min 6 0 20 33 33 33 45 50 
Max 88 88 66 85 75 66 80 70 
Table 11.5 Summary of the mean baseline scores for women with GSI randonUsed to 
use the FemAssist device. SD = standard deviation, Min = minimum value recorded, 
Max = maximum recorded. [PF = physical function, SF = social function, PRL = 
physical role limitation, ERL = emotional role limitation, MH = mental health, OF = 











PF SF PRL ERL MH OF Pain GPH 
Domains of the SF-36 
Figure 11.5 Mean baseline scores on each domain of the SF-36 questionnaire for 
women with GSI randomised to use the FemAssist device. 
The domain of physical role limitation was most affected while all the other domains 
of the SF-36 questionnaire were secondarily influenced. 
? R9 
Mean scores on each domain of the SF-36 questionnaire pre 
treatment (FemAssist) 
2A QUALITY OF LIFE SCORES AFTER TREATMENT 
INCELLAACE GROUP 
. Wd 
KINGS HEALTH QUESTIONNAIRE 
The Kings Health Questionnaire quality of life scores for women obtained following 
utilisation of the Reliance device (n7-3 1) are illustrated in table 11.6 and figure 11.6 
M[EAN SCORES ON THE DONIAINS OF 
THE KINGS HEALTH QUESTIONNAIRE 
POST TREATMENT 
Domains GHP InImp EL RL S/E PersL Physl, SL SM 
Mean 28.3 41.3 35.5 33.8 27.3 23.2 32.3 23.6 31 
SD 20.51 16.95 27 22.22 22.74 26 20.4 21.45 19.6 
Min 0 0 0 0 0 0 0 0 0 
Max 75 66.6 100 83.3 83.3 100 66.6 77.7 60 
Table 11.6 Summary of the post treatment scores for women with GSI randonUsed to 
use the Reliance device. SD = standard deviation, Min = minunum value recorded, 
Max = maximum recorded. {GIHP = General health perception, InImp = Incontinence 
impact, EL = Emotional limitation, RL = Role limitation, S/E = Sleep/ energy 
disftubance, PersL = Personal limitation, PhysL= Physical limitation, SL = Social 
limitation, SM = Severity measures. I 
? R9 
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0 
Figure 11.6 Mean post treatment scores on each domain of the KHQ for women with 
GSI randonlised to use the Reliance device. 
Following treatment with the Reliance device the domains of personal and social 
limitation caused the least constraint to their QoL, while the domains of incontinence 
impact still caused the most interference. 
NO 
GHP InImp EL RL SIE PersL PhysL SL SM 
Domains of the KHQ 
2B QUALITY OF LIFE SCORES AFTER TREATMENT 
RELIANCE GROUP 
UK SHORT FORM-36 
HFAILTH SURVEY QUESTIONNAIRE 
The UK SF-36 questionnaire quality of life scores for women obtained following 
utillsation of the Reliance device (n7-3 1) are illustrated in table 11.7 and figure 11.7 
MEAN SCORES ON THE DOMAINS OF 
THE UK SHORT FORM-36 
POST TREATMENT 
Domain PF SF PRL ERL M111 E/F PAIN GHP 
Mean 88.9 85.7 67.5 61.9 60.1 54.6 62.2 60.8 
SD 3.76 5.85 7.09 5.42 5.58 6.41 6.47 4.84 
Min 80 75 59 50 50 43 50 50 
Max 97 100 89 74 66 66 80 66 
Table 11.7 Summary of the mean post treatment scores for women with GSI 
randoinised to use the Reliance device. SD = standard deviation, Min = minimum 
value recorded, Max = maximum recorded. [PF = physical function, SF = social 
function, PRL = physical role limitation, ERL = emotional role limitation, ME = 
mental health, OF = energy/fatigue, GIIP = general health perception] 
?. 91 








Figure 11.7 Mean post treatment scores on each domain of the SF-36 questionnaire 
for women with GSI randormsed to use the Reliance device. 
The domains of physical and social function on the SF-36 questionnaire caused the 
least disruption to their QoL while the other domains were not as well improved. 
79? 
PF SF PRL ERL MH E/F Pain GPH 
Domains of the SF-36 
2C QUALITY OF LIFE SCORES AFTER TREATMENT 
FENUSSIST GROUP rici 
KINGS HEALTH QUESTIONNAME 
The Kings Health Questionnaire quality of life scores for women obtained following 
utilisation of the FernAssist device (n---36) are illustrated in table 11.8 and figure 11.8 
MIEAN SCORES ON THE DONLAINS OF 
THE K[NGS HEALTH QUESTIONNAH; tE 
POST TREATMENT 
Domains GIUP bdmp EL RL S/E PersL PhysL SL SM 
Mean 31.6 48.2 34.9 41.2 22.1 24.2 17.1 22.5 29.1 
SD 18.6 19.1 33 15.3 19.6 22 19.45 23 16.9 
min 0 0 0 0 0 0 0 0 0 
Max 80 77 90 85 88 100 100 77 85 
Table 11.8 Summary of the post treatment scores for women with GSI randomised to 
use the FemAssist device. SD = standard deviation, Min = minimum value recorded, 
Max = maximum recorded. (GHP = General health perception, InImp = Incontinence 
impact, EL = Emotional limitation, RL = Role limitation, S/E = Sleep/ energy 
disturbance, PersL =- Personal limitation, PhysL= Physical limitation, SL = Social 
limitation, SM = Severity measures. I 
793 
Mean scores on each domain of the KHQ post treatment 
(FemAssist) 
60 





Figure 11.8 Mean post treatment scores on each domain of the KHQ for women with 
GSI randomised to use the FemAssist device. 
The domains of physical and social limitation on the Kings Health Questionnaire 
caused the least disruption to their QoL while the other domains were not as well 
improved. The domain of incontinence impact still caused the most problem for 
incontinent women using the FemAssist device similar to the findings in women using 
the Reliance. 
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GHP InImp EL RL SIE PersL PhysL SL SM 
Domains of the KHQ 
2D QUALITY OF LIFE SCORES AFTER TREATMENT 
IVENIASSIST GROUP I 
UK SHORT FORM-36 
HEALTH SURVEY QUESTIONNAI 
The UK SF-36 questionnaire quality of life scores for women obtained following 
utilisation of the FemAssist device (n7--36) are illustrated in table 11.9 and figure 11.9. 
MIEAN SCORES ON THE DOMAINS OF 
THE UK SHORT FORM-36 
POST TREATMENT 
Domains PF SF PRL ERL MH E/F PAIN GUIP 
Mean 84 83.6 71.9 61.9 62.7 78.2 62.5 59.5 
SD 5.88 6.15 13.7 3.97 3.02 10.4 5.03 5.06 
Min 66 66 6 55 60 42 50 50 
Max 90 99 88 66 66 100 77 66 
Table 11.9 Summary of the mean post treatment scores for women with GSI 
randomised to use the FemAssist device. SD = standard deviation, Min == mimmum 
value recorded, Max = maximum recorded. [PF = physical function, SF = social 
function, PRL = physical role limitation, ERL = emotional role limitation, ME 
mental health, OF = energy/fatigue, GIIEP = general health perception] 
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Domains of the SF-36 
Figure 11.9 Mean post treatment scores on each domain of the SF-36 questionnaire 
for women with GSI randornised to use the FemAssist device. 
After treatment with the FemAssist device the SF 36 domains of physical and social 
function were least influenced and the other domains not as well controlled. 
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PF SF PRL ERL MH E/F Pain GPH 
3A COMPARISON OF PRE AND POST TREATMENT SCORES 
RELIANCE GROUP 
KINGS HEALT111 QUESTIONNAIRE 
Assessment was made of whether there was any difference in the quality of life scores 
for each of the domains from the baseline results as a consequence of device usage for 
those completing the trial. Analysis was performed for each domain of the SF36 and 
the KH Q for each of the groups, Reliance and FemAssist. Figures 11.10 and 11.11 
and table 11.10 summarises the estimates of the groups means and paired differences 
in the measures between the scores obtained using the KHQ questionnaire at baseline 
and 6 month post treatment with the Reliance device (n--31 pairs). 
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MEAN SCORES ON THE DOMAINS OF THE KINGS HEALTH 
QUESTIONNAUMPRE AND POST TREATMENT 
Domains GHP InImp EL RL S/E PersL PhysL SL SM 
Baseline 28.9 75.9 40.8 
1 
51 26.7 28.8 58.5 34.4 53.5 
6 month 28.3 41.3 35.5 33.8 27.3 23.2 32.3 23.6 31 
Paired differences (N= 31, paired t-test statistics) 
Mean 0.61 34.6 5.21 17.2 -0.5 5.6 26.3 13.8 22.6 
SD 11.7 21.2 16.1 15.3 17.9 20.7 21.7 18.68 16.6 
SEM 2.03 3.7 2.8 2.7 3.1 3.6 3.8 4.17 2.9 
2-tail sig 0.77 0.000 0.072 0.000 0.87 0.133 0.000 0.004 0.000 


















Table 11.10 Summarv of the estimates of the Lyrou-ns means and diff erences in the 4-ý 
measures between the scores obtained using the KHQ at baseline and 6 month post 
Reliance treatirnent. SID = standard deviation, SEM = standard error of mean, 95% Cl 
= 95% confidence interval. (GHP = General health perception, InImp = Incontinence 
impact, EL = Emotional limitation, RL = Role limitation, S/E =: Sleep/ energy 
disturbance, PersL = Personal limitation, PhysL= Physical limitation, SL = Social 
C! limitation, SM = Seventy meastures. 
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Figure 11.10 Comparison of measures of QoL (KHQ) at baseline and after 6 months 
therapy With the Reliance device. Lines join the means. Lower scores represent 
better QoL. 
Mean scores on each domain of the KHQ pre & post treatment 
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Figurell. 11 Mean pre and posttreatment scores on each domain of the KHQ. 
Greatest changes in the quality of life of women with GSI using the Reliance device 
were observed in the domains of incontinence impact, role and physical limitation- 
These modifications were striking and considered clinically significant. There was 
not much alteration in their general health perception and energy levels however. The 
remaining measures of QoL as assessed on this questionnaire were also influenced in 
a favourable direction. 
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3B COMPARISON OF PRE, AND POST TREATMENT SCORES 
R, ELLA, NCE GROUP 
UK SHORT FORM-36 
HEALTH SURVEY QUESTIONNAIRE 
Figures 11.12 and 11.13 and table 11.11 summarises the estimates of the groups 
means and differences in the measures between the scores obtained using the SF 36 
questionnaire at baseline and 6 month post treatment with the Reliance device. 
MEAN SCORES ON THE DOMAINS OF 
THE UK SHORT FORM-36 QUESTIONNAHM 
PRE AND POST TREATMENT 
Domains PF SF PRI, ERIL ME E/F PAIN GHP 
Baseline 68.3 68.9 36.5 62.5 60.7 53.4 61.6 60.3 
6 month 88.9 85.7 67.8 61.9 60.1 54.6 62.2 60.8 
Paired differences (N=31. ) paired t-test statistics) 
Mean -20.84 -16.69 -30.6 0.36 -0.27 -1.36 -0.76 -0.21 
SD 6.7 6.72 10.13 4.8 4.57 4.73 6.26 3.44 
SEM 1.166 1.17 1.764 0.837 0.797 0.824 1.1 0.6 
2-tail sig 0.000 0.000 0.000 0.67 0.73 0.11 0.5 0.73 



















Tablell. 11 Summary of the mean SF-36 scores for women with GSI randomised to 
use the Reliance device on entry to the study and after 6 months of device utilisation. 
SD = standard deViation, SEM = standard error of mean. [PF = physical function, SF 
loo 
= social function, PRL = physical role limitation, ERL = emotional role limitation, 
ME = mental health, E/F = energy/fatigue, GHP = general health perception. 













Figure 11.12 Comparison of measures of QoL (SF 36) at baseline and after 6 months 
of therapy With the Reliance device. Lines join the means. Higher scores represent 
better QoL. 
Mean scores on each domain of the SF-36 questionnaire 
post treatment (Reliance) 
100- -- 
80- 1-960.7 53.4 
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PF SF PRL ERL MH E/F PAIN GHP 
Domains of the SF-36 
pre & 
13 Pre therapy 
0 Post therapy 
Figure 11.13 Comparison of mean pre and post treatment scores on each domain of 
the SF-36 questionnaire for women with GSI randomised to use the Reliance device. 
As a consequence of Reliance device utilisation the greatest changes recorded on the 
SF-36 questionnaire arose in the domains of physical role limitation and in physical 
and social function. 
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PF SF PRL ERL MH E/F Pain GHP 
Measures (domains) of QoL [SF 36] 
3C COMPARISON OF PRE, AND POST TREATMENT SCORES 
FEMASSIST GROUP 
KINGS HEALTH QUESTIONNAME 
Figures 11.14 and II- 15 and table 11.12 summanses the estimates of the groups 
means and differences in the measures between the scores obtained using the Kings 
Health Questionnaire at baseline and 6 month post treatment With the FemAssist 
device (n=36 pairs). 
MEAN SCORES ON THE DOMAINS OF 
THE KINGS HEALTH QUESTIONNAIRE 
PRE AND POST TREATMENT 
Domains GHP InImp EL RIL S/E PersL PhysL SL SM 
Baseline 30.4 75.2 42.1 38.2 33 27 49.1 32.2 55.3 
6 month 31.6 48.2 34.9 41.2 22.1 24.2 17.1 22.5 29.1 
Paired differences (paired West statistics) 
Mean 1.11 29.6 4.66 10.1 0.94 3.36 22.3 5.2 18.6 
SD 8.6 12.5 14.1 12.2 22.1 18.1 21.2 3.04 14.2 
SEM 1.98 2.6 2.9 3.45 3.81 3.55 2.98 3.66 3.2 
2-tail sig 0.68 0.000 0.56 0.081 0.04 0.754 0.000 0.03 0.000 


















, Fthp PQt1rnntf-. q nf the ornjins means and diff erences in the -- 
measures between the scores obtained using the KHQ at baseline and 6 month post 
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FemAssist treatment. SD = standard deviation, SEM = standard error of mean, 95% 
CI = 95% confidence interval. (GHP = General health perception, InImp 
Incontinence impact, EL = Emotional limitation, RL = Role limitation, S/E = Sleep/ 
energy disturbance, PersL = Personal limitation, PhysL= Physical limitation, SL 
Social limitation, SM = Seventy measures. I 
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Figure 11.14 Comparison of measures of QoL (KHQ) at baseline and after 6 months 
therapy With the FemAssist device. Lines join the means. Lower scores represent 
better QoL. 
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Figure 11.15 Comparison of mean pre and post treatment scores on each domain of 
the KHQ for women with GSI randomised to use the FemAssist device. 
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Greatest changes in the quality of life of women with GSI using the Fem-Assist device 
were observed in the domains of incontinence impact, physical limitation and severity 
measures of incontinence. These modifications were striking and considered 
clinically significant. There was not much alteration in their general health 
perception, emotional and personal limitation and energy levels however. The 
remaining measures of QoL as assessed on this questionnaire were also influenced in 
a favourable direction, albeit moderately. 
104 
3D COMPARISON OF PRE AND POST TREATMENT SCORES 
FEMASSIST GROUP 
UK SHORT FORM-36 
"" IV, ""'ALTH SURVEY QUESTIONNAIRE 
Figures 11.16 and 11.17 and table 11.13 summarises the estimates of the groups 
means and differences in the measures between the scores obtained using the SF-36 
questionnaire at baseline and 6 month post treatment with the FemAssist device. 
MEAN SCORES ON THE DOMAINS OF 
THE UK SHORT FORN-36 QUESTIONNAIRE 
PRE AND POST TREATMENT 
Domains PF SF PRL ERL MR E/F PAIN GHP 
Basetine 62.1 65 36.5 61 59.8 55.8 57.9 61.8 
6 month 84 83.6 71.9 61.9 62.7 78.2 62.5 59.5 
Paired differences (N=36, paired t-test statistics) 
Mean -18.39 -19.93 -35.6 3.5 -4.29 -22.54 2.61 0.56 
SD 8.84 9.56 16.19 10.92 8.97 10.4 8.9 8 
SEM 1.538 1,666 2.81 1.87 1.53 18.2 1.55 1.37 
2-tail sig 0.000 0.000 0.000 0.71 0.19 0.23 0.10 0.69 

















Table 11.13 Summary of the mean SF-36 scores for women with GSI randomised to 
use the FemAssist device on entry to the study and after 6 months of device 
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utilisation. SD = standard deviation, Min = minimum value recorded, Max = 
maximum recorded. [PF = physical function, SF = social function, PRL = physical 
role limitation, ERL emotional role limitation, ME = mental health, E/F 
energy/fatigue, GHP general health perception] 
Comparison of QoL scores before & after 
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Figure 11.16 Comparison of measures of QoL (SF 36) at baseline and after 6 months 
therapy With the FemAssist device. Lines join the means. Fhgher scores represent 
better QoL. 
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post treatment (FemAssist) 0 Pre therapy 
84 1". 64 N Post therapy 78.24 . 64 78.24 78 R2 6Z65 62.48 






PF SF PRL ERL MH ElF PAIN GHP 
Domains of the SF-36 
Figure 11.17 Comparison of mean pre and post treatment scores on each domain of 
the SF-36 questionnaire for women with GSI randomised to use the FemAssist 
device. 
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Following treatment with the FemAssist device the greatest changes were observed in 
the domains of physical role limitation and physical and social functioning. Energy 
and sleep levels seemed to be more favourable but the remaining measures of quality 
of life were little influenced. 
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4 BASELINE DATA COMPARED WITH POPULATION NORMS AND 
PATILENTS WITH LONG STANDING ILLNESS 
UK SHORT FORM 36 
HEALTH SURVEY QUFSTIONNAtRE 
The baseline SF-36 scores for women receiving the Reliance and FemAssist devices 
were compared with the mean SF-36 scores for the general population (Figures 11.18 
& 11.19). Population norms for the dimensions of the SF-36 were obtained from the 
Oxford Regional Healthy Lifestyle Survey '. 
Reliance group compared to population 
norms before treatment 
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Figure 11.18 Baseline data of incontinent women randomised to use the Reliance 
device (n=48) compared with mean SF-36 scores for the general population and 
patients reporting long-standing illness. 
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Figure 11.19 Baseline data of incontinent women randomised to use the FemAssist 
device (n=53) compared with mean SF-36 scores for the general population and 
patients reporting long-standing illness. 
At study inclusion, both groups of incontinent women were below the norms for 
healthy women in the general population for all the domains of the UK SF-36quality 
of life questionnaire. In particular the domains of general health perception and role 
limitation were less favourable possibly because of emotional problems and physical 
restrictions. Women with GSI had similar scores to those with long-standing illness 
in the domains of general health perception, energy and fatigue levels. Women with 
long-standing illness suffer more and have greater levels of pain compared to women 
with urinary incontinence although social function and emotional role limitations are 
greater for women with urinary incontinence. However incontinent women recorded 
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worse quality of life on the remaining measures than women with long standing 
illness. 
Age 
Compared to general population scores women less than 45 years of age have lower 
scores in the domains of physical function, social function, physical role Iftnitations, 
pain and general health, although there was no significant correlation of age and any 
individual SF-36 domain score. 
There was no significant correlation between the age of the women in the study, the 
duration of their symptoms and the SF-36 domain scores, although younger women 
appeared to have greater overall impairment than older women and present earlier for 
investigation of their urinary complaints. 
URINARY SYMPTOMS 
Part III of the KHQ consists of ten questions and asks respondents to indicate both the 
urinary symptoms from which they are suffering and how bothersome they are. Both 
groups were comparable at baseline. 
In table 11.14, the mean urinary symptom scores to each of the questions for women 
with GSI are shown (aggregated data). The table also illustrates the mean scores 
before and after treatment with each device. Multiple stepwise linear regression 
analysis was used to determine the effect of individual urinary symptoms on the total 
KHQ score. Urge incontinence (multiple R =-- 0.436; T=4.392, frequency (multiple R 
= 0.498; T=4.831), stress incontinence (multiple R=0.601; T= 4.821, nocturia 
(multiple R=0.615, T=4.262) and urgency (multiple R=0.649; T=3.526) all 
significantly influenced the total KHQ score (p<0.01), whereas other symptoms in the 
questionnaire did not. 
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URINARY SYMPTOM SCORES RECORDED ON THE KHQ 
Aggregated RELIANCE (N=31) FEMASSIST (N=36) 
baseline Baseline Post Baseline Post 
data therapy therapy 
synwtom 
Frequency 1.78(3.0) 1.69(3.0) 1.55(2.0) 1.65(3.0) 1.59(2.0) 
Urgency 1.89(3.0) 1.71(3.0) 1.86(3.0) 1.76(3.0) 1.83(3.0) 
Urge 1.86(3.0) 1.81(3.0) 1.79(3.0) 1.55(3.0) 1.62(3.0) 
Incontinence 
Nocturia 1.6(2.0) 1.59(2.0) 1.66(2.0) 1.66(2.0) 1.71(2.0) 
Nocturnal 0.24(0.0) 0.15(0.0) 0.18(0.0) 0.19(0.0) 0.21(0.0) 
Enuresis 
Stress 2.4(3.0) 2.5(3.0) 1.5(1.0) 2.3(3.0) 1.52(1.0) 
Incontinence 
Intercourse 0.67(0.0) 0.56(0.0) 0.7(0.0) 0.62(0.0) 0.65(0.0) 
Incontinence 
Recurrent 0.35(0.0) 0.15(0.0) 0.19(0.0) 0.2(0.0) 0.22(0.0) 
UTIS 
Bladder pain 0.30(0.0) 0.17(0.0) 0.19(0.0) 0.22(0.0) 0.19(0.0) 
Table 11.14 Scores on Part HI of the KHQ (Symptom analysis) for the aggregated 
data and before and after treatment in both groups. Numbers represent the mean score 
and the number in brackets the modal score. Score =0 (i. e. not a problem); Score I 
bothered aI ittle; Score 2= bothered moderately; Score 3= bothered a lot. 
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5A COMPARISON OF POST TREATMENT SCORES 
WITH POPULATION NORMS 
RELLANCE GROUP 
UK SHORT FORM 36 
HEALTH SURVEY QUESTIONNAIRE 
The 6 months post-treatment UK SF-36 scores for women using the Reliance device 
were compared with the scores obtained at study inclusion and is illustrated in the bar 
chart below (Figure 11.20 and 11.2 1) 
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Figure 11.20 Data for incontinent women using the Reliance device after six months 
(n=33) compared with mean SF-36 scores for the general population and patients 
reporting long-standing illness. 
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Figure 11.21 Incontinent women using the Reliance device after six months (n=33) 
compared with mean SF-36 scores for the general population and patients reporting 
long-standing illness. 
By 6 months post-treatment with the Reliance device the study patients were 
comparable to the general population norms for the domains of physical and social 
function and energy and fatigue levels. This is consistent with the improvement in 
scores from baseline to 6 months post-treatment, which was demonstrated above. 
However they recorded less favourable quality of life scores in the measures of 
physical role linlitation, emotional role limitation, mental health and pain. Their 
general perception of health was also less favourable and still comparable to patients 
with long-standing illness. 
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norms after treatment 
5B COMPARISON OF POST TREATMENT SCORES 
WITH POPULATION NORMS 
FENIASSIST GROUP 
UK SHORT FORM 36 
HEALTH SURVEY QUESTIONNAMIE 
The 6 months post-treatment UK SF-36 scores for women us Mig the Fem. Assist device 
were compared with the scores obtained at study inclusion and is illustrated in the bar 
chart below (Figure 11.22 and 11.23) 
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Figure 11.22 Data for incontinent women using the FemAssist device (n=36) after 
six months compared with mean SF-36 scores for the general population and patients 
reporting long standing illness. 
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FemAssist group compared to population 
norms after treatment 
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Figure 11.23 Data for incontinent women using the FemAssist device (n=36) after 
six months compared with mean SF-36 scores for the general population and patients 
reporting long standing illness. 
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GROUPS COMPARABLE AT BASELINE 
UK SHORT FORM 36 
HEALTH SURVEY QUESTIONNAIRE 
The two groups were evaluated before the interventions to verify that they were 
comparable in respect of the disruption to their quality of life on the SF-36 and KHQ. 
Based on the Wilcoxon signed rank sum test, there was no significant difference in 
the mean scores for each domain of each QoL questionnaire for the data obtained. 
(Figures 11.24 to 11.27) 
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Figure 11.24 Bar chart illustrating that the two groups, FemAssist and Reliance users 
were well matched at entry to the study with respect to their SF 36 QoL scores. 
317 
Comparison of baseline SF 36 QoL scores 
for both arout)s 
Reliance 
Comparison of baseline Kings Health QoL 
-FemAssis U. co) 
PF SF PRL ERL MH E/F Pain GHP 
Measures (domains) of QoL [SF 36] 
Figure 11.25 Line graph illustrating that the two groups, FemAssist and Reliance 
users, were well matched at entry to the study with respect to their SF 36 QoL scores. 
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Figure 11.26 Bar chart illustrating that the two groups, FemAssist and Reliance users 
were well matched at entry to the study With respect to their Kings Health 
Questionnaire QoL scores. 
scores for both 
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Figure 11.27 Line graph illustrating that the two groups, FemAssist and Reliance 
users, were well matched at entry to the study with respect to their Kings Health 
Questionnaire QoL scores. 
The results illustrate that the two groups were comparable at baseline with respect to 
the Kings Health Quality of life questionnaire and the SF-36 Quality of life 
instrument. 
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COMPARISON OF POST TREATMENT QOL SCORES 
FENUSSIST VS RELUNCE 
KINGS HEALTH QUESTIONNAHZE 
I also assessed whether there was any difference in the mean QoL scores in each 
domain of the KHQ in each group at the end of the trial. The Wilcoxon signed rank 
sum test was used to assess difference in the median scores for each domain of each 
QoL questionnaire for the data obtained at the end of the trial (Figures 11.28 and 
11.29 and Table 11.15). 
COMPARISON OF MEAN SCORES ON THE ICINGS HEALTH 
QUESTIONNAIRE FOR BOTH GROUPS AFTER TREATMENT 
Domain GHP InImp EL RL S/E PersL PhysL SL SM 
Reliance 
(n--31) 
28.3 413 37.6 33.8 
I 
27.3 23.2 23.3 23.6 30.9 
Femassist 
(n-- 3 6) 
31.6 48.2 
I 





2-tail sig 0.635 - 0.04 0.845 003 0.05 0.781 0.05 0.355 0.645, 
Tnhip. I1 -11 ; %immarv of the evaimates of the Larmuns means and 
diff erences in the GY 
measures between the scores obtained using the KHQ 6-month post Reliance and 
FemAssist treatment. SD = standard deviation, SEM = standard error of mean, 95% 
Cl = 95% confidence interval. JGIHP = General health perception, InImp = 
Incontinence impact, EL = Emotional limitation, RL = Role limitation, S/E = Sleep/ 
energy disturbance, PersL = Personal limitation, PhysL= Physical limitation, SL = 
Social limitation, SM = Seventy measures. 
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Comparison of KHO QoL scores for both 
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Figure 11.28 Bar chart demonstrating the differences in the Kings Health 
Questionnaire mean scores for the two groups as a result of using the different 
devices. 
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Questionnaire mean scores for the two groups as a result of using the different 
devices. 
Comparison of KHQ QoL scores for both 
aroug)s at the end of treatment 
l?. I 
Measures (domains) of QoL [KHQ]] 
The quality of life improvement in both groups as a consequence of device utilisation 
was very similar as assessed by the measures on the Kings Health Questionnaire. 
There was a significantly more favourable response in the Reliance group in the 
quality of life measures of role limitation but women using the FemAssist device 
expressed less physical limitation and higher levels of energy and less fatigue. 
COMPARISON OF POST TREATMENT QOL SCORES 
(IRIE'LUNCE VS FENUSSIST) 
UK SHORT FORM 36 
HEALTH SURVEY QUESTIONNAUCE 
Assessment was also made of whether there was any difference in the mean QoL 
scores in each domain of the SF-36 questionnaire in each group at the end of the trial. 
The Wilcoxon signed rank sum test was used to assess difference in the median scores 
for each domain of each QoL questionnaire for the data obtained at the end of the trial 
(Figures 11.30 and 11.31 and Table 11.16). 
COMPARISON OF THE MEAN SCORES ON THE UK SHORT FORM-36 
QUESTIONNAIRE FOR BOTH GROUPS AFTER TREATMENT 
Domain PF SF PRL ERL NIH E/F PAIN GHP 
Reliance 88.9 85.7 67.8 61.9 
1 
60.1 54.6 61.2 60.8 
Femassist 84 83.6 71.9 61.9 62.7 78.2 62.5 59.5 
2-tail sig 
1 




1 0.067_ 1 0.001 0.416 
Table 11.16 Summary and comparison of the mean SF-36 scores for women with 
GSI using the Reliance and FemAssist devices for 6 months. SD = standard 
deviation. [PF = physical function, SF = social function, PRL = physical role 
1 1). 1). 
limitation, ERL = emotional role limitation, ME = mental health, E/F = 
energy/fatigue, GHP == general health perception] 








Figure 11.30 Bar chart demonstrating the differences in the SF 36 questionnaire 
scores for the two groups as a result of using the different devices. 
Comparison of SF 36 QoL scores for both 
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Figure 11.31 Line graph demonstrating the differences in the SF 36 questionnaire 
scores for the two groups as a result of using the different devices. 
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PF SF PRL ERL MH EIF Pain GHP 
Measures (domains) of QoL [SF 36] 
PF SF PRL ERL MH E/F Pain GHP 
Measures (domains) of QoL [SF 36] 
The quality of life improvement in both groups as a consequence of device utilisation 
was very similar as assessed by the measures on the SF-36 questionnaire. There was 
a marginally more favourable response in the Reliance group in the quality of life 
measures of physical function and physical role limitation but women using the 
FemAssist device expressed higher levels of energy and less fatigue. 
Reference 
'Jenkinson C, Coulter A, Wright L. Short form 36 (SF-36) health survey 
questionnaire: normative data for adults of working age. BMJ 1993 306: 1437-1440. 
CHAPTER TNVELVIE 
SIDE EFFECTS EXPERIENCED BY 
THE RELMACE AND FENUSSIST GROUPS 
11)15 
The side effects, adverse events and complications experienced by both groups of 
women during device utilisation are summarised in tables 12.1 and 12.2. The adverse 
events of haematuria and pyuria are recorded and noted in the absence of bacteriuna 
and infection. 
Adverse events and complications experienced during the trial in women using 
the Reliance device 
Number 
1 month 3 months 
Spotting 4(8.3%) 1(2.1%) 0 
Urethritis/ 4(8.3%) 
inflammation 
Haematuria 1(2.1%) 0 0 
Pyuria 1(2.1%) 0 0 
6 months OveraH 







UTI 2(4.2%) 0 3(6.3%) 5(10.4%) 
Table 12.1 Side effects, adverse events and complications associated with Reliance 
device use. 
I'M 
Adverse events and complications experienced during the trial in women us' g 
the Fem4ssist device 
Number 
1 month 3 months 6 months Overall 
Spotting 6(11.3%) 3(5.7%) 4(7.5%) 13(24.5%) 




Asymptomatic 3 (5.7%) 2(3.8%) 2(3.8%) 7(13.2%) 
Bacteriuria 
UTI 2(3.8%) 1(1.9%) 3(5.7%) 6(11.3%) 
Table 12.2 Side effects, adverse events and complications associated with FemAssist 
device use. 
There were no serious adverse events reported in either group. 
Device migration 
There was no case of device migration into the urethra or bladder with use of either 
device. However, on one occasion when a subject was being instructed on how to use 
and insert the Reliance device, it was noted that she inserted it into the urethra with 
the meatal plate of the device just beyond the meatus. With a lubricated gloved 
finger, the device was milked back by external pressure on the urethra. There were no 
cases of obvious urethral trauma externally on clinical examination. 
1? 7 
Spotting 
Spotting was much more commonly reported in women using the FemAssist device 
and was probably related to the suction effect of the device. It occurred with 
aggressive overuse of the device and not with less frequent utilisation. All incidences 
resolved after a short period of approximately 24 hours of suspended use of the 
device. 
Urethritis 
Urethritis was much more common in the Reliance group and was expected of a 
device inserted into the urethra, although overall, the number of cases was only few. 
It was nevertheless a cause for patients to withdraw from the trial. 
Haematuria 
Haernaturia was not observed on routine testing in the absence of infection in the 
Fem-Assist group and only rarely in the Reliance group. It is likely that this occurred 
much more frequently in clinical practice and would be recorded more often with 
increased frequency of urinalysis. 
Bacteriuria 
Cases of asymptornatic bacteriuria were similar in both groups of device users and 
were one of the most frequently noted adverse events In the study. Both symptomatic 
and asymptornatic bacteriuria were treated with the appropriate antimicrobial therapy 
for 5 days while device use was suspended. 
URINARY TRACT INFECTION 
Reliance group 
There were five (10.4%) symptomatic infections per 188 patient months of use which 
corresponds to one UTI per 37.6 patient months. No patient expenenced fever, chills, 
I? R 
and loin or flank pain. None of the subjects suffered any sequelae of their positive 
urine cultures. 
FemAssist group 
There were six (11.3%) symptomatic infections per 237 patient months of use, which 
corresponds to one UTI per 39.5 patient months. No patient experienced fever, chills, 
loM or flank pain and none of the subjects suffered any sequelae of their positive 
urine cultures. 
MEATAIL / VAGINAL CHANGES 
IN DEVICE USERS 
Erythema 
A small area of erythema was noted in all patients using the FemAssist device, which 
was discrete, flush to the skin and under the area of contact with the device. The 
erythema was noted once the device was removed and resolved after 5- 10 min. In 
no case was erythema, persistent. This finding was consistent with the pressure effect 
of the device. No sequelae were reported. Erythema was noted in two women using 
the Reliance device. The area of skin change was adjacent to the meatal plate of the 
device on the inner aspect of the labia minora. The two women discontinued the trial 
as a result. 
Petechial Haemorrhage 
Small mild petechial haemorrhages were noted in 8 (15.1%) women overall using the 
FemAssist device, adjacent to the external urethral meatus, under the points of contact 
with the device. These were consistent with the trauma associated with the vacuum 
effect of the device. No subject developed bruising which could be described as 
ecchymosis as has been described with other devices such as the Cap Sure. Petechial 
haemorrhages were not noted in Reliance device users. 
There were no documented cases of urethral prolapse, vaginal bleeding, urinary 
retention or gross haematuria or frank mucosal bleeding during the study. 
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COMFORT 
The sensation of discomfort or irritation did not appear to signify any physical tissue 
damage to the vagina and urethral meatus when physical examination was performed 
except in one case. One subject felt labial irritation and discomfort ftom the edges of 
the FemAssist device. It was felt that the rim of the device was in contact with the 
medial walls of the labia majora. The injury was compounded by the patient's 
clinical findings of mild atrophic vaginitis and a tight dry vagina] introitus. Device 
use was discontinued for one week while the subject applied oestrogen cream locally 
to the vagina (Ovestin cream - one application daily). The duration of treatment was 
one week. The subject was keen to restart device usage so this was resumed without 
adverse events for the rest of the trial. She was however, encouraged to use Vaseline 
ointment to the skin of the vagina in addition to lubricating the contact surface of the 




ANALYSIS OF DROPOUTS 
NON-RESPONDERS 
III 
Planning and organisation was geared to obtaining the highest possible recruitment 
but some "non-responders" remained. Non-responders are unlikely to be typical of 
the remainder of the sample. They may be more or less likely to suffer GSI and hence 
their omission is likely to lead to biases when drawing conclusions firom the results of 
the sample. As much indirect data as possible was obtained about the non-responders 
so as to make an estimate of the kind of bias which may be introduced by their 
omission. 
The number of subjects who dropped out of the study and the reasons given for 
discontinuing the trial are shown in tables. 
Number of subjects dropping out of the trial 
1 month 3 months 6 months overall 
Reliance 6(12.5%) 7(14.6%) 2(4.2%) 17(35.4%) 
FemAssist 6(11.3%) 6(11.3%) 5(9.4%) 17(32.1%) 
Table 13.1 Number of women who elected to discontinue the trial at each period of 
assessment and overall for each device group. 
Reasons for discontinuing the trial 










Table 13.2 Reasons given by the subjects in each group for discontinuing the trial. 
V- 
-, -or each group of 
device users, the demographic, histoncal and clinical parameters 
were examined between the set of women who completed the study and those who did 
not (Table 13.3 and 13.4). This was performed to ascertain if there were any 
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statistically significant differences observed between women who completed the 
study and those who did not when patient background characteristics were examined. 
Differences observed between women who completed the study 
and those who did not (Reliance group) 
Background Not completing Completed Paired difference 
characterMcs 6 months (n=17) study (n=31) p-value 
Mean age (years) 46.9 52.24 0.143 
Mean number of 4.67 5.15 0.22 
IIEPD 
Mean number of 11.25 10.55 0.67 
incontinence 
pads used per 5 days 
Mean PWT gain at 28.7 33 0.35 
baseline (g/hr) 
Table 13.3 The differences in demographic and clinical parameters for Reliance 
device users between the set of women who completed the study and those who did 
not. 
Despite discontimnng treatment (n= 17), 7 (41.2%) women felt that it had been 
beneficial in stopping leakage whilst they were able to use a Reliance device and four 
(23.5%) found benefit with the FemAssist device. 
All "responders" in both groups felt that their lives were still affected to some degree 
by their unnary symptoms and this was reflected in the QoL questionnaires. No 
subject felt that their treatment had been worse than their urinary symptoms. 
There was no difference in the mean age, menopausal status or the use of HRT 
between those completing and not completing the study in either device group. Nor 
was there any difference detected between the groups in the severity of GSI detected 
on urodynamic testing. 
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Differences observed between women who completed the study 
and those who did not (FemAssist group) 
Background Not completing Completed Paired 
characterMcs 6 months (n=17) study (n=36) difference 
p-value 
Mean age (years) 47.5 50.1 0.133 
Mean number of EEPD 4.88 5.10 0.42 
Mean number of 10.2 11.3 0.12 
incontinence 
pads used per 5 days 
Mean PVff gain at 30.1 28.9 0.48 
baseline (g/hr) 
Table 13.4 The differences in demographic and clinical parameters for FemAssist 
device users between the set of women who completed the study and those who did 
not. 
The majority of women who discontinued the trial had a greater degree of 
"bothersome" foreign body sensation and discomfort with each device used. They 
also experienced a greater degree of difficulty with device placement than 
(C responders". 
Unne loss with specific activities and the overall degree of control of "wetness" was 
similar in responders and non-responders using the Reliance device. However, these 
two outcome measures were less favourable in those discontinuing use of the 
FemAssist device. 
Those who discontinued the trial had significantly worse outcome in the measures of 
urinary leakage assessed on the urinary diary and PWT data in both groups at one 
month- 
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QUALITY OF LIFE 
Reliance 
Women who discontinued using the Reliance device had significantly less favourable 
scores (KHQ) in the domains of "incontinence impact" (p=0.05), severity of 
symptoms (p=0.02) and "physical role limitation" (p=0.02) than women who 
completed the trial of the Reliance device. There were no significant differences in 
the other domains assessed by the KHQ. 
The only difference detected between responders and non-responders in the scores of 
the SF36 was in the domain of "role limitation due to physical problems". Non- 
responders had significantly less favourable scores in this domain. 
FemAssist 
Women who discontinued using the FemAssist device had significantly less 
favourable scores (KHQ) in the domains of "Incontinence impact" (p = 0.0 1) and 
"severity of symptoms" (p = 0.04) 







The purpose of evaluation is to demonstrate whether these continence devices have 
been successful or to what degree they have failed to achieve the stated aims. In this 
study it was possible to determine not only whether the devices were effective at 
achieving the desired outcome but with what consequences. This been clarified, one 
can then relate this narrow perspective to an overall framework which incorporates 
the use of continence devices within a coherent health strategy for addressing the 
needs of the incontinent woman. Based on the activities upon which they were tested, 
the women recruited to the trial had a major degree of "wetness" or severity of 
incontinence. The two groups were also comparable in respect of features known to 
affect outcome. Additionally, one of the merits of this study is that responders to 
treatment were defined clinically and with an established scale score and hence has 
the advantage of certainty about the exact degree of response. 
PATEENT SATISFACTION 
No matter how wel-I a device works, if it is uncomfortable or difficult to use,, its role in 
treating incontinence is limited. Over time, there is a trend for both devices to 
become more comfortable to wear and easier to place. The FemAssist device is 
especially consistently rated better than the Reliance in this regard. Proficiency at 
correct placement is the key to this phenomenon. The sensation of discomfort or 
irritation did not appear to signify any physical tissue damage to the vagina and 
urethral meatus. 
Women experience similar foreign body sensation when using either device with a 
reduction in foreign body sensation over time. This sensation occurs early in device 
utilisation or not at all, with no residual effect. Overall, there is a high user 
satisfaction with the FemAssist device. Experienced gained with continued use 
(learning curve) proves beneficial in terms of ease of insertion and placement, 
comfort of use and habituation for both devices. The experience seems to be more 
amenable with the FemAssist than the Reliance device. 
PATIENT RATED DRYNESS 
Both the FemAssist and Reliance devices allow most users to feel completely dry or 
significant improvement while performing specific activities and in an overall 
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manner. As a result, women are also likely to participation in more provocative 
manoeuvres over time. However, Reliance users score consistently higher than those 
using the FemAssist. Incontinent women do not feel they are made worse by device 
use. 
QUANTIEFICATION OF URINE LOSS 
Incontinence episodes per day 
Use of either device is associated with a significant reduction in the mean number of 
incontinence episodes per day. The individual patient responses categonse most 
women to be made "moderately or significantly improved" in the Reliance group. No 
subject is made "dry" or "worse" with device use in this group. These responses are 
consistently maintained over time. 
The individual patient responses categonse most women to be made "slightly, 
moderately or significantly improved" in the FemAssist group. The FemAssist device 
is more likely to result in better reduction in the mean IIEPD with longer duration of 
use. No subject using this device is made "worse" but approximately 11% are 
categorised as "dry". These responses are also consistently maintained over time. 
Comparison with other studies is illustrated in table 14.1. 
Incontinence episodes with device use (mean) 
Device Type Baseline Study conclusion 
Adhesive continence patch 13.3/week 4.3/week 
CapSure shield 
2. 3.4/day 0.6/day 
Introl 3 4/day 0.4/day 
FemAssist (present study) 4.9/day I/day 
Reliance (present study) 5.11/day 1.33/day 
Table 14.1 Studies of different devices recording mean incontinence episodes with 
device utilisation. 
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Number of continence pads used over 5-days 
Use of either device is associated with a significant reduction in the mean number of 
continence pads used over 5 days. The individual patient responses categorise most 
women to be made "significantly improved" III the Reliance group at an early 
assessment. No subject is made "dry" or "worse" with device use in this group. 
These responses are consistently maintained over time. 
The individual patient responses categonse most women to be made "no better" with 
initial use of the FemAssist device. With continued use they are made "significantly 
improved" over time but not categorised as "dry". Few studies have used the number 
of continence pads utilised as an outcome measure. The Conveen continence guard is 
associated with a reduction in pads used per day from a baseline of 2.5 to 1.6 at study 
conclusion 4. The FernAssist and Reliance compare favourably with these figures 
(11.1 pads to 4.33 per 5 days [FemAssist], and 10.6 pads to 3.43 pads per 5 days 
[Reliance]. 
Pad weight test data 
The effectiveness or control of incontinence as determined by pad weight testing in 
both groups is associated with a significant reduction 'in urine loss during device use. 
The individual patient responses rate most women to be "dry" using the Reliance 
device. The remainder is improved to some degree. 
The individual patient responses characterise most women to be "moderately 
improved" or "slightly improved" using the FemAssist device. The remainder is 
" significantly improved" or "unchanged". Only a few could be categonsed as "dry". 
Comparison with other studies is illustrated in table 14.2. 
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Mean pad weight test gains for various continence devices 
Device Type Baseline Study conclusion 
Adhesive continence patch 1.1 g/hr 0.44g/hr 
CapSure shield 2 6.8g/hr 0.18g/hr 
Conveen (Hahn et al 1996) 5 41.6g/hr 13.9g/hr 
Introl (Foote et al 1996) 3 57g/hr 9g/hr 
FemAssist (Prashar et alp. 55.7g/hr 17.8g/hr 
FemAssist (Tincello et al 1997Y. 21 g/hr 4.9g/hr 
FemAssist (present study) 28.3g/hr 3.6g/hr 
Reliance (Staskin et al 1996) 8 42.7g/hr 2.2g/hr 
Reliance (Pigne et al 1997)9. 36g/hr lOg/hr 
Reliance (Mifler et a] 1996)10. 46.4g/hr 2.4g/hr 
Reliance (present study) 31.2g/hr 1.3g/hr 
Table 14.2 Studies of different devices recording mean PWT gains with device 
utilisation. 
FEMASSIST VS RELIANCE 
The Reliance device is far superior to the FemAssist in reducing the amount of urine 
lost on a pad-weighing test and is more likely to render a patient "dry". However this 
supremacy is not extended to other measures to quantify leakage of urine. The 
number of incontinence episodes per day and the number of continence pads needed 
over five days at the study end-point are comparable in each group of device users. It 
is tempting to interpret that what we are seeing at a given time in the relatively 
artificial setting of the laboratory is an accurate reflection of what a woman 
experiences during her daily activities while using a continence device. Nevertheless, 
these last two measures are much more in keeping with patient experiences and 
expectations and hence must be bestowed greater accord. The overall impression was 
that the urinary diary data better reflected the patients sentiment while wearing the 
devices from day to day rather than the PWT results. 
Altogether, control of stress incontinence is not complete in the majority of women 
using either device, but particularly so in the case of the FemAssist group. This is 
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largely due to the limitations of this device, not having sufficient adhesive power to 
consistently prevent urinary leakage around the vacuum seal. However, for a 
significant proportion of women it is, like the Reliance device, effective for severe 
and moderate genuine stress incontinence alike. 
RISK REDUCTION AND NUMBERS NEEDED TO BE TREATED. 
The relative risk reduction, the absolute risk reduction and numbers needed to be 
treated demonstrate a high degree of device efficacy in both groups. To achieve a 
result of better than 2 or more incontinence episodes/day 1.1 incontinent women 
would need to be treated using either device. To achieve a result of better than 3 or 
more pads used per 5 days, 1.4 incontinent women would need to be treated using a 
Reliance device and 1.6 with a FemAssist device. 
Similarly, to achieve a result of better than 3g or less mean PWT gain, 2.1 
incontinent women would need to be treated using a Reliance device and 3.8 with a 
FemAssist device. 
The number needed to be treated is time-dependent, which may affect the relative 
rankings of the numbers needed to be treated in trials of different lengths. Only if a 
treatment produces a constant relative risk reduction over time does the number 
needed to be treated decrease as the length of follow up increase. 
There is another disadvantage to combining the baseline risk and risk reduction into 
a single number in determining the absolute risk reduction and number needed to be 
treated. It simply reflects the average number of patients that must be treated in order 
to prevent some degree of incontinence, but does not indicate the fate of the other 
patients. At our present level of knowledge we have clues but can not precisely 
predict which one of the patients will be responsive to therapy with a continence 
device and in whom the therapy will have side effects. 
TUAE OF BENEFFIr 
An important finding in this study is that both devices maintain efficacy for a period 
of six months after response to initial treatment. One addendum is that 
for most 
women, they must use the FemAssist device for at least one month 
before the greatest 
benefit can be expected. The advantage of the Reliance is consolidated by the shorter 
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time to experience an optimal response. Nevertheless, efficacy consistency at the 
end-point of the study suggests that this would also be maintained in the long term for 
both devices. 
MECHANISM OF ACTION AND RESIDUAL EFFECT 
The Reliance appears to work immediately. It is a relatively inflexible device and it is 
our clinical impression that when in place, there is diminished mobility of the urethra 
and bladder neck when patients strain. In addition to the device being obstructive to 
the outflow of urine, it may also help to maintain proper pressure transmission to the 
proximal urethra. The balloon tip permits the device to remain in place during normal 
and strenuous exercise. 
When using the FemAssist, some women require a longer period of time before 
mastering correct device placement so as to gain an optimal effect. It is purely an 
observation, but the FemAssist appears to have a residual effect whereby some 
women experienced persistence of improvement after device discontinuation and may 
provide a potential therapeutic effect. This may have occurred because of the indirect 
biofeedback effect or bladder training behavioural exercise of keeping a urinary diary 
or because of being closely involved in a clinical trial. Alternatively, there may be an 
independent resolute effect possibly due to a physical consequence. One can only 
speculate that this is due to the aftermath on the soft tissue microenvironment in the 
region of the periurethral vasculature causing increased blood flow, oedema and 
congestion of the tissues around the bladder neck and proximal urethra. This plexus 
is known to be a contributing factor in the mechanism of urinary continence in 
women. One theory explains GSI on the basis of short urethral length ". Intra- 
operative studies have shown that stretching of the urethral smooth muscle sphincter 
mechanism results in significant increase in urethral functional length and closure 
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pressure . 
It may be that the presence of the Fem-Assist device over the external 
meatus and the suction action it applies causes stretch of these critical structures and 
coaptation of the walls of the urethra. This will have the effect of increasing urethral 
resistance to escape of urine at rest, during bladder filling and under conditions of 
stress, and changes in position. This clinical observation requires further study 
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QUALM OF LIFE 
It is possible to assess the quality of life of women with urinary incontinence using 
multi-dimensional quality of life questionnaires such as the SF-36 and the KHQ 
combined. Although clinical trials often report significant improvement in urinary 
symptoms and objective pad test results following device use, these may be of limited 
clinical value if the women themselves do not experience improved QoL. Quality of 
life assessment is of clinical relevance as the scales can quantify the impact of urinary 
incontinence and the scores can show an improvement following successful treatment. 
For this reason QoL assessment would appear to be an important inclusion in clinical 
trials of these new devices for stress incontinence. 
BASELINE QUALITY OF LIFE SCORES 
The baseline Kings Health Questionnaire (and SF-36) quality of life scores for women 
randomised to use both device portray the majority of incontinent women as a group 
who consider their general health to be good. As might be expected with a disease 
specific questionnaire, incontinence impact scores are higher than those of all other 
domains. Physical and role limitation and severity measures are moderately 
influenced by GSI. Sleep and energy least affect the incontinent women but personal 
and social limitation are slightly more altered while emotional limitation is 
moderately higher in comparison. 
The SF-36 questionnaire also demonstrates that incontinent women suffered mostly in 
the domains of physical role limitation with moderate but certain disruption to their 
quality of life in other domains. 
QUALITY OF LIFE SCORES AFTER TREATMENT 
KINGS HEALTH QUESTIONNAIRE 
RELLANCE GROUP 
Because incontinence affects interpersonal aspects of life most dramatically, it is 
gratifying that following treatment with the Reliance, device women with GSI 
experience an improvement in their quality of life with the least constraint in the 
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domains of personal and social limitation and energy, while the domains of 
incontinence impact, although influenced in a favourable direction, still cause the 
most interference. The greatest changes in better quality of life are observed in the 
domains of incontinence impact, severity measures, physical social and role 
limitation. These alterations are obvious to the patients and considered clinically 
evident. Overall, Reliance device users do not adjust their general health perception 
and energy levels. They are still limited by emotions and personal feelings although 
not as greatly. 
FEMASSIST GROUP 
Following utilisation of the Fem-Assist device the quality of life (KHQ and SF-36) 
domains of personal and social limitation and energy are least disrupted while the 
other domains are not as well improved. Greatest changes in the quality of life of 
women with GSI using the FemAssist device are observed in the domains of 
incontinence impact, energy levels, physical and social limitation and severity 
measures of incontinence. These modifications are remarkable and also considered 
clinically significant. However, the domain of incontinence impact still causes the 
most problem for incontinent women using the FemAssist device similar to the 
findings in women using the Reliance. There is not much alteration in their general 
health perception, emotional, role and personal limitation however. 
SF-36 QUESTIONNAME 
The greatest changes in the SF-36 scores were observed in the domains of physical 
and social function and physical role limitation and were similar in both groups. 
BASELINE DATA COMPARED WITH POPULATION NORMS AND 
PATIENTS WITH LONG STANDING ILLNESS 
At study inclusion, both groups of incontinent women had poorer quality of life in all 
the domains of the LJK SF-36 quality of life questionnaire than that which is expected 
for healthy women in the general population. In particular they had a less favourable 
perception of their general health - albeit still good. 
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The incontinent women in this study are similar to those with long-standmg illness 
in the domains of general health perception, energy and fatigue levels. Pain does not 
feature to be a problem as in other chronic illnesses, although social function and 
emotional role limitations are greater for women with urinary incontinence. 
COMPARISON OF POST TREATMENT SCORES 
WITH POPULATION NORMS 
After treatment with both the Reliance and FemAssist devices, the QoL domains (UK 
SF-36) of physical and social function and energy and fatigue levels are similar to 
healthy women in the general population. However they do not enjoy the same 
favourable quality of fife scores in the measures of physical role limitation, emotional 
role limitation, mental health and pain- 
COMPARISON OF POST TREATNIENT QOL SCORES 
IFENUSSIST VS RELIANCE 
At the end of the study women using the Reliance and FernAssist devices express a 
similar perception of their general health and their emotional personal and social 
limitations. Significant differences could be detected between the devices as to the 
impact of incontinence on their lives (KHQ). Significantly better QoL scores are 
obtained in the domains of incontinence impact and role limitation in Reliance users 
whereas FemAssist users score better in the domains of sleep/energy disturbance and 
physical limitation. Interestingly, there is no real difference in the measures of 
severity of incontinence between the groups, with both devices providing a favourable 
response in this dorn i 
There are significant differences in the SF-36 scores detected after device use with 
more favourable QoL conferred by the FemAssist device in the domains of 
sleep/energy and physical role limitation. Reliance device users are accorded better 
QoL in the domains of physical function. Device usage does not result in any 
significant difference between the groups in the domains of general health perception, 
pam, mental health, emotional role Iffnitation and social function. 
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RESPONDERS Vs NON-RESPONDERS 
The study has demonstrated that urinary incontinence results in impairment in many 
aspects of the quality of life of sufferers, yet it is not possible to predict on the basis of 
urinary symptoms and the severity of incontinence alone the degree of this 
impairment. All told, the improvement seen in QoL scores is determined by the initial 
severity of the QoL score, the sensitivity of the questionnaire to change and the 
degree of improvement offered by the particular device. 
Age, menopause status or the use of HRT are not modifyiýng factors, but younger 
women appeared to have greater overall impairment in their quality of life than older 
women. Nevertheless, this research shows that elderly women with GSI have 
significant QoL impairment as a result of their urinary symptoms and are equally 
likely to benefit from the use of a continence device as younger women. 
If women have significant bothersome foreign body sensation, discomfort or 
difficulty with placement of a device, they are much more likely to discontinue device 
use even though the device may be beneficial in reducing the severity of incontinence. 
This really characterises the experience of the Reliance user, whereby non-responders 
enjoyed initial relief in terms of reduction in both subjective and objective severity of 
incontinence, but gave up because of nuisance side effects and difficulty handling the 
device. The reverse is true of the FemAssist, where non-responders seem dissatisfied 
because of poor efficacy with specific activities and overall control of "wetness". 
Women with greater initial QoL impairment and more bothersome urinary symptoms 
with a greater incontinence impact are less likely to respond to treatment and more 
likely to discontinue device use. In this way the urinary symptom specific 
questionnaire can be used to predict women in whom devices are most likely to be 
effective. This is a useful observation. Continence devices should still be offered to 
all women with quality of life impairment resulting from GSI providing there are no 
contraindications because they work in the majority. However, targeting women with 
greater QoL impairment for more definitive treatment is likely to be more beneficial 
as containment of incontinence is unsatisfactory. 
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Bias 
There are many potential biases in responding to the KHQ and it is probable that the 
data collected from the women who did attend does not accurately represent the total 
population of women with GSI. Thirty-four (33.7%) women failed to complete the 
study, possibly as a result of the additional appointments required for its completion. 
Consequently women who were dry with device use or for whom a hospital 
appointment was inconvenient may have declined to attend. As a result a greater 
proportion of those who did respond to repeat QoL questioning are likely to have had 
residual problems to discuss and therefore poorer overall QoL. 
Women with greater problems and presumably greater quality of life impairment are 
more likely to want to be seen and women who are more anxious about the 
investigation and their future management are also more likely to be seen than women 
who are only slightly inconvenienced by their urinary symptoms. Elderly women for 
whom travel to the hospital may be difficult and employed women who find it hard to 
take time off from work are also possibly underrepresented in this group. Almost all 
of the women who attend our unit however, have significant urinary symptoms, by the 
very fact that they have sought help in the first place. 
In addition, many women responding to the KHQ register vocational impairment as 
one of the problems caused by their urinary symptoms and it is documented that a 
considerable number took time off from work to attend the hospital for follow-up. It 
is more likely therefore that these women are under represented in the follow-up 
phase of the study. Absence from work and inconvenience of travel to Kings would 
be greater after treatment, especially if this had been successftd, when there would be 
little additional benefit for the patient. Women who were cured or improved by the 
devices after one month and had few problems did not attend for final follow-up and 
were under represented in the final phase of the study. 
Thus, the improvement in quality of life documented with the KHQ is likely to 
underestimate the true improved quality of life gained by use of the device for all the 
women attending for the initial assessment. 
URINARY SYMPTOMS (KIIIQ) 
There is a significant reduction in the "bothersome" scores for the symptom of stress 
incontinence as assessed using the KHQ after therapy with either device also showing 
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a reduction in the modal score firom three to one. There is also a trend to a reduction 
in the mean "bothersome" scores for the symptom of frequency. Subjects not having 
to ensure they keep their bladders empty to reduce the nsk of an incontinence episode 
may explam this. 
ADVERSE EVENTS 
The weighing up of the risks of treatment against the risks of no intervention is a 
question of risk balancing. The risks that the individual is prepared to accept will be 
in proportion to the expected benefits gained in terms of improvements III quality of 
life. Women with urinary incontinence already run and presumably accept the risks 
of perineal discomfort and embarrassing leakage as a result of their condition and I 
expect this has a part to play in the acceptability of the problems experienced with the 
use of continence devices. 
Despite the Reliance device being a urethral insert its design is sufficiently effective 
that migration into the urethra or bladder is not a problem, as might be anticipated. 
Frank haernaturia, is not observed in the absence of infection with use of either 
device. Overuse of the FemAssist device is likely to lead to spotting of blood as a 
result of the suction effect. The Reliance device does not seem to irritate the 
surrounding area as much to produce this effect. However, the reverse is true of 
urethritis, this being more common in the Reliance group. It would be incorrect to 
state that urethritis was a minor problem. It certainly occurred infrequently but when 
it did, it was distressing for the patients concerned. 
Bacteriuria 
Asymptornatic bacteriuria is a common occurrence in both groups of device users but 
its clinical significance remains unclear. Experience in CISC provides insight into the 
expected adverse events with repeated daily introduction of a catheter-like device into 
the urethra. Thus the circumstances under which it occurs with the Reliance device is 
easily understood. The indwelling "plug" and its placement may provide a 
microenvironment conducive to the growth of bacteria and infection. 
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This does not explain a similar incidence with a non-insurtable suction device like the 
FemAssist. It may be that the FemAssist, by way of meatal occlusion and coaptation 
of the device in close proximity with the walls of the urethra permits ascending 
microbiological invasion of the bladder increasing the susceptibility to infection. 
URINARY TRACT WFECTION 
The low prevalence rate of positive urine cultures compares favourably to age- 
specific historical figures of 10 - 38% 
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. The rate of positive urine cultures (10.3% 
Reliance, 11.4% FemAssist) is similar in both groups of device users, and for the 
Reliance, matches that observed in other studies 8 (Table 14.3). However, the rate of 
infection in this study of FernAssist users is much higher than observed by other 
investigators 14 15 . This is perplexing and surprising. We can offer little explanation 
other than the possibility that, to get better containment of leakage, these women 
utilised a greater amount of device manipulation with consequent infection. The rate 
of infection fell over the duration of the study and one may infer that before women 
become more proficient in device insertion and avoiding contamination, the initial 
"learning curve" accounts for these prevalent early infections. With practice, the 
degree of manipulation required for device placement and removal decreases, and as 
does the risk of cystitis. None of the subjects suffered any sequelae of their positive 
urine cultures. 
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Urinary tract infection with use of continence devices 
Device UTI (%) 
Adhesive continence patch (North et al 1998) 0% 
CapSure(Bellin et al 1998) 2 3.5% 
Introl (Foote et al 1996) 3 15.4% 
FemAssist (Versi et al 1998) 14 0% 
FemAssist (Rabin et al 1997) 15 0% 
FemAssist (present study) 11.3% 
Reliance (Staskin et al 1996) 8 11% 
Reliance (Pigne et al 1997) 9 14% 
Reliance (Miller et al 1996) 10 30% 
Reliance (present study) 10.4% 
Table 14.3 The rates of urinary tract infection with device use reported in the 
literature in comparison with this study. 
Erythema 
A small discrete area of erythema under the area of contact with the device is to be 
expected in all women using the FemAssist. These are anticipated due to the wider 
area of contact and suction mechanisms of the device. Once the device is removed 
this pressure effect resolves after 5- 10 min with no long term sequelae. The suction 
effect of this device is also very likely to result in small mild petechial haemoffhages 
under the points of contact with the skin. These clear spontaneously upon cessation 
of device use and require no treatment. 
The meatal plate of the Reliance device only very occasionally causes skin irritation 
but is more likely to result in the patient discontinuing use. Petechial haemoffhages 
are not manifest in Reliance device users. 
The observations suggest that the FemAssist device may cause a change in the soft 
tissue microenvironment with which it is in contact as well as a deeper effect beyond 
the surface of contact due to the vacuum or suction effect of the device. This may 
lead to congestion in the tissues, bruising and petechial haemorrhages. In this respect 
the FemAssist device is comparable to other external adhesive devices, such as 
IIS() 
transdermal oestrogen patches, which have approximately a 10% incidence of skin 
irritation. 
What is unclear is whether or not women with atrophic genital changes should be 
encouraged to use vaginal oestrogen cream to reduce the risk of mucosal damage. 
This advice does seem inherently sensible but requires further appraisal. 
As a group few women experienced any adverse physical side effects while wearing 
either device. The incidence of adverse events is well within the range expected with 
other commonly accepted self-catheterisation techniques and continence aids. 
Additionally, these events tend to decrease in frequency over time so devices are 
generally well tolerated, which is an important attribute for long term treatment. 
In women having long term catheterisation, bacteriuna should be expected and 
extended prophylaxis is not only expensive but is also likely to result in the selection 
of resistant organisms 16 . Hence, antimicrobial treatment of asymptomatic bacteriuria 
is probably not justified in these subjects and should be reserved for those in whom it 
is clinically indicated. 
CONIPLUNCE 
When estimating the likely benefit of continence devices, we must also consider the 
likelihood that patients will comply with the intervention. This trial has incorporated 
certain compliance-improving strategies not applied in routine clinical practice. For 
example, all women regularly consulted a clinician with an interest in continence and 
its management. Hence, the results of this study may have overestimated the benefit 
of continence devices that may be obtained in a routine clinical setting without such 
intensive guidance, education and support. Any measure of the clinical benefit of an 
intervention such as continence devices may vary considerably in different trials of 
the same or similar therapy because of different patient populations, trial designs or 
chance. Differences may have occurred because therapy was evaluated in a setting 
designed to maximise compliance rather than as part of routine patient care 17 . The 
clinical trial was also of finite duration and, because the benefits of treatment change 
with time, one can only provide suggestions about the consequences of continuing 
therapy in the long run. 
I C% I 
PATIENT PRFFERIFNCE 
One of the guiding principles of economics is that individuals are assumed to be the 
best judges of their own welfare -people know what is good for them. Thisideals 
not always a central theme in the traditional paternalistic model of medicine. The 
patient relies on the doctor's expertise for information. But where treatment choices 
exist it would appear that clinical decision-making might be improved if patient 
preferences were elicited. The effectiveness of many health programs is shifting 
emphasis and becoming increasingly dependent upon the willingness of individuals to 
accept a more active role in caring for their health. There are many factors which 
influence women to comply with preventative behaviour for urinary incontinence. 
These may include the value placed by an individual on a particular goal and the 
individual's estimate of the likelihood that a given action will achieve that goal. It is 
difficult to measure the individual's desire to avoid urinary incontinence and the 
belief that devices can prevent urinary incontinence and by compliant action, will 
reduce the threat. 
Women are more likely to use either device primarily during activities associated with 
urine loss rather than for casual use for occasional incontinence. All the same, as 
incontinence affects each individual differently, some women use devices for 
occasional incontinence which is associated with a large disruption to their quality of 
life. 
COST 
Dunng the 6 months period women used approximately 948 FemAssist devices. This 
was at a total cost of E7,1 10 and approximately f57.34 per patient. 
During the 6 months period women used approximately 12,981 Reliance devices. 
This was at a total cost of L12,981 and approximately E127.26 per patient. This 
represents an increase in cost of E69.92 or2.2 times the cost of using the FernAssist 
device. This is only a very crude costing, but does give some indication of the 
expense which may be incurred by the individual woman. 
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RFLATIONSRR BETWEEN E4PUTS AND OUTCOMES 
The evidence from the trial supports the alternative hypothesis that devices result in a 
reduction in the symptom of stress incontinence but this may be difficult to explain. 
Inputs from other mechanisms and from informal sources may also be important. One 
has to acknowledge the likelihood that systematic variations in the pattern of inputs 
which are outside the control of the study may have a direct bearing on the outcome 
and are a potential source of bias. Did follow-up achieve better outcomes because 
patients were reviewed and instructed as appropriate or because compliance was 
encouraged? In this thesis I tried to go beyond the erudite demonstration of statistical 
associations between device use and reduction in PWT gains or incontinence 
episodes. The patient's subjective assessment of the device and the use of a urinary 
incontinence specific quality of life instrument to measure the impact of these devices 
greatly help to specify what occurs at the intermediate steps between the input and 
outcome. 
The study has demonstrated that there is a strong association between both the 
improved outcome and device utilisation. Also, the Reliance device is associated with 
a significantly greater reduction in these parameters than the FemAssist device. It 
may be argued that the associations of good clinical outcome with device usage were 
in reality secondarily associated with other factors. Statistical tests suggest that the 
probability is low that the observed associations are chance occurrences so 
consequently have a high probability of being true associations. The associations may 
be spurious and a product of the way in which the investigation was carried out. I 
tried to ensure, through rigorous study methodology and design with care to reduce 
bias, that like was being compared with like. There are certain criteria which help to 
infer that the results of efficacy and safety are due to device usage. 
Plausibility 
Greater weight can be given to the results as it fits in with what is known about the 
pathology of GSI and about the effects of the same and sirrUlar devices in the 
management of women with stress incontinence, as published in the literature. 
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Consistency 
When various investigators working in different populations carried out studies, 
similar results of device efficacy and safety were obtained as noted in chapter four. 
This demonstrates a certain consistency in the outcome of this trial with regard to the 
effects of the devices. The large differences in the objective outcome measures found 
in both groups from baseline at study conclusion are consistent with the findings of 
others, supporting results that reflect real differences in pre-treatment status rather 
than group differences as a result of bias. 
Strength 
There is a marked statistical difference in the outcome measures compared to when 
not using a device. This is clinically significant and has a beneficial impact on the 
subjects. Accordingly, this confers a degree of strength to the association with 
clinical improvement as a consequence of device usage. 
Conclusion 
0 Quality of life measures would appear to be ideally suited for use in clinical 
trials to assess the efficacy of new treatments for containment of unimary 
incontinence such as continence devices. 
0 Quality of life scores significantly improve following treatment of urinary 
incontinence in women who are subjectively cured or improved by use of a 
continence device. 
0 In the context of a clinical trial, objective improvements In pad weight tests 
and incontinence episodes on the urinary diary although highly desirable are 
still of secondary important to the improvement in quality of life conferred on 
the women treated. 
Many of the devices currently employed have a high degree of objective 
success. The benefits of new devices and continence aids may therefore best 
be measured by the difference in quality of life conferred. 
0 Measuring quality of life in women with incontinence is critical to 
understanding the full impact of the condition, and this prospective data may 
I'SA 
be critical in establishing reliable estimates of levels of impairment that can be 
used for clinical decision making. 
9 In conditions like stress incontinence, in which general health perception is 
good and the likelihood of disease-related fatality is low, assessment of quality 
of life might lead to less invasive conservative therapies such as continence 
devices. 
0 The results of the study reveal that, using subjective and objective measures of 
efficacy and safety, both devices are effective in the containment of urinary 
leakage in women with GSI. 
0 The Reliance device is significantly superior to the FemAssist on several 
measures of efficacy. This may be attributed partly to the failure of the 
FemAssist but also to the potential superior efficacy of the Reliance. 
0 Although not tested in this study, devices may be an important alternative to 
absorbent products and other management strategies. 
Long-term studies of continence devices would be difficult to carry out and 
require determination and motivation from investigators and patients to persist 
with treatment, as patient attrition is a problem. 
0 The significant reduction in unne loss during device use compares favourably 
to other devices as assessed by the outcome measures. 
Stratification of the women into moderate or severe GSI confirms that the 
devices are equally effective for both these levels of severity of incontinence. 
0 Analysis of the women who withdrew from the study confirms device efficacy 
in this subgroup as well. 
FUTURE 
Urinary incontinence is not life threatening but is a quality of life issue with 
considerable impact upon the wellbeing of those who suffer. There is a growing 
awareness of what can be done to help the woman with stress incontinence and some 
important developments have occurred. There are an increasing number of 
continence clinics addressing the particular needs of women and a rising number of 
physiotherapists specialising in the management of stress incontinence. The 
establishment of various national continence organisations such as the ICS UK, the 
I rN Is 
Continence Foundation and the Kings Fund help to improve public awareness and 
professional education and also focus government and industry support. The ICS has 
also established the Continence Promotion Committee to address continence 
awareness and promotion around the world. 
Independent continence is the preferred outcome. At the outset if this is not going to 
be rapidly achieved then social continence should be established. It may now be 
possible to develop various strategies to shift the patient to a state of independent 
continence. Having achieved this with the use of devices, we can expect an improved 
state of wellbeing and self-esteem and overall better quality of life for some women. 
As medicine and health care move towards the 2 I't Century, treatment would appear 
to be increasingly less about extending the length of life and more about improving its 
quality. Future incremental gains in health will be purchased at the price of increased 
risk-taking. This is not to suggest that management of incontinence with devices is 
risky, but new innovations carry new risks. 
Factors likely to improve compliance and 
result in successful device utflisation 
Team support 
Correct instructions 
Enthusiasm, attitude in carers? 
Well trained carers 
Patient motivation and compliance. 
Interest, support, reassurance and review by carers. 
Attitudes, which accept urinary incontinence as a personal failing, must be changed. 
All women can be helped to manage their incontinence through education and 
information about the condition and the therapies available. Their quality of life can 
be expected to improve with successful continence management but this depends on 
patient motivation and compliance. 
Research in urinary incontinence in adult women remains impaired by lack of 
standardisation of outcome variables. The use of primary and secondary outcomes on 
different areas or domains should help overcome some of these difficulties. Success 
in this regard will not only enhance knowledge of actual treatment strategies but also 
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stimulate the development of new ones. One of the benefits of evaluation is to enable 
improvements in strategies in the management of urinary incontinence and with 
respect to the future introduction of similar initiatives into continence device research. 
This can be viewed as ensuring the presence of a "feedback loop" linking evaluation 
findings to future plans so that the lessons learned can be incorporated into the design 
of the new programs. 
NMY N1FW CONTINENCE AIDDS? 
DO INCONTINENT WOMEN NEED DEVICES? 
Evidence about consumers' perspectives on continence services is growing 18 . 
So 
much so that political pressure has been brought to bear and the Department of Health 
has sponsored public awareness campaigns in both 1994 and 1995. Also, with an 
increasingly ageing population and increasing public awareness, demands for the 
continence service look set to increase in the future. 
The need for health care is defined as "the appropriate level of provision of health 
care interventions that is both effective and desired by the population"' 9. With 
soaring costs of health and long term care, the health service providers need to 
develop home care policies which provide high quality, low cost care in the home and 
community. This requires a multidisciplinary approach based around the primary care 
physician and community health care workers. New types of treatment are emerging, 
hence, it is highly desirable to widen the scope of management to a program of home 
and community care. Women seek medical advice when their symptoms cause 
discomfort, distress, inconvenience, disturbance and departure from their normal state 
of health and interference with their quality of life. The aim of treatment is to 
alleviate suffering, remove symptoms and return women to a normal state of health. 
With these goals in mind, considerable interest has emerged in the use of devices to 
contain the symptoms of stress incontinence. 
In many countries the budget for incontinence disposables has proved very difficult 
to control in many areas. It has been suggested that implementing research findings 
to improve clinical practice in managing urinary incontinence should result in 
significant cost savings 20. It is difficult to generalise concerning the need for further 
development of continence devices, given the varying stages of development at 
present. It is likely however, that the most useful developments in coming years will 
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arise from work which builds on existing devices. There is considerable scope in 
many cases for refinement of design, improved materials with a softer consistency 
and of longer shelf life and adaptations to particular situations. 
WHY ARE AIDS NECESSARY? 
Incontinence may not resolve with treatment 
Intractable incontinence 
Contain and disguise incontinence 
Provide symptom relief and better quality of life 
Comfort and dignity 
Application in primary health care 
In 198 1, the Engineering Board of the Scientific Research Council in England 
developed a list of biotechnological research priorities. Since alleviation of human 
hardship was a major goal, the following criteria were used to determine prioritiesý': 
- An identified and significant medical need that is not being met because of the 
shortcoming in existing aids 
-A lack of research effort aimed at developing better aids 
- The availability of scientific and/or technical knowledge to make significant 
progress at a reasonable cost 
- Acceptable costs of implementation 
- The presence of organisational apparatus for implementation 






Toilets and toilet substitutes 
Odour control 
IISR 
Previously developed external urinary incontinence devices for women had been 
described but assessment of efficacy was difficult, since prior reports frequently 
lacked detail. They concluded that there was no satisfactory wearable collection 
device for women who had urinary incontinence so development was given a high 
priority. 
The concept of need is central to the provision of continence care in women as it 
defines the objectives of care. Needs can be defined in a variety of different ways and 
perspectives. Measures of need incorporate value judgements about what should be 
accepted as appropriate goals. Needs can be assessed against some ideal standard. 
They can be defined in terms of a minimum level below which women should not fall 
and can be assessed by reference to comparisons with standards achieved by other 
individuals. The comparative approach offers a compromise between largely 
indefinable ideals and highly restrictive ii UM standards. Thus, - the need 
for 
continence devices can be defined in terms of the standards known to be achieved by 
comparable methods of containment of urinary leakage (i. e. pads, pants, conservative 
and surgical therapy). In selecting an appropriate measure of the need for continence 
devices, one must consider whose perspective and defi-nition of need is important. 
Traditionally, judgements about needs of incontinent women have been regarded as 
the province of the medical profession. As treatment options for incontinence expand 
and evolve, patients are playing a bigger role in management of their condition than 
ever before. Some measures rely on the individual's own perception of need, a sense 
of discrepancy between being incontinent and what ought to be (dry). It is the 
expression of these needs that prompts the patient to seek help. 
Many health care professionals who treat female urinary incontinence (urologists 
gynaccologists and general practitioners) continue to recommend management 
ffoCtiVe 22. options they consider less than eI It has been well documented that women 
with persisting incontinence do not use optimal aids for protection. For example, in 
one study 20% of clinicians recommended the use of absorbent pads, while only 8% 
rated them as the most effective option 23. Also, almost half of the incontinent women 
were dissatisfied with the first treatment recommended by their physician. Given a 
choice between behavioural techniques, pharmacological agents and surgery, 67% of 
those with stress incontinence initially chose non-sur ical treatment options to help 91 
self-manage their incontinence 
24 
. However, clinicians and patients alike must 
recognise that unlike surgery, where dryness is maintained without patient 
I'SQ 
participation, the use of mechanical devices requires active participation to maintain 
dryness. 
It is not possible to perform a double blind RCT to assess the efficacy and safety of 
these devices. This trial was not only a comparative study where the patients acted as 
their own controls, but was also carried out to assess the applicability of two 
contemporary continence devices and patients response to their use. This study 
demonstrates that the Reliance and Fem. Assist have complementary benefits and the 
efficacy of both devices in reducing stress incontinence coupled with a benevolent 
side-effect profile commends these continence aids for the long-term treatment of 
women with GSL This would offer strong support to the need for different types of 
devices to satisfy patient preferences, possibly utilising different mechanisms of 
action to limit side effects. Quality of life measurement prior to treatment would 
seem an ideal method for selecting women who are most likely to benefit from 
continence devices. Because the diagnosis of GSI was clearly made in compliance 
with established criteria, generalisation and application of the results to a broader 
population of all women with incontinence must be considered cautiously. But a 
single study's results cannot form the basis of clinical practice. Our clinical 
knowledge base comes from the results of trials by different research groups, working 
with different populations possibly using different methods. The closest 
approXiMation to the efficacy of continence devices is likely to come from an 
amalgam of the evidence gained from this and previous trials utilising these devices in 
women with stress incontinence. The results of this study and the others identified 
support and advocate continued development and implementation of research into 
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VICAL IH Zi I ATUS QUESTIONNAIRE (SF-36) 
THE. FOLLOW. ING; QPESTIONS ASK FOR YOUR VIEWS ABOUT YOUR 
HEALTH, i HOW Y. OU FEEL AND HOW WELL YOU ARE ABLE TO DO YOUR 
USUAL ACTIVITIES. IF YOUARE UNSURE ABOUT HOW TO ANSWER ANY 
QUESTION; " PLEASE 01YETHE BEST ANSWER YOU CAN AND MAKE ANY 
COMMENTS IN THE SýACE AVAILABLE. AFTER QUESTION 10. 
Please tick one 
1. In general would you say your health Is: 
Excellent 
0 





Q-QMaLQd LQ--Qrm_y_Car_aUQ. how would you rate your health in gerjerýjj 
noyy? 
Much better now than orip. par ago 
Somewhýit hetler now than ofie year aqr) 
Ahout the same 
oomewhat w(-)r! -, (, now than one ye- r ago 




HEALTH AND DAILY ACTIVITIES 
3. The following questions are about activities you might do during atypical 
day. Does your health limit you in these activities? Ifso, howmuch? 
Please tick one circle on each line 
Yes, Yes, No, not 
limited limited limited 
------------ 
a lot a little at all 
-- --- 
a. Vigorous activ*Iie , such as 





participating in strenuous sports 
--------------- - --- ------ 
b. MQderate activities, such as 
------ ---- 
moving a table, pushing a 




c. Lifting or carrying groceries 
------- 0 ------- 0 ------ 0 
--------------- d. C14bing several flights of stairs 
--- --- 0 ------- 0 0 
--------------- 
e. Climbing -Qua 
flight of stairs 
-- --- 0 ------- 0 0 
--------------- f. Bending, kneeling or stooping 
------- 0 ------- 0 0 
--------------- 
g. Walking more than a mile 
-- --- ------- 0 0 
--------------- h. Walking half a mile 
--- - 0 -------- 0 ---- 0 
--------------- i. Walking 100 Yard 
-- 0 
j. Bathing and dressing yourself 
4. During the pa5j_4_MQhS, have you had any of the following problems with your work 
or other regular daily activities aa Aje5UIt-Q"VULIýIIY-5iQ-EtLhV-alth? 
Answer Yes or No to each question 
YL IS NO 
a Cut down on the you sppnt on wnrý (-)r offler activitip-s 
lh, -m yol) W( 
I 
)(Ild like 
c Werp limit(-d in ; hp ýirij f)f wcvý nr other iclivities 
,f 'IctivIt 
d lidd 
(0- g it took extra efforl) 
6 
5. During the past 4 weeks, have you had any of the following problems with 
your work or other regular daily activities as a resuft of any emotional 
problems (such as feeling depressed or anxious)? 
Answer Yes or No to each question 
YES NO 
a. Cut down on the amount of time you spent on work or other activities 
00 
b. Accomplished less than you would like 
00 
c. Didn't do work or other activities as carefully as usual 
00 
6. During the past 4 weeks, to what extent has your physical health or 
emotional problems inter-fered with your normal social activities with 
family, friends, neighbours or groups? 
Please tick one 






Quite a bit 
Extremely 







8. During the Ua5j-4-wTeK5, how much did pa_j[j interfere with yolir normal 
work (including work both outside the home and housework)? 
Not 0 ill 
A littlo hit 
(Juite a bit 
Fxtrernely 
For office t', 
6 
For off ic( 
I YOUR FEELINGS 
9. These questions are about how you feel and how things have been with 
you during the past month. (For each question, please indicate the one 
answer that comes closest to the way you have been feeling) 
Please fick one circle on each line 













the past month: time time the time time time time 
?0 f lf ll fl f 
0 0 0 0 0 
a. Did you ee u o i e 
---------------- --- ---- -- --- --- 
b. Have you been a very nervous 
0 0 0 0 0 0 
person? 
---------------- --- ---- -- --- --- 
c. Have you felt so down in the 
dumps that nothing could cheer 
000 00 0 
you up? 
------------------------------- 
d. Have you felt calm and 
peaceful? 
000 00 0 
------------------------------- 
e. Did you have a lot of energy? 
000 00 0 
------------------------------- 




g. Did you feel worn out? 
h. Have you been a happy 
person? 
------------- 
i. Did you feel tired? 
() 
0 0 0 0 0 







C) 0 0 0 0 
CI) 0000 
Has Your [jQawLjjntQ-d-Y-QU[ 
QQjaf ItIfIg (like vis 





HEALTH IN GENERAL 
10. Please choose the answer that best describes how Ili& orfaLw each of the 
followIng statements Is for you. 
Please tick one circle on each line 
















than other people 
--------------- ---- --- ---- ----- 
b. I am as healthy as anybody I 
know 
0 0 0 0 0 
C. I expect my health to get worse 
0 0 0 0 0 
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Todays date 199 
How would you describe your 












How much do you think your 
bladder problem affects your 
life ? 




Please tick one answer 
0 
Please turn the page 
10 
Office u! 
We would like to know what your bladder problems are and how much 
they affect you. From the list below choose ONLY THOSE PROBLEMS 
that you have at present- 
How much do they affect you ? 
A Little Moderately Alot 
FREQUENCY; going to the toilet 
ft 
0 0 0 
very o en. 
NOCTURIA; getting up at night to 
ass urine 
0 0 0 
p . 
URGENCY; a strong and difficult 0 0 0 
to control desire to pass urine. 
URGE INCONTINENCE; urinary 
leakage associated with a strong 
0 0 0 
desire to pass urine. 
STRESS INCONTINENCE; urinary 
leakage with physical activity 0 0 0 
eg coughing, sneezing, running. 
NOCTURNAL ENURESIS; wetting 0 0 0 
the bed at night. 
INTERCOURSE INCONTINENCE; 
l int i l k ith 
0 0 0 
sexua - ur nary ea age w 
ercourse. 
FREQUENT WATERWORKS 0 0 
INFECTIONS; 
BLADDER PAIN; 0 0 0 
OTHER SPECIFY; 0 0 
Please turn the page 
Off-ice Ilse 









Below are some daily activities that can be affected by bladder problems. How much does your bladder problem affect you 7 
We would like you to answer every question. Simply tick the circle that applies to you. 
ROLE LIMITATIONS Not at all Slightly Moderately Alot 
To what extent does your bladder 
problem affect your household 
tasks (eg cleaning, shopping etc) 
0 0.0 0 
Does your bladder problem affect 
your job, or your normal daily act- 
0"0 0 
ivities outside the home? 
Not at all Slightly Moderately Alot 
PHYSICAUSOCIAL LIMITATIONS 
Does your bladder problem affect 
your physical activities (eg going 
00 0 0 
for a walk, run, sport, gymn etc)? 
Does your bladder problem affect 00 0 0 
your ability to travel? 
Does your bladder problem limit 
your social life 70000 
Does your bladder problem limit 
your ability to see/visit friends ?0000 
Not Not at Slightly Moderately Alot 
PERSONAL RELATIONSHIPS applicable all 
Does your bladder problem affect 0 0 0 0 0 
your relationship with your 
partner? 
Does Your bladder problem affect 
0 0 0 U U 
your sex life? 
Does your bladder problem affect 
your family life? 
0 0 0 
Please turn the page 
Office use F1 F1 n n_ El 1: 1 11 11 H 
Kings's Health Questionnaire, Version 7 
EMOTIONS 
Does your bladder problem make 
you feel depressed? 
Does your bladder problem make 
you feel anxious or nervous? 
Does your bladder problem make 
you feel bad about yourself? 
SLEEP / ENERGY 
Does your bladder problem affect 
your sleep 7 
Do you feel worn out/ tired? 
Do you do any of the following?; 






Never Sometimes Often All the time 
If so how much ? Never Sometimes Often All the time 
Wear pads to keep dr-y? 
0 0 0 0 
Be careful how much fluid you 
drink? 








they get wet? 
Worry in case you smell? 
Office use [ -1 F-1 [A Ll 1: 1 Fl F-I F-I F-I 
THANKYOU, NOW CHECK THAT YOU HAVE ANSWERED ALL THE QUESTIONS 




The age distribution at study inclusion for each group is shown in Table Al. 
Age (years) d istribution at study inclusIOR 
Age 21-30 31-40 41-50 51-60 61-70 71-80 Total 
Groups 
Reliance 1 8 21 15 3 0 48 
(2%) (16.7%) (43.7%) (31.3%) (6.3%) 
FemAssist 1 10 21 16 4 1 53 
(1.9%) (18.9%) (39.6%) (30.2%) (7.5%) (1.9%) 
Table Al The patient age distribution at study inclusion for each group. 
EASE AND COMFORT OF DEVICE USE 
The patient rating of ease of device placement and comfort of use recorded at each 
follow-up visit for each group is recorded in Table A2 and Table A3 respectively. 
Patient rating of "ease" of placement of each device 
Over the period of the trial 
1 Month 3 Months 6 Months 
Score Reliance FemAssist Reliance FemAssist Reliance FemAssist 
1 4 8 6 14 5 17 
2 23 24 14 23 15 16 
_ 3 12 10 8 2 10 2 
_ 4 4 3 1 2 1 1 
5 1 2 0 0 0 0 
_ Missing 4 6 19 12 17 17 
Table A2 Patient ratings on ease of device placement recorded at each tollow-up visit 
for each group. (Score 1= Very easy, Score 5= Extremely difficult) 
Patient rating of "comfort" of device use 
Over the period of the trial 
IM onth 3 Months 1 6 Months 
Score Reliance FemAssist Reliance FemAssist Reliance FemAssist 
1 2 8 5 12 5 12 
2 12 IS 12 22 11 20 
_ 3 23 13 11 6 13 3 
4 5 6 0 11 2 01 
5 2 2 1 0 0 0 
Missin_g_ L±_ 6 19 12 17 17 
Table A3 Patient ratings on comfort of device use recorded at each follow-up visit 
for specific groups. (Score 1= Very comfortable, Score 5= Extremely uncomfortable) 
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CONTROL OF INCONTINENCE WITH DEVICE USE 
ASSESSMENT OF SUBJECTIVE DEGREE OF DRYNESS 
The baseline severity of wetness for each group, at each stage of assessment, is shown 
in Tables A4, and A5. 
Baseline severity of "wetness" for each activity 
Of women in individual groups 
Score Rel I Fem R m Rel I Fem Rel T-Fem 
Sitting/lying Standin g Walking Lift/bending 
1 17 19 11 18 5 8 2 0 
2 11 16 14 16 13 14 2 2 
_ 3 17 18 15 19 14 14 16 15 
_ 4 3 0 8 0 14 17 19 22 
_5 
0 0 0 0 2 0 9 14 
Table A4 The scoring of the degree of "wetness" or the seventy of incontinence as 
assessed by the women in each group on entry to the trial for the activities of 
sitting/lying, standing, walking, lifting and bending. [(I = no urine loss, 5= severe 
loss) Rel = Reliance group, Fem = FemAssist group] 
Baseline severity of "wetness" for each activity 
of women in individual gro ps 







1 2 0 0 0 1 0 
2 1 2 0 2 1 1 
3 6 11 0 11 2 12 
4 22 24 5 22 4 22 
5 17 16 40 18 40 18 
Table A5 The scoring of the degree of "wetness" or the severity of incontinence as 
assessed by the women in each group on entry to the trial for the activities of low 
impact exercise, high impact exercise and coughing/sneezing/laughing. 
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PATIENT RETED DRYNESS WITH DEVICE USE 
Patient rated dryness for the activities tested at the one-month visit are recorded in 
tables A6 and AT 
1-Month severity of "wetness" scores for each activity 
tested in individual groups 
- Score Rel I Fem Re I FFem Rel Fem Rel Fem 
Sitting/lying Standin g Walking Lift/be ding 
1 42 47 42 44 40 30 40 27 
2 0 0 0 3 2 6 2 8 
3 0 0 0 0 11 0 0 0 
4 0 0 0 0 0 0 0 0 
5 0 0 0 0 0 0 0 0 
Table A6 The scoring of the degree of "wetness" or the seventy of incontinence as 
assessed by the women in each group for the activities of sitting/lying, standing, 
walking, lifting and bending. [(I = no urine loss, 5= severe loss) Rel = Reliance 
group, Fern = FemAssist group] 
I. -Month severity of "wetness" scores for each activity 
tested in individual groups 







1 38 22 24 0 31 17 
2 3 14 14 10 11 15 
3 0 0 0 20 0 13 
4 0 11 0 17 0 21 
5 0 0 0 0 0 1 
Table A7 The scoring of the degree of "wetness" or the severity of incontinence as 
assessed by the women in each group for the activities of low impact exercise, high 
impact exercise and coughing/sneezing/laughing. 
Patient rated dryness for the activities tested at the three-month visit are recorded in 
tables A8 and A9. 
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3-month severity of "wetness" scores for each activity 
tested in individual groups 
Score Rel I Fem Rel Fem Rel I Fem Rel Fem 
Sitting/lying Standi g Walkin g Lift/ben ding 
1 29 41 29 38 27 31 27 31 
2 0 0 0 3 2 6 2 6 
3 0 0 0 0 0 2 0 1 
4 0 0 0 0 0 2 0 2 
5 0 0 0 0 0 0 0 0 
Table A8 The scoring of the degree of "wetness" or the severity of incontinence as 
assessed by the women in each group for the activities of sitting/lying, standing, 
walking, lifting and bending. [(I = no urine loss, 5= severe loss) Rel = Reliance 
group, Fem = FemAssist group] 
3-month severity of "wetness" scores for each activity 
tested in individual groups 







1 27 26 12 5 21 19 
2 2 10 14 15 8 20 
3 0 2 0 17 0 2 
4 0 3 0 0 0 0 
5 0 0 0 0 0 0 
Table A9 The scoring of the degree of "wetness" or the severity of incontinence as 
assessed by the women in each group for the activities of low impact exercise, high 
impact exercise and coughing/sneezing/laughing. [(1 = no urine loss, 5= severe loss) 
Rel = Reliance group, Fem = FemAssist group] 
Patient rated dryness for the activities tested at the six-month visit are recorded 
in 
tables Al 0 and Al. I- 
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6-month severity of "wetness" scores for each activity 
tested in individual groups 
Score Rel I Fem Rel Fem Rel I Fem Rel Fem 
Sitting/lying Standi g Walking Lift/bending 
1 31 36 31 34 29 33 31 33 
2 0 0 0 2 2 5 1 3 
3 0 0 0 0 0 5 0 0 
4 0 0 0 0 0 
5 0 0 0 0 0 0 0 0 
Table A10 The scoring of the degree of "wetness" or the severity of incontinence as 
assessed by the women in each group for the activities of sitting/lying, standing, 
walking, lifting and bending. [(I = no urine loss, 5= severe loss) Rel = Reliance 
group, Fem = FemAssist group] 
6-month severity of "wetness" scores for each activity 
tested in individual groups 







1 29 28 17 5 19 20 
2 2 2 13 1 12 18 
3 0 6 0 30 0 3 
4 0 0 0 0 0 0 
5 0 0 0 0 0 0 
Table Al 1 The scoring of the degree of "wetness" or the severity of incontinence as 
assessed by the women in each group for the activities of low impact exercise, high 
impact exercise and coughing/sneezing/laughing. 
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ASSESSMENT OF THE URINARY DIARY 
INCONTINENCE EPISODES PER DAY 
Incontinence episodes per day (IEPD) in women using the Reliance device. 
Patient 
number 
Baseline 1-month 3-months 6-months 
1 5 2 2 




6 5 2 1 
7 4 2 1 1 
8 5 1 
9 5 1 
10 5 2 
11 6 2 
12 5 1 2 
13 5 1 
14 5 1 1 
15 6 2 2 2 
16 5 2 1 
17 5 1 1 1 
18 5 1 1 1 
19 5 2 1 1 
20 5 2 
21 6 2 2 
22 5 2 2 2 
23 4 1 1 2 
24 4 1 1 1 
25 6 2 2 1 
26 5 2 
27 4 2 1 1 
28 5 2 
29 6 2 1 2 
30 4 2 2 
31 4 
32 6 1 1 1 
33 4 
34 6 2 1 1 
35 7 1 
36 6 2 1 
37 4 1 1 1 
38 5 2 




Baseline 1-month 3-months 6-months 
40 4 1 2 2 
41 6 1 1 
42 7 2 1 1 
43 6 2 2 2 
44 4 
45 6 2 
46 6 
47 6 2 1 1 
48 4 
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IEPD in women using the FernAssist device. 
Patient 
number 
Baseline 1-month 3-months 6-months 
1 51 2 2 1 
2 5 
3 4 2 2 1 
4 5 2 2 
5 5 2 2 1 
6 4 1 1 1 
7 4 2 2 2 
8 6 2 3 
9 4 2 2 1 
10 6 1 2 1 
11 6 2 2 0 
12 5 1 2 1 
13 7 2 2 1 
14 5 1 1 0 
15 5 1 1 0 
16 4 1 2 
17 5 1 1 0 
18 5 1 
19 5 1 
20 5 1 2 1 
21 5 2 2 1 
22 5 2 2 1 
23 6 2 2 1 
24 6 2 3 1 
25 5 2 3 2 
26 5 1 2 1 
27 4 1 2 1 
28 5 1 1 0 
29 4 2 2 0 
30 4 2 1 
31 4 
32 6 2 3 2 
33 6 2 3 2 
34 5 2 3 2 
35 5 2 3 
36 5 2 1 1 
37 4 2 2 1 
38 5 1 2 1 
39 4 2 2 1 
40 4 2 2 1 
41 4 1 2 1 





Baseline 1-month 3-months 6-months 
44 6 2 2 
45 5 
46 4 
47 6 2 3 1 
48 4 
49 6 1 
50 4 
51 4 2 
52 6 
53 8 2 
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PADS USED OVER 5 DAYS 
The number of pads used over 5 days in women using the Reliance device 
Patient 
number 
Baseline 1-month 3-months 6-months 
1 5 3 3 
2 11 5 3 3 
3 10 6 4 
4 10 6 4 
5 10 6 4 4 
6 11 5 4 
7 12 5 3 3 
8 11 5 3 
9 10 5 3 
10 12 6 
11 9 6 
12 10 5 5 5 
13 10 5 
14 10 4 3 3 
15 10 4 3 3 
16 12 4 3 
17 12 6 3 3 
18 11 5 4 4 
19 12 3 3 3 
20 11 5 
21 10 6 3 
22 12 6 4 4 
23 10 5 3 3 
24 9 4 4 3 
25 9 4 3 3 
26 8 4 
27 8 4 4 4 
28 8 5 
29 11 5 3 3 
30 12 4 3 
31 12 
32 12 6 3 4 
33 11 
34 12 5 4 4 
35 11 5 
36 10 5 
37 9 5 4 5 
38 10 4 
39- 10 6 3 4 
40- 11 5 5 4 
41 12 5 4 




Baseline 1-month 3-months 6-months 




47 11 5 3 3 
48 11 3 3 
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The number of pads used over 5 days in women using the FemAssist device. 
Patient Baseline I-month 3-months 6-months 
number 
IIII 
1 10 5 5 4 
2 10 
3 11 
4 10 5 4 5 
5 9 6 4 
6 10 6 5 4 
7 10 6 5 4 
8 9 7 4 
9 10 6 5 4 
10 8 5 5 5 
11 11 5 5 
12 14 6 5 5 
13 12 7 5 4 
14 11 6 5 4 
15 11 7 5 4 
16 10 6 5 
17 9 6 4 4 
18 11 6 4 4 
19 9 5 
20 12 5 4 4 
21 11 5 4 4 
22 11 5 5 5 
23 12 5 5 5 
24 13 5 5 4 
25 13 5 4 4 
26 12 6 4 4 
27 12 6 4 4 
28 9 5 4 4 
29 12 5 5 5 
30 8 5 5 
31 10 
32 14 5 5 5 
33 13 6 4 5 
34 15 5 5 5 
35 15 5 4 4 
36 12 5 4 
37 14 9 4 4 
38 11 7 5 4 
39 10 6 4 4 
40 10 6 5 5 
41 11 6 5 5 
42 11 7 5 5 














46 12 5 
47 12 7 4 4 
48 12 
49 11 5 
50 11 
51 12 7 
52 10 
53 11 5 
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PAD WEIGHT TEST DATA 
The pad weight test gains for women in the Reliance group. 
Patient 
number 
Baseline 1-month 3-months 6-months 
1 44.1 0.2 0.6 0.7 
2 14.8 1.3 1.6 1.7 
3 37.5 2.1 1.9 
4 48.9 0.8 0.8 
5 37.2 0.8 1.2 0.5 
6 11.1 0.1 0.9 
7 27.8 0.7 0.9 0.5 
8 4.1 0.7 0.8 
9 11.4 0.1 0.2 
10 58.6 2.1 
11 55.2 1.2 
12 40.3 3.5 2.1 2. 
13 3.8 0.6 
14 17.6 0.4 0.8 0.9 
15 48.3 1.7 2.3 1.9 
16 20 0.3 0.5 
17 99. 0.3 4.6 0.1 
18 1.2 0.2 0 2.5 
19 1.3 0.6 0.6 
20 21.1 0.5 
21 1.7 1.4 0.5 
22 5.1 0.6 0.5 0.4 
23 64.5 0.5 0.3 0.4 
24 97.2 0.5 0.6 0.2 
25 33.3 0.5 0.3 0.6 
26 30.8 0.5 
27 32.4 0.3 0.5 0. 
28 1.2 0 
29 18.3 0.2 0 0.3 
30 1.1 0.7 0.3 
31 9.7 
32 52.5 0.5 0.2 0.4 
33 63.6 
34 9.8 0.5 1.8 0.5 
35 5 0.8 
- 36 36.6 0.1 0.4 
37- 19.3 0.8 0.5 0.9 
38 21 0.4 
_ 39 7.2 0.7 0.4 0.3 




Baseline 1-month 3-months 6-months 
41 18.8 2.1 1.8 
42 1.6 0.5 0.5 0.6 




47 56.7 1.1 0.8 0.8 
48 37.4 0.9 
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The pad weight test gains for women in the FemAssist group. 
Patient 
number 
Baseline 1-month 3-months 6-months 
1 40 2 3.5 3.5 
2 20 
3 36 3 3 3 
4 49 1.5 4 
5 38 3.5 4 4 
6 16 0.5 4 4 
7 33 3.5 3.5 4 
8 5 3.5 3.5 
9 14 4 4 4 
10 60 4.5 4 4 
11 40 6 3 4 
12 22 5 3 4 
13 13 3.2 4 4 
14 128 2.1 2 3 
15 44 2.1 2 3 
16 25 2 2 
17 100 2 2 3 
18 2 5 4 3 
19 15 4 
20 3 4 4 3.5 
21 15 2 4 4 
22 6 2 4 3 
23 15 3 4 4 
24 40 3 3 4 
25 36 3.2 4 4 
26 22 3.2 3 4 
27 5 4.5 6 5.5 
28 15 4 5 5 
29 15 3 4 4 
30 23 4 4 
31 6 
32 12 5 2.5 3 
33 60 3 4 4 
34 10 2.2 2 3 
35 6 3.5 2 
36 33 3.5 4 4 
37- 19 3.8 4 4 
38 22 3 2 2 
39- 15 3 4 4 
40 12 3 2 2.5 
41 22 5 4 4 




Baseline 1-month 3-months 6-months 
43 33 3 
44 38 4.5 4 3 
45 25 
46 25 4 
47 55 3 3.5 3 
48 40 
49 31 2 
50 38 
51 34 2 
52 28 
53 35 4 
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BASELINE QUALITY OF LIFE SCORES 
RELIANCE GROUP 
KINGS HEALTH QUESTIONNAIRE 
The baseline Kings Health Questionnaire quality of life scores for women randomised 
to use the Reliance device (n=48) are illustrated below. The first column records the 
individual patients who are assigned a number, I to 48. 
GHP Inimp EL RIL SL S/E PersL Physi SM 
1 0 66.6 11.1 16.6 0 33.3 0 33.3 33.3 
2 25 22.2 22.2 66.6 11.1 33.3 50 33.3 50 
3 51 66.6 100 66.6 33.3 33.3 50 66.6 66.6 
4 25 66.6 40 16 33.3 0 0 66.6 33.3 
5 25 100 88.8 66.6 55.5 16.6 33.3 83.3 66.6 
6 0 66.6 44.4 16 11.1 33.3 50 33.3 60 
7 50 100 33.3 66.6 55.5 16.6 33.3 66.6 50 
8 25 33.3 22.2 0 11.1 50 0 16.6 40 
9 25 66.6 22.2 33.3 22.2 50 16.6 50 60 
10 25 33.3 0 33.3 0 50 0 50 26.6 
11 0 66.6 11.2 33.3 22.2 0 33.3 66.6 33.3 
12 25 66.6 44.4 33.3 0 83 0 50 40 
13 50 33.3 0 33.3 40 0 0 33.3 33.3 
14 0 100 33.3 50 11.1 0 0 33.3 50 
15 50 10 100 100 55.5 50 83.3 66.6 66.6 
16 50 66.6 44.4 66.6 66.6 33.3 100 66.6 80 
17 20 100 88.8 83.3 44.4 50 1606 100 66.6 
18 0 100 100 66.6 100 66.6 100 100 73.3 
19 33.3 50 0 0 25 0 33.3 33.3 50 
20 50 66.6 66.6 33.3 0 66.6 33.3 50 80 
21 25 66.6 33.3 33.3 66.6 33.3 16.6 66.6 60 
22 60 100 77.7 66.6 100 83 100 83.3 73.3 
23 25 100 55.5 66.6 44.4 33.3 0 66.6 33.3 
24 25 66.6 33.3 66.6 44.4 33.3 33.3 83.3 66.6 
25 25 100 0 83.3 33.3 0 0 66.6 80 
26 50 100 100 16.6 100 16.6 0 100 73.3 
27 0 66.6 22.2 100 0 33.3 0 16.6 40 
28 25 66.6 22.2 33.3 66.6 50 0 66.6 66.6 
29 25 100 55.5 33.3 33.3 0 0 50 53.3 
30 50 66.6 11.1 66.6 33.3 0 0 50 33.3 
31 50 33.3 22.2 0 0 83.3 0 0 53.3 
32 0 100 33.3 100 22.2 0 33.3 33.3 80 
33 66.6 66.6 0 33.3 33.3 0 0 100 33.3 
34 25 66.6 55.5 66.6 22.2 50 100 66.6 26.6 
35 0 66.6 11.1 0 0 16.6 0 50 33.3 
36 25 66.6 22.2 66.6 1 22.2 _ 0 0 50 33.3 
37 50 100 22.2 66.6 44.4 0 66.6 83.3 80 
38 66.6 66.6 25 25 0 0 33.3 33.3 25 
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GHP Inimp EL RIL S/E PersL Physl SL SM 
39 0 66.6 11.1 100 22.2 16.6 0 50 26.6 
40 25 100 66.6 66.6 66.6 33.3 66.6 66.6 73.3 
41 25 100 44.4 66.6 44.4 16.6 33.3 66.6 73.3 
42 50 66.6 22.2 0 00 33.3 16.6 50 40 
43 25 66.6 44.4 66.6 66.6 0 33.3 66.6 66.6 
44 50 100 100 50 55.5 16.6 33.3 83.3 73.3 
45 0 66.6 33.3 66.6 44.4 0 66.6 66.6 66.6 
46 50 100 11.1 50 22.2 33.3 33.3 66.6 26.6 




66.6 66.6 80 
48 0 66.6 33.3 100 22.2 1- rl 6. 6 16.6 0 50 26.6 
GHP= General health perception, Inimp= Incontinence impact, EL= Emotional 
limitation, RL= Role limitation, S/E= Sleep/energy disturbance, PersL= Personal 
limitation, PhysL= Physical limitation, SL= Social limitation, SM= Severity 
measures. 
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BASELINE QUALITY OF LIFE SCORES 
RELIANCE GROUP 
UK SHORT FORM 36 
HEALTH SURVEY QUESTIONNAIRE 
The baseline SF-36 questionnaire quality of life scores for women randomised to use 
the Reliance device (n=48) are illustrated below. 
PF SF PRIL ERL MH E/F PAIN GHP 
1 70 75 25 66 63 55 66 59 
2 65 65 43 61 60 50 60 58 
3 63 66 33 55 66 60 66 55 
4 66 66 30 60 63 55 60 57 
5 65 66 40 60 1 60 60 61 58 
6 75 75 20 70 66 60 67 65 
7 72 77 20 70 65 60 70 60 
8 65 65 22 61 60 57 69 62 
9 72 77 28 68 1 60 57 68 64 
10 70 76 38 70 60 51 64 63 
11 64 65 40 58 55 48 71 65 
12 71 70 43 70 66 55 60 60 
13 66 74 44 71 1 62 50 66 59 
14 68 70 25 66 58 46 66 58 
15 74 58 36 60 59 49 68 62 
16 77 59 33 61 54 49 58 66 
17 66 66 36 61 66 48 59 63 
18 65 77 39 60 64 55 55 64 
19 80 66 40 58 1 58 50 56 59 
20 77 69 41 55 61 55 58 58 
21 63 71 36 58 62 65 58 56 
22 67 77 41 59 1 59 60 59 60 
23 66 72 44 61 55 59 60 61 
24 65 68 41 62 58 58 66 62 
25 59 66 45 66 57 57 57 59 
26 70 65 50 60 66 56 54 58 
27 64 77 46 66 64 58 58 58 
28 66 74 25 65 163 64 61 60 
29 80 78 35 67 63 62 62 65 
30 71 77 30 70 60 58 58 58 
31 70 74 33 71 64 50 57 59 
32- 65 66 36 65 61 55 62 57 
33 66 60 39 66 65 54 70 54 
34- 76-8 60 40 63 63 58 74 62 
- 35 - 71 63 45 64 166 48 50 60 
36 72 62 44 68 58 40 55 58 
37 64 65 46 66 54 45 58 59 
38 69 70 48 61 55 48 59 60 
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PF SF PRL ERIL I MH E/F PAIN GHP 
39 68 77 44 50 1 58 49 66 64 
40 63 66 46 55 1 57 51 65 59 
41 65 71 49 58 55 54 64 57 
42 59 63 30 54 56 51 59 57 
43 69 69 25 59 63 52 58 69 
44 77 67 25 60 1 66 48 57 60 
45 75 71 30 66 62 45 58 61 
46 60 70 33 64 59 50 59 66 
47 72 62 36 58 59 51 66 60 
48 64 62 33 59 58 46 59 59 
PF = physical function, SF = social function, PRL = physical role limitation, ERL = 
emotional role limitation, MH = mental health, E/F = energy/ fatigue, GHP = general 
health perception. The first column records the individual patients who are assigned a 
number, 1 to 48. 
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BASELINE QUALITY OF LIFE SCORES 
FEMASSIST GROUP 
KINGS HEALTH QUESTIONNAIRE 
The baseline Kings Health Questionnaire quality of life scores for women randomised 
to use the FemAssist device (n=53) are illustrated below. 
GHP Inimp EL RII, SL S/E PersL Physl SM 
1 0 66.6 11.1 16.6 0 33.3 0 33.3 33.3 
2 25 100 22.2 16.6 11.1 33.3 0 33.3 50 
3 51 0 100 66.6 33.3 33.3 50 66.6 66.6 
4 25 33.3 40 16.6 33.3 0 0 25 33.3 
5 25 100 88.8 66.6 55.5 16.6 33.3 83.3 66.6 
6 0 66.6 44.4 16.6 11.1 33.3 50 33.3 60 
7 50 66.6 33.3 66.6 55.5 16.6 33.3 66.6 50 
8 25 100 22.2 0 11.1 50 0 16.6 40 
9 25 66.6 22.2 33.3 22.2 50 16.6 50 60 
10 50 100 0 33.3 0 50 0 50 26 
11 0 66.6 11.1 33.3 22.2 0 33.3 66.6 33.3 
12 25 66.6 44.4 33.3 0 83.3 0 50 40 
13 50 66.6 0 33.3 40 0 0 33.3 33.3 
14 0 100 33.3 50 11.1 0 0 33.3 50 
15 50 100 100 100 55.5 50 83.3 66.6 66.6 
16 50 66.6 44.4 66.6 66.6 33.3 100 66.6 80 
17 20 100 88.8 83 44.4 50 16.6 100 66.6 
18 75 100 100 66.6 100 66.6 100 100 73.3 
19 33.3 66.6 0 0 25 0 33.3 33.3 50 
20 50 66.6 66.6 33.3 0 66.6 33.3 50 33.3 
21 25 33.3 33.3 33.3 0 33.3 16.6 16.6 60 
22 75 100 77.7 66.6 100 83.3 100 83.3 73.3 
23 25 100 55.5 66.6 44.4 33.3 0 66.6 33.3 
24 25 66.6 33.3 66.6 44.4 33.3 33.3 83.3 66.6 
25 75 100 0 83 33.3 0 0 66.6 80 
26 50 100 100 16.6 100 16.6 0 100 73.3 
27 0 66.6 22.2 16.6 0 33.3 0 16.6 40 
28 25 66.6 22.2 33.3 11.1 50 0 66.6 66.6 
29 25 100 55.5 33.3 33.3 0 0 50 53.3 
30 50 66.6 11.1 66.6 33.3 0 0 50 33.3 
31 50 33.3 22.2 0 0 83.3 0 0 53.3 
32 0 66.6 33.3 33.3 22.2 0 33.3 33.3 20 
33 66.6 66.6 0 33.3 33.3 0 0 33.3 33.3 
34- 25 66.6 55.5 66.6 22.2 50 0 66.6 26.6 
35- 0 66.6 11.1 0 0 16.6 0 50 6.6 
36 25 100 22.2 66.6 22.2 0 0 50 33.3 
37 50 100 22.2 66.6 44.4 0 66.6 83.3 80 
38- 66.6 33.3 25 25 0 0 33.3 33.3 25 
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GHP Inimp EL RL SL S/E PersL Physl SM 
39 0 33.3 11.1 16.6 22.2 16.6 0 50 26.6 
40 25 100 66.6 66.6 66.6 33.3 66.6 66.6 73.3 
41 25 100 44.4 66.6 44.4 16.6 33.3 66.6 73.3 
42 50 66.6 22.2 0 0 33.3 16.6 50 40 
43 25 66.6 44.4 66.6 11.1 0 33.3 66.6 66.6 
44 50 100 100 50 55.5 16.6 33.3 83.3 73.3 
45 0 66.6 33.3 66.6 44.4 0 33.3 66.6 66.6 
46 50 100 11.1 50 22.2 33.3 33.3 66.6 26.6 
47 50 100 66.6 66.6 55.5 33.3 66.6 66.6 80 
48 0 66.6 33.3 16.6 22.2 16.6 16.6 50 26.6 
49 50 66.6 33.3 50 33.3 33.3 16.6 50 50 
50 0 50 0 66.6 22.2 16.6 16.6 50 50 
51 0 100 40 33.3 33.3 33.3 33.3 66.6 66.6 
52 50 50 40 50 22.2 33.3 33.3 50 66.6 
53 60 100 66.6 33. 3.3 16.6 16.6 50 26.6 
The first column records the individual patients who are assigned a number, 1 to 53. 
GHP= General health perception, Inimp= Incontinence impact, EL= Emotional 
limitation, RL= Role limitation, S/E= Sleep/energy disturbance, PersL= Personal 
limitation, PhysL= Physical limitation, SL= Social limitation, SM= Severity 
measures. 
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The baseline SF-36 questionnaire quality of life scores for women randomised to use 
the FemAssist device (n=53) are illustrated below. 
PF SF PRIL ERIL MH E/F PAIN GHP 
1 66 66 33 66 66 66 80 66 
2 66 66 43 66 66 66 66 66 
3 66 66 60 66 55 55 60 50 
4 55 55 55 55 55 55 66 50 
5 55 55 55 55 66 66 55 50 
6 77 0 22 77 1 55 55 55 66 
7 66 88 33 77 50 55 77 55 
8 66 77 33 66 55 66 66 55 
9 66 80 25 66 66 66 66 55 
10 6 80 25 55 66 55 55 66 
11 55 66 33 55 44 55 66 70 
12 55 80 33 66 55 50 55 70 
13 70 66 66 66 75 55 55 70 
14 77 66 20 55 66 44 66 66 
15 66 55 20 55 66 66 66 55 
16 66 55 25 66 55 55 55 66 
17 77 66 25 66 5 44 45 60 
18 70 70 25 55 55 50 45 60 
19 88 70 33 55 66 66 45 60 
20 77 66 33 66 66 55 55 66 
21 66 55 33 66 44 66 70 55 
22 66 59 25 50 58 55 70 55 
23 55 55 25 50 6 50 66 55 
24 55 66 44 50 66 50 50 60 
25 55 70 44 55 55 50 50 60 
26 85 80 55 55 44 66 55 58 
27 66 66 55 66 44 66 66 66 
28 55 88 33 44 55 60 66 66 
29 74 80 33 44 55 55 55 66 
30 66 66 25 55 155 60 55 50 
31 66 66 25 85 66 66 55 50 
32 - -ýO 55 33 66 66 66 66 55 
33 ý0- 55 45 33 55 55 77 55 
34 60 44 33 60 44 77 66 
35 55 55 55 60 44 60 66 
36 66 55 55 55 60 44 60 66 
37- -3-5 66 66 44 55 4 60 50 
38 ý5- 66 55 66 154 60 50 
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39 70 66 50 55 66 55 55 50 
40 77 55 50 66 50 55 55 70 
41 66 55 44 55 50 44 60 70 
42 66 55 22 66 1 50 55 60 55 
43 70 55 33 66 66 66 55 55 
44 66 60 33 55 66 66 55 66 
45 55 60 33 55 33 66 55 66 
46 55 60 33 66 66 55 66 55 
47 78 60 40 55 66 55 55 55 
48 66 60 40 55 155 33 55 66 
49 66 66 40 66 66 55 66 66 
50 70 66 40 66 66 66 50 66 
51 70 55 33 55 55 55 66 70 
52 66 55 40 55 60 55 66 55 
53 55 70 40 66 --- 
t50 
50 50 55 
PF = physical function, SF = social function, PRL = physical role limitation, ERL = 
emotional role limitation, MH = mental health, E/F = energy/ fatigue, GHP = general 
health perception. The first column records the individual patients who are assigned a 
number, 1 to 53. 
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The Kings Health Questionnaire quality of life scores for women obtained following 
utilisation of the Reliance device (n=3 1) are illustrated below. The first column 
records the individual patients who are assigned a number, I to 48. 
GHP Inimp EL RL SL S/E PersL Physl SM 
1 0 0 0 0 o 33.3 0 16.6 14.6 
2 25 33.3 22.2 16.6 11.1 33.3 0 33.3 25 
5 25 33.3 77.7 33.3 44.4 33.3 33.3 33.3 25 
7 50 33.3 33.3 33.3 33.3 0 33.3 33.3 25 
9 25 33.3 22.2 33.3 0 33.3 16.6 16.6 20 
12 25 33.3 22.2 16.6 0 66.6 0 16.6 13.3 
14 0 33.3 16.6 16.6 0 33.3 0 16.6 0 
15 50 66.6 100 83.3 55.5 66.6 83.3 66.6 53.3 
16 50 33.3 33.3 33.3 22.2 33.3 33.3 33.3 20 
17 25 66.6 88.8 50 11.1 33.3 16.6 33.3 25 
18 50 33.3 33.3 33.3 33.3 33.3 33.3 16.6 60 
19 33.3 50 0 0 25 0 33.3 33.3 33.3 
21 25 33.3 33.3 33.3 0 33.3 16.6 16.6 40 
22 75 66.6 77.7 33.3 77.7 83.3 83.3 33.3 53.3 
23 0 33.3 44.4 50 22.2 0 33.3 80 
24 25 33.3 33.3 33.3 33.3 33.3 16.6 33.3 26.6 
25 25 33.3 0 33.3 22.2 0 00 33.3 33.3 
27 25 66.6 11.1 16.6 22.2 33 33.3 33.3 13.3 
29 25 66.6 44.4 33.3 0 83.3 33.3 33.3 46.6 
30 40 33.3 0 33.3 22.2 0 0 33.3 26.6 
32 0 33.3 22.2 33.3 11.1 0 33.3 16.6 6.6 
34 25 33.3 33.3 33.3 22.2 33.3 0 33.3 26.6 
36 25 33.3 33.3 50 22.2 0 0 33.3 6.6 
37 25 66.9 22.2 66.6 22.2 0 33.3 66.6 60 
39 0 33.3 11.1 16.6 11.1 16.6 0 16.6 6.6 
40 25 33.3 33.3 33.3 33.3 33.3 33.3 0 20 
41 75 80 44.4 66.6 44.4 16.6 33.3 66.6 73 
42 25 33.3 22.2 0 0 33.3 16.6 16.6 26.6 
43 35 33.3 55.6 66.6 33.3 0 66.6 33.3 40 
47 45 66.6 100 666 88.8 33.3 66.6 100 53.3 
48 0 33.3 33.3 22.2 16.6 0 16.6 20 
GHP= General health perception, Inimp= Incontinence impact, EL= Emotional 
limitation, RL= Role limitation, S/E= Sleep/energy disturbance, PersL= Personal 
limitation, PhysL= Physical limitation, SL= Social limitation, SM= Severity 
measures. 
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The SF-36 questionnaire quality of life scores for women obtained following 
utilisation of the Reliance device (n=3 1) are illustrated below. The first column 
records the individual patients who are assigned a number, I to 48. 
PF SF PRL ERIL MH E/F PAIN GHP 
1 88 84 65 66 66 52 67 55 
2 90 84 66 60 66 66 65 50 
5 87 87 80 62 55 56 56 66 
7 90 85 65 66 66 62 72 62 
9 87 89 66 74 1 50 62 66 66 
12 91 100 69 66 66 55 60 62 
14 88 89 69 70 65 55 62 55 
15 91 85 66 56 63 46 66 60 
16 90 86 64 66 1 50 52 64 66 
17 86 86 69 60 66 49 55 59 
18 80 80 62 66 63 60 57 66 
19 80 84 67 60 64 56 60 65 
21 88 78 84 55 58 61 80 55 
22 87 90 68 55 64 65 71 1 66 
23 88 85 69 66 50 55 70 63 
24 85 84 67 66 60 52 62 66 
25 90 89 70 60 1 60 60 50 60 
27 90 89 77 66 66 55 55 55 
29 97 100 63 66 60 61 66 66 
30 90 96 64 60 66 66 60 59 
32 86 90 89 60 57 57 66 55 
34 87 80 80 60 58 62 70 66 
36 89 80 61 66 55 43 60 55 
37 94 85 60 60 50 46 60 55 
39 94 88 64 59 66 44 60 66 
40 89 84 59 50 55 54 63 60 
41 92 75 61 55 50 52 57 57 
42 95 79 60 50 59 46 55 54 
43 86 77 66 66 63 50 51 66 
47- 88 87 69 60 64 50 60 66 
- 48 - 84 77 64 68 63 49 66 60 
PF = physical function, SF = social function, PRL = physical role limitation, ERL = 
emotional role limitation, MH = mental health, E/F = energy/ fatigue, GHP = general 
health perception. 
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The Kings Health Questionnaire quality of life scores for women obtained following 
utilisation of the FemAssist device (n=36) are illustrated below. 
GHP Inimp EL RL SL S/E PersL Physl SM 
1 0 0 0 0 0 33.3 0- 16.6 14.6 
3 75 33.3 22.2 16.6 11.1 33.3 0 33.3 25 
5 50 66 77.7 33.3 44.4 16.6 33.3 0 25 
6 50 33.3 33.3 33.3 33.3 0 33.3 33.3 25 
7 50 66 22.2 33.3 0 33.3 16.6 16.6 20 
9 25 33.3 22.2 16.6 0 66.6 0 16.6 13.3 
10 55 33.3 16.6 33.3 0 33.3 0 16.6 0 
11 0 66.6 100 83.3 55.5 0 83.3 16.6 53.3 
12 25 33.3 33.3 33.3 22.2 33.3 33.3 33.3 20 
13 50 66.6 88.8 66.6 11.1 50 16.6 0 25 
14 0 33.3 33.3 33.3 33.3 33.3 33.3 16.6 25 
15 50 50 0 66.6 25 0 33.3 33.3 33.3 
17 25 33.3 33.3 33.3 0 33.3 16.6 16.6 40 
18 50 66.6 77.7 50 66.6 66.6 100 16.6 33.3 
20 25 33.3 44.4 33.3 33.3 33.3 0 33.3 20 
21 25 33.3 33.3 33.3 33.3 33.3 16.6 16.6 26.6 
22 75 66.6 0 33.3 22.2 0 0 16.6 33.3 
23 25 66.6 22.2 0 0 33.3 0 0 26.6 
24 25 66.6 44.4 33.3 0 33.3 33.3 33.3 46.6 
25 25 33.3 0 33.3 22.2 0 0 33.3 26.6 
26 0 66.6 22.2 33.3 11.1 0 33.3 33.3 6.6 
27 0 33.3 33.3 33.3 22.2 33.3 0 16.6 26.6 
28 25 33.3 33.3 50 22.2 0 0 33.3 6.6 
29 25 66.6 22.2 66.6 22.2 0 33.3 33.3 60 
32 0 33.3 11.1 16.6 11.1 16.6 0 16.6 6.6 
33 75 33.3 33.3 33.3 33.3 33.3 33.3 16.6 20 
34 25 80 44.4 66.6 33.3 16.6 33.3 0 66.6 
36 25 33.3 22.2 33.3 0 33.3 16.6 0 26.6 
37 50 33.3 33.3 66.6 33.3 0 66.6 16.6 40 
38 50 33.3 44.4 50 22.2 0 0 0 80 
39 0 66.6 11.1 66.6 22.2 33.3 33.3 33.3 13.3 
40 25 66.6 100 66.6 88.8 33.3 66.6 
- 
33.3 53.3 
41- -B- 33.3 33.3 0 22.2 16.6 0 100 20 
42 25 66 33.3 85 22.2 0 33.3 16.6 45 
44 33.3 75 1 33.3 1 66.6 1 22.2 0 33.3 0 50 
47 50 75 1 33.3 1 
(--T4p== Cf-neral health t)erceDtion- I 
66.6 1 22.2 16.6 33.3 0 
nimn= Incontinence imnact- EL= Emotional 
33.3 
limitation, RL= Role limitation, S/E= Sleep/energy disturbance, PersL= Personal 
limitation, PhysL= Physical limitation, SL= Social limitation, SM= Severity 
measures. 
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The SF-36 questionnaire quality of life scores for women obtained following 
utilisation of the FernAssist device (n=36) are illustrated below. 
PF SF PRL ERL MH E/F PAIN GHP 
1 77 77 77 55 60 60 60 60 
3 80 77 77 55 60 60 60 60 
5 80 77 85 66 66 160 60 60. 
6 80 90 80 60 60 60 66 66 
7 80 88 77 60 60 66 66 60 
9 88 85 77 55 60 66 66 60 
10 77 85 75 55 60 1 66 60 66 
11 77 85 70 66 60 66 66 66 
12 88 90 70 66 66 60 60 60 
13 80 90 70 66 60 1 60 60 60 
14 88 90 88 58 66 60 60 66 
15 88 88 66 58 66 60 60 66 
17 80 80 66 60 66 66 77 66 
18 80_ 88 6 60 66 66 75 60 
20 80 80 80 60 60 60 60 60 
21 66 88 80 66 60 60 60 60 
22 77 88 77 66 60 1 60 60 66 
23 90 66 75 60 60 66 60 66 
24 88 85 75 60 60 60 60 60 
25 85 85 77 66 60 60 66 55 
26 88 99 70 66 66 60 60 50 
27 90 88 70 66 66 43 60 50 
28 88 88 70 66 66 1 46 66 55 
29 77 88 77 66 66 1 60 66 50 
32 88 80 77 66 60 60 66 55 
33 88 80 77 60 60 60 63 55 
34 88 80 61 60 66 55 60 60 
36 90 80 77 60 66 1 55 60 60 
37 90 75 65 60 60 55 55 60 
38 90 80 65 66 60 60 50 64 
39 80 80 65 60 66 66 62 60 
40 88 80 88 66 1 66 60 66 55 
41 90 80 62 66 66 60 66 55 
42 - 88 -- 80 65 60 60 66 60 66 
44 90 90 65 60 66 0 66 70 
47 88 88 88 66 66 60 62 60 
PF = physical function, SF = social function, PRL = physical role limitation, ERL = 
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